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Abstract 
 
Although Malaria rates are on the decline due to the efforts of the World Health 
Organization and other organizations dedicated to the eradication of this disease, a relaxed 
attitude towards the development of new antimalarial entities would be flawed. Due to the 
emergence of resistance in the parasite, the almost 50% world-wide reduction in malarial death 
rates that have been produced over the past 15 years are threatening to be lost 
New drugs are urgently needed and our approach focuses on the re-evaluation and 
optimization of the historic antimalarial ICI 56,780. Due to its causal prophylactic activity, along 
with its ability to prevent transmission and potent blood schizonticidal activities, it was revisited 
with the hopes of first understanding which functionalities were responsible to the compound’s 
activity. Secondly, we wanted to optimize the substituents in the 3, 6 and 7-positions. Finally and 
most importantly, we wanted to address the cross-resistance problem of the ICI 56,780 scaffold. 
Initial, analogues showed the importance of the ester in facilitating the convergence of 
the RI towards 1. Although those analogues lost activity in W2, TM90-C2B, and Pb, they were 
our first glimpse at this important trend that was later exploited in our 3-halo-6-butyl-7-(2-
phenoxyethoxy)quinolin-4(1H)-one and 3-halo-6-butyl-2-methyl-7-(2-phenoxyethoxy)quinolin-
xiii 
 
4(1H)-ones which showed RI values of < 5 for our best analogues. Although our lead compound 
3-bromo-6-butyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H 
)-one possessed decreased activities as compared to ICI 56,780 at 2.60 nM for W2, 12.2 
nM for TM90-C2B and 2.12 nM for Pb, it had 100% inhibition of parasite development on day 6 
PE in our scouting assay and 61% inhibition on day 6in our Thompson model, increased from 
the < 2% value given by the ICI 56,780. 
Solubility and unfavorable in vivo stability were still major issues for this scaffold. 
Therefore, a series of piperazinyl 4(1H)-quinolones with greatly enhanced solubility were 
designed and tested in detailed structure activity relationships and structure property relationship 
studies. Initial results showed that 7-piperazinyl-4(1H)-quinolones possessed greatly increased 
solubilities when compared to ICI 56,780 analogues. Primarily, the linker length and the 
piperazine core was probed. This showed that compounds with a single carbon spacer were most 
active. Further testing of the 6-position gave methyl 6-methyl-4-oxo-7-((4-phenylpiperazin-1-
yl)methyl)-1,4-dihydroquinoline-3-carboxylate with W2 and TM90-C2B values of 0.435 nM and 
147 nM respectively. Substitution on the piperazinyl phenyl gave the most active compounds 
however the RI of >1500 was unacceptable. Because of this, 3-halo substituents were added to 
these quinolones with promising results. With RIs of < 3, the compounds were promising, 
however they were not active in vivo. However, methyl 6-methoxy-4-oxo-7-((4-(4-
(trifluoromethyl)phenyl)piperazin-1-yl)methyl)-1,4-dihydroquinoline-3-carboxylate and methyl 
6-methyl-4-oxo-7-((4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)methyl)-1,4-dihydroquinoline-
3-carboxylate both gave cures in our in vivo Thomson model. 
xiv 
 
These studies highlight the potential in using detailed structural activity and structural 
property studies to re-evaluate and optimize historic antimalarials. These studies have introduced 
a new generation of soluble 4(1H)-quinolones with high potency against P. falciparum. 
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Chapter 1 Drug Discovery and its use for Developing Antimalarials 
1.1  Malaria 
Malaria is one of the most widespread infectious diseases with about 3.4 billion people at 
risk of infections.
1, 2
 Typically, five species of parasites have been known to commonly infect 
humans, these include P.falciparum, P. vivax, P. ovale, P.malariae, and P. knowlesi.
3
 In the 
documented history of human malaria, P. knowlesi was thought to only infect non-human 
primates. However, it has been shown to be the cause of a substantial part of that region’s 
malaria cases.
4, 5
 The P. vivax strain has dormant liver stages or hypnozoites that have been 
known to lie dormant for months to years and cause relapse in individuals infected with this 
strain.
6-8
 P. falciparum is the most deadly species causing about 1 million deaths per year.
3
 
Although malaria fatalities have been steadily falling, a very concerning emergence of resistance 
has occurred. This resistance is not only to the WHO recommended artemisinin-based 
combination therapy (ACT) but also the parasite’s vector, the mosquito, becoming resistant to 
insecticides which much of the success to date in controlling malaria is credited.
9, 10
  Due to the 
alarming resistance emergence, new methods of combating the disease must be explored. One of 
those methods is the development of new drugs. However to be most effective, these new drugs 
must be effective against multiple stages of the parasite’s life cycle.11  
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Figure 1.1: Malaria Life Cycle
12
 
 
The malaria parasite has a complex life cycle with many stages in two different host species 
(Figure 1.1) making it difficult to target. When an infected female Anopheles mosquito takes a 
blood meal from a human host, she injects sporozoites into the host and the exo-erytrocytic cycle 
of the parasite’s life cycle begins. The parasite first invades and infects the liver. After 
multiplication in the liver cells, they then are released into the blood where they begin their 
erythrocytic cycle. During this phase, the clinical symptoms of the disease, which generally 
include fever, fatigue, vomiting and headaches, begin to show. The parasites consecutively 
3 
 
invade red blood cells, in which they multiply up to a point where the red blood cells burst 
releasing more parasites. These parasites in turn infect new red blood cells increasing the parasite 
burden in the human host. During this time some of the blood merozoites develop into male and 
female gametocytes, which are infectious to a mosquito taking a blood meal from this infected 
host. A third sporogonic cycle now begins in the mosquito. During this cycle, gametes fuse and 
develop into an ookinete, then to an oocyst, and finally the oocyst ruptures to release more 
sporozoites. These sporozoites invade the salivary mosquito’s glands so that they will be injected 
into a new human host.
12
 
1.2  Parasite Stage Specificity Action and Quinolones as Antimalarials 
Many protozoa have a sexual and asexual stage which they cycle between.
11
 There have 
been many drugs used historically to combat malaria and due to its complex life-cycle, each 
stage has its druggable targets and specific drugs that are active against it. The main three stages 
of the malaria’s life cycle are the ones where the parasite resides in the liver, in red blood cells, 
as well as the gametocyte stages, which are critical for transmission from the human to the 
mosquito.
1-3, 9, 11-18
  
In order to completely (radically cure) an infected individual, the exo-erytrocytic (EE) 
stages, namely the liver parasite forms and the gametocytes of the parasite, must be completely 
cleared as well as all blood stages.
19
 Primaquine, an 8-aminoquinoline, is known to clear 
dormant hypnozoites and is the drug of choice used for P. vivax and P. ovale. Because of this 
reason, primaquine is usually given to patients with proven P. vivax and/or P. ovale infections, 
many times as a combination therapy with another antimalarial.
20, 21
 Primaquine can also be used 
as a potent gametocytocidal agent against mature gametocytes of P. falciparum. Other 8-
aminoquinolines effective against the EE stages of malaria include pamaquine and tafenoquine.
13
 
4 
 
These 8-aminoquinolines were for a substantial time the only compounds that displayed 
multistage parasite activity. 
4(1H)-quinolones 1.1 have been known to be active against malaria since the World War 
II when endochin 1.2 was shown to have prophylactic activity.
22
 4(1H)-Quinolone 1.2 was 
shown to have activity against the three stages of the mosquito life cycle in an avian malaria 
model.
23
 It however failed to be active in initial human trials and its activity was further 
disproven in radical cure assays done at the Walter Reed Army Institute of Research.
22
 A small 
SAR focusing on the 3-position of the scaffold was performed by Casey provided only two 
active compounds. This further proved the suspicions that a major liability of this scaffold was 
its in vivo stability. Further optimization of 1.2 done by the Kyle and Manetsch laboratories 
discovered that the 3-alkyl group was a liability not only for stability but solubility as well. 
Using Dr. Topliss’ operational scheme, compound 1.2 was optimized from an activity and 
property standpoint to yield pre-clinical candidates P4Q-391 1.3 and ELQ-300 1.4. Both were 
shown to be potent against clinically relevant W2 and TM90-C2B strains, however 1.4 was 
ultimately chosen as the clinical candidate with EC50s of 1.8 and 1.7 nM respectively. 
Furthermore 1.3 showed potent sporozoite inhibition, essentially stopping a liver infection from 
ever taking place. Lastly, 1.4 was shown to be potent against the gametocyte stage of the parasite 
stopping the development in the mosquito vector.
22, 24, 25
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Figure 1.2: Structures of Key 4(1H)-quinolones 
 
1.3 ICI 56,780 
 
Figure 1.3: ICI56,780 and analogue 
 
Another example of a multi stage active compound is the quinolone ester, ICI56,780 1.5 
discovered by Riley and Peters in 1970.
25
 It was found to be to a causal prophylactic and blood 
schizonticidal agent in P. berghei rodent models at doses of 0.05 mg/kg. However, ICI 56,780 
6 
 
1.5 was found to confer rapid resistance to the parasite as P. berghei infected mice developing 
resistance after only one passage.
25, 26
 In the 90’s Puri and Dutta revisited the compound 
abandoned 20 years earlier retesting ICI 56,780 and close analogues thereof in P. cynomolgi 
infected Rhesus monkeys in the gold standard assay for hypnozoites drug efficacy. Impressively, 
the compounds produced radial cures as the animals did not relapse even 120 days after exposure 
confirming its potency against hypnozoites at 15mg/kg.
22, 26
 This compound was ultimately 
abandoned due to its induction of resistance as well as suboptimal property profile. However, the 
combination of antimalarial activities against the blood and liver stages of the parasite as well as 
the sexual gametocyte stages in the mosquito vector make this scaffold a promising multistage 
antimalarial candidate for optimization. 
In 2011 a limited SAR of 7-(2-phenoxyethoxy)-4(1H)-quinolones was published.
27
 Cross 
et al. described the synthesis and antimalarial activity of 29 aryl and alkyl ICI 56,780 analogues. 
The work in this publication mainly focused on three main points, namely (a) the replacement of 
the 6-alkyl moiety with methoxy, methyl and halo substituents, (b) the substitution of the 3-ester 
functionality with alkyl chains and hetero-aromatic rings, and (c) the functionalization of the 7-
substituent with different ethers. The author’s main focus was on the resolution of the cross-
resistance with atovaquone that plagues the ICI 56,780 scaffold. The authors were able to resolve 
the resistance problem with one of their best compounds the 3-aryl substituted quinolone, 6-
butyl-3-(2-fluoro-4-(trifluoromethyl)phenyl)-7-(2-phenoxyethoxy)-4(1H)-quinolone (1.6), with 
EC50s of 28 nM for W2 and 31 nM for TM90-C2B. This garnered overall improvement of the 
compound’s RI to 1.11, a vast improvement over the parent compound. However, aryl-
substituted quinolones significantly lost activity against the liver stages of the parasite.
22, 27, 28
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Figure 1.4: Synopsis of ICI 56,780 analogues by the Manetsch and Kyle laboratories 
 
 
 
Figure 1.5: Synopsis of Quinolone-esters by the Guy laboratory 
 
Work done by the Guy laboratory demonstrated the use of the 2-position to enhance the 
solubility of 3-ester containing quinolones.
29, 30
 The synthesis and activities of about 100 2-aryl-
8 
 
4(1H)-quinolones were reported in the publication.
29, 30
 Although, the focus of this SAR was 
mainly in the 2-position, the authors also did some probing of the 3-position using methodical 
approach. Although there were compounds with moderate activities and solubilities, they were 
overall much less potent than previously reported 4(1H)-quinolone esters. Furthermore no liver 
stage or gametocyte testing was reported on these compounds.
22, 29, 30
 
 
1.4  WR 243246, Dihydroacridinediones, Acridines and 1,2,3,4-tetrahydroacridones 
The acridine/acridone research has always been a story of little brother-big brother 
rivalry, with the 4(1H)-quinolones always being slightly more appealing as antimalarials. Interest 
in the acridines’ usage as antimalarials began from its discovery as an antiprotozoal agent, with 
its first usage from the dye acridine orange 1.7 with an IC50 of 466 nM for the 3D7 strain. 
Development of this dye led to the synthesis of quinacrine 1.8 in 1932.
13
 1.8 had its peak usage 
during WWII but was overtaken by chloroquine 1.9 because the later was deemed safer,
22
 more 
effective and more bioavailable. Right after the ending of WWII in 1947, Stephen and coworkers 
reported the antimalarial activity of 1,2,3,4-tetrahydroacridin-9(10H)ones 1.10 (THAs) in P. 
gallinaceum infected chicks.
31
 THAs were similar to the acridines with the difference being that 
one ring is fully reduced. Although there were some active compounds, due to the superior 
activity of 1.1, efforts on optimization were focused on them instead of the THAs until the 
parasite’s resistance to 1.9 became overwhelming. Synthesis of pyronaridine 1.11 and floxacrine 
1.12 in 1970s led to a revived interest in these scaffolds. Structurally analogous to THAs, 
Durckheimer showed 1.12, a dihydroacridinedione (DHA), to have blood stage activity as well 
as prophylactic activity.
32
 1.12 has liabilities that included poor solubility, cross resistance with 
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atovaquone 1.13, and slight cytotoxicity. Kesten and coworkers reported WR243246 1.14 and its 
imine prodrug WR243251 1.15, two DHAs, to be the lead compounds in their publication of  
 
 
Figure 1.6: Structures of Relevant Acridones and 1,2,3,4 tetrahydroacridones 
10 
 
 
close to 80 THAs along with about 70 prodrug versions.
33
 Further tests with prodrug WR243251 
1.15 gave cures in P. berghei infected mice at doses of 12 mg/kg and in P. falciparum infected 
Aotus monkeys. Although the compound displayed excellent in vivo blood stage activity, 
ultimately it was abandoned due to cross-resistance to atovaquone, high production costs, and 
instability of the imine prodrug due to decomposition of the unstable imine prodrug. Adverse 
cardiovascular and neurological effects were also reported with this prodrug.
13, 22
  
Recently, the Manetsch and Kyle laboratories reported the structure-activity and 
structure-property relationships of almost 120 THAs using the Topliss operational scheme as the 
approach to investigate the benzeniod core. Due to synthetic limitations previous work on the 
scaffold focused on the mono-substituted analogues, however synthetic design allowed for 
further development of the THA scaffold. Overall, modest in vitro activities were obtained and 
most potent compounds had electron donating substituents in the 6-position with electron 
withdrawing groups in the 7-position. Although substituting the 5-position and 8-position 
provided more soluble compounds, most if not all of the activity was lost when compounds were 
substituted solely in those positions. The aliphatic ring was also optimized. Initially, the ring size 
was probed and the six-membered ring was most preferred. Substitutions in positions3 and 4 
positions included dimethyl and diflouro substitutions as well as carbon replacement with either 
sulfur or nitrogen. The most potent compound was 6-(4-(4-(trifluoromethoxy)benzyl)phenyl)-
1,3,4,10-tetrahydroacridin-9(2H)-one (1.16) with IC50s of 12.2 nM and 9.10 nM for W2 and 
TM90-C2B strains. Although there were THAs with desirable solubility, THAs that were potent 
seemed to have suboptimal solubilities and microsomal stabilities.
11
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Figure 1.7: Synopsis of 1,2,3,4 Tetahydroacridin-9(10H)-ones by Manetsch and Kyle 
laboratories 
 
1.5 Modern Drug Discovery 
Modern drug discovery is fundamental to the production of new lead compounds, which 
can be further developed to clinical drugs.  Drug discovery has made great strides in the past few 
decades due to the new understanding of various biochemical pathways yielding a variety of new 
targets that can be used to treat diseases that were considered once untreatable due to lack of 
understanding. Conventional drug discovery approaches such as high-throughput screening 
(HTS) and combinatorial chemistry are fundamental in medicinal chemistry. Both these methods 
rely on the synthesis of high numbers of compounds sorted into libraries that are used for 
screening purposes making them quite inefficient and expensive. Combinatorial chemistry (CC) 
became mainstream in the 90s; however, uses of it can be seen as far back as the 60s with 
Merrifield’s usage of the approach in the solid phase synthesis of peptides. One of the key 
strategies often employed in CC is the mix and split method. In the mix and split method, a 
12 
 
compound is divided into a predetermined portions. These portions are then coupled to a 
different reagent. After the reaction, all portions are mixed and the cycle is repeated. This 
method can be used to create libraries of hundreds of compounds in a short time.
11, 34
 The 
mixtures obtained can be directly tested against the intended target and any active samples can 
then be isolated by a specific deconvolution process.
35
 In high-throughput screens, large libraries 
of compounds (generally tens of thousands or more) are created and screened using sophisticated 
automated liquid handling tools, robotics and methods of detection.
11
 Because of the high 
number of compounds being screened an automated form of data analysis is usually required to 
keep up with the massive amount of raw data obtained. More detailed follow-up assays are 
preformed from hit compound where these compounds are cherry-picked from the wells that 
they originated from.  Because of the great expense of this process, most academic labs do not 
have the equipment or the personnel for such a task and usually resort to medium-throughput 
screening instead.  
1.6 Phenotypic VS Target Based Screens 
For the past century, there have been two general methods that have dictated the 
beginning stages of the drug development process. These include phenotypic and target-based 
screening. Phenotypic screens have been the foundation of drug development and at its core 
relies on the observation of a singular parameter for the determination of activity. These 
parameters can range from the production or lack there-of, of particular proteins all the way to 
cell death, essentially looking at the effect that the tested compound prompts in the target cell or 
organism. Target-based screening on the other hand relies on measuring the effect that the tested 
compound has on the target protein, usually in a pure version. A study done by Swinney and 
Anthony, where over 180 small molecule drug compounds that were approved for use over a 10 
13 
 
year period, probed which screening method was used to in the discovery of these drugs. 56% of 
the new molecular entities found were the result of phenotypic screening while only 34% were a 
result of target-based screens causing the authors to conclude that the key advantage of 
phenotypic screens was that the leads identified through this method are more likely to already 
possess relevant mechanisms of actions. However finding the target protein or cascade of the 
lead compound identified by phenotypic screens has been shown to be difficult. Over the past 35 
years, phenotypic screens have been slowly replaced by target screens due to the ease in 
obtaining purified relevant pure targets associated in a biological process. Alternative methods 
have used target-based screens in its quest to develop new drugs.
36, 37
 
1.7  Research Aims. 
Due to the length of time it takes for drug development, proactive efforts are needed now 
to find new methods to combat malaria. Antimalarial drugs must be developed that not only kill 
one stage of the parasite but can block transmission of the infectious gametocytes, kill the liver 
hypnozoites and the blood erythrocytes as well. One method to keep the cost and time needed for 
drug development is in recycling old drugs in three main ways. First is the development of new 
combination therapies using these drugs. Secondly is using therapeutic agents originally 
developed for other targets into agents that could potentially be used as antimalarials and lastly 
by optimizing these classic scaffolds that are seen over and over again in the malaria literature to 
provide more desirable methods of combating the disease by a combination of structure-activity 
and structure property relationships, thereby increasing activity, solubility and stability.  
Through using methodical approaches, the quinolone esters, which although was curative 
in the gold standard Rhesus monkey-sporozoite challenge assays and ultimately abandoned, were 
revisited with hopes of addressing the stability and resistance index issues. Secondly, using 
14 
 
solubilizing groups, it was attempted to boost the solubility while maintaining activity. Finally, 
the solubility and permeability of all compounds were tested.  
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Chapter 2: Structural Activity and Structural Relationship Properties of ICI 
56,780: Overcoming Cross-resistance in Plasmodium 
2.1 Overview 
Although malaria death rates are on the decline due the WHO and other organizations 
dedicated to the eradication of this disease, a relaxed attitude towards the development of new 
antimalarial entities would be flawed. Due to the emergence of resistance in the parasite, the 
gains that have been produced are threatening to be reversed
1
. Effective drug treatment remains 
the cornerstone of malaria control,
2
 however, due to resistance of the parasite to many of the 
common antimalarials and artemisinin. Due to the limited chemical chemotypes active against 
malaria, researchers have begun to optimize old antimalarial agents or drugs, evaluating these in 
current preclinical efficacy models and assessing these for proper physicochemical properties.
3-5
. 
Antimalarials once thought to be unfitting therapeutic agents were revisited with a new 
understanding of parasitology and physicochemical properties needed for a viable drug. This 
approach has been shown to be effective for endochin
6-9
, 4(1H)-quinolone, floxacrine
3, 10-13
, a 
tetrahydroacridone, and the simplified chloroquine analogue AQ-13
5, 14
, among others
3, 7
 
4(1H)quinolone ester ICI 56,780
10, 15, 16
 (2.1) is an example of another historical scaffold that is 
primed for recycling. Compound 2.1 was found to be curative at 15 mg/kg however, resistance 
was observed after only one passage in P. berghei infected mice and the compound was 
eventually abandoned.
16
 Work done by Manetsch and Guy labs showed that considerable 
16 
 
optimization can be done to offset some of the liabilities of the compound class, such as 
solubility and resistance.
17-19
 They do not, however, address some of the fundamental questions 
about why 2.1 has such broad range anti-malarial activity as no detailed structure-activity and 
structure-property relationship studies have been done on this class of compounds. Given the 
promise of this scaffold, a parallel blood SAR, liver SAR and SPR was done in order to gain a 
deeper understanding of this promising scaffold. 
 
Figure 2.1 Antimalarial structures primed for recycling 
 
2.2 Synthetic Chemistry.  
Previous efforts to optimize ICI 56,780 (2.1a) analogues using Suzuki-Miyaura cross 
couplings yielded less than desirable activities. Furthermore, the cross resistance and properties 
were not optimal.
19
 In our efforts to improve the bioavailability as well as better understand the 
structural reasons for the broad spectrum activity for 2.1a, a pronounced SAR was undertaken 
initially with a small number of analogues (Table 2.1). Their goal was to individually assess the 
3-ester, 6-butyl and 7-phenoxy-ethoxy groups’ contribution to the overall activity of 2.1a. 
17 
 
Compound 2.1a was synthesized over an eight step sequence previously reported.
19
. Compound 
2.1b was synthesized by the alkylation of N-(3-hydroxyphenyl)acetamide (2.2a), followed by 
subsequent deprotection and Gould-Jacobs cyclization. Compounds 2.1c and 2.1d were both 
prepared using Gould-Jacobs cyclizations of the appropriate anilines along with dimethyl 2-
(methoxymethylene)malonate (2.5a) (Scheme 2.1) while 2.8a-c, were synthesized by the 
removal of the ester moiety of their respective equivalents through a two-step sequence of first 
refluxing in 10% sodium hydroxide then heating the intermediate acid in toluene at 270 
o
C for 5 
minutes (Scheme 2.2). Due to the difficulty obtaining highly substituted anilines, the seven and 
six positions of the scaffold (see Tables 2.2 and 2.3) were modified independently. Compounds 
2.1k-v and 2.8awere all accessed through commercially available amines as opposed to 2.1e-j, 
which were synthesized through a similar sequence used for compound 2.1a. Using protected 
phenols 2.2 and phenyl bromides followed by subsequent acetamide deprotection of 2.3 yielded 
amines 2.4, which were subsequently cyclized to quinolone esters 2.1 (Scheme 2.1). 
It was unknown if the butyl chain in the original 2.1a was the optimal length. Therefore, 
the 6-position was modified to range from a hydrogen to a pentyl chain. Compounds 2.1w, 2.1x, 
and 2.1y were all synthesized starting from 1-bromo-4-nitro-2-(2-phenoxyethoxy)benzene 
(2.11a) via 1-bromo-2-methoxy-4-nitrobenzene (2.9). Due to phenol 2.10a not being 
18 
 
Scheme 2.1: Synthesis of quinolones 2.1a-v
19 
 
 
Scheme 2.2: Synthesis of decarboxylated quinolones 2.8a-c 
 
commercially available, it had to be synthesized from the readily available anisole 2.9 with a 
BBr3 deprotection, followed by a routine alkylation to give 2.11a, the needed starting material for 
the next sequence of reactions.
19
 The alkynyl nitrobenzenes 2.12 were all synthesized via slightly 
different routes which were dependent on the type of alkynyl starting material needed (Scheme 
2.2). The nitrobenzene starting material of 2.1w was first subjected to a Sonogashira-cross 
coupling using TMS-acetylene, with PdCl2(PPh3)2, CuI, and TEA in good yield, followed by 
TBAF deprotection of the acetylene to yield 2.12a.
20
 To access the nitro alkyne 2.12b, needed 
for 2.1x, a one-pot coupling and deprotection using trimethyl(prop-1-yn-1-yl)silane, Pd(OAc)2, 
and TBAF using microwave irradiation was employed to give the desired product in low 
yields.
21
 Lastly, analogue 2.12c was obtained using 1-pentyne, PdCl2(PPh3)2, CuI, PPh3, and 
diethyl amine in a microwave reactor in good yields.
22
 Each alkyne 2.12 was reduced using 
similar hydrogenation conditions in order to reduce both the alkyne and nitro groups to the 
corresponding alkyl-anilines 2.4. These were all subjected to standard Gould-Jacobs conditions 
in order to obtain the title compounds 2.1w-y (Scheme 2.3). 
 
20 
 
Scheme 2.3 Synthesis of varying linker length 4(1H)-quinolones 2.1w-y 
 
α
 R = H: i) TMS acetylene, PdCl2(PPh3)2, CuI, triethylamine, 85 
o
C, 1 h; ii) TBAF, THF, RT, 5 
min; R = methyl: trimethyl(prop-1-yn-1-yl)silane, Pd(OAc)2, TBAF, THF, MW 120 
o
C, 15 min; 
R = propyl: 1-pentyne, PdCl2(PPh3)2, CuI, PPh3, diethylamide, THF, MW 120 
o
C, 25 min; 
 
Next a small group of electron donating and electron withdrawing groups were synthesized. This 
chemistry allowed access to the single carbon chain compound 2.1ac along with analogues 2.1z, 
2.1aa, and 2.1ab. These compounds were synthesized from an alkylation of 2.10 followed by a 
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Scheme 2.4 Synthesis of quinolones 2.1z-ac probing 6-position electronics 
 
tin chloride reduction of nitrobenzenes 2.11b-e to give anilines 2.4z-ac which were cyclized to 
give the desired quinolones 2.1z–ac (Scheme 2.4). It was thought that the methyl ester group of 
2.1a could potentially be a metabolic liability. Therefore analogues were prepared, in which the 
methyl ester group was replaced by amides, nitrile, keto, ethyl, and other esters were. The amide 
functionalities were introduced by the aminolysis of 2.1a using trimethyl aluminum and the 
appropriate amine in dry benzene
23
 to yield compounds 2.13a-g in moderate to low yield after 
purification using preparative HPLC (Scheme 2.5). 
Scheme 2.5 Synthesis of 3-amide substituted compounds 2.13a-g 
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Scheme 2.6 Synthesis of 3-cyano-4(1H)-quinolone 6ad 
 
In order to access ester 2.1ag and 2.1af the correct methylene malonate had to be synthesized from the corresponding 
malonate.  The cyanide was synthesized from aniline 2.4a and the commercially available ethyl-2-cyano-3-ethoxyacrylate (2.5b). 
Standard Gould-Jacobs cyclization afforded the title compound 2.1ad in low yield (Scheme 2.6).  
 
A three-step process was used to obtain 2.1ae. First ethyl butyrate (2.13) was reacted with diethyl oxalate (2.14) to give the 
diester compound 2.15 
24
 which was used as a starting material along with the appropriate aniline 2.4a to synthesize 2.1ae (Scheme 
2.7). Surprisingly, the expected penultimate intermediate, ethyl 6-butyl-3-ethyl-4-oxo-7-(2-phenoxyethoxy)-1,4-dihydroquinoline-2- 
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Scheme 2.7 Synthesis of 3-ethyl substituted quinolone 2.1ae 
 
carboxylate did not form and the de-carboxylated 2.1ae was obtained directly after cyclization 
(Scheme 2.7). Ketone 2.18g was synthesized through a standard Conrad-Limpach cyclization. 
Halide 2.18e was an intermediate to 3-aryl substituted quinolones previously reported.
19
. These 
compounds were synthesized from compounds 2.8b and 2.8e using NBS, NCS or NIS in DMF 
(Scheme 2.8). 
 
Scheme 2.8 3-ester to 3-halide replacement 
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2.3  Antimalarial Activity and Cytotoxicity.  
All synthesized compounds were routinely tested against the clinically relevant multidrug 
resistant malarial strains W2 (pyrimethamine and chloroquine resistant strains) and TM90-C2B 
(mefloquine, chloroquine, atovaquone, pyrimethamine resistant strains) as previously reported.
8
 
Due to the emergence and rapid acquisition of cross resistance,
25
 each compound is also 
evaluated on its resistance index or RI, which is the ratio of the effective concentrations needed 
to kill 50% of the population of parasites (EC50) for TM90-C2B and W2 strains (EC50 TM90-
C2B/ EC50 W2). Ideally, the RI of a compound should lie between 0.3 and 3 in order to not 
possess features needed to rapidly induce resistance in the parasite. A subset of compounds were 
also tested in an in vitro liver cell assay using P. berghei sporozoites expressing luciferase, 
harvested from mosquito salivary glands and allowed to infect HEPG2 hepatoma cells in order to 
assess if they possessed sporozoitocidal activity.
7
 Similar to the RI, liver blood indices (LBI) 
were assessed in order to relate Pb with W2 (EC50 Pb/EC50 W2) and Pb with TM90-C2B. (EC50 
Pb/EC50 TM90-C2B). This allowed a more simplified way of comparing the different assays 
being simultaneously run. Additionally, each compound was also tested for cytotoxicity using 
mammalian J774 cell lines in a 96 well plate format. 
2.4  Structural Activity Relationships.  
Compound 2.1a was found to have excellent EC50s for W2 at 39.0 pM however it 
suffered from a two orders of magnitude drop in activity for the multi-drug resistant strain 
TM90-C2B, with an EC50 value of 7.89 nM. Compound 2.1a also showed excellent in vitro liver 
stage activity in P. berghei (Pb) infected cells with an EC50 of 52.0 pM. Initially, each substituent 
in 3-, 6-, and 7-position was removed one at a time to give compounds, 2.1b, 2.1c and 2.8b. 
25 
 
Interestingly, the removal of the 6-butyl or 7-(2-phenoxyethoxy) group left moderately active 
compounds 2.1b and 2.1c with EC50 values against W2 of 2.80 and 1.58 nM respectively, 
whereas both maintained subnanomolar liver stage activity. In contrast, removal of the ester 
functionality in 3-position severely affected the potency, dropping the EC50 constants of W2, 
TM90-C2B and Pb to 328 nM, 430 nM, and 5.82 nM respectively. This seemed to suggest the 
importance of the ester in liver stage activity. Despite the severe potency reduction for 
compound 2.8b, it was noted that the resistance index (RI) equaled 1.31, which stands in stark 
contrast to the large RI values for compounds 2.1a and 2.1b. Following, a set of compounds, 
2.1d, 2. 8a, and 2.8c, was tested, in which two of the 3-, 6- and 7-substituents were 
simultaneously removed. Both 2.1d and 2.8c retained respectable potency against W2; however 
both were devoid of any activity against TM90-C2B. Similar to compound 2.8b, when the ester 
group was removed in compounds 2.8a, inhibition against W2 was lost, however the RI value 
converged towards 1. Importantly, it was also observed that compounds 2.8a, 2.8b, and 2.8c 
while lacking the ester group in 3-position were the least potent analogues against Pb of the 
entire subseries (Table 2.1). 
Due to the scarcity and costs of commercially available, di- and tri-substituted anilines 
along with the awareness that 3-ester-substituted 4(1H)-quinolones 2.1b and 2.1c still retained 
moderate blood stage activity, a set of compounds were synthesized, in which the 7- or 6-
position were probed (Tables 2.2 and 2.3). Due to possible metabolic instabilities of the 2- 
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Table 2.1: Removal of 2.1 substituents to determine what is needed for activity
α
 
 
Compound R
1 
R
2
 R
3
 
EC50 
W2 
(nM) 
EC50 
TM90-C2B 
(nM) 
EC50 
Pb 
(nM) 
EC50 
J774 
(µM) 
RI
β
 
LBI
γ
 LBI
δ
 
2.1a (CH2)3CH3 O(CH2)2OPh CO2CH3 0.039 7.89 0.052 >46.0 202 0.75 0.007 
2.8a (CH2)3CH3 O(CH2)2OPh H 328 430 5.82 >21.9 1.31 56.4 0.012 
2.8c (CH2)3CH3 H H 352 > 12400 395 >49.7 >37.8 0.89 <0.032 
2.1c (CH2)3CH3 H CO2CH3 1.58 222 0.819 >38.6 140 0.52 0.004 
2.8b H O(CH2)2OPh H 5960 7680 >354 >35.6 1.29 0.06 >0.046 
2.1b H O(CH2)2OPh CO2CH3 2.80 73.6 0.286 >29.5 26.3 9.79 0.004 
2.1d H H CO2CH3 200 6590 3.65 >57.8 33.0 54.8 0.0005 
α
Chloroquine (CQ), Atovaquone (ATO), and Dihydroartemisinin (DHA),  are internal controls for each in vitro assay. CQ (131 nM TM90-C2B 
and 162 nM W2) , ATO (0.53 nM W2 and >170 nM TM90-C2B) and DHA (1.8 nM W2 and ,0.9 nM). N.D.: not determined. 
β
 RI = TM90-C2B/W2; 
γ
 LBI = W2/Pb; 
δ
 LBI = TM90-C2B/Pb 
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phenoxyethoxy substituent in 4(1H)-quinolone 2.1b, analogue 2.1j was designed in which one of 
the oxygens in the 7-(2-phenoxyethoxy) moiety was replaced by a methylene. This compound 
2.1j, which in comparison to analogue 2.1b was 4 times more active against W2 with an EC50 of 
0.711 nM, displayed a tenfold drop in activity against TM90-C2B. This was mirrored in the Pb 
activities where there was an 18 fold drop in the activity of 2.1j as compared to the reference 
2.1a from EC50s of 0.052 nM in 2.1a to 5.26 nM in 2.1j. The length of the alkyl chain was also 
shortened in hopes of improving about 4(1H)-quinolone 2.1j, however, analogues 2.1k, 2.1h, 
and 2.1i were all worse than the reference 2.1j. Finally, in order to test electronics and steric 
effects, compounds substituted in 7-position with chloro, phenyl, and fluoro substituents were 
tested. 7-Chloro and 7-phenyl substituents were not tolerated as compounds 2.1l and 2.1m were 
devoid of antimalarial activity whereas 7-fluoro-4(1H)-quinolone 2.1n was active against W2 
and TM90-C2B with EC50s of 26.2 nM and 395 nM, respectively. 
A similar study was conducted investigating possible moieties in the quinolone’s 6-
position. Once again, analogue 2.1g containing the 2-phenoxy-ethoxy moiety in 6-position was 
the most potent analogue against W2, TM90-C2B and Pb with EC50 constants equaling 14.4 nM, 
3,670 nM, and 11.1 nM, respectively. Compounds 2.1e and 2.1f, close analogues of 2.1g, were 
the only other analogues of this subseries displaying EC50 constants with double digit activity 
against W2. Overall,  with the exception of 2.1u, which was devoid of activity, probing of the six 
position gave mediocre compounds leading to the belief that is was overall less important than 
the seven position. 
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Table 2.2: Structure activity relationship of the 7-positionα 
 
Compound R
1 
EC50 
W2 
(nM) 
EC50 
TM90-C2B 
(nM) 
EC50 
Pb 
(nM) 
EC50 
J774 
(µM) 
RI
β
 
LB
γ
I LBI
δ
 
2.1d H 200 6590 3.65 >57.8 33.0 54.8 0.0006 
2.1b O(CH2)2OPh 2.80 73.6 0.286 29.5 26.3 9.79 0.004 
2.1k OPh 16.6 1940 110 9.12 117 0.15 0.057 
2.1h OCH2Ph 1830 8080 ND 18.9 4.42 ND ND 
2.1i O(CH2)2Ph 139 7740 ND 17.2 55.7 ND ND 
2.1j O(CH2)3Ph 0.711 >784 5.26 1.48 >1100 0.14 <0.007 
2.1l Cl 2360 5800 ND >42.1 2.46 ND ND 
2.1m Ph 2560 11300 ND 26.2 4.41 ND ND 
2.1n F 26.2 395 ND >35.8 15.1 ND ND 
α
Chloroquine (CQ), Atovaquone (ATO), and Dihydroartemisinin (DHA), are internal controls for each in 
vitro assay. CQ (131 nM TM90-C2B and 162 nM W2), ATO (0.53 nM W2 and >170 nM TM90-C2B) 
and DHA (1.8 nM W2 and, 0.9 nM). N.D.: not determined. 
β
 RI = TM90-C2B/W2; 
γ
 LBI = W2/Pb; 
δ
 LBI = TM90-C2B/Pb 
In a subseries of close analogues, the optimal length of the 6-alkyl residue was 
investigated leading to the design of compounds 2.1ac, 2.1w, 2.1x, 2.1y and 2.1ai. 7-Methyl-
substituted 4(1H)-quinolone 2.1ac had a modest activity with an EC50 of 2.01 nM for W2, and 
EC50 of 499 nM for TM90C2B, and Pb EC50 of 152 nM. Antimalarial potency increased as the 
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Table 2.3: Structure activity relationship of the 6-position
α
 
 
Compound R
1 
EC50 
W2 
(nM) 
EC50 
TM90-C2B 
(nM) 
EC50 
Pb 
(nM) 
EC50 
J774 
(µM) 
RI
β
 
LBI
γ
 LBI
δ
 
2.1d H 200 6590 3.65 ND 33.0 54.8 0.0006 
2.1o OCH3 482 >10700 79.6 6.18 >22.2 6.05 <0.007 
2.1p OCH2CH3 292 >10100 ND >40.4 >34.6 ND ND 
2.1q CH(CH3)2 354 >10200 ND >40.8 >28.8 ND ND 
2.1r Cl 614 82200 46.6 >42.2 134 13.1 0.006 
2.1s O(pFl)Ph 117 5710 ND >31.9 48.8 ND ND 
2.1t CH2CH3 145 >10800 ND >43.2 >74.5 ND ND 
2.1w (CH2)3CH3 352 >12400 >354 >35.6 >35.2 0.99 0.029 
2.1u Ph 2090 7180 >179 >35.8 3.43 11.6 <0.025 
2.1v OPh 381 7060 ND 26.6 18.5 ND ND 
2.1e OCH2Ph 11.6 1100 127 7.59 64.8 0.091 0.115 
2.1f O(CH2)2Ph 24.6 3050 6.97 2.20 124 3.53 0.002 
2.1g O(CH2)3Ph 14.4 3670 11.1 17.1 255 1.30 0.003 
α
Chloroquine (CQ), Atovaquone (ATO), and Dihydroartemisinin (DHA),  are internal controls for each in 
vitro assay. CQ (131 nM TM90-C2B and 162 nM W2) , ATO (0.53 nM W2 and >170 nM TM90-C2B) 
and DHA (1.8 nM W2 and ,0.9 nM). N.D.: not determined. 
β
 RI = TM90-C2B/W2; 
γ
 LBI = W2/Pb; 
δ
 LBI = TM90-C2B/Pb 
number of methylene units were added until the alkyl chain length reached four carbons and 
decreased as methylene units were added past four carbons In general, all compounds in this 
subseries were potent with most displaying subnanomolar EC50 values for W2, and with the 6-
butyl-substituted 4(1H)-quinolone being the most potent one. 
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Table 2.4: Optimal aliphatic chain length in 6-position
α 
 
Compound R
1 
EC50 
W2 
(nM) 
EC50 
TM90-C2B 
(nM) 
EC50 
Pb 
(nM) 
EC50 
J774 
(µM) 
RI
β
 
LBI
γ
 LBI
δ
 
2.1b H 2.80 73.6 0.286 29.5 26.3 9.79 0.004 
2.1ac CH3 2.01 499 152 28.3 1.52 0.66 1.00 
2.1w CH2CH3 0.461 65.3 0.737 27.2 142 1.60 0.011 
2.1x (CH2)2CH3 0.157 42.4 <0.060 >34.8 270 2.62 >0.001 
2.1a (CH2)3CH3 0.039 7.89 0.052 >46.0 202 0.75 0.007 
2.1y (CH2)4CH3 0.183 68.7 <0.56 >31.7 375 0.33 >0.008 
α
Chloroquine (CQ), Atovaquone (ATO), and Dihydroartemisinin (DHA), are internal controls for each in 
vitro assay. CQ (131 nM TM90-C2B and 162 nM W2), ATO (0.53 nM W2 and >170 nM TM90-C2B) 
and DHA (1.8 nM W2 and ,0.9 nM). N.D.: not determined. 
β
 RI = TM90-C2B/W2; 
γ
 LBI = W2/Pb; 
δ
 LBI = TM90-C2B/Pb 
 In the same vein, table 2.5 was made to probe the some steric and electronic effects of 
the 6-position. Six chloro and six bromo compounds 2.1ab and 2.1z possessed moderate activity 
with 2.1ab having an EC50 of 9.93 nM and 617 nM for W2 and TM90-C2B while 2.1z had EC50s 
4.47 and 847 nM for W2 and TM90-C2B. Both 2.1ab and 2.1z also possessed subnanomolar Pb 
EC50s of 0.063 nM and 0.336 nM respectively. Interestingly 2.1aa had an RI of 1.60 with good 
activities for both blood and liver stages. It was also observed by the direct comparison pairs 
between compounds 2.1aa and 2.1o, and between 2.1ab and 2.1r where the addition of the 7-(2-
phenoxyethoxy) group increases the activity for W2 by >60 fold and >130 for TM90-C2B.  
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Table 2.5: Structural activity relationship of 6-position using electron withdrawing and donating groups
α
 
 
Compound R
1 
EC50 
W2 
(nM) 
EC50 
TM90-
C2B 
(nM) 
EC50 
Pb 
(nM) 
EC50 
J774 
(µM) 
RI
β
 
LBI
γ
 LBI
δ
 
2.1ac CH3 2.01 499 152 >22.8 1.52 0.656 1.00 
2.1aa OCH3 6.93 11.1 17.5 >27.1 1.60 0.396 1.57 
2.1ab Cl 9.93 617 0.063 >26.7 62.1 158 0.0001 
2.1z Br 4.47 847 0.336 >24.0 189.5 13.3 0.0004 
α
Chloroquine (CQ), Atovaquone (ATO), and Dihydroartemisinin (DHA),  are internal controls for each in 
vitro assay. CQ (131 nM TM90-C2B and 162 nM W2) , ATO (0.53 nM W2 and >170 nM TM90-C2B) 
and DHA (1.8 nM W2 and ,0.9 nM). N.D.: not determined. 
β
 RI = TM90-C2B/W2; 
γ
 LBI = W2/Pb; 
δ
 LBI = TM90-C2B/Pb 
Following the six and seven position, the 3-position was probed. A natural metabolite of 
the ester 2.1a is the acid 2.7a. Therefore it was synthesized in order to see whether it could be the 
active form of the compound. With activities of 64.0 nM for W2, 1110 for TM90-C2B and 0.267 
nM for Pb, it was not as active as its parent; however, all activity was not lost. Esters 2.1af-ag, 
were potent showing slight loss in activity as the alkyl chain was extended from 0.143 nM W2 
EC50 for the ethyl ester (2.1af) to 0.592 nM W2 EC50 for the t-butyl ester 2.1ag. Furthermore, all 
were active against Pb with subnanomolar EC50s for all three esters. Changing the ester to an 
amide dropped activity slightly. Amide 2.13a was the most active at 13.3 nM for W2 and 3980 
nM for TM90-C2B. As the alkyl chain increased in size activity decreased with compound 2.13e, 
containing the t-butyl amide, being completely inactive having activities in the µM range. The 
exception was quinolone 2.13h, having activity of 266 nM for W2 and 2880 nM for TM90-C2B, 
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seeming to suggest that and the dual hydrogen bond donor is not needed. Also, when each amide 
is compared to its ester counterpart, the ester is in all cases much more active, indicating the 
hydrogen bond acceptor may be preferred over the donor. Interestingly, cyano compound 2.1ad 
had W2 activity in the high double digit nM range being about two times as active as its reduced 
form 2.1ae. When the ester was converted to a ketone (as in 2.13i), the activity dropped by 
almost 250 fold for W2 moving to 9.67 nM, the change for TM90-C2B was not as pronounced, 
however, with only a 48 fold difference. Lastly, complete removal of the ketone leaving just an 
alkyl chain (2.1ae) was potent having an EC50 of 0.440 nM for W2, 1.92 nM for TM90-C2B, and 
2.65 for Pb. With an RI of 4.36, it showed once again that removal of the ester left compounds 
with better RIs (Table 2.6).  
Table 2.6: Structural activity relationship of the 3 position using ester isosteres
α
. 
 
Compound R
1 
EC50 
W2 
(nM) 
EC50 
TM90-
C2B 
(nM) 
EC50 
Pb 
(nM) 
EC50 
J774 
(µM) 
RI
β
 
LBI
γ
 LBI
δ
 
2.8a H 328 430 5.82 >21.9 1.31 56.4 0.014 
2.7a CO2H 64.0 1110 0.267 >26.2 17.3 240 0.0002 
2.1a CO2CH3 0.039 7.89 0.052 >46.0 202 0.75 0.007 
2.1af CO2CH2CH3 0.143 100 0.007 >24.4 699 19.6 0.00007 
2.1ag CO2CH(CH3)2 0.154 93.8 0.677 >23.6 609 0.227 0.006 
2.1ah CO2C(CH3)3 0.592 105 0.554 5.62 177 1.07 0.005 
2.1ae CH2CH3 0.440 1.92 2.65 0.360 4.36 0.166 1.38 
2.1ad CN 97.2 3170 6.09 >27.6 32.6 15.7 0.002 
2.13a CONHCH3 13.3 3980 2.87 >24.5 299 4.63 0.0007 
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2.13b CON(CH3)2 56.7 >6120 122 15.3 >108 0.46 <0.020 
2.13c CONCH2CH3 206 >6120 ND >24.5 >29.7 ND ND 
2.13d CONHCH2CH2OH 253 5890 12.8 >23.6 23.3 0.05 0.002 
2.13e CONHCH(CH3)2 3330 5140 ND >23.7 1.54 ND ND 
2.13f CONHC(CH3)3 328 719 ND 22.9 2.19 ND ND 
2.13h CONH2 266 2880 ND 16.5 10.8 ND ND 
2.13i COCH3 9.67 378 ND ND 39.1 ND ND 
α
Chloroquine (CQ), Atovaquone (ATO), and Dihydroartemisinin (DHA), are internal controls for each in 
vitro assay. CQ (131 nM TM90-C2B and 162 nM W2), ATO (0.53 nM W2 and >170 nM TM90-C2B) 
and DHA (1.8 nM W2 and, 0.9 nM). N.D.: not determined. 
β
 RI = TM90-C2B/W2; 
γ
 LBI = W2/Pb; 
δ
 LBI = TM90-C2B/Pb 
2.18e was synthesized as an intermediate for a separate purpose however its testing gave 
an active compound having EC50s of 0.867 nM for W2 and 5.87 for TM90-C2B. With an RI of 
6.77, other 3-halo analogues were made, with and without a 2-methyl group. 3-chloro analogues 
2.18a, and 2.18b had RIs of 11.7 and 9.79 respectively. 2.18a’s EC50s of 15.2 nM for W2 and 
178 nM for TM90-C2B and 2.18b’s EC50 of 6.92 nM for W2 and 67.7 nM for TM90-C2B 
showed that the 2-methyl was about two times more active than the 2-hydrogen analogue. The 3-
bromo mirrors 2.18c and 2.18d showed W2 activities of 4.64 nM and 2.60 nM respectively and 
TM90-C2B activities of 48.7 nM and 12.2 nM respectively. With RIs of 10.5 and 4.69 it 
followed the trend seen with the chlorinated versions 2.18a and 2.18b. 2.18g and 2.18e followed 
the trend of the previous four PEQs; the 2-methyl substituted analogues were about 2 times more 
active than the 2-hydrogen analogues and with RIs of 4.91 for 18g and 6.77 nM for 18e these 
compounds all six 3-halo substituted PEQs consistently had the best RI values of the entire 
series. It was also observed that removal of just the 6-butyl group in 2.18f destroys all W2 and 
TM90-C2B activity with uM activities for both. Although, 2.18f was completely inactive it was  
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Table 2.7: Structural activity relationships of various 4(1H)-quinolones
α
. 
Compound Structure 
EC50 
W2 
(nM) 
EC50 
TM90-C2B 
(nM) 
EC50 
Pb 
(nM) 
EC50 
J774 
(µM) 
RI
β
 LBI
γ
 LBI
δ
 
2.19 
 
2700 >6080 152 6.08 >2.25 17.8 <0.025 
2.20 
 
0.802 105 0.546 4.07 131 1.47 0.005 
2.21 
 
0.459 64.7 <0.049 21.3 141 0.107 <0.0008 
2.22 
 
5990 12200 ND >50.0 2.04 ND ND 
2.23  >7350 >7350 ND >29.4 >1.00 ND ND 
α
Chloroquine (CQ), Atovaquone (ATO), and Dihydroartemisinin (DHA),  are internal controls for each in vitro assay. CQ (131 nM TM90-C2B 
and 162 nM W2) , ATO (0.53 nM W2 and >170 nM TM90-C2B) and DHA (1.8 nM W2 and ,0.9 nM). N.D.: not determined. 
β
 RI = TM90-C2B/W2; 
γ
 LBI = W2/Pb; 
δ
 LBI = TM90-C2B/Pb 
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Table 2.8: 3-halo substituted 4(1H)-quinolones with and without 2 methyl groups
α
. 
 
Compound R
1 
R
2
 
EC50 
W2 
(nM) 
EC50 
TM90-C2B 
(nM) 
EC50 
Pb 
(nM) 
EC50 
J774 
(µM) 
RI
β
 
LBI
γ
 LBI
δ
 
2.18a Cl H 15.2 178 ND ND 11.7 ND ND 
2.18b Cl Me 6.92 67.7 ND ND 9.79 ND ND 
2.18c Br H 4.64 48.7 ND ND 10.5 ND ND 
2.18d Br Me 2.60 12.2 ND ND 4.69 ND ND 
2.18g I H 1.23 6.04 ND ND 4.91 ND ND 
2.18e I Me 0.867 5.87 ND ND 6.77 ND ND 
2.18f I O(CH2)2OPh 1400 4300 ND ND 3.07 ND ND 
α
Chloroquine (CQ), Atovaquone (ATO), and Dihydroartemisinin (DHA),  are internal controls for each in 
vitro assay. CQ (131 nM TM90-C2B and 162 nM W2) , ATO (0.53 nM W2 and >170 nM TM90-C2B) 
and DHA (1.8 nM W2 and ,0.9 nM). N.D.: not determined. 
β
 RI = TM90-C2B/W2; 
γ
 LBI = W2/Pb; 
δ
 LBI = TM90-C2B/Pb 
interesting that the RI value of 3.07 followed the trend of the other 3-halo substituted 
analogues and displayed that some amount of synergy could be in effect. 
2.5 Structure Property Relationship  
All quinolones were tested for solubility and Log d in parallel to activity. The original ICI 
compound possessed inferior solubility, not even being able to be detected at the experimental 
conditions. Removal of the ester raised the solubility at lower pH to a respectable 26.5 µM, 
however it quickly fell off to 1.1 µM at pH 6.5.  In general compounds with a 7-(2-
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phenoxyethoxy) group were more soluble, presumably due to a combination of increased 
polarity and bulkiness of the group. This could also be explained, however, by the group’s ability 
to hinder π-π stacking in solution. Compounds where the oxygen was removed from that group 
had slightly lower solubility numbers overall. Insertion of the amide moieties did not have the 
influence on solubility that was expected; however the bulkier amides 2.13b and 2.13f along 
with the polar 2.13d were some of the more soluble entries of the group. Although better than the 
original compound, halides 2.18a-e and 2.18g did not possess elevated solubility levels. 
Intriguingly, the methyl group in the two position lowered solubility compared to compounds 
without. Compounds 2.20 and 2.19 were both much more soluble compared to 2.1a showing that 
blocking N to O hydrogen bonding can help quinolone scaffolds. Analogue 2.22 was an extreme 
case where both N to O hydrogen bonding and π – π stacking were interrupted leading to the 
very soluble analogue. Strikingly, there was no observable correlation between log d and 
solubility (Graph 2.1). 
Graph 2.1: No correlation between Sol and log d 
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Table 2.9: Solubility and log D for all 4(1H)-quinolones
α
 
 
Compound R
1
 R
2
 R
3
 
Solubility
α
 
pH 2.0 
µM 
Solubility 
pH 6.5 
µM 
Log D 
pH 3.0 
 
Log D 
pH 7.4 
 
2.1a (CH2)3CH3 O(CH2)2OPh CO2CH3 * * 3.43 3.68 
2.8a (CH2)3CH3 O(CH2)2OPh H ****** ** 3.28 3.66 
2.8c (CH2)3CH3 H H * * 2.01 2.34 
2.1c (CH2)3CH3 H CO2CH3 ****** **** 2.04 2.41 
2.8b H O(CH2)2OPh H **** **** 2.13 2.46 
2.1b H O(CH2)2OPh CO2CH3 **** **** 2.14 2.53 
2.1d H H CO2CH3 ***** **** 0.33 0.76 
2.1k H OPh CO2CH3 *** *** 2.04 2.36 
2.1h H OCH2Ph CO2CH3 * * 2.07 2.38 
2.1i H O(CH2)2Ph CO2CH3 **** ***** 2.33 2.65 
2.1j H O(CH2)3Ph CO2CH3 *** *** 2.69 2.99 
2.1l H Cl CO2CH3 ****** **** 1.07 1.47 
2.1m H Ph CO2CH3 **** * 1.94 2.31 
2.1n H F CO2CH3 **** *** 0.620 1.03 
2.1o OCH3 H CO2CH3 ***** ***** 0.720 1.09 
2.1p OCH2CH3 H CO2CH3 ** ** 1.09 1.46 
2.1q CH(CH3)2 H CO2CH3 * * 1.55 1.90 
2.1r Cl H CO2CH3 *** **** 1.06 1.46 
2.1s O(pFl)Ph H CO2CH3 ** *** 2.07 2.39 
2.1t CH2CH3 H CO2CH3 **** * 1.20 1.58 
2.1u Ph H CO2CH3 ***** *** 1.93 2.24 
2.1v OPh H CO2CH3 *** **** 1.99 2.30 
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2.1e OCH2Ph H CO2CH3 *** ** 2.10 2.42 
2.1f O(CH2)2Ph H CO2CH3 *** ** 2.36 2.69 
2.1g O(CH2)3Ph H CO2CH3 * * 2.66 2.98 
2.1ac CH3 O(CH2)3Ph CO2CH3 ** * 2.75 3.08 
2.1w CH2CH3 O(CH2)3Ph CO2CH3 * * 2.78 3.04 
2.1x (CH2)2CH3 O(CH2)3Ph CO2CH3 ** * 3.03 3.32 
2.1a (CH2)4CH3 O(CH2)3Ph CO2CH3 * * 3.70 3.97 
2.1y (CH2)5CH3 O(CH2)3Ph CO2CH3 * * 4.31 4.60 
2.1ac OCH3 O(CH2)3Ph CO2CH3 *** * 2.08 2.40 
2.1aa Cl O(CH2)3Ph CO2CH3 * * 2.70 2.97 
2.1ab Br O(CH2)3Ph CO2CH3 * * 2.64 3.05 
2.1z (CH2)3CH3 O(CH2)3Ph CO2H * ** 4.04 4.28 
2.1af (CH2)3CH3 O(CH2)3Ph CO2CH2CH3 * * 3.65 3.89 
2.1ag (CH2)3CH3 O(CH2)3Ph CO2CH(CH3)2 * * 2.66 3.00 
2.1ah (CH2)3CH3 O(CH2)3Ph CO2C(CH3)3 **** ** 3.24 3.65 
2.1ae (CH2)3CH3 O(CH2)3Ph CH2CH3 ** * 3.75 4.07 
2.1ad (CH2)3CH3 O(CH2)3Ph CN * * 3.54 3.85 
2.13a (CH2)3CH3 O(CH2)3Ph CONHCH3 * * 3.76 4.05 
2.13b (CH2)3CH3 O(CH2)3Ph CON(CH3)2 ***** ***** 2.90 3.21 
2.13c (CH2)3CH3 O(CH2)3Ph CONCH2CH3 * * 4.05 4.35 
2.13d (CH2)3CH3 O(CH2)3Ph 
CONHCH2CH2O
H 
****** **** 3.04 3.48 
2.13e (CH2)3CH3 O(CH2)3Ph CONHCH(CH3)2 *** *** ND ND 
2.13f (CH2)3CH3 O(CH2)3Ph CONHC(CH3)3 **** * 4.01 4.30 
2.13h (CH2)3CH3 O(CH2)3Ph CONH2 *** * 4.03 4.30 
2.18g (CH2)3CH3 O(CH2)3Ph COCH3 **** **** 3.05 3.89 
2.18a (CH2)3CH3 O(CH2)3Ph Cl *** **** 3.53 4.31 
2.18c (CH2)3CH3 O(CH2)3Ph Br **** *** 3.68 4.04 
2.18h (CH2)3CH3 O(CH2)3Ph I ** * 3.91 4.23 
α
 (*) Solubility < 1 μM. (**) 1 < solubility < 1.9 μM. (***) 2 μM < solubility < 3.9 μM. (****) 4 μM < solubility < 
9.9 μM. (*****) 10 μM < solubility < 20 μM.(******) Solubility >20 μM. ND: not determined. 
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Table 2.10: Solubility and Log d of Various 4(1H)-quinolones
α
 
Compound Structure 
Solubility 
pH 2.0 
µM 
Solubility 
pH 6.5 
µM 
Log D 
pH 3.0 
 
Log D 
pH 7.4 
 
2.18e 
 
***** ***** 3.34 3.84 
2.18d 
 
* ** 3.84 4.20 
2.18b 
 
*** ** 3.70 4.01 
2.18f 
 
* * 2.69 3.05 
2.19 
 
**** **** 5.08 3.66 
2.20 
 
**** **** 3.57 3.90 
2.21 
 
*** *** 3.28 3.65 
2.22 
 
****** ****** 0.730 1.17 
2.23  ***** *** 2.36 2.73 
α
 (*) Solubility < 1 μM. (**) 1 < solubility < 1.9 μM. (***) 2 μM < solubility < 3.9 μM. (****) 4 μM < solubility < 
9.9 μM. (*****) 10 μM < solubility < 20 μM.(******) Solubility >20 μM. ND: not determined. 
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2.6 In vivo Efficacy Evaluation of Selected Compounds in an Efficacy Scouting Assay.  
Sixteen 4(1H)-quinolones with potent in vitro activity against blood stages of P. 
falciparum were chosen to be screened for in vivo efficacy scouting assay in a previously 
reported P. berghei infected mouse model (Table 2.11).
6
 Criteria such as in vitro liver stage 
activity, RI and LBI indices, as well as key physicochemical properties were also considered for 
the selection of the screening candidates. The screening was performed by treating two infected 
mice with a single, 50 mg/kg oral dose of test compound suspended PEG400 on day 1 post-
exposure (PE) followed by assessing parasitemia on days 3 and 6 PE. Compounds with a 
parasitemia reduction of greater than 50% on days 3 and 6 PE were considered to be active. The 
original compound 2.1a was one of the most active candidates in the group with 76.9% 
inhibition on day 3 PE and 49% inhibition on day 6 PE (Table 2.11). Quinolone ester 2.6j and 3-
bromo-4(1H)-quinolone 2.18d were the only other two compounds that displayed a parasitemia 
reduction similar to the original compound 2.1a with 47.1% and 49.5% inhibition on day 6 PE. 
Analogues 2.6g, 2.20, 2.6ae, and 2.21 with >65% inhibition on day 3 PE were considered 
promising, nevertheless the lack of significant parasitemia reduction on day 6 PE suggested that 
these compounds may not be metabolically stable enough. A similar outcome was observed for 
the 3-aryl-substituted 6-chloro-7-methoxy-4(1H)-quinolones compound series, for which 
metabolic stability has been detrimental for the development of curative antimalarials.
6
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Table 2.11: Results of the In Vivo Efficacy Scout Screening
α
. 
 
Compound 
% Inhibition 
Day 3 PE 
% Inhibition 
Day 6 PE 
  Compound 
% Inhibition 
Day 3 PE 
% Inhibition 
Day 6 PE 
2.1e 46.2 0.0   2.18d 100 49.5 
2.1f 7.69 0.0   2.19 40.0 0.0 
2.1g 76.9 0.0   2.20 76.9 13.7 
2.1k 40.0 29.8   2.13d 40.0 0.0 
2.1i 60.0 0.0   2.18g 20.0 10.5 
2.1j 69.2 47.1   2.1ae 69.2 17.7 
2.1ab 0.00 0.0   2.21 80.0 0.00 
2.1a 76.9 49.0   2.18e 53.9 19.6 
Amodiquine 95.5 99.9   Atovaquone 96.3 99.8 
α
 percent inhibition compared to untreated animals 
2.7  In Vivo Efficacy Evaluation of Frontrunner Compounds.  
For the evaluation of frontrunner compounds in vivo, a modified Thompson test model 
was used. Using mice infected with 1 x 10
6
 Plasmodium berghei-GFP parasites, compounds 
were dosed orally on days 3, 4, and 5 at a 10mg/kg concentration of compound suspended or 
dissolved in HEC/Tween. On days 3, 6, 9, 13, 21, and 30 PE, parasitemia was monitored by flow 
cytometry. Compounds were evaluated by the reduction of parasitemia on day 6 PE and the 
survival up to day 30 PE. Compounds with parasitemia levels less than 1% on day 30 PE were 
considered cures and animals with greater and 40% parasitemia levels were euthanized. Two 
PEQs were chosen for this detailed Thompson experiment. Compound 6b showed no inhibition 
on day 6 and mice were euthanized on day 13, the same day as the controls. This negative result 
is most likely due to the poor solubility and poor metabolic stability of the 6b. The second 
compound tested, 18d, showed 61% inhibition on day 6. However, parasitemia rapidly 
rebounded for in the mice dosed with this compound and the mice had to be euthanized by day 
13. This could likely due to the lack of metabolic stability of this compound as well as rapid 
clearance or rapid mode of action. 
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Table 2.12: Results of Thompson Test. 
Compound 
Dose 
(mg/kg) 
% 
Inhibition 
Day 6 
Avg. 
Day of Death 
2.1a 10 0 13 
2.18d 10 61 13 
α 
percent inhibition as compared to untreated control animals 
 
2.8 Conclusion. 
Due to the promising results of past recycling of old antimalarials and the promise of 
4(1H)-quinolone esters, we synthesized a library of 68 quinolones with a variety of substituents, 
focusing on the -3, -6, and -7 positions. The library was tested in vitro against W2 and TM90-
C2B, two clinically relevant P. falciparum strains. Furthermore compounds with promising W2 
and TM90-C2B activities were tested for in vitro liver stage activity. All compounds were also 
tested in solubility and log D assays in parallel, as an attempt to predict in vivo efficacy. 
 Overall, these quinolones possess very good activities in vitro activities with many 
compound possessing low nanomolar activities for W2. They also were not toxic in J774 
cytotoxicity assays. However, most compounds possessed poor solubility values and due to their 
poor half-live times, their activity was not translated well to in vivo tests. 
There was however, invaluable data gained from the analogues synthesized as it was 
shown that 3- ester group seems to be very important to addressing the RI values as 3-halide 
compounds had excellent RI values. We also learned that the 7- position was most important for 
blood stage activities however, there could be some synergy between the six and seven positions 
due to the combination of the six and seven substituted compounds being much more active than 
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the six or seven substituted compounds were separately. Compound 6d and 18d were both tested 
in vivo using a modified Thompson test. There was a marked increase in the parasite inhibition 
for compound 18d over 6b on day 6 showing the improvement over the original compound. 
Although, it showed less blood and liver activity than the predecessor 6b the in vivo activity on 
day 6 showed its superiority overall. The blood and liver stage activities of these quinolone esters 
along with the discovery of the 3-halo-4(1H)-quinolones lead us to believe that there is still 
much potential in this scaffold and further optimization of solubility and stability could lead to 
cures for this scaffold. 
2.8  Experimental Section 
2.8.1 General Information 
All reagents and solvents were obtained from Aldrich Chemical Co. and used without 
further purification. NMR spectra were recorded at ambient temperature on a 400 MHz or 500 
MHz Varian NMR spectrometer in the solvent indicated. All 
1
H NMR experiments are reported 
in δ units, parts per million (ppm) downfield of TMS, and were measured relative to the signals 
of chloroform (7.26 ppm) and dimethylsulfoxide (39.5 ppm) with 
1
H decoupled observation. 
Data for 
1H NMR are reported as follows: chemicals shift (δ ppm), multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, p = pentet, sext = sextet, sept = septet, oct = octet, m = multiplet), 
integration and coupling constant (Hz) whereas 
13
C NMR analyses were reported in terms of 
chemical shift. NMR data was analyzed by using MestReNova Software version 6.0.2-5475. The 
purity of the final compounds was determined to be ≥95% by high-performance liquid 
chromatography (HPLC) using an Agilent 1100 LC/MSD-VL with electrospray ionization. Low-
resolution mass spectra were performed on an Agilent 1100 LC/MSD-VL with electrospray 
ionization. High-resolution mass spectra (HRMS) were performed on an Agilent LC/MSD TOF 
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system G3250AA. Analytical thin layer chromatography (TLC) was performed on silica gel 60 
F254 precoated plates (0.25 mm) from EMD Chemical Inc., and components were visualized by 
ultraviolet light (254 nm). EMD silica gel 230-400 (particle size 40-63 µm) mesh was used for 
all flash column chromatography. Microwave heating was performed in a single-mode Anton 
Paar Monowave 300 and all microwave-irradiated reactions were conducted in heavy-walled 
glass vials sealed with Teflon septa. 
2.8.2 General Procedure A for the synthesis of enamine intermediates from 
anilines 
Aniline (5 mmol) and dimethyl methoxy methylene malonate (7.6 mmol) were added to a 
flask and heated to 110 
o
C for 30 minutes (monitored by TLC). After cooling, diethyl ether was 
added at which point precipitation occurred. This solid was collected by filtration and used in the 
next step without further purification. 
2.8.3 General Procedure B for the synthesis of quinolone esters from enamine 
intermediates. 
Enamine intermediate (5.8 mmol) was added to toluene (11.6 mL) and heated in a 
microwave reactor for 150 seconds at 280 
o
C. The precipitated product was filtered and washed 
with cold methanol. The solid residue was in most cases recrystallized in 4:1 MeOH:DMF to 
afford the final product. 
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2.8.4 General Procedure C for the synthesis of quinolone acids from quinolone 
esters 
An ester (4 mmol) was refluxed for 2 hours in 10% NaOH (10 mL) solution. It was then 
cooled and acidified to pH 5 where the precipitate was filtered and washed with water. It was 
dried and used in the next step without further purification. 
2.8.5 General Procedure D for the synthesis of quinolones from quinolone acids 
A carboxylic acid (5 mmol) and toluene (10 mL) were refluxed in a microwave for 5 
minutes at 280 
o
C. Diethyl ether was added to the reaction and the resulting precipitate was 
collected and washed with cold methanol. 
2.8.6 General Procedure E for the alkylation of phenols 
To N-(3-hydroxyphenyl)acetamide (15 mmol) was added (2-bromoethoxy)benzene (19.5 
mmol) along with Cs2CO3 (45 mmol) and DMF (30 mL). The reaction was heated at 40 
o
C 
overnight. The reaction was extracted with DCM, dried over Na2SO4, filtered, and concentrated 
under reduced pressure. The crude product was recrystallized in hexanes/ethyl acetate. 
2.8.7 General Procedure F for the removal of acetamide protecting groups 
An acetamide (4 mmol) along with KOH (40 mmol) and 9:1 DI water:ethanol (50 mL) 
was refluxed overnight. After the reaction was complete, the ethanol was removed under reduced 
pressure. The residue was then dissolved in DCM washed with DI water, dried over Na2SO4, 
filtered and concentrated under reduced pressure. The resulting oil could then be used without 
further purification in most cases. If not, aqueous HCl was added and the solution was washed 
with EA. The aqueous layer was basified then washed with EA and the organic layer was dried 
over Na2SO4, filtered and concentrated under reduced pressure. 
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2.8.8 General Procedure G for the synthesis of quinolone amides from quinolone 
esters 
An amine or amine hydrochloride (2 mmol) and trimethyl aluminum were added 
dropwise at 0 
o
C. The reaction was then stirred at room temperature for 30 minutes. At that time, 
methyl 6-butyl-4-oxo-7-(2-phenoxyethoxy)-1,4-dihydroquinoline-3-carboxylate was added as a 
solid and the reaction was allowed to reflux overnight. The reaction was purified using 
preparative HPLC to yield the title compound. 
2.8.9 General Procedure H for the synthesis of 3-halo substituted quinolones 
Quinolone (1 mmol) and N-halo succinimide (2.2 mmol) were refluxed in DMF (5 mL) 
for two hours. The reaction was concentrated and water was added. The resulting precipitate was 
filtered and recrystallized in acetone. 
2.8.10 General Procedure I for the synthesis of quinolones from anilines using 
Conrad-Limpach conditions 
 An aniline (5 mmol) along with acetoacetate (10 mmol), benzene (20 mL) and a few 
drops of AcOH were refluxed overnight using Dean-Stark conditions. After all the water was 
removed, the reaction was concentrated, making sure to remove all acetic acid. To the resulting 
oil was added 4 mL of toluene and the reaction was heated in a microwave at 275 
o
C for 5 
minutes. After cooling, the reaction was dropped into cold ether and scratched to accelerate 
precipitation. The solid was filtered and washed with methanol.  
2.8.11  Compound Characterization 
 
47 
 
N-(3-(2-phenoxyethoxy)phenyl)acetamide 2.2b: was synthesized following general procedure 
E in 91% yield. 
1H NMR (400 MHz, DMSO) δ 9.94 (s, 1H), 7.37 (s, 1H), 7.35 – 7.26 (m, 2H), 
7.26 – 7.10 (m, 2H), 7.02 – 6.91 (m, 3H), 6.66 (dd, J = 8.1, 1.5 Hz, 1H), 4.27 (td, J = 5.2, 3.5 Hz, 
4H), 2.05 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 168.44, 158.60, 158.33, 140.56, 129.56, 
120.78, 114.50, 111.63, 108.85, 105.61, 66.27, 66.17, 24.11. HRMS (ESI-TOF) m/z: [M + H]
+
 
calcd for C16H17NO3  272.1281; found 272.1284. 
 
Dimethyl 2-(((3-(2-phenoxyethoxy)phenyl)amino)methylene)malonate 2.6a: was synthesized 
following general procedure A in 86% yield. 
1H NMR (400 MHz, DMSO) δ 10.69 (d, J = 13.9 
Hz, 1H), 8.44 (d, J = 13.9 Hz, 1H), 7.30 (tt, J = 8.1, 2.5 Hz, 3H), 7.06 (t, J = 2.2 Hz, 1H), 7.02 – 
6.91 (m, 4H), 6.78 (dd, J = 8.2, 2.2 Hz, 1H), 4.37 – 4.33 (m, 2H), 4.32 – 4.28 (m, 2H), 3.73 (s, 
3H), 3.66 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 167.57, 165.25, 159.40, 158.26, 151.40, 
140.63, 130.57, 129.52, 120.74, 114.45, 111.07, 109.85, 104.15, 92.72, 66.53, 66.08, 51.12, 
51.09. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C20H21NO6 372.1442; found 372.1429. 
 
4-oxo-7-(2-phenoxyethoxy)-1,4-dihydroquinoline-3-carboxylic acid 2.7b: was synthesized 
following general procedure C in 77% yield. 
1H NMR (400 MHz, DMSO) δ 13.29 (s, 1H), 8.82 
(s, 1H), 8.20 (d, J = 8.9 Hz, 1H), 7.29 (ddd, J = 8.2, 7.3, 4.9 Hz, 4H), 6.98 (dd, J = 13.1, 7.6 Hz, 
3H), 4.48 (dd, J = 5.5, 2.8 Hz, 2H), 4.39 (dd, J = 5.3, 2.9 Hz, 2H).
 13
C NMR (101 MHz, DMSO) 
δ 177.62, 166.46, 162.41, 158.17, 144.98, 141.47, 129.55, 126.99, 120.86, 118.53, 116.40, 
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114.49, 107.29, 101.33, 67.16, 65.88. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C18H15NO5 
326.1023; found 326.1010. 
 
N-(4-(benzyloxy)phenyl)acetamide 2.3c: was synthesized following general procedure E in 
98% yield. 
1
H NMR (400 MHz, DMSO-d6) δ 9.80 (s, 1H), 7.53 – 7.47 (m, 2H), 7.45 – 7.41 (m, 
2H), 7.41 – 7.35 (m, 2H), 7.34 – 7.29 (m, 1H), 6.97 – 6.92 (m, 2H), 5.05 (s, 2H), 2.02 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 167.73, 154.07, 137.19, 132.76, 128.36, 127.73, 127.63, 120.50, 
114.76, 69.35, 23.80. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C15H15NO2 242.1176; found 
242.1200. 
 
N-(4-(3-phenylpropoxy)phenyl)acetamide 2.3e: was synthesized following general procedure 
E in 94% yield. 
1H NMR (400 MHz, DMSO) δ 9.79 (s, 1H), 7.51 – 7.45 (m, 2H), 7.31 – 7.14 (m, 
5H), 6.88 – 6.82 (m, 2H), 3.90 (t, J = 6.4 Hz, 2H), 2.78 – 2.68 (m, 2H), 2.05 – 1.94 (m, 5H).13C 
NMR (101 MHz, DMSO) δ 167.62, 154.33, 141.39, 132.50, 128.31, 128.30, 125.79, 120.44, 
114.39, 66.75, 31.48, 30.44, 23.76. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C17H19NO2 
270.1489; found 270.1471. 
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N-(3-(benzyloxy)phenyl)acetamide 2.3f: was synthesized following general procedure E in 
98% yield. 
1
H NMR (400 MHz, DMSO-d6) δ 9.91 (s, 1H), 7.46 – 7.42 (m, 2H), 7.42 – 7.36 (m, 
3H), 7.35 – 7.29 (m, 1H), 7.18 (t, J = 8.1 Hz, 1H), 7.11 (dt, J = 8.1, 1.3 Hz, 1H), 6.71 – 6.66 (m, 
1H), 5.06 (s, 2H), 2.03 (s, 3H).
 13C NMR (101 MHz, DMSO) δ 168.76, 159.00, 140.95, 137.50, 
129.88, 128.85, 128.22, 128.07, 111.97, 109.55, 106.23, 69.53, 24.52. HRMS (ESI-TOF) m/z: 
[M + H]
+
 calcd for C15H15NO2 242.1176; found 242.1162. 
 
N-(3-(3-phenylpropoxy)phenyl)acetamide 2.3h: was synthesized following general procedure 
E in 99% yield. 
1
H NMR (400 MHz, CDCl3) δ 9.24 (s, 2H), 7.37 (d, J = 1.9 Hz, 2H), 7.26 – 7.21 
(m, 4H), 7.16 – 7.11 (m, 9H), 6.59 (dt, J = 7.4, 2.1 Hz, 2H), 3.86 (t, J = 6.3 Hz, 4H), 2.76 – 2.68 
(m, 4H), 2.12 (s, 6H), 2.00 (tt, J = 12.9, 6.3 Hz, 4H). 
13
C NMR (101 MHz, CDCl3) δ 169.18, 
162.35, 159.14, 141.22, 139.59, 129.15, 128.17, 128.08, 125.58, 111.96, 109.85, 106.19, 66.54, 
36.15, 31.79, 30.52, 24.01. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C17H19NO2 270.1489; 
found 270.1464. 
 
4-(benzyloxy)aniline 2.4e: was synthesized following general procedure F in 93% yield. 
 
1
H NMR (400 MHz, CDCl3) δ 7.46 – 7.36 (m, 4H), 7.35 – 7.30 (m, 1H), 6.86 – 6.81 (m, 2H), 
6.67 – 6.62 (m, 2H), 5.00 (s, 2H), 3.31 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 152.04, 140.31, 
137.58, 128.57, 127.86, 127.57, 116.46, 116.14, 70.85. 
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4-(3-phenylpropoxy)aniline 2.4g: was synthesized following general procedure F in 98% yield. 
1H NMR (400 MHz, CDCl3): δ 7.29 –7.16 (m, 5H,), 6.75 –6.60 (m, 4H), 3.88 (t, J = 6.4 Hz 2H), 
3.40 (s, 2H), 2.79 (t, J = 7.4 Hz 2H), 2.06 (dt, J = 7.4/6.4 Hz 2H). 13C NMR (100 MHz, CDCl3): 
δ 152.2, 141.6, 139.9, 128.5, 128.3, 125.8, 116.4, 115.7, 67.6, 32.1, 30.9. HRMS (ESI-TOF) m/z: 
[M + H]
+
 calcd for C15H17NO Calcd.: 227.1310; Found 227.1310 (MS). 
 
2-bromo-5-nitrophenol 2.10b: To a charged round bottom flask, backfilled with argon, was 
added 1-bromo-2-methoxy-4-nitrobenzene (10 g, 43.098 mmol) followed by boron tribromide 
solution (1.0 M in DCM, 107.5 mL) at 0 
o
C. The reaction mixture was stirred for 24 hours at 
room temperature before quenching with DI water. The organic layer was washed with DI water, 
dried over Na2SO4, filtered and concentrated under reduced pressure. It was used in the next step 
without further purification. (9.2 g, 99% yield) 
1H NMR (400 MHz, CDCl3) δ 7.84 (s, 1H), 7.79-
7.59 (m, 2H), 5.92 (br s, 
1
H). 
13
C NMR (101 MHz, CDCl3) δ 152.97, 148.49, 132.62, 117.44, 
116.43, 111.20. 
 
1-bromo-4-nitro-2-(2-phenoxyethoxy)benzene 2.11b: To a solution of 2-bromo-5-nitrophenol 
(9g, 0.04128 mol) in anhydrous DMF (90 mL) at room temperature was added sodium hydride 
(1.82 g, 0.0454 mol). After stirring the resulting solution for 10 minutes, (2-
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bromoethoxy)benzene (9.96g, 0.04954 mol) was added slowly. The reaction was then stirred for 
24 hours then quenched with water and diluted with DCM (150 mL). The organic layer was 
dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified 
by recrystallization from ethyl acetate to afford the title compound (6.95 g, 50% yield).
1
H NMR 
(400 MHz, CDCl3) δ 7.86 (d, J = 2.3 Hz, 1H), 7.77 – 7.66 (m, 2H), 7.33-7.26 (m, 2H), 7.00-6.93 
(m, 3H), 4.49 (dd, J = 5.6, 3.5 Hz, 2H), 4.41 (dd, J = 6.0, 3.5 Hz, 2H). 
13
C NMR (101 MHz, 
CDCl3) δ 158.37, 133.68, 129.55, 121.38, 120.28, 116.91, 114.73, 108.08, 68.58, 66.18. HRMS 
(ESI) calcd for C14H12BrNO4 [M+Na]+ : 359.9842, Found: 359.9855 
 
4-bromo-3-(2-phenoxyethoxy)aniline 2.4z: To a solution of 1-bromo-4-nitro-2-(2-
phenoxyethoxy)benzene (572 mg, 1.6916 mmol) in ethanol (5 mL) was added zinc powder (1.1 
g, 16.916 mmol) and acetic acid (0.97 mL, 16.916 mmol) at 0 
o
C. The solution was allowed to 
warm to room temperature and stirred until the disappearance of the starting material was 
observed as indicated by TLC (4 hours). The reaction solution was filtered through celite then 
concentrated under reduced pressure. The residue was dissolved in DCM (10 mL), washed with 
sodium bicarbonate, DI water and brine, dried over Na2SO4, filtered and concentrated under 
reduced pressure. The  crude product was purified by flash chromatography to give the title 
compound (486 mg, 93% yield).
1H NMR (400 MHz, DMSO) δ 7.33 – 7.26 (m, 2H), 7.11 (d, J = 
8.5 Hz, 1H), 7.02 – 6.98 (m, 2H), 6.97 - 6.92 (m, 1H), 6.37 (d, J = 2.4 Hz, 1H), 6.13(dd, J = 8.5, 
2.4 Hz, 1H), 5.28 (s, 2H), 4.31 (dd, J = 5.3, 3.0 Hz, 2H), 4.24 (dd, J = 5.8, 2.8 Hz, 2H). 
13
C NMR 
(101 MHz, DMSO) δ 158.77, 155.38, 150.21, 133.10, 129.94, 121.20, 115.06, 108.45, 100.28, 
67.56, 66.64. HRMS (ESI) calcd for C14H14BrNO2 [M+H]+ : 308.0281, Found: 308.0268. 
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4-methoxy-3-(2-phenoxyethoxy)aniline 2.4aa: To a solution of 1-methoxy-4-nitro-2-(2-
phenoxyethoxy)benzene (3.2 mmol) in ethanol (10 mL) was added zinc powder (32 mmol) and 
acetic acid (32 mmol) at 0 
o
C. The solution was allowed to warm to room temperature and stirred 
until the disappearance of the starting material was observed as indicated by TLC (4 hours). The 
reaction solution was filtered through celite then concentrated under reduced pressure. The 
resulting residue was dissolved in DCM, washed with sodium bicarbonate, DI water and brine, 
dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified 
by flash chromatography to give the title compound in 75% yield. 
1
H NMR (400 MHz, DMSO) 
δ 9.80 (s, 1H), 7.35 (d, J = 2.2 Hz, 1H), 7.30 (t, J = 7.9 Hz, 2H), 7.10 (dd, J = 8.7, 2.2 Hz, 1H), 
6.99 (d, J = 9.08 Hz, 1H), 6.95 (t, J = 7.47 Hz, 2H), 6.89 (d, J = 8.7 Hz, 1H), 4.30 (dd, J = 5.5, 
2.9 Hz, 2H), 4.23 (dd, J = 5.5, 2.9 Hz, 2H), 3.71 (s, 3H), 2.01 (s, 3H). 
13
C NMR (101 MHz, 
DMSO) δ 167.75, 158.26, 147.46, 144.88, 132.95, 129.49, 120.69, 114.47, 112.44, 111.57, 
105.89, 67.11, 66.14, 55.72, 23.87. HRMS (ESI) calcd for C17H19NO4 [M+H]+ : 302.1387, 
Found: 302.1377. 
 
3-(benzyloxy)aniline 2.4e: was synthesized following general procedure E in 91% yield.  
 
1
H NMR (500 MHz, CDCl3) δ 7.47 (d, J = 7.1 Hz, 2H), 7.45 – 7.39 (m, 2H), 7.36 (dd, J = 8.3, 
6.1 Hz, 1H), 7.10 (t, J = 8.0 Hz, 1H), 6.48 – 6.42 (m, 1H), 6.38 – 6.31 (m, 2H), 5.05 (s, 2H), 3.67 
(s, 2H). 
13
C NMR (126 MHz, CDCl3) δ 160.05, 147.89, 137.29, 130.19, 128.61, 127.93, 127.52, 
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108.24, 104.88, 102.05, 69.86. HRMS (ESI) calcd for C13H13NO [M+H]+ : 200.1070, 
Found:200.1091. 
 
3-(3-phenylpropoxy)aniline 2.4j: was synthesized following general procedure E in 89% yield. 
1
H NMR (500 MHz, CDCl3) δ 7.30 (t, J = 7.5 Hz, 2H), 7.22 (dd, J = 12.6, 7.1 Hz, 3H), 7.06 (t, J 
= 8.0 Hz, 1H), 6.33 (dd, J = 8.2, 2.2 Hz, 1H), 6.29 (dd, J = 7.9, 1.9 Hz, 1H), 6.25 (t, J = 2.1 Hz, 
1H), 3.93 (t, J = 6.3 Hz, 2H), 3.65 (s, 2H), 2.89 – 2.75 (m, 2H), 2.10 (dd, J = 14.8, 6.6 Hz, 2H). 
13
C NMR (126 MHz, CDCl3) δ 160.28, 147.84, 141.69, 130.16, 128.63, 128.49, 125.99, 107.93, 
104.75, 101.76, 66.74, 32.26, 30.96. HRMS (ESI) calcd for C15H17NO [M+H]+ : 228.1383, 
Found: 228.1364. 
 
Dimethyl 2-(((4-(benzyloxy)phenyl)amino)methylene)malonate 2.6ee: was synthesized 
following general procedure A in 97% yield. 
1
H NMR (400 MHz, CDCl3) δ 10.97 (d, J = 13.7 
Hz, 1H), 8.47 (d, J = 13.7 Hz, 1H), 7.42 – 7.28 (m, 5H), 7.25 – 7.20 (m, 1H), 6.75 – 6.68 (m, 
3H), 5.02 (s, 2H), 3.85 – 3.80 (m, 3H), 3.75 (d, J = 3.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
169.22, 165.76, 159.97, 151.98, 140.28, 136.40, 130.67, 128.60, 128.09, 127.42, 111.08, 109.84, 
104.18, 92.95, 70.09, 51.53, 51.38. HRMS (ESI) calcd for C19H19NO5 [M+H]+ : 342.1336, 
Found:342.1319. 
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Dimethyl 2-(((4-phenethoxyphenyl)amino)methylene)malonate 2.6f: was synthesized 
following general procedure A in 97% yield.
1
H NMR (400 MHz, CDCl3) δ 10.78 (d, J = 13.7 
Hz, 1H), 8.29 (d, J = 13.8 Hz, 1H), 7.13 – 7.01 (m, 6H), 6.53 – 6.42 (m, 3H), 3.96 (t, J = 7.0 Hz, 
2H), 3.63 (s, 3H), 3.56 (d, J = 1.3 Hz, 3H), 2.88 (t, J = 7.0 Hz, 2H). 
13
C NMR (101 MHz, CDCl3) 
δ 169.39, 165.99, 160.17, 152.19, 140.35, 138.02, 130.75, 129.04, 128.61, 126.68, 110.96, 
109.72, 104.05, 92.98, 68.93, 51.67, 51.54, 35.77. 
 
Dimethyl 2-(((3-(benzyloxy)phenyl)amino)methylene)malonate 2.6h: was synthesized 
following general procedure A in 89% yield. 
1
H NMR (400 MHz, CDCl3) δ 11.00 (d, J = 13.9 
Hz, 1H), 8.43 (d, J = 13.9 Hz, 1H), 7.45 – 7.29 (m, 5H), 7.09 – 7.03 (m, 2H), 6.99 – 6.93 (m, 
2H), 5.03 (s, 2H), 3.84 (s, 3H), 3.76 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 169.51, 166.05, 
156.44, 152.87, 136.64, 132.84, 128.64, 128.11, 127.45, 118.89, 116.07, 91.94, 70.38, 51.52, 
51.37. 
 
Dimethyl 2-(((3-phenethoxyphenyl)amino)methylene)malonate2.6i: was synthesized 
following general procedure A in 96% yield. 
1
H NMR (500 MHz, CDCl3) δ 11.02 (d, J = 13.8 
Hz, 1H), 8.46 (d, J = 13.9 Hz, 1H), 7.30 (tt, J = 13.5, 6.9 Hz, 5H), 7.08 (d, J = 8.9 Hz, 2H), 6.91 
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(t, J = 6.0 Hz, 2H), 4.17 (t, J = 7.1 Hz, 2H), 3.86 (s, 3H), 3.80 – 3.77 (m, 3H), 3.11 (t, J = 7.1 Hz, 
2H). 
13
C NMR (126 MHz, CDCl3) δ 169.67, 166.23, 156.65, 153.06, 138.12, 132.76, 129.10, 
128.65, 126.71, 119.02, 115.83, 91.94, 69.21, 51.66, 51.51, 35.88. 
 
Dimethyl 2-(((3-(3-phenylpropoxy)phenyl)amino)methylene)malonate 2.6j: was synthesized 
following general procedure A in 96% yield. 
1
H NMR (500 MHz, CDCl3) δ 11.01 (d, J = 13.7 
Hz, 1H), 8.54 (d, J = 13.8 Hz, 1H), 7.37 – 7.16 (m, 6H), 6.78 – 6.65 (m, 3H), 3.98 (t, J = 6.2 Hz, 
2H), 3.87 (d, J = 0.5 Hz, 3H), 3.80 (d, J = 0.6 Hz, 3H), 2.83 (t, J = 7.6 Hz, 2H), 2.19 – 2.08 (m, 
2H). 
13
C NMR (126 MHz, CDCl3) δ 169.47, 166.04, 160.41, 152.29, 141.38, 140.38, 130.79, 
128.60, 128.57, 126.12, 111.07, 109.63, 104.01, 92.97, 67.19, 51.73, 51.59, 32.19, 30.82. 
 
dimethyl 2-(((4-ethoxyphenyl)amino)methylene)malonate 2.6m: was synthesized following 
general procedure A in 97% yield. 
1H NMR (400 MHz, DMSO) δ 10.72 (d, J = 14.1 Hz, 1H), 
8.33 (d, J = 14.1 Hz, 1H), 7.32 – 7.24 (m, 2H), 6.97 – 6.88 (m, 2H), 4.00 – 3.95 (m, 2H), 3.71 (s, 
3H), 3.64 (s, 3H), 1.30 (t, J = 7.0 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 167.78, 165.37, 
156.02, 152.22, 132.67, 119.38, 115.22, 91.32, 63.29, 50.92, 14.58. 
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dimethyl 2-(((3-chlorophenyl)amino)methylene)malonate 2.6r: was synthesized following 
general procedure A in 75% yield. 
1
H NMR (500 MHz, CDCl3) δ 11.01 (d, J = 13.2 Hz, 1H), 
8.48 (d, J = 13.6 Hz, 1H), 7.30 (t, J = 8.1 Hz, 1H), 7.20 – 7.09 (m, 2H), 7.02 (dd, J = 8.1, 1.5 Hz, 
1H), 3.86 (s, 3H), 3.79 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 169.35, 165.81, 151.81, 140.46, 
135.84, 131.03, 125.12, 117.39, 115.61, 94.10, 51.89, 51.74. 
 
 
dimethyl 2-(((4-ethylphenyl)amino)methylene)malonate2.6t: was synthesized following 
general procedure A in 50% yield. 
1H NMR (400 MHz, DMSO) δ 10.72 (d, J = 14.1 Hz, 1H), 
8.41 (d, J = 14.1 Hz, 1H), 7.28 (d, J = 8.5 Hz, 2H), 7.22 (d, J = 8.5 Hz, 2H), 3.72 (s, 3H), 3.65 (s, 
3H), 2.58 (q, J = 7.6 Hz, 2H), 1.16 (t, J = 7.6 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 167.66, 
165.31, 151.71, 140.49, 137.18, 128.87, 117.78, 91.97, 51.05, 51.03, 27.48, 15.57. 
 
dimethyl 2-(((4-phenoxyphenyl)amino)methylene)malonate 2.6v: was synthesized following 
general procedure A in 93% yield.
1
H NMR (400 MHz, DMSO-d6) δ 10.76 (d, J = 14.0 Hz, 1H), 
8.37 (d, J = 14.0 Hz, 1H), 7.42 – 7.34 (m, 4H), 7.12 (tq, J = 7.3, 0.9 Hz, 1H), 7.05 – 6.97 (m, 
4H), 3.72 (d, J = 0.6 Hz, 3H), 3.65 (d, J = 0.6 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 167.61, 
165.30, 156.86, 153.58, 151.97, 135.29, 130.01, 123.36, 119.84, 119.64, 118.29, 92.18, 51.03, 
51.01. 
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1-methyl-4-nitro-2-(2-phenoxyethoxy)benzene 2.11e: was synthesized following general 
procedure E in 96% yield.  
1
H NMR (500 MHz, CDCl3) δ 7.83 – 7.78 (m, 1H), 7.76 (s, 1H), 7.33 
(t, J = 7.8 Hz, 2H), 7.28 (d, J = 8.3 Hz, 1H), 7.04 – 6.96 (m, 3H), 4.42 (dd, J = 10.3, 4.5 Hz, 4H), 
2.32 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 158.63, 157.05, 147.19, 135.56, 130.76, 129.67, 
121.37, 116.18, 114.78, 106.01, 67.50, 66.37, 16.78.HRMS (ESI) calcd for C15H15NO4 [M+H]+ : 
342.1336, Found:342.1360. 
 
4-chloro-3-(2-phenoxyethoxy)aniline 2.4ab: was synthesized following general procedure F in 
87% yield. 
1
H NMR (500 MHz, CDCl3) δ 7.36 – 7.28 (m, 2H), 7.11 (d, J = 8.4 Hz, 1H), 7.03 – 
6.95 (m, 3H), 6.33 (d, J = 2.5 Hz, 1H), 6.25 (dd, J = 8.4, 2.5 Hz, 1H), 4.39 – 4.27 (m, 4H), 3.68 
(s, 2H). 
13
C NMR (126 MHz, CDCl3) δ 158.58, 154.77, 146.39, 130.59, 129.53, 121.16, 114.81, 
112.30, 108.61, 101.72, 67.74, 66.33. HRMS (ESI) calcd for C19H19NO5 [M+H]+ : 274.1074, 
Found:274.1099. 
 
 
4-methyl-3-(2-phenoxyethoxy)aniline 2.4ac: To a flame dried flask was added 1-methyl-4-
nitro-2-(2-phenoxyethoxy)benzene (10 mmoles) and SnCl2 (40 mmoles) and 300 mL of ethanol. 
The reaction was refluxed for 3 hours. The EtOH was removed and 4M KOH was added until 
basic and the reaction was extracted with EA. The reaction was then dried and concentrated to 
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give the title compound in 75 % yield.  
1
H NMR (500 MHz, CDCl3) δ 7.33 (t, J = 8.0 Hz, 2H), 
7.01 (t, J = 7.7 Hz, 3H), 6.94 (d, J = 7.6 Hz, 1H), 6.30 – 6.23 (m, 2H), 4.37 – 4.32 (m, 2H), 4.30 
– 4.26 (m, 2H), 3.54 (s, 2H), 2.15 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 158.82, 157.54, 
145.56, 131.23, 129.58, 121.10, 117.13, 114.83, 107.55, 100.01, 66.81, 66.64, 15.48. HRMS 
(ESI) calcd for C15H17NO2 [M+H]+ : 244.1332, Found:244.1320. 
 
Dimethyl 2-(((4-methoxyphenyl)amino)methylene)malonate 2.6o:  was synthesized following 
general procedure A in 85% yield.
1H NMR (400 MHz, DMSO) δ 10.70 (s, 23H), 8.32 (s, 24H), 
7.35 – 7.30 (m, 6H), 6.98 – 6.93 (m, 10H), 3.75 (s, 2H), 3.71 (s, 176H), 3.64 (s, 13H). 13C NMR 
(101 MHz, DMSO) δ 167.70, 165.38, 156.72, 152.26, 132.81, 119.48, 114.75, 91.32, 55.36, 
55.31, 50.99, 50.94. 
 
Dimethyl 2-(([1,1'-biphenyl]-4-ylamino)methylene)malonate 2.6u: was synthesized following 
general procedure A in 79% yield. 
1H NMR (400 MHz, DMSO) δ 10.76 (s, 23H), 8.46 (s, 25H), 
7.71 – 7.64 (m, 111H), 7.49 – 7.42 (m, 105H), 7.37 – 7.32 (m, 21H), 3.74 (s, 2H), 3.67 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 167.97, 165.69, 151.62, 139.61, 139.19, 136.86, 129.36, 128.18, 
127.75, 126.76, 118.58, 93.23, 51.61, 51.57, 51.56, 51.53. 
59 
 
 
Dimethyl 2-(((4-chlorophenyl)amino)methylene)malonate 2.6r: was synthesized following 
general procedure A in 56% yield
 1H NMR (400 MHz, DMSO) δ 10.68 (d, J = 11.3 Hz, 1H), 
8.38 (d, J = 11.9 Hz, 1H), 7.42 (s, 4H), 3.73 (s, 3H), 3.66 (s, 3H). 
13
C NMR (101 MHz, DMSO) 
δ 167.75, 165.63, 151.66, 138.93, 129.80, 128.99, 119.94, 93.63, 51.61, 51.55. 
 
Dimethyl 2-(((4-(4-fluorophenoxy)phenyl)amino)methylene)malonate 2.6s: was synthesized 
following general procedure A in 86% yield
 1
H NMR (400 MHz, CDCl3) δ 11.02 (d, J = 13.7 
Hz, 1H), 8.44 (d, J = 13.8 Hz, 1H), 7.11 – 7.06 (m, 2H), 7.05 – 6.98 (m, 2H), 6.98 – 6.91 (m, 
4H), 3.83 (d, J = 0.6 Hz, 3H), 3.75 (d, J = 0.6 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ 169.42, 
165.91, 160.09, 157.68, 155.02, 152.72, 152.69, 152.61, 134.64, 120.37, 120.29, 119.55, 118.87, 
116.50, 116.27, 92.56, 51.56, 51.41. 
 
Dimethyl 2-(((3-chlorophenyl)amino)methylene)malonate 2.6l: was synthesized following 
general procedure A in 29%yield.
 1
H NMR (400 MHz, CDCl3) δ 11.00 (d, J = 13.0 Hz, 1H), 8.46 
(d, J = 13.5 Hz, 1H), 7.29 (t, J = 8.0 Hz, 1H), 7.16 – 7.09 (m, 2H), 7.02 – 6.98 (m, 1H), 3.85 (s, 
60 
 
3H), 3.78 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 169.31, 165.77, 151.76, 140.45, 135.82, 
131.00, 125.08, 117.37, 115.57, 94.11, 51.85, 51.70. 
 
Dimethyl 2-(((3-fluorophenyl)amino)methylene)malonate 2.6m: was synthesized following 
general procedure A in 39% yield. 
1
H NMR (400 MHz, CDCl3) δ 11.01 (d, J = 13.3 Hz, 1H), 
8.46 (d, J = 13.6 Hz, 1H), 7.32 (dd, J = 14.3, 8.0 Hz, 1H), 6.93 – 6.80 (m, 3H), 3.84 (s, 3H), 3.77 
(s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 169.31, 165.76, 164.94, 162.48, 151.81, 140.93, 140.83, 
131.38, 131.29, 113.06, 111.95, 111.74, 104.70, 104.45, 93.99, 51.83. 
 
dimethyl 2-(((4-isopropylphenyl)amino)methylene)malonate 2.6q:  was synthesized 
following general procedure A in 96% yield. 
1H NMR (400 MHz, DMSO) δ 10.72 (s, 43H), 8.40 
(s, 44H), 7.31 – 7.23 (m, 204H), 3.72 (s, 4H), 3.65 (s, 10H), 2.93 – 2.81 (m, 182H), 1.19 (s, 5H), 
1.17 (s, 14H). 
13C NMR (101 MHz, DMSO) δ 167.69, 165.30, 151.77, 145.11, 137.25, 127.39, 
117.79, 91.95, 51.06, 51.04, 51.01, 50.99, 32.82, 23.81. 
 
Methyl 6-butyl-4-oxo-7-(2-phenoxyethoxy)-1,4-dihydroquinoline-3-carboxylate 2.1a: was 
synthesized following general procedure A and B as a white powder in 22% yield. 
1
H NMR (500 
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MHz, CDCl3) δ 9.29 (s, 1H), 8.18 (s, 1H), 7.77 (s, 1H), 7.34 – 7.27 (m, 2H), 7.03 – 6.92 (m, 3H), 
4.62 – 4.57 (m, 2H), 4.47 – 4.43 (m, 2H), 4.12 (s, 3H), 2.84 – 2.79 (m, 2H), 1.70 – 1.62 (m, 2H), 
1.37 (q, J = 7.5 Hz, 2H), 0.92 (t, J = 7.3 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 170.15, 168.60, 
164.87, 158.55, 144.49, 142.02, 138.11, 129.70, 124.16, 121.46, 114.78, 114.05, 103.32, 100.52, 
68.51, 65.83, 54.01, 31.20, 30.50, 22.58, 13.97. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for 
C23H25NO5 396.1806; found 396.1780. 
 
6-butyl-4-oxo-7-(2-phenoxyethoxy)-1,4-dihydroquinoline-3-carboxylic acid 2.7a: was 
synthesized following general procedure C as yellow powder in 68% yield. 
1
H NMR (500 MHz, 
DMSO) δ 8.73 (s, 1H), 7.98 (s, 1H), 7.30 (t, J = 7.6 Hz, 3H), 7.05 – 6.89 (m, 3H), 4.43 (s, 4H), 
2.71 – 2.60 (m, 2H), 1.54 (dt, J = 14.8, 7.5 Hz, 2H), 1.25 (dd, J = 14.5, 7.3 Hz, 2H), 0.83 (t, J = 
7.3 Hz, 3H). 
13C NMR (126 MHz, DMSO) δ 214.93, 204.35, 198.46, 196.01, 181.60, 177.76, 
169.00, 167.17, 162.74, 158.47, 155.69, 152.20, 144.81, 137.36, 104.96, 103.59, 68.67, 66.98, 
59.48, 51.36. 
 
6-butyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one 2.8a: was synthesized by general procedure 
D as an off white solid in 21% yield. JM_2_245: 
1
H NMR (600 MHz, CDCl3) δ 13.07 (s, 1H), 
8.02 – 7.93 (m, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.13 – 7.04 (m, 2H), 6.89 (s, 1H), 6.76 (dd, J = 
10.7 Hz, 4.1, 1H), 6.74 – 6.68 (m, 2H), 6.13 (t, J = 12.5 Hz, 1H), 4.04 (dd, J = 11.4 Hz, 7.6 Hz, 
62 
 
2H), 3.97 – 3.90 (m, 2H), 2.53 – 2.40 (m, 2H), 1.41 – 1.30 (m, 2H), 1.08 (dq, J = 14.8 Hz, 7.4 
Hz, 2H), 0.67 – 0.58 (m, 3H). 13C NMR (151 MHz, CDCl3) δ 178.69, 160.55, 158.71, 141.11, 
139.38, 130.77, 129.67, 121.32, 114.78, 67.01, 66.21, 31.89, 30.13, 22.64, 14.09. HRMS (ESI-
TOF) m/z: [M + H]
+
 calcd for C21H23NO3 338.1751; found 338.1729. 
 
Methyl 6-butyl-4-oxo-1,4-dihydroquinoline-3-carboxylate 2.1c: was synthesized following 
general procedure A and B as a white powder in 33% yield. 
1H NMR (400 MHz, DMSO) δ 8.54 
(s, 1H), 7.95 (s, 1H), 7.57 (dd, J = 32.1 Hz, 7.9, 2H), 3.73 (s, 3H), 2.69 (t, J = 7.1 Hz, 2H), 1.64 – 
1.52 (m, 2H), 1.30 (dd, J = 14.1 Hz, 7.6 Hz, 2H), 0.89 (t, J = 7.2 Hz, 3H). 
13
C NMR (101 MHz, 
DMSO) δ 186.05, 184.62, 173.71, 145.35, 138.78, 132.78, 127.21, 124.15, 119.68, 51.04, 34.46, 
33.05, 21.62, 13.76. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C15H17NO3 260.1281; found 
260.1262. 
 
Methyl 4-oxo-7-(2-phenoxyethoxy)-1,4-dihydroquinoline-3-carboxylate 2.1b: was 
synthesized following general procedure B in 48% yield. 
1H NMR (400 MHz, DMSO) δ 11.32 
(s, 1H), 7.69 (s, 1H), 7.16 (d, J = 69.3 HZ, 1H), 6.48 (s, 2H), 6.20 (d, J = 27.9 Hz, 5H), 3.56 (d, J 
= 20.9 Hz, 4H), 2.90 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 161.35, 158.21, 145.08, 140.67, 
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129.55, 127.61, 122.93, 120.83, 114.49, 114.31, 109.47, 104.97, 101.00, 97.01, 66.86, 65.95, 
58.65, 51.07. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C19H17NO5 340.1180; found 340.1153. 
 
Methyl 4-oxo-1,4-dihydroquinoline-3-carboxylate 2.1d: was synthesized following general 
procedure B in 25% yield. 
1H NMR (400 MHz, DMSO) δ 12.34 (s, 1H), 8.57 (s, 1H), 8.16 (dd, J 
= 8.1, 0.9 Hz, 1H), 7.75 – 7.67 (m, 1H), 7.61 (d, J = 8.2 Hz, 1H), 7.45 – 7.38 (m, 1H), 3.74 (s, 
3H).
13C NMR (101 MHz, DMSO) δ 173.35, 165.36, 145.06, 138.93, 132.41, 127.25, 125.62, 
124.71, 118.77, 109.48, 51.11, 51.09. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C11H9NO3 
204.0655; found 204.0638 
 
7-(2-phenoxyethoxy)quinolin-4(1H)-one 2.8b: was synthesized following general procedure D 
in 45% yield. 
1
H NMR (400 MHz, DMSO-d6) δ 11.54 (d, J = 5.4 Hz, 1H), 7.99 (d, J = 8.6 Hz, 
1H), 7.81 (dd, J = 7.3, 6.0 Hz, 1H), 7.33 – 7.28 (m, 2H), 7.01 – 6.94 (m, 5H), 5.97 – 5.92 (m, 
1H), 4.43 – 4.34 (m, 7H). 13C NMR (101 MHz, DMSO) δ 176.42, 160.81, 158.23, 141.68, 
139.08, 129.55, 126.89, 120.81, 120.34, 114.49, 113.23, 108.58, 99.94, 66.69, 66.00. HRMS 
(ESI-TOF) m/z: [M + H]
+
 calcd for C17H15NO3 282.1125; found 282.1120. 
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6-butylquinolin-4(1H)-one 2.8c: was synthesized following general procedure D in 39% yield. 
1H NMR (400 MHz, DMSO) δ 7.86 (dd, J = 6.7, 4.6 Hz, 2H), 7.55 (d, J = 8.5 Hz, 1H), 7.46 (dd, 
J = 8.5, 2.0 Hz, 1H), 6.01 (d, J = 7.3 Hz, 1H), 2.64 (t, J = 7.6 Hz, 2H), 1.61 – 1.51 (m, 2H), 1.27 
(dd, J = 14.8, 7.4 Hz, 2H), 0.87 (t, J = 7.3 Hz, 3H). HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for 
C13H15NO 202.1226; found 202.1199. 
 
Methyl 6-(benzyloxy)-4-oxo-1,4-dihydroquinoline-3-carboxylate 2.1e: was synthesized 
following general procedure B in 13% yield. 
1H NMR (400 MHz, DMSO) δ 12.15 (s, 1H), 8.50 
(s, 1H), 8.06 (d, J = 9.3 Hz, 1H), 7.48 (d, J = 7.3 Hz, 2H), 7.42 (t, J = 7.2 Hz, 1H), 7.36 (d, J = 
7.1 Hz, 1H), 7.09 (s, 1H), 5.22 (s, 2H), 3.72 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 172.78, 
165.37, 161.29, 145.02, 140.56, 136.24, 128.51, 128.07, 127.82, 127.54, 121.42, 114.58, 109.45, 
101.25, 69.64, 51.05. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C18H15NO4 310.1074; found 
310.1072. 
 
methyl 4-oxo-6-phenethoxy-1,4-dihydroquinoline-3-carboxylate 2.1f: was synthesized 
following general procedure B in 17% yield. 
1H NMR (400 MHz, DMSO) δ 12.08 (s, 1H), 8.51 
(s, 1H), 8.04 (d, J = 8.3 Hz, 1H), 7.34 (s, 4H), 7.23 (s, 1H), 7.05 – 6.96 (m, 2H), 4.29 (s, 2H), 
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3.72 (s, 3H), 3.09 (s, 2H). HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C19H17NO4 324.1230; 
found 324.1227 
 
Methyl 4-oxo-6-(3-phenylpropoxy)-1,4-dihydroquinoline-3-carboxylate 2.1g: was 
synthesized following general procedure B in 18% yield. 
1
H NMR (400 MHz, DMSO-d6) δ 
12.33 (s, 1H), 8.51 (s, 1H), 7.56 (dd, J = 16.3, 5.9 Hz, 2H), 7.35 (dd, J = 8.9, 2.9 Hz, 1H), 7.27 
(dt, J = 8.2, 7.1 Hz, 4H), 7.19 (dd, J = 11.3, 4.3 Hz, 1H), 4.05 (t, J = 6.3 Hz, 2H), 3.73 (s, 3H), 
2.80 – 2.75 (m, 2H), 2.06 (dd, J = 8.4, 6.9 Hz, 2H). 13C NMR (101 MHz, DMSO) δ 172.77, 
155.94, 143.84, 141.31, 133.32, 128.34, 128.32, 125.85, 122.46, 121.03, 120.59, 108.30, 106.21, 
67.13, 51.04, 31.44, 30.24. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C20H19NO4 338.1387; 
found 338.1381. 
 
Methyl 7-(benzyloxy)-4-oxo-1,4-dihydroquinoline-3-carboxylate 2.1h: was synthesized 
following general procedure B in 10% yield. 
1
H NMR (400 MHz, DMSO-d6) δ 8.52 (s, 1H), 7.66 
(d, J = 2.7 Hz, 1H), 7.60 (d, J = 9.0 Hz, 1H), 7.48 (d, J = 7.3 Hz, 2H), 7.40 (t, J = 7.4 Hz, 3H), 
7.33 (d, J = 14.2 Hz, 1H), 5.20 (s, 2H), 3.73 (s, 3H). 
13C NMR (126 MHz, DMSO) δ 172.76, 
165.56, 155.55, 144.28, 136.75, 128.44, 127.89, 127.71, 122.58, 120.96, 115.37, 108.22, 107.51, 
106.81, 69.54, 51.01. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C18H15NO4 310.1074; found 
310.1072. 
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Methyl 4-oxo-7-phenethoxy-1,4-dihydroquinoline-3-carboxylate 2.1i: was synthesized 
following general procedure C in 13% yield. 
1
H NMR (400 MHz, DMSO-d6) δ 12.32 (s, 1H), 
8.51 (s, 1H), 7.59 – 7.54 (m, 2H), 7.36 – 7.30 (m, 5H), 7.26 – 7.20 (m, 1H), 4.28 (t, J = 6.7 Hz, 
2H), 3.73 (s, 3H), 3.07 (t, J = 6.7 Hz, 2H).
 13C NMR (101 MHz, DMSO) δ 172.75, 165.49, 
155.72, 143.84, 138.26, 133.32, 128.94, 128.48, 128.32, 126.30, 122.37, 120.56, 108.32, 106.42, 
68.52, 51.04, 34.75. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C19H17NO4 324.1230; found 
324.1225. 
 
methyl 4-oxo-7-(3-phenylpropoxy)-1,4-dihydroquinoline-3-carboxylate 2.j: was synthesized 
following general procedure B in 16% yield. 
1
H NMR (400 MHz, DMSO-d6) δ 12.09 (s, 1H), 
8.50 (s, 1H), 8.05 (d, J = 6.5 Hz, 1H), 7.33 – 7.18 (m, 5H), 6.99 (s, 2H), 4.06 (s, 2H), 3.72 (s, 
3H), 2.77 (s, 2H), 2.08 (s, 2H). HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C20H19NO4 338.1387; 
found 338.1384. 
 
Methyl 4-oxo-7-phenoxy-1,4-dihydroquinoline-3-carboxylate 2.1k: was synthesized 
following general procedure B in 8% yield over 2 steps. 
1H NMR (400 MHz, DMSO) δ 12.15 (s, 
1H), 8.48 (d, J = 28.8 Hz, 1H), 8.14 (d, J = 8.9 Hz, 1H), 7.49 (t, J = 7.8 Hz, 2H), 7.29 (t, J = 7.4 
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Hz, 1H), 7.19 (d, J = 7.9 Hz, 2H), 7.08 (dd, J = 8.9 Hz, 2.1 Hz, 1H), 6.99 (d, J = 2.0 Hz, 1H), 
3.72 (s, 3H). 
13
C NMR (101 MHz, DMSO) δ 172.80, 165.27, 160.72, 154.69, 145.30, 140.56, 
130.42, 128.18, 125.06, 122.69, 120.41, 115.60, 109.59, 104.39, 51.09. HRMS (ESI-TOF) m/z: 
[M + H]
+
 calcd for C17H13NO4 296.0917; found 296.0916 
 
Methyl 7-chloro-4-oxo-1,4-dihydroquinoline-3-carboxylate 2.1l: was synthesized following 
general procedure B in 49% yield. 
1H NMR (500 MHz, DMSO) δ 12.35 (s, 52H), 8.62 (d, J = 
4.1 Hz, 37H), 8.15 (t, J = 6.0 Hz, 44H), 7.72 – 7.63 (m, 40H), 7.49 – 7.40 (m, 47H), 3.80 – 3.68 
(m, 104H). 
13
C NMR (126 MHz, CDCl3) δ 172.36, 168.11, 147.02, 145.30, 140.55, 131.48, 
126.24, 120.93, 118.37, 104.90, 54.57. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C11H8NClO3 
238.0266; found 238.0247 
 
Methyl 4-oxo-7-phenyl-1,4-dihydroquinoline-3-carboxylate 2.1m: was synthesized following 
general procedure B in 33% yield. 
1
H NMR (500 MHz, CDCl3) δ 10.64 (s, 1H), 9.43 (d, J = 1.1 
Hz, 1H), 8.61 (d, J = 8.7 Hz, 1H), 8.41 (d, J = 1.6 Hz, 1H), 8.17 (dd, J = 8.7, 1.6 Hz, 1H), 7.78 – 
7.74 (m, 2H), 7.56 (ddt, J = 7.1, 5.6, 3.7 Hz, 3H), 4.16 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 
172.25, 168.28, 151.21, 146.24, 137.25, 130.54, 129.77, 129.66, 127.90, 125.42, 118.65, 118.26, 
115.94, 113.67, 104.44, 54.41. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C17H13NO3 280.0968; 
found 280.0966. 
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methyl 7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 2.1n: was synthesized following 
general procedure B in 21% yield. 
1H NMR (500 MHz, DMSO) δ 12.34 (s, 6H), 8.61 (d, J = 2.0 
Hz, 5H), 8.20 (dt, J = 9.0, 4.0 Hz, 6H), 7.38 (dt, J = 9.8, 2.2 Hz, 5H), 7.31 – 7.23 (m, 8H), 3.78 – 
3.71 (m, 15H). HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C11H8NFO3 222.0561; found 
222.0551. 
 
Methyl 6-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate 2.1o: was synthesized 
following general procedure B in 15% yield. 
1H NMR (400 MHz, DMSO) δ 12.33 (s, 1H), 8.51 
(s, 1H), 7.57 (t, J = 6.3 Hz, 2H), 7.34 (dd, J = 8.9, 3.0 Hz, 1H), 3.85 (s, 3H), 3.73 (s, 3H). 
13
C 
NMR (101 MHz, DMSO) δ 172.79, 165.50, 156.61, 143.83, 133.35, 128.51, 122.22, 120.56, 
108.35, 105.50, 55.47, 51.07. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C12H11NO4 234.0761; 
found 234.0746. 
 
methyl 6-ethoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate 2.1p: was synthesized following 
general procedure B in 24% yield. 
1
H NMR (500 MHz, CDCl3) δ 9.25 (s, 1H), 8.21 (d, J = 9.2 
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Hz, 1H), 7.76 – 7.65 (m, 2H), 4.25 (q, J = 6.9 Hz, 2H), 4.14 (s, 3H), 1.54 (t, J = 7.0 Hz, 3H). 13C 
NMR (126 MHz, CDCl3) δ 170.69, 168.42, 160.02, 142.67, 135.39, 130.07, 122.95, 121.73, 
104.41, 102.91, 65.13, 54.25, 14.47. 
 
Methyl 6-isopropyl-4-oxo-1,4-dihydroquinoline-3-carboxylate 2.1q: was synthesized 
following general procedure B in 23% yield.
1H NMR (400 MHz, DMSO) δ 12.26 (s, 1H), 8.49 
(s, 1H), 7.95 (d, J = 1.8 Hz, 1H), 7.59 (dd, J = 8.5, 2.1 Hz, 1H), 7.51 (d, J = 8.5 Hz, 1H), 3.69 (s, 
3H), 3.05 – 2.93 (m, 1H), 1.21 (s, 3H), 1.20 (s, 3H). 13C NMR (101 MHz, DMSO) δ 173.36, 
165.44, 145.03, 144.64, 137.28, 131.33, 127.20, 122.14, 118.89, 109.18, 51.08, 33.15, 23.82. 
HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C20H19NO6 246.1125; found 246.1105. 
 
Methyl 6-chloro-4-oxo-1,4-dihydroquinoline-3-carboxylate 2.1r: was synthesized following 
general procedure B in 23% yield. 
1H NMR (400 MHz, DMSO) δ 12.50 (s, 4H), 8.62 (s, 5H), 
8.08 (d, J = 2.4 Hz, 4H), 7.76 (dd, J = 8.8, 2.5 Hz, 5H), 7.67 (d, J = 8.8 Hz, 5H), 3.75 (s, 15H). 
13
C NMR (101 MHz, CDCl3) δ 171.31, 167.96, 145.95, 138.62, 137.98, 136.69, 123.65, 123.18, 
120.89, 105.05, 54.29. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C11H18NClO3 238.0266; 
found 238.0241. 
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methyl 6-(4-fluorophenoxy)-4-oxo-1,4-dihydroquinoline-3-carboxylate 2.1s: was synthesized 
following general procedure B in 31% yield. 
1
H NMR (400 MHz, CDCl3) δ 13.92 (s, 1H), 9.31 
(d, J = 10.0 Hz, 1H), 8.33 (dd, J = 9.3, 1.6 Hz, 1H), 7.83 (dt, J = 9.3, 2.3 Hz, 1H), 7.69 (s, J = 2.6 
Hz, 1H), 7.26 – 7.06 (m, 4H), 4.12 (s, 3H). HRMS (ESI-TOF) m/z: [M + H]+ calcd for 
C17H12NFO4 314.0823; found 314.0794. 
 
Methyl 6-ethyl-4-oxo-1,4-dihydroquinoline-3-carboxylate 2.1t: was synthesized following 
general procedure B in 14% yield. 
1
H NMR (400 MHz, DMSO-d6) δ 12.30 (s, 1H), 8.53 (s, 1H), 
7.97 (d, J = 1.2 Hz, 1H), 7.56 (dt, J = 14.4, 5.2 Hz, 2H), 3.73 (s, 3H), 2.72 (t, J = 7.5 Hz, 2H), 
1.22 (t, J = 7.6 Hz, 3H).
 13C NMR (101 MHz, DMSO) δ 173.74, 165.89, 145.06, 140.91, 137.61, 
133.07, 127.69, 124.12, 119.27, 109.63, 51.51, 28.29, 16.00. HRMS (ESI-TOF) m/z: [M + H]
+
 
calcd for C13H13NO3 232.0968; found 232.0965. 
 
Methyl 4-oxo-6-phenyl-1,4-dihydroquinoline-3-carboxylate 2.1u: was synthesized following 
general procedure B in 21% yield. 
1H NMR (400 MHz, DMSO) δ 12.44 (s, 1H), 8.60 (s, 1H), 
8.38 (d, J = 2.1 Hz, 1H), 8.04 (dd, J = 8.6, 2.2 Hz, 1H), 7.72 (ddd, J = 5.8, 4.1, 0.8 Hz, 3H), 7.54 
– 7.49 (m, 2H), 7.43 – 7.38 (m, 1H), 3.76 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 172.37, 
168.39, 145.35, 143.47, 139.29, 137.83, 137.06, 129.63, 129.52, 127.69, 122.02, 121.85, 120.47, 
116.82, 113.96, 104.72, 54.36. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C17H13NO3 280.0968; 
found 280.0947. 
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Methyl 4-oxo-6-phenoxy-1,4-dihydroquinoline-3-carboxylate 2.1v: was synthesized 
following general procedure B in 11% yield. 
1
H NMR (400 MHz, DMSO-d6) δ 12.45 (s, 1H), 
8.56 (s, 1H), 7.69 (d, J = 8.6 Hz, 1H), 7.56 – 7.41 (m, 4H), 7.21 (t, J = 7.4 Hz, 1H), 7.09 (d, J = 
7.9 Hz, 2H), 3.72 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 172.62, 165.32, 156.12, 154.28, 
144.58, 134.92, 130.24, 128.50, 124.35, 124.12, 121.22, 119.24, 112.00, 108.64, 51.09. HRMS 
(ESI-TOF) m/z: [M + H]
+
 calcd for C17H13NO4 296.0917; found 296.0907. 
 
Methyl 6-ethyl-4-oxo-7-(2-phenoxyethoxy)-1,4-dihydroquinoline-3-carboxylate 2.1w: was 
synthesized following general procedure B in 5% yield. 
1H NMR (600 MHz, DMSO) δ 12.06 (s, 
1H), 8.44 (s, 1H), 7.86 (s, 1H), 7.32 – 7.21 (m, 2H), 7.00 – 6.89 (m, 4H), 4.38 (s, 4H), 3.67 (s, 
3H), 2.59 (q, J = 7.4 Hz, 4H), 1.11 (t, J = 7.5 Hz, 3H). HRMS (ESI-TOF) m/z: [M + H]
+
 calcd 
for C21H21NO5 368.1493; found 368.1471. 
 
Methyl 4-oxo-7-(2-phenoxyethoxy)-6-propyl-1,4-dihydroquinoline-3-carboxylate 2.1x: was 
synthesized following general procedure B in 38% yield. 
1
H NMR (600 MHz, CDCl3) δ 10.55 (s, 
1H), 9.25 (s, 1H), 8.17 (s, 1H), 7.69 (s, 1H), 7.29 (dd, J = 8.3, 7.6 Hz, 2H), 6.97 (t, J = 7.3 Hz, 
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1H), 6.94 (d, J = 8.0 Hz, 2H), 4.57 (dd, J = 5.3, 3.2 Hz, 2H), 4.43 (dd, J = 5.3, 3.2 Hz, 2H), 4.10 
(s, 3H), 2.77 (t, 2H), 1.74 – 1.67 (m, 2H), 0.95 (t, J = 7.4 Hz, 3H).  
 
Methyl 4-oxo-6-pentyl-7-(2-phenoxyethoxy)-1,4-dihydroquinoline-3-carboxylate 2.1y: was 
synthesized following general procedure B in 27% yield. 
1
H NMR (600 MHz, CDCl3) δ 12.33 (s, 
1H), 9.25 (s, 1H), 8.14 (s, 1H), 7.78 (s, 1H), 7.31 – 7.25 (m, 2H), 7.00 – 6.89 (m, 3H), 4.57 (d, J 
= 3.5 Hz, 2H), 4.42 (d, J = 1.9 Hz, 2H), 4.11 – 4.00 (m, 3H), 2.82 – 2.73 (m, 2H), 1.70 – 1.60 
(m, 2H), 1.34 – 1.25 (m, 4H), 0.90 – 0.79 (m, 3H). 13C NMR (151 MHz, CDCl3) δ 170.10, 
168.65, 164.76, 158.59, 144.54, 142.17, 138.01, 129.68, 124.10, 121.44, 114.81, 114.09, 103.30, 
100.66, 68.50, 65.88, 53.93, 31.62, 30.75, 28.74, 22.52, 14.03. 
 
Methyl 6-bromo-4-oxo-7-(2-phenoxyethoxy)-1,4-dihydroquinoline-3-carboxylate 2.1z: 4-
bromo-3-(2-phenoxyethoxy)aniline was cyclized using general procedure A and B to give the 
title compound in 42% yield over 2 steps.  
1
H NMR (400 MHz, CDCl3) δ 12.86 (s, 1H), 9.36 (s, 
1H), 8.68 (s, J = 2.7 Hz, 1H), 7.83 (s, 1H), 7.33 – 7.23 (m, 2H), 7.03 – 6.91 (m, 3H), 4.67 – 4.61 
(m, 2H), 4.50 – 4.44 (m, 2H), 4.12 (s, J = 2.6 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 180.98, 
170.22, 168.22, 162.47, 158.44, 145.88, 141.88, 129.74, 129.09, 121.68, 118.49, 115.03, 104.05, 
101.90, 69.79, 65.94, 54.33. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C19H16NBrO5 418.0285; 
found 418.0249. 
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Methyl 6-methoxy-4-oxo-7-(2-phenoxyethoxy)-1,4-dihydroquinoline-3-carboxylate 2.1aa: 
was synthesized following general procedure B in 34% yield. 
1
H NMR (600 MHz, CDCl3 with 3 
drops TFA) δ 10.68 (s, 1H), 9.18 (s, 1H), 7.81 (s, 1H), 7.59 (s, 1H), 7.30 – 7.22 (m, 2H), 7.00 – 
6.89 (m, 3H), 4.60 (dd, J = 5.3, 3.3 Hz, 2H), 4.44 (dd, J = 5.2, 3.3 Hz, 2H), 4.10 (s, 3H), 4.04 (s, 
3H). 
13
C NMR (151 MHz, CDCl3) δ 168.94, 168.57, 158.48, 157.88, 152.20, 142.64, 138.26, 
129.65, 121.50, 114.98, 114.88, 103.65, 101.80, 101.74, 69.08, 65.88, 56.70, 54.03. HRMS 
(ESI-TOF) m/z: [M + H]
+
 calcd for C20H19NO6 370.1285; found 370.1272. 
 
Methyl 6-methyl-4-oxo-7-(2-phenoxyethoxy)-1,4-dihydroquinoline-3-carboxylate 2.1ac: was 
synthesized following general procedure B in 31% yield. 
1H NMR (500 MHz, DMSO) δ 12.10 
(d, J = 6.6 Hz, 1H), 8.48 (d, J = 6.6 Hz, 1H), 7.90 (s, 1H), 7.31 (t, J = 7.8 Hz, 2H), 7.05 (s, 1H), 
7.01 (d, J = 8.1 Hz, 2H), 6.96 (t, J = 7.3 Hz, 1H), 4.41 (s, 4H), 3.72 (s, 3H), 2.21 (s, 3H). 
13
C 
NMR (126 MHz, DMSO) δ 172.71, 159.84, 158.37, 144.42, 139.05, 129.54, 126.82, 124.75, 
121.00, 120.84, 114.63, 109.34, 100.43, 99.10, 67.17, 66.05, 51.04, 15.98. 
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6-butyl-N-methyl-4-oxo-7-(2-phenoxyethoxy)-1,4-dihydroquinoline-3-carboxamide 2.13a: 
was synthesized following general procedure G in 25% yield. 
1H NMR (600 MHz, DMSO) δ 
12.42 (s, 1H), 9.95 (d, J = 4.6 Hz, 1H), 8.63 (s, 1H), 7.95 (s, 1H), 7.30 (t, J = 7.9 Hz, 2H), 7.11 
(s, 1H), 7.00 (d, J = 8.1 Hz, 2H), 6.95 (t, J = 7.3 Hz, 1H), 4.41 (d, J = 1.5 Hz, 4H), 2.85 (d, J = 
4.5 Hz, 3H), 2.67 – 2.59 (m, 2H), 1.59 – 1.48 (m, 2H), 1.25 (tt, J = 12.3 Hz, 6.2 Hz, 3H), 0.83 (t, 
J = 7.4 Hz, 3H). 
13C NMR (151 MHz, DMSO) δ 175.35, 172.00, 165.22, 159.90, 158.39, 142.52, 
139.36, 129.66, 129.51, 125.67, 120.80, 114.54, 110.71, 99.11, 67.08, 66.01, 31.20, 29.34, 25.30, 
21.83, 13.70. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C23H26N2O4 395.1965; found 395.1941. 
 
6-butyl-N,N-dimethyl-4-oxo-7-(2-phenoxyethoxy)-1,4-dihydroquinoline-3-carboxamide 
2.13b: was synthesized following general procedure G in 20% yield. 
1
H NMR (600 MHz, 
DMSO) δ 7.95 (s, 1H), 7.85 (s, 1H), 7.30 (t, J = 7.9 Hz, 2H), 7.04 – 6.98 (m, 3H), 6.95 (t, J = 7.3 
Hz, 1H), 4.40 (s, 4H), 2.95 (s, 3H), 2.87 (s, 3H), 2.61 (t, J = 7.6 Hz, 2H), 1.57 – 1.50 (m, 2H), 
1.28 – 1.23 (m, 2H), 0.84 (t, J = 7.3 Hz, 3H).13C NMR (151 MHz, DMSO) δ 172.02, 167.33, 
159.45, 158.39, 139.51, 139.03, 129.50, 128.68, 125.66, 120.78, 119.63, 118.04, 114.54, 98.73, 
66.95, 66.05, 31.34, 29.30, 21.88, 13.73. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C24H28N2O4 
409.2122; found 409.2108. 
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6-butyl-N-ethyl-4-oxo-7-(2-phenoxyethoxy)-1,4-dihydroquinoline-3-carboxamide 2.13c: was 
synthesized following general procedure H in 17% yield. 
1H NMR (400 MHz, DMSO) δ 10.08 
(d, J = 5.4 Hz, 1H), 8.63 (s, 1H), 7.95 (s, 1H), 7.39 – 7.24 (m, 2H), 7.10 (s, 1H), 7.06 – 6.90 (m, 
3H), 4.41 (s, 4H), 2.68 – 2.58 (m, 2H), 1.54 (t, J = 7.6 Hz, 2H), 1.25 (dd, J = 15.9, 8.4 Hz, 4H), 
1.13 (t, J = 7.2 Hz, 3H), 0.83 (t, J = 7.3 Hz, 3H). 
 
6-butyl-N-(2-hydroxyethyl)-4-oxo-7-(2-phenoxyethoxy)-1,4-dihydroquinoline-3-
carboxamide 2.13d: was synthesized following general procedure G in 22% yield.   
1H NMR (400 MHz, DMSO) δ 12.57 (s, 1H), 10.20 (s, 1H), 8.63 (d, J = 6.0, 1H), 7.96 (s, 1H), 
7.35 – 7.27 (m, 2H), 7.13 (s, 1H), 7.02 – 6.92 (m, 3H), 4.42 (s, 4H), 3.51 (t, J = 5.7, 2H), 3.39 (d, 
J = 5.1, 2H), 2.68 – 2.59 (m, 2H), 1.53 (dd, J = 15.1, 7.8, 2H), 1.24 (dt, J = 23.8, 12.0, 2H), 0.84 
(t, J = 7.3, 3H). HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C24H28N2O5 425.2071; found 
425.2043. 
 
6-butyl-N-isopropyl-4-oxo-7-(2-phenoxyethoxy)-1,4-dihydroquinoline-3-carboxamide 2.13: 
was synthesized following general procedure H in 35% yield. 
1H NMR (400 MHz, DMSO) δ 
12.38 (s, 1H), 10.08 (d, J = 7.4 Hz, 1H), 8.62 (s, 1H), 7.94 (s, 1H), 7.29 (t, J = 7.6 Hz, 2H), 7.08 
(s, 1H), 7.01 – 6.91 (m, 3H), 4.40 (s, 4H), 4.06 (dq, J = 13.4, 6.7 Hz, 1H), 2.60 (t, J = 7.5 Hz, 
2H), 1.59 – 1.46 (m, 2H), 1.27 – 1.21 (m, 2H), 1.17 (d, J = 6.5 Hz, 6H), 0.82 (t, J = 7.3 Hz, 3H). 
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13C NMR (126 MHz, DMSO) δ 175.41, 163.73, 159.83, 158.39, 142.76, 139.55, 129.51, 129.49, 
125.60, 120.79, 119.94, 114.54, 110.61, 99.23, 67.07, 66.01, 31.06, 29.27, 22.83, 21.78, 13.73. 
 
6-butyl-4-oxo-7-(2-phenoxyethoxy)-1,4-dihydroquinoline-3-carbonitrile 2.1ad: was 
synthesized following general procedure A and B in 21% yield.
1H NMR (400 MHz, DMSO) δ 
12.56 (s, 1H), 8.55 (d, J = 51.3 Hz, 1H), 7.79 (d, J = 36.7 Hz, 1H), 7.29 (d, J = 7.0 Hz, 2H), 7.13 
– 6.83 (m, 4H), 4.41 (s, 4H), 2.61 (s, 2H), 1.52 (s, 2H), 1.24 (d, J = 7.2 Hz, 2H), 0.83 (t, J = 6.8 
Hz, 3H). 
13
C NMR (101 MHz, DMSO) δ 173.63, 160.22, 158.35, 145.92, 139.34, 130.23, 
129.50, 125.36, 120.79, 118.89, 117.02, 114.52, 99.57, 93.32, 67.14, 65.97, 31.10, 29.21, 21.80, 
13.69. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C22H22N2O3 363.1703; found 363.1708 
 
6-butyl-3-ethyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one 2.13j: Ethyl butyrate (1mmoles) was 
reacted with diethyl oxalate (2.1mmoles) to give the diester compound that was used as a starting 
material in PEQ-852 and was synthesized following general procedure H in 39% yield. 
JM_3_294: 
1
H NMR (400 MHz, DMSO-d6) δ 11.36 (s, 1H), 7.82 (s, 1H), 7.68 (s, 1H), 7.34 – 
7.27 (m, 2H), 7.01 – 6.91 (m, 4H), 4.38 (q, J = 5.1 Hz, 4H), 2.59 (t, J = 7.5 Hz, 2H), 2.41 (q, J = 
7.4 Hz, 2H), 1.57 – 1.48 (m, 2H), 1.25 (h, J = 7.4 Hz, 2H), 1.09 (t, J = 7.4 Hz, 3H), 0.83 (t, J = 
7.3 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 176.04, 159.38, 158.88, 140.24, 135.56, 129.96, 
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127.76, 125.92, 122.35, 121.22, 119.07, 114.99, 98.47, 67.25, 66.54, 31.85, 29.75, 22.28, 21.02, 
14.20, 10.69. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C23H27NO3 366.2064; found 366.2044. 
 
6-butyl-3-chloro-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one 2.18b: was synthesized 
following general procedure G in 52% yield. 
1
H NMR (400 MHz, DMSO-d6) δ 11.92 (s, 1H), 
7.80 (d, J = 23.4 Hz, 1H), 7.36 – 7.29 (m, 2H), 7.05 – 6.92 (m, 4H), 4.42 (q, J = 6.7, 5.7 Hz, 4H), 
3.36 (s, 3H), 2.61 (q, J = 7.7 Hz, 2H), 2.52 (p, J = 1.9 Hz, 2H), 1.61 – 1.49 (m, 2H), 1.27 (q, J = 
7.4 Hz, 2H), 0.86 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 170.49, 159.76, 158.84, 
146.44, 139.02, 129.94, 128.78, 127.79, 125.88, 121.22, 114.97, 109.99, 98.44, 67.37, 66.48, 
31.76, 31.69, 29.68, 22.27, 18.96, 14.17. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for 
C22H24NClO3 386.1518; found 386.1513 
 
3-bromo-6-butyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one 2.18c: was synthesized following 
general procedure H in 66% yield. 
1
H NMR (400 MHz, DMSO-d6) δ 12.06 (s, 1H), 7.85 (s, 1H), 
7.30 (ddd, J = 8.7, 5.7, 2.0 Hz, 2H), 7.07 – 6.90 (m, 5H), 4.39 (s, 4H), 2.65 – 2.58 (m, 2H), 1.56 
– 1.48 (m, 2H), 1.26 (dd, J = 12.4, 5.1 Hz, 2H), 0.83 (t, J = 7.3 Hz, 3H). HRMS (ESI-TOF) m/z: 
[M + H]
+
 calcd for C21H22NBrO3 416.0856; found 416.0842. 
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3-bromo-6-butyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one 2.18d: was synthesized 
following general procedure H in 74% yield. 
1
H NMR (400 MHz, DMSO-d6) δ 11.85 (s, 1H), 
7.72 (s, 1H), 7.22 (t, J = 7.8 Hz, 2H), 7.07 – 6.73 (m, 4H), 4.32 (s, 5H), 2.52 (t, J = 7.6 Hz, 2H), 
2.43 (s, 3H), 1.57 – 1.35 (m, 2H), 1.16 (q, J = 7.3 Hz, 2H), 0.75 (t, J = 7.3 Hz, 3H). 13C NMR 
(101 MHz, DMSO) δ 170.81, 159.78, 158.82, 147.92, 139.17, 129.94, 128.90, 126.04, 121.22, 
117.20, 114.96, 106.03, 98.41, 67.35, 66.48, 31.68, 29.68, 22.26, 21.71, 14.16.  HRMS (ESI-
TOF) m/z: [M + H]
+
 calcd for C22H24NBrO3 430.1012; found 430.1010 
 
6-butyl-3-iodo-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one 2,18e: was synthesized 
following general procedure H in 65% yield. 
1H NMR (400 MHz, DMSO) δ 12.16 (s, 1H), 8.51 
(s, 1H), 7.91 (s, 1H), 7.34 (s, 1H), 7.02 (s, 4H), 4.44 (s, 4H), 3.76 (s, 2H), 2.64 (s, 3H), 1.56 (s, 
2H), 1.28 (s, 2H), 0.87 (s, 3H). HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for C22H24NIO3 
478.0874; found 478.0852. 
 
3-iodo-7-(2-phenoxyethoxy)quinolin-4(1H)-one 2.18f: was synthesized following general 
procedure H in 59% yield. 
1
H NMR (400 MHz, DMSO-d6) δ 11.98 (d, J = 5.2 Hz, 1H), 8.42 (d, 
J = 5.5 Hz, 1H), 8.05 – 7.99 (m, 1H), 7.35 – 7.27 (m, 2H), 7.00 (tdd, J = 11.7, 8.7, 5.0 Hz, 5H), 
4.43 – 4.32 (m, 4H). 13C NMR (101 MHz, DMSO) δ 339.21, 327.65, 324.93, 311.06, 307.93, 
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296.26, 294.24, 287.54, 283.80, 281.21, 281.07, 266.71, 247.34, 233.51, 232.68. HRMS (ESI-
TOF) m/z: [M + H]
+
 calcd for C17H14NIO3 408.0091; found 408.0081. 
 
Methyl 6-butyl-1-hydroxy-4-oxo-7-(2-phenoxyethoxy)-1,4-dihydroquinoline-3-carboxylate 
2.19: was synthesized using a three step procedure previously reported. 
1
H NMR (400 MHz, 
DMSO) δ 10.84 (s, 4H), 8.01 (s, 4H), 7.73 (d, J = 9.0 Hz, 4H), 7.30 (t, J = 7.9 Hz, 9H), 6.96 (dd, 
J = 17.8, 7.7 Hz, 14H), 4.35 (d, J = 3.6 Hz, 17H), 4.17 (q, J = 7.1 Hz, 9H), 3.39 – 3.26 (m, 11H), 
2.47 (d, J = 7.5 Hz, 7H), 1.53 – 1.41 (m, 9H), 0.82 (t, J = 7.3 Hz, 13H). 13C NMR (101 MHz, 
DMSO) δ 169.62, 160.70, 158.37, 152.85, 141.64, 132.12, 129.50, 124.05, 120.76, 114.54, 
106.98, 100.81, 66.80, 65.97, 60.82, 31.27, 28.66, 21.81, 14.37, 13.72. 
 
Methyl 6-butyl-1-methyl-4-oxo-7-(2-phenoxyethoxy)-1,4-dihydroquinoline-3-carboxylate 
2.20: To PEQ-128 (3 mmol) was added methyl iodide (3.3 mmol) in methanol at 0 
o
C. After the 
reaction was complete the solvent was removed the reaction was purified via flash 
chromatography to give the title compound in 89% yield.  
1H NMR (400 MHz, DMSO) δ 17.73 
(s, 1H), 17.09 (s, 1H), 16.45 (t, J = 7.9 Hz, 2H), 16.20 (s, 1H), 16.13 (dd, J = 12.6, 7.7 Hz, 3H), 
13.67 (d, J = 4.5 Hz, 2H), 13.58 – 13.53 (m, 2H), 13.03 (d, J = 7.6 Hz, 3H), 12.88 (s, 3H), 11.77 
(t, J = 7.5 Hz, 2H), 10.71 – 10.62 (m, 2H), 10.43 – 10.37 (m, 2H), 9.98 (t, J = 7.3 Hz, 3H). 13C 
NMR (101 MHz, DMSO) δ 172.21, 165.28, 159.83, 158.38, 149.46, 139.92, 129.50, 129.18, 
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126.63, 121.58, 120.77, 114.52, 109.16, 98.67, 67.27, 66.03, 51.06, 40.83, 31.16, 29.10, 21.81, 
13.70. 
 
Methyl 7-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylate 2.22: To 5-methylpyridin-
2-amine (5 mmol) was added dimethyl 2-(methoxymethylene)malonate (6 mmol) and methanol 
(25 mL). The reaction was heated for 5 hours at 170 
o
C. The resulting solution was concentrated 
and recrystallized to give the title compound in 5% yield. 
1H NMR (400 MHz, DMSO) δ 9.06 (d, 
J = 7.2 Hz, 1H), 8.84 (s, 1H), 7.68 (s, 1H), 7.44 (d, J = 7.1 Hz, 1H), 3.79 (s, 3H), 2.53 (s, 3H). 
 
6-butyl-3-iodo-7-(2-phenoxyethoxy)quinolin-4(1H)-one 2.18g: was synthesized following 
general procedure H in 57% yield. 
1
H NMR (400 MHz, DMSO-d6) δ 11.96 (s, 1H), 8.38 (s, 1H), 
7.82 (s, 1H), 7.32 – 7.28 (m, 2H), 7.01 – 6.93 (m, 4H), 4.39 (s, 4H), 2.60 (t, J = 7.5 Hz, 2H), 1.52 
(t, J = 7.4 Hz, 2H), 1.27 – 1.21 (m, 2H), 0.83 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, DMSO) δ 
172.27, 159.35, 158.38, 143.78, 139.68, 129.50, 129.00, 125.86, 120.78, 116.63, 114.53, 98.47, 
80.51, 66.94, 66.03, 31.25, 29.27, 21.80, 13.72. HRMS (ESI-TOF) m/z: [M + H]
+
 calcd for 
C17H14NIO3 408.0091; found 408.0081 
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6-butyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one: was synthesized using Conrad-
Limpach cyclization of aniline 2.4a with the corresponding acetoacetate following general 
procedure I. 
1H NMR (400 MHz, DMSO) δ 11.35 (s, 1H), 7.74 (s, 1H), 7.31 (t, J = 7.8 Hz, 2H), 
7.05 – 6.87 (m, 4H), 5.79 (s, 1H), 4.38 (d, J = 6.7 Hz, 4H), 2.58 (t, J = 7.4 Hz, 2H), 2.29 (s, 3H), 
1.58 – 1.47 (m, 2H), 1.25 (dd, J = 14.6, 7.3 Hz, 2H), 0.83 (t, J = 7.3 Hz, 3H). 13C NMR (101 
MHz, DMSO) δ 176.87, 159.75, 159.09, 149.21, 140.85, 130.18, S12 127.88, 125.94, 121.45, 
119.12, 115.23, 108.68, 98.82, 67.50, 66.77, 32.03, 29.87, 22.51, 20.02, 14.42. HRMS (ESI) 
calcd for C22H25NO3 [M+H]+ : 352.1907, found 352.1900 
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Chapter 3: Design and Synthesis of an Orally Bioavailable Series of 7-
Piperazinyl Substituted 4(1H)-Quinolones with Potent Antimalarial Efficacy 
3.1  Overview 
 
 
Figure 3.1: Design of piperazinyl-substituted 4(1H)-quinolones derived from historical 
compound ICI 56,780 (3.1) 
 
The overall design of the soluble 4(1H)-quinolone pharmacophore is shown in Fig.2. It is 
based on the insights gained from our previously studied series of 4(1H)-quinolone esters which 
indicated that the presence of the unique substituents of compounds 3.1 and 3.2 including the 
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carboxylic ester or bromo group at the 3-position and the phenoxyethoxy substituent at the 7-
position are crucial for antimalarial activity, whereas the effect of the positions in positions 2 and 
6 on overall activity is minimum. However, the latter can possibly influence the overall 
hydrophobicity and resistance index in the 4(1H)-quinolone molecules.
8
 As a starting point for 
the design, we have decided to proceed with the 4(1H)-quinolone pharmacophore containing a 3-
substituted carboxylic ester group and a piperazinyl moiety in 7-position. The piperazinyl moiety 
was selected for three reasons: (1) a highly ionizable piperazine may enhance the aqueous 
solubility of 4(1H)-quinolones; (2) a straightforward base mediated or reductive N-alkylation of 
piperazines provides an easy synthetic access; and (3) commercial availability of various 
substituted piperazines allows the synthesis of diversified set of piperazinyl 4(1H)-quinolones.  
3.2 Synthetic Chemistry 
Initially a set of 7-piperazinyl-substituted 4(1H)-quinolone esters with differing alkyl 
chain lengths between the 4(1H)-quinolone core and the piperazinyl moiety were synthesized. 
These linker lengths were varied from zero to two with each linker length requiring a different 
synthetic path. Nucleophilic aromatic substitution was attempted initially for linkers with the 
piperazine directly attached to the quinolone core, using substituted nitro-benzenes 3.3 along 
with the required piperazine followed by subsequent reduction and thermal cyclization to yield 
4(1H)-quinolones 3.8a-b. This approach, however, was only successful when the 4(1H)-
quinolone core was sufficiently electron deficient (Scheme 3.1).
26
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Scheme 3.1: Synthesis of 7-piperazyl-4(1H)-quinolones 
 For cases when the 4(1H)-quinolone core was not electron deficient enough, a six step 
sequence needed to be performed. Initially, the required substituted aniline or benzyl amine 3.9 
was reacted with two equivalents of 2-chloroethanol to give the diol 3.10. This was subjected to 
a chlorination with POCl3 in CH2Cl2 followed by a cyclization with a substituted nitroaniline
27
 
and reduced with tin(II)chloride to give the required amino piperazine 3.4, which was further 
reacted using standard Gould-Jacob protocol to afford compounds 3.8c-o (Scheme 3.2).
19
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Scheme 3.2: Alternate synthetic route for the preparation of 7-piperazyl-4(1H)-quinolones 
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Compounds with one carbon between the 4(1H)-quinolone core and the piperazine’s 
nitrogen were prepared starting from 2-substituted (3-aminophenyl)methanol 3.11. Using the 
appropriate alcohol as a starting point, it was reacted with dimethyl 2-
(methoxymethylene)malonate (3.6) to yield the corresponding enamines 3.12 where the alcohol 
was oxidized using Dess-Martin periodinane followed by standard direct reductive amination 
conditions to yield substituted piperazines 3.7.
28
 These were then cyclized using microwave 
conditions to yield 4(1H)-quinolones 3.8p-ak (Scheme 3.3). 
 Compounds with a two carbon linker between the piperazine’s nitrogen and the 4(1H)-
quinolone core were synthesized through a four step process that initially included an alkylation 
of substituted nitrophenethyl bromides with corresponding piperazines 3.14.
29
 Intermediate 3.4 
was reduced using tin chloride and the resulting aniline 3.5 was subjected to standard Gould-
Jacob conditions to give quinolone esters 3.8al-am (Scheme 3.4).  
A similar approach was used for the synthesis of 6-piperazyl-substituted 4(1H)-quinolone 
esters, however, (4-aminophenyl)methanol (3.11) was used instead. The same four step sequence 
involving the enamine formation followed by Dess-Martin oxidation, direct reductive amination 
and cyclization was performed to yield compounds, 3.8ao-ar (Scheme 3.5) 
  
87 
 
 
Scheme 3.3: Synthetic route for the preparation of compounds containing one methylene unit 
between the 4(1H)-quinolone core and the piperazine’s nitrogen. 
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Scheme 3.4: Synthesis of 4(1H)-quinolones with a two carbon linker between the piperazine’s 
nitrogen and the 4(1H)-quinolone core  
 
 
Scheme 3.5: Synthesis of 6-piperazinyl substituted 4(1H)-quinolones. 
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Lastly 3-halo-7-piperazinyl-substituted 4(1H)-quinolone esters 3.8at-au were synthesized 
from piperazinyl aniline 3.5as and Meldrum’s acid30 followed by thermal cyclization to give the 
3-unsubstituted 4(1H)-quinolone 3.8as. This was followed by the use of the appropriate reactive 
N-halo succinimide to obtain the required 3-halo compounds 3.8at and 3.8au. The same 
approach was used for the 3-halo-2 methyl-substituted 4(1H)-quinolones 3.8aw and 3.8ax with 
the exception being that a Conrad-Limpach cyclization using ethyl acetoacetate was used instead 
of the above mentioned cyclization with Meldrum’s acid to give compound 3.8av. This was 
reacted with the appropriate N-halo succinimide to procure compounds 3.8aw and 3.8ax 
(Scheme 3.6). 
Scheme 3.6: Synthesis of 3-halo-4(1H)-quinolones containing a piperizyl moiety 
 
3.3  Structural Activity Relationships 
Due to the poor solubility of previously published 3.1 analogues, a set of ionizable 
piperazine containing 4(1H)-quinolones were introduced with the main aim of this study being to 
enhance their aqueous solubility while maintaining or improving their antimalarial activity in 
vitro. The initial, small set of 6-hydrogen-7-piperazinyl-substituted 4(1H)-quinolones containing 
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a 0-2 carbon linker between the piperazine and the 4(1H)-quinolone’s benzenoid ring were 
prepared to identify the optimum spacer length. Compounds with two carbons between the 
4(1H)-quinolone core and the piperazinyl moiety showed the lowest activities of the group with 
the phenyl piperazine 3.8al showing activities of 25.6 nM for W2 and 1500 nM for TM90-C2B, 
while the benzyl piperazine 3.8am was less active at 116 nM for W2 and 6170 nM for TM90-
C2B. Lastly, the para-methoxybenzyl piperazine 3.8an was the most active for W2 at 11.6 nM 
but the least active for TM90-C2B showing activities greater than 5740 nM. Compound 3.8am 
was the only out of the three that was tested for P. berghei (Pb) activities and displayed an EC50 
of 157 nM. 
Compounds with piperazines directly attached to the quinolone core were more active 
than ones with two carbons. Of the direct linkages, 3.8a was the most active with activities of 
4.45 nM, 248 nM, and 74.1 nM for W2, TM90-C2B, and Pb respectively. Compounds 3.8b and 
3.8d had experimentally identical values for the W2 strain with activities of 16.2 nM and 19.9 
nM respectively, along with 860 nM and 1340 nM for TM90-C2B respectively.  
Overall, compounds with a one-carbon linker were the most active. 4(1H)-quinolones 
3.8p, 3.8q, and 3.8t were identical all with low single digit nM activities for W2. The phenyl-
substituted 3.8p had the most potent Pb activities of the three with an EC50 of 4.74 nM, however 
the TM90-C2B activity of 483 nM gave it a suboptimal RI value of 386. The benzyl-substituted 
compound 3.8q was about 10 times less potent for Pb at 43.7 nM and three times more potent 
against TM90-C2B with an EC50 of 153 nM. The para-methoxybenzyl-substituted analogue 3.8p 
was least active against TM90-C2B exhibiting an activity of 799 nM and an EC50 of 83.4 nM. 
Further rigidification, however, as done in the dioxolane-containing 4(1H)-quinolone 3.8s caused 
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a dramatic 100-fold reduction in W2 antimalarial activity. Although all compounds were active 
they still suffered from high RI values signaling that they may induce cross-resistance in the 
parasite (Table 3.1). 
Table 3.1: Exploration of various N-substituted piperazine moieties in 7-position of the 4(1H)-
quinolone’s benzenoid ring to enhance the solubility and antimalarial activityα 
 
Compound R n 
EC50 
W2 
(nM) 
EC50 
TM90-C2B 
(nM) 
EC50 
Pb 
(nM) 
EC50 
J774 
(µM) 
RI
β
 LBI
γ
 LBI
δ
 
3.8w  1 10.8 1380 169 24.9 128 0.064 0.122 
3.8a  0 4.45 248 74.1 27.5 55.7 0.06 0.299 
3.8p  1 1.25 483 4.74 3.94 386 0.264 0.010 
3.8al  2 25.6 1500 ND 25.5 58.6 ND ND 
3.8b  0 16.2 860 84.5 26.5 53.1 0.192 0.098 
3.8q  1 1.41 153 43.7 10.4 109 0.032 0.29 
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3.8am  2 116 6170 157 24.7 53.2 0.74 0.025 
3.8e  0 19.9 1340 ND ND ND ND ND 
3.8t  1 2.50 799 83.4 5.13 320 2.50 0.104 
3.8an  2 11.6 >5740 ND 23.0 >495 ND ND 
3.8s  1 157 >5740 ND 23.0 >36.6 ND ND 
α
Chloroquine (CQ), Atovaquone (ATO), and Dihydroartemisinin (DHA), are internal controls for each in 
vitro assay. CQ (131 nM TM90-C2B and 162 nM W2), ATO (0.53 nM W2 and >170 nM TM90-C2B) 
and DHA (1.8 nM W2 and, 0.9 nM). N.D.: not determined. 
β
 RI = TM90-C2B/W2; 
γ
 LBI = W2/Pb; 
δ
 LBI = TM90-C2B/Pb 
The antimalarial potency of the phenyl or different benzyl-substituted piperazinyl 4(1H)-
quinolones with varying linker length followed a consistent trend of C1> C0 > C2, restricting the 
further studies only focused to the piperazinyl 4(1H)-quinolones containing C1 or C0 spacer. It 
has also been observed from the above SAR that the 4(1H)-quinolones with polar substituents 
were found to be more aqueous soluble but with a diminished antimalarial activity, whereas the 
opposite effect is observed for the analogues having hydrophobic substituents. Therefore, a 
subtle balance between antimalarial activity and physiochemical properties is of highly important 
in order to identify more drug like small molecules. With these considerations in mind, a small 
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series of 6-methyl and 6-methoxy analogues retaining the 7-piperazinyl moiety was prepared and 
tested for their blood and liver stage antimalarial activity. 
4(1H)-quinolone 3.8x was the most active of the group being very potent for W2 with an 
EC50 of 0.435 nM and 147 nM for TM90-C2B it also possessed single digit activity for Pb at 
6.92 nM. When the N-phenyl-piperazine of 3.8x was exchanged with a N-benzyl-piperazine in 
3.8y, antimalarial activity fell slightly for W2 to 1.45 nM and more so for TM90-C2B to 890 
nM. If the 6-methyl group of 3.8x was exchanged with a 6-methoxy substituent in 3.8ae, there 
was about a three-fold drop in activity to 1.62 nM and 493 nM for W2 and TM90-C2B. When 
the the 4(1H)-quinolone’s benzenoid ring substitutions were both changed to 6-methoxy-7-
benzyl-piperazine in 3.8af, there was a 10 fold drop in activity for W2 and about a 200 fold drop 
in TM90-C2B activity. Para-methoxybenzyl piperazines 3.8z and 3.8n were the least active with 
the 6-methyl analogue having activities of 2.40 nM and 1020 nM for W2 and TM90-C2B and the 
6-methoxy analogue having 9.97 nM and 2750 nM activities.  
Following the previous trend, the C0 spacer compounds were less active than their C1 
spacer mirrors. Interestingly, the antimalarial activity of 6-phenyl-substituted piperazine 3.8c 
was hampered by 10-fold for W2. However, its RI was more than 13 times better than its C1 
analogue. Meanwhile, there was no difference in the activity of 6-methoxy analogue 3.8d with 
3.8c for W2 or TM90-C2B. The benzyl-substituted 3.8k was three times more potent for W2 
with an EC50 of 13.2 nM but the TM90-C2B activity remained unchanged. Surprisingly, methyl 
7-(4-benzylpiperazin-1-yl)-6-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (3.8l) had 
close to a 10 fold increase in potency TM90-C2B while the W2 activity remained virtually 
unchanged from 3.8c giving it an RI of 3.11.  
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Table 3.2: Investigation of the effect of substituent at 6-position of 4(1H)-quinolone benzenoid 
ring on solubility and antimalarial activityα 
 
Compound R
1
 R
2
 n 
EC50 
W2 
(nM) 
EC50 
TM90-C2B 
(nM) 
EC50 
Pb 
(nM) 
EC50 
J774 
(µM) 
RI
β
 LBI
γ
 LBI
δ
 
3.8c  -Me 0 45.5 1110 ND 16.7 24.3 ND ND 
3.8x  -Me 1 0.435 147 6.92 11.9 338 15.9 0.05 
3.8d  -OMe 0 37.2 804 ND 16.8 21.6 ND ND 
3.8ae  -OMe 1 1.62 493 113 24.5 298 0.014 0.23 
3.8k  -Me 0 13.2 982 ND ND 74.4 ND ND 
3.8y  -Me 1 1.45 890 ND ND 613 ND ND 
3.8l  -OMe 0 63.6 198 ND ND 3.11 ND ND 
3.8af  -OMe 1 5.45 2830 9.26 23.7 519 1.70 0.003 
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3.8n  -Me 0 ND ND ND ND ND ND ND 
3.8z  -Me 1 2.40 1022 ND ND 426 ND ND 
3.8o  -OMe 0 ND ND ND ND ND ND ND 
3.8ag  -OMe 1 9.97 2750 52.4 ND 276 5.26 0.019 
3.8aa  -Me 1 5.63 2750 ND ND 488 ND ND 
3.8ah  -OMe 1 6.89 4020 ND ND 583 ND ND 
α
Chloroquine (CQ), Atovaquone (ATO), and Dihydroartemisinin (DHA), are internal controls for each in 
vitro assay. CQ (131 nM TM90-C2B and 162 nM W2), ATO (0.53 nM W2 and >170 nM TM90-C2B) 
and DHA (1.8 nM W2 and, 0.9 nM). N.D.: not determined. 
β
 RI = TM90-C2B/W2; 
γ
 LBI = W2/Pb; 
δ
 LBI = TM90-C2B/Pb 
Overall, it was observed that the phenyl-substituted piperazines were slightly more active 
than the corresponding benzyl analogues against both the blood and liver stages. The 6-methyl 
substituent tended to slightly increase the antimalarial activity whereas the opposite effect is true 
for methoxy substituent, and the effect appeared consistent for all the phenyl and benzyl-
substituted piperazines. While all the piperazinyl 4(1H)-quinolones displayed low potencies 
(micromolar) against a multidrug-resistant TM90-C2B strain, we noted that 6-methyl and 
methoxyphenylpiperazinyl quinolones found to be relatively more active against TM90-C2B, 
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although the RI is still not in an acceptable range. Following the exploration of the six position 
and with data showing that the phenyl piperazines were more active than others, the electronics 
of the phenyl piperazinyl moiety was investigated. The electron withdrawing groups fluorine and 
trifluoromethyl were used along with the electron donating methoxy group. Of all the 
compounds in this subset, the 6-hydrogen substituted 3.8h was not active with µM activities for 
both strains and was inactive in the liver stage assay. The methoxy-substituted 3.8j had about 
100 fold better activities for W2 and TM-90C2B with EC50s of 24.5 nM and 1930 nM 
respectively. Furthermore it had a very respectable EC50 of 1.25 nM for Pb. When the 6-position 
was changed to a methyl as in 3.8i, it had even better activity with a low single digit nM value of 
1.75 for W2, a 429 nM value for TM90-C2B, and 0.357 nM for Pb. The single carbon spacer 
contemporaries of 3.8h-i (3.8u, 3.8aj and 3.8ac) were much more active. This followed the same 
trends as previous compounds of the single carbon spacer being more tolerated than compounds 
with no carbons between the quinolone core and the piperazine. Comopunds 3.8u and 3.8aj were 
experimentally the same for W2 at 1.75 nM and 1.79 nM respectively. 4(1H)-quinolone 3.8ac 
was about twice as potent at 843 pM for W2, however the RI was much higher for this analogue 
was 413, 3 times higher than 3.8aj and 5 times higher than 3.8u. Substituting the aromatic group 
on the piperazine with the electron donating methoxy group generally produced compounds that 
were about half as active as compounds containing the electron withdrawing containing groups, 
with the exceptions being 3.8e. When compared to 3.8h, compound 3.8e showed over a 200 fold 
increase in potency for W2 with an EC50 of 7.76 nM and over a 100 fold increase in potency for 
TM90-C2B with an EC50 of 154 nM. The next set of electron withdrawing correspondents 
introduced a 6-substituted trifluoromethyl group giving compounds 3.8v, 3.8ak and 3.8ad. These 
compounds were overall the most active of the group. Compound 3.8ad was active at 66 pM for 
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W2 and 101 nM for TM90-C2B while 3.8ak and 3.8v rounded out the group with W2 EC50s of 
6.42 and 0.315 nM and TM90-C2B activities of 208 and 122 nM respectively. The 4(1H)-
quinolones with electron donating phenyl piperazines were less active than their electron 
deficient counterparts, however the same trends followed. The 6-methyl substituted quinolones 
were largely more active than the 6- unsubstituted and the 6-methoxy quinolones were the least 
active (Table 3.3).  
Among the 4-substituted phenylpiperazinyl 4(1H)-quinolones, the 6-H-substituted 
analogues displayed preference of potencies towards the Pb strain over the W2 stain and in 
contrast a reversed preference has been observed with 6-methyl and 6-methoxy analogues, while 
the difference in the potencies appeared to be very pronounced for 6-methoxy analogues. 
Although we found few of the 4-phenylpiperazinyl-6-methyl-4(1H)-quinolones to be very 
promising with their TM90-C2B potencies as low as 100 nM, their potency difference with W2 
stain yielding high RI values is a main concern at this point.  
 
Table 3.3: Investigation of the electronic influence of phenyl piperazinyl moiety and the effect 
of substituent at 6-position of the quinolone benzenoid ring on solubility and antimalarial 
activityα 
 
Compound R
1
 R
2
 n 
EC50 
W2 
(nM) 
EC50 
TM90-C2B 
(nM) 
EC50 
Pb 
(nM) 
EC50 
J774 
(µM) 
RI
β
 LBI
γ
 LBI
δ
 
3.8h -F -H 0 2080 16900 <100 ND 8.12 <0.048 0.006 
3.8j -F -OMe 0 24.5 1930 1.25 ND 78.8 0.051 0.0006 
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3.8i -F -Me 0 1.17 429 0.357 ND 366 0.305 0.0008 
3.8u -F -H 1 1.75 131 1.06 2.00 74.9 1.65 0.008 
3.8aj -F -OMe 1 1.79 218 32.3 23.5 122 0.055 0.148 
3.8ac -F -Me 1 0.843 348 2.64 15.7 413 0.319 0.008 
3.8e -OMe -H 0 7.76 154 ND ND 19.8 ND ND 
3.8ae -OMe -H 1 3.56 222 0.123 4.73 62.4 28.9 0.0006 
3.8g -OMe -OMe 0 42.9 1980 ND ND 46.2 ND ND 
3.8ai -OMe -OMe 1 3.38 861 10.4 15.7 255 3.08 0.012 
3.8f -OMe -Me 0 ND ND ND ND ND ND ND 
3.8ab -OMe -Me 1 0.575 177 4.11 23.7 308 7.15 0.023 
3.8v -CF3 -H 1 0.315 122.0 15.6 ND 387 49.5 0.13 
3.8ak -CF3 -OMe 1 6.42 208.5 ND ND 32.5 ND ND 
3.8ad -CF3 -Me 1 0.066 101.1 ND ND 1530 ND ND 
α
Chloroquine (CQ), Atovaquone (ATO), and Dihydroartemisinin (DHA), are internal controls for each in 
vitro assay. CQ (131 nM TM90-C2B and 162 nM W2), ATO (0.53 nM W2 and >170 nM TM90-C2B) 
and DHA (1.8 nM W2 and, 0.9 nM). N.D.: not determined. 
β
 RI = TM90-C2B/W2; 
γ
 LBI = W2/Pb; 
δ
 LBI = TM90-C2B/Pb 
We next considered whether a positional change of the piperazinyl scaffold from 7-
position to 6-position might retain high solubility and the antimalarial potencies against all 
strains with an acceptable RI. A subset of analogues 3.8ap-ar was prepared by simply switching 
the piperazinyl moiety from position 7 to 6 and evaluated for their antimalarial potencies. All the 
6-piperazinyl analogues displayed poor activity compared to their 7-substituted counterparts with 
3-digit nanomolar W2 activity. The exception was the 4-trifluoromethylphenyl analogue 3.8ar 
which displayed a 2-digit nanomolar W2 activity. However, their potencies against the TM90-
C2B stain were identical, all in submicromolar range. Though the potency difference in the 
strains is reduced to some extent, a remarkable drop in the antimalarial activities and solubility 
observed for 6-piperazinyl analogues compared to their 7-position counterparts makes the 6-
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position of the benzenoid inappropriate for piperazinyl moiety. These results further substantiate 
our initial hypothesis that the presence of piperazinyl moiety on 7-position is essential for 
antimalarial activity. 
Table 3.4: Activities of 6-piperazinyl substituted 4(1H)-quinolonesα 
 
Compound R 
EC50 
W2 
(nM) 
EC50 
TM90-C2B 
(nM 
EC50 
Pb 
(nM) 
EC50 
J774 
(µM) 
RI
β
 LBI
γ
 LBI
δ
 
3.8ao -H 150.8 3200 ND ND 21.2 ND ND 
3.8ap -OMe 163.5 2900 ND ND 17.5 ND ND 
3.8aq -F 106.0 2900 ND ND 27.7 ND ND 
3.8ar -CF3 45.2 2900 ND ND 64.1 ND ND 
α
Chloroquine (CQ), Atovaquone (ATO), and Dihydroartemisinin (DHA), are internal controls for each in 
vitro assay. CQ (131 nM TM90-C2B and 162 nM W2), ATO (0.53 nM W2 and >170 nM TM90-C2B) 
and DHA (1.8 nM W2 and, 0.9 nM). N.D.: not determined. 
β
 RI = TM90-C2B/W2; 
γ
 LBI = W2/Pb; 
δ
 LBI = TM90-C2B/Pb 
3-halo piperazines were developed in order to try to mirror the success they brought in 
resolving the RI in the 3.1 analogues. (Table 2.8) The 3-chloro analogue 3.8au was least active at 
1060 nM and 2290 nM, however with an RI of 2.16, it gave hope that the 3-halo effect could be 
distributed to the piperazines. When the 3-chloro substituent was replaced with a 3-bromo, 
activity was gained going to 812 nM for W2 and slightly lost for TM90-C2B dropping to 2430 
nM for TM90-C2B. Like the 3.1 analogues, addition of a 2-methyl substituent gave rise to more 
potent compounds with the chloro-substituted 3.8ar having activities of 38.5 and 52.1 nM for 
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W2 and TM90-C2B, giving it an RI of 1.35. The 3-bromo 3.8aw was even more potent with 
EC50s of 25.1 for W2 and 25.5 for TM90-C2B, and RI of 1.01 (Table 3.5). There was however a 
30 fold difference in Pb activities between the two with 3.8at having an EC50 0.858 nM while 
3.8aw had an EC50 of 26.2 nM. 
Table 3.5: Ester replacement with halogen with and without 2-methyl substitutionsα 
 
Compound R
1
 R
2
 
EC50 
W2 
(nM) 
EC50 
TM90-C2B 
(nM) 
EC50 
Pb 
(nM) 
EC50 
J774 
(µM) 
RI
β
 LBI
γ
 LBI
δ
 
3.8au -Cl -H 1060 2290 ND ND 2.16 ND ND 
3.8ax -Cl -Me 38.5 52.1 ND ND 1.35 ND ND 
3.8at -Br -H 812 2430 0.858 ND 2.99 0.001 0.0004 
3.8aw -Br -Me 25.1 25.5 26.2 ND 1.01 1.04 1.03 
3.8av -H -Me 1220 1450 ND ND 1.19 ND ND 
α
Chloroquine (CQ), Atovaquone (ATO), and Dihydroartemisinin (DHA), are internal controls for each in 
vitro assay. CQ (131 nM TM90-C2B and 162 nM W2), ATO (0.53 nM W2 and >170 nM TM90-C2B) 
and DHA (1.8 nM W2 and, 0.9 nM). N.D.: not determined. 
β
 RI = TM90-C2B/W2; 
γ
 LBI = W2/Pb; 
δ
 LBI = TM90-C2B/Pb 
3.4 Structure Property Relationships Studies 
Encouragingly, the piperazines were overall much more soluble than the ICI 56,780 
analogues previously described in chapter 2. Not surprisingly, there seemed to be a pH 
dependence in the solubility and log D for most analogues. All compounds synthesized with two 
carbon linkers had excellent solubility at both pHs, being comparable or more soluble than our 
upper limit of 100 µM. The log D values of the corresponding C2 compounds were much more 
diverse. Phenyl-substituted 3.8al had acceptable log D value of 5.11 at pH 7.4, however at pH 
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3.0 the value was only 1.27. Comparatively, the benzyl-substituted 3.8am had much lower log D 
values of 0.69 and 1.72 for pH 3.0 and 7.4 respectively. The last C2 compound, the para-
methoxybenzyl-substituted 6an behaved very similar to 3.8am with log D values of 0.75 for pH 
3.0 and 1.68 for pH 7.4. This showed the impact the aromatic vs aliphatic character of the 
piperazine had on affecting the quinolone’s permeability. The analogues with no carbons 
between the piperazine and the quinolone core were least soluble, however, because the values 
were in most cases under the maximum value in the assay (100 µM), it was easier to see trends. 
There was a marked difference in solubility between phenyl benzyl and para-methoxybenzyl 
analogues. The phenyl piperazine 3.8a had solubilities of 15 and 5 for pHs 2.0 and 6.5 
respectively. When the aniline character on both sides was extended to amine character on one 
side as in the benzyl piperazine 3.8b, solubility rose to 70.3 µM for pH 2 and solubility was ≥ 
100 µM for pH 2 when para-methoxybenzyl quinolone 3.8e was used. Substituting the 6-position 
with a methyl 3.8d or methoxy 3.8c also increased solubility as compared to its 6-hydrogen 
substituted analogue 3.8a. The log D had an opposite effect. As the aniline character was 
changed to amine character, the log D dropped substantially for the low pH values. The same 
solubility and log D effect was mirrored in the C1 quinolones. When the piperazinyl moiety was 
moved from the 7 to the 6-position, the effect at low pH could not be observed however, at pH 
6.5 the all had lower solubilities than their 7-substituted counterparts. Lastly, 3-halo piperazines 
had a marked solubility difference between lower and higher pHs. Furthermore, the addition of 
2-methyl groups further lowered solubility with the 2-methyl, 3-bromo quinolone (3.8aw) being 
265 times less soluble than the 2-hydrogen, 3-bromo quinolone (3.8at) (Table 3.6-3.8).  
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Table 3.6: Solubility and log D of piperazinyl 4(1H)-quinolones. 
 
Compound R
1
 R
2
 N 
Solubility
α
 
pH 2.0 
µM 
Solubility 
pH 6.5 
µM 
Log D 
pH 3.0 
 
Log D 
pH 7.4 
 
3.8w  -H 1 ****** ****** 0.780 1.73 
3.8a  -H 0 ** ** 2.08 2.58 
3.8p 
 
-H 1 ****** ****** 0.78 0.86 
3.8al 
 
-H 2 ****** ****** 1.27 5.11 
3.8b  -H 0 ***** ***** 0.75 2.21 
3.8q  -H 1 ****** ****** 1.08 2.06 
3.8am  -H 2 ****** ****** 0.69 1.72 
3.8d  -H 0 ****** **** 0.88 2.08 
3.8t  -H 1 ****** ****** 0.80 1.66 
3.8an  -H 2 ****** ****** 0.75 1.68 
3.8s  -H 1 ****** ****** 0.97 0.87 
3.8c  -Me 0 ****** **** 1.98 2.31 
3.8x  -Me 1 ****** ***** 1.03 2.81 
3.8d  -OMe 0 ****** ** 2.36 2.64 
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3.8ae  -OMe 1 ****** ****** 0.89 1.32 
3.8k  -Me 0 ****** ****** 1.03 2.37 
3.8y 
 
-Me 1 ****** ****** 0.79 1.94 
3.8l  -OMe 0 ***** **** 0.92 2.03 
3.8af  -OMe 1 ****** ***** 0.84 1.28 
3.8n  -Me 1 ****** ****** 1.11 1.96 
3.8z  -OMe 1 ****** ****** 1.35 2.03 
3.8aa  -Me 1 ****** ****** 1.09 2.38 
3.8ah  -OMe 1 ****** ****** 0.880 1.84 
3.8h -F -H 0 ** ** 1.89 2.28 
3.8j -F -OMe 0 ***** **** 1.86 2.70 
3.8i -F -Me 0 *** *** 1.96 3.10 
3.8u -F -H 1 ****** ****** 1.09 2.38 
3.8aj -F -OMe 1 ***** ****** 0.90 1.31 
3.8ac -F -Me 1 ****** **** 1.19 2.90 
3.8e -OMe -H 0 **** *** 1.18 2.44 
3.8ae -OMe -H 1 ****** **** 0.91 2.11 
3.8g -OMe -OMe 0 ***** *** 1.17 2.48 
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3.8ai -OMe -OMe 1 ****** ****** 1.23 2.19 
3.8f -OMe -Me 0 ** ** 1.45 3.16 
3.8ab -OMe -Me 1 ****** *** 1.05 2.61 
3.8v -CF3 -H 1 ****** ** 1.69 3.23 
3.8ak -CF3 -OMe 1 ** ** 0.85 1.29 
3.8ad -CF3 -Me 1 ****** ** 1.81 3.73 
α
 (*) Solubility < 1 μM. (**) 1 < solubility < 19.9 μM. (***) 20.0 μM < solubility < 39.9 μM. (****) 40.0 μM < 
solubility < 59.9 μM. (*****) 60 μM < solubility < 79.9 μM. (******) Solubility ≥80 μM. ND: not determined. 
 
Table 3.7: Solubility and log d of 6-substituted piperazinyl containing quinolonesα 
 
Compound R 
Solubility
α
 
pH 2.0 
(µM) 
Solubility 
pH 6.5 
(µM) 
Log D 
pH 3.0 
 
Log D 
pH 7.4 
 
3.8ao -H ****** *** 0.95 2.03 
3.8ap -OCH3 ****** *** 0.94 1.91 
3.8aq -F ****** ****** 1.06 2.17 
3.8ar -CF3 ****** * 1.74 3.01 
α
 (*) Solubility < 1 μM. (**) 1 < solubility < 19.9 μM. (***) 20.0 μM < solubility < 39.9 μM. (****) 40.0 μM < 
solubility < 59.9 μM. (*****) 60 μM < solubility < 79.9 μM. (******) Solubility ≥80 μM. ND: not determined. 
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Table 3.8: Continued solubility of piperazinyl containing quinolones
α
 
 
Compound R R
2
 
Solubility
α
 
pH 2.0 
(µM) 
Solubility 
pH 6.5 
(µM) 
Log D 
pH 3.0 
 
Log D 
pH 7.4 
 
3.8au -Cl -H ****** **** 1.10 2.57 
3.8ax -Cl -CH3 ****** ** 1.34 2.73 
3.8at -Br -H ****** *** 1.19 2.91 
3.8aw -Br -CH3 ****** * 1.37 2.83 
3.8av -H -CH3 ****** ****** 0.88 2.44 
α
 (*) Solubility < 1 μM. (**) 1 < solubility < 19.9 μM. (***) 20.0 μM < solubility < 39.9 μM. (****) 40.0 μM < 
solubility < 59.9 μM. (*****) 60 μM < solubility < 79.9 μM. (******) Solubility ≥80 μM. ND: not determined. 
 
3.5 In vivo Efficacy Evaluation of Selected Compounds in an Efficacy Scouting Assay. 
 Thirty compounds with potent in vitro activity against both P. falciparum strains were 
chosen to undergo an efficacy scouting assay in P. berghei infected mice. The screens involved a 
single 50mg/kg oral dose 1 day post exposure followed by the assessment of parasitemia on days 
3 and 6. The threshold for active compounds was inhibition greater than 50% on days 3 and 6. 
Compounds 3.8am, 3.8s, 3.8h, 3.8ab, and 3.8l all showed no inhibition at day 6 PE. Compounds 
3.8q, 3.8y, 3.8af, 3.8n, 3.8z, 3.8a, 3.8c, 3.8d, 3.8ap, and 3.8ax displayed little to moderate 
protection on day six (10-35%), delaying the parasites growth.  Compounds 3.8b and 3.8t were 
just under the threshold of activity, with both showing percent inhibition in the lower forties. 
Lastly, compounds tested, 3.8u, 3.8ac, 3.8ak, 3.8ad, 3.8at, 3.8ax, 3.8v, 3.8au, 3.8ae, 3.8ai, and 
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3.8aw,  all showed excellent activities (>70%) in these scout assays with 3.8ak, 3.8ad, and 3.8v 
and 3.8aw having completely inhibited parasite growth even on day 6. (Table 3.9). 
Table 3.9: In vivo scouting assay results on day 3 and 6 post exposureα 
α
 percent inhibition compared to untreated animals 
3.6 In Vivo Efficacy Evaluation of Frontrunner Compounds.  
Using a modified Thompson test model, frontrunner compounds were evaluated in vivo. 
Mice were infected with 1 x 10
6
 Plasmodium berghei –GFP parasites and compounds were 
dosed orally in days 3, 4 and 5 with a 10mg/kg concentration of compound suspended or 
dissolved in HEC/Tween or PEG 400. Parasitemia was observed by flow cytometry on days 3, 6, 
9, 13, 21, and 30 post exposure (PE). Compound evaluation was done based on their reduction of 
parasitemia on day 6 PE and animal survival up to day 30 with compounds displaying 
parasitemia levels of less than 1% on day 30 PE considered to be cures. Lastly, animals with 
more than 40% parasitemia levels were euthanized. A down-selection process occurred from the 
thirty compounds chosen for the scouting assay. Using the in vivo efficacies, RI, LBI, solubility 
Compound 
% Inhibition 
Day 3 PE 
% Inhibition 
Day 6 PE   
Compound 
% Inhibition 
Day 3 PE 
% Inhibition 
Day 6 PE 
3.8b 46.2 43.1   3.8s 40.0 0 
3.8q 100 12.3   3.8ah 60 0 
3.8y 100 24.6   3.8a 38.5 27.5 
3.8af 80.0 19.3   3.8c 80.0 31.6 
3.8am 46.2 0   3.8d 70.0 33.0 
3.8t 69.2 41.2   3.8ap 84.6 31.4 
3.8n 80.0 14.0   3.8ax 46.2 15.7 
3.8z 100 24.6   3.8ae 100 82.4 
3.8ae 100 39.2   3.8ab 100 0 
3.8u 100 98.0   3.8ai 100 70.6 
3.8ac 100 98.3   3.8aj 100 56.9 
3.8ak 100 100   3.8v 100 100 
3.8ad 100 100   3.8l 0 0 
3.8at 0 94.2   3.8au 0 71.9 
3.8ax 100 86.4   3.8aw 100 100 
Amodiaquine 95.5 99.9   Atovaquone 96.3 99.8 
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and log D, 8 compounds were chosen to be used evaluated in our modified Thompson test. For 
all experiments, atovaquone was used as positive control.
31, 32
 
Quinolones 3.8at, 3.8aw and 3.8ax, all had the same day of death as the untreated at 13. This 
was surprising for compound 3.8aw due to its inhibition of 90% on day 6. The remaining 
compounds, 3.8u, 3.8ac, 3.8ak, 3.8ad, 3.8v all had 100% inhibition on day 6. Of these five 
compounds, 3.8u, 3.8ac, and 3.8v had some prolonged survival in comparison to the untreated 
group, however the animals had to be euthanized at day 21 for each of these compounds. The 
remaining compounds both produced cures in more than half of the group, with 3.8ad curing 3 of 
the 5 and 3.8ak curing 4 of the 5 animals (Table 3.10). 
Table 3.10: Results of Thompson Test
 α
 
Compound 
Dose 
(mg/kg) 
% 
Inhibition 
Day 6 
Avg. 
Day of Death 
No of Cures 
3.8u 10 100 21 0/5 
3.8at 10 33 13 0/5 
3.8ax 10 11 13 0/5 
3.8ac 10 100 21 0/5 
3.8ak 10 100 N/A 4/5 
3.8ad 10 100 N/A 3/5 
3.8v 10 100 21 0/5 
3.8aw 10 90.2 13 0/5 
Atovaquone 10 100 N/A 5/5 
α 
percent inhibition as compared to untreated control animals 
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3.7 Conclusions 
Due to our promising results with the previously discussed quinolone esters, we 
synthesized a library of 49 piperazinyl 4(1H)-quinolone esters with the hopes of increasing 
solubility while maintaining or improving activity. The optimal linker length between the 4(1H)-
quinolone’s benzenoid ring and piperazinyl moiety was first explored, followed by the 
optimization of the N phenyl and benzyl substitutents. Next, the electronics of the aromatic ring 
was explored followed by the optimal placement on the quinolone ring. Lastly the RI was 
attempted to be lowered by the previously employed replacement of the ester in the three-
position with either a chlorine or bromine. All compounds were tested in vitro against the 
clinically relevant W2 and TM90-C2B P. falciparum strains. All compounds were also tested in 
house for solubility and log D in parallel, assessing physicochemical properties in an attempt to 
help select in vivo candidates. After a down-selection process, promising compounds were tested 
in in vivo efficacy test.  
Overall, the piperazine-containing quinolones displayed good activity in vitro with many 
possessing low nanomolar activity against W2. The solubility values were also significantly 
improved as compared to 4(1H)-quinolones of past generations. They also maintained their non-
toxic nature as shown in J774 cytotoxicity assays.  
The piperazine compounds suffered from the same RI issues as their predecessors and similarly, 
introduction of the halogen in the three-position reduced the RI substantially. Furthermore, we 
learned that the piperazinyl moiety was much more tolerated in the 7-position as compared to the 
6-position. Furthermore, when the carbon spacer between the piperazine and 4(1H)-quinolone 
core was changed from 1 the activity suffered. Next, electron withdrawing groups on the 
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piperazinyl aromatic group were most potent.  Despite the cross-resistance issues, the piperazinyl 
compounds when subjected to in vivo antimalarial activity in mice infected with Plasmodium 
berghei showed very good protection, with two compounds giving cures. Remarkably, the most 
in vitro active 4-fluoro-phenyl substituted piperazine derivatives displayed a 100% protection 
even after 6 days of PE substantiating the in vitro SAR studies conducted on this novel series of 
piperazinyl 4(1H)-quinolones.  
3.8 Experimental: 
3.8.1 General Information 
All reagents and solvents were obtained from Aldrich Chemical Co. and used without 
further purification. NMR spectra were recorded at ambient temperature on a 400 MHz or 500 
MHz Varian NMR spectrometer in the solvent indicated. All 
1
H NMR experiments are reported 
in δ units, parts per million (ppm) downfield of TMS, and were measured relative to the signals 
of chloroform (7.26 ppm) and dimethylsulfoxide (39.5 ppm) with 
1
H decoupled observation. 
Data for 
1
H NMR are reported as follows: chemicals shift (δ ppm), multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, p = pentet, sext = sextet, sept = septet, oct = octet, m = multiplet), 
integration and coupling constant (Hz) whereas 
13
C NMR analyses were reported in terms of 
chemical shift. NMR data was analyzed by using MestReNova Software version 6.0.2-5475. The 
purity of the final compounds was determined to be ≥95% by high-performance liquid 
chromatography (HPLC) using an Agilent 1100 LC/MSD-VL with electrospray ionization. 
Melting points were determined using a MEL-TEMP 3.0 instrument and are uncorrected. Low-
resolution mass spectra were performed on an Agilent 1100 LC/MSD-VL with electrospray 
ionization. High-resolution mass spectra (HRMS) were performed on an Agilent LC/MSD TOF 
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system G3250AA. Analytical thin layer chromatography (TLC) was performed on silica gel 60 
F254 precoated plates (0.25 mm) from EMD Chemical Inc., and components were visualized by 
ultraviolet light (254 nm). EMD silica gel 230-400 (particle size 40-63 µm) mesh was used for 
all flash column chromatography. Microwave heating was performed in a single-mode Anton 
Paar Monowave 300 and all microwave-irradiated reactions were conducted in heavy-walled 
glass vials sealed with Teflon septa. 
3.8.2 General Procedure A for the piperazinyl alkylation 
A mixture of piperazine (1 equiv), 3-nitrobenzyl bromide/3-nitrophenethyl bromide (1.1 
equiv) and TEA (1.5 equiv) in anhydrous THF was stirred for overnight at room temperature. 
The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (3 x 20 mL).  
The combined organic extracts were dried over Na2SO4, filtered, and concentrated under reduced 
pressure. The crude was purified by flash chromatography (90:20 → 70:30, hexanes:EtOAc) to 
afford the title compounds. 
3.8.3 General Procedure B for NO2 reduction 
A mixture of nitro compound (1 equiv) and SnCl2 (3 equiv) in absolute ethanol was 
refluxed for 3h. The reaction was neutralized with 4N KOH solution and extracted with EtOAc. 
The combined organic extracts were dried over Na2SO4, filtered, and concentrated under reduced 
pressure. The crude was purified by flash chromatography using 100% ethyl acetate. 
3.8.4 General Procedure C for enamine formation  
A neat mixture of aniline/aminobenzyl alcohol (1 equiv) and dimethyl 2-
(methoxymethylene)malonate (1.05 equiv) was heated at 110 °C for 30 min. The reaction 
mixture was allowed to cool to room temperature while precipitation arose. Diethyl ether was 
111 
 
added to the mixture to improve the precipitation. The solid was filtered off and washed with 
diethyl ether, dried under vacuum, and used directly for the further transformations. 
3.8.5 General Procedure D for the oxidation of alcohols using Dess-Martin 
periodinane 
To a solution of alcohol (1.0 equiv) in anhydrous CH2Cl2 was added the Dess-Martin 
periodinane (1.5 equiv) at room temperature. The resulting mixture was stirred for 3 h at room 
temperature. The mixture was treated with aqueous NaHCO3 solution and filtered through a 
sintered funnel while washing with CH2Cl2. The organic phase was separated, dried over 
Na2SO4, filtered, and concentrated to give the aldehyde in almost pure form which was used 
directly for further transformations. 
3.8.6 General Procedure E for the reductive amination of aldehydes 
To a mixture of aldehyde (1 equiv) and piperazine/piperazinyl hydrochloride (1.2 equiv) 
in anhydrous THF was added anhydrous MgSO4 (2 equiv) followed by N,N-
diisopropylethylamine (2.5 equiv) at room temperature, and the resulting solution was stirred 
vigorously for 30 min. To this was then added sodium triacetoxyborohydride (2 equiv). The 
reaction was stirred for an additional 4 h at room temperature, quenched with saturated NaHCO3 
solution, and extracted with EtOAc. The combined organic fractions were washed with brine, 
dried over Na2SO4, and concentrated under reduced pressure. The crude was purified by flash 
chromatography gradient elution (80:20 → 50:50, hexanes:EtOAc) to afford the title compounds.  
3.8.7 General Procedure F for the thermal 4(1H)-quinolone cyclization 
The enamine in toluene was subjected to microwave heating at 280 °C for 4 min. The 
reaction mixture was allowed to cool to room temperature while precipitation arose. Diethyl 
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ether was added to the mixture to improve the precipitation. The solid was filtered off and 
washed with diethyl ether.  The solid containing the unreacted enamine and quinolone regio-
isomers was then refluxed in methanol (in most of the cases unless it is mentioned otherwise) for 
1 h and filtered hot to give the title quinolones in purest form.  
3.8.8 General Procedure G for the synthesis of 3- halo substituted piperizinyl 
4(1H) quinolones 
To a solution of quinolone (1 equiv) in anhydrous CH2Cl2 was added freshly 
recrystallized NBS/NCS (1.2 equiv) at room temperature, and the resulting mixture was stirred 
overnight. The reaction was concentrated and the crude was purified by either recrystallization or 
HPLC. 
 
3.8.9 Compound characterization data: 
 
1-(3-nitrophenethyl)-4-phenylpiperazine (3.4al): was obtained as a pale yellow semi-solid 
(600 mg,  62% yield) by alkylation of phenyl piperazine (500 mg, 3.08 mmol) with 3-
nitrophenethyl bromide (780 mg, 3.4 mmol) following general method A. 
1
H NMR (400 MHz, 
CDCl3): δ 8.16 – 8.04 (m, 2H), 7.57 (d, J = 7.6 Hz, 1H), 7.46 (t, J = 7.9 Hz, 1H), 7.33 – 7.23 (m, 
2H), 7.00 – 6.82 (m, 3H), 3.31 – 3.17 (m, 4H), 2.96 (t, J = 7.8 Hz, 2H), 2.71 (q, J = 5.5, 5.0 Hz, 
6H). 
13
C NMR (101 MHz, CDCl3): δ 151.19, 148.30, 142.28, 135.04, 129.20, 129.10 (2C), 
123.57, 121.30, 119.80, 116.08 (2C), 77.34, 77.03, 76.71, 59.52, 53.17 (2C), 49.12 (2C), 33.08. 
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1-benzyl-4-(3-nitrophenethyl)piperazine (3.4am): was obtained as an orange yellow oil (800 
mg,  63% yield) by alkylation of benzyl piperazine (690 mg, 4.0 mmol) with 3-nitrophenethyl 
bromide (1.0 g, 4.3 mmol) following general method A. 
1
H NMR (400 MHz, CDCl3): δ 8.06 (t, J 
= 2.0 Hz, 1H), 8.03 (ddd, J = 8.1, 2.4, 1.1 Hz, 1H), 7.54 – 7.50 (m, 1H), 7.41 (t, J = 7.9 Hz, 1H), 
7.32 – 7.20 (m, 5H), 3.51 (s, 2H), 2.91 – 2.85 (m, 2H), 2.65 – 2.59 (m, 2H), 2.59 – 2.45 (m, 8H). 
13
C NMR (101 MHz, CDCl3): δ 148.25, 142.45, 138.02, 135.01, 129.18 (2C), 129.14, 128.19 
(2C), 127.03, 123.55, 121.19, 77.41, 77.10, 76.78, 63.02, 59.56, 53.12 (2C), 53.02 (2C), 33.12. 
 
1-(4-methoxybenzyl)-4-(3-nitrophenethyl)piperazine (3.4an):was obtained as an orange 
yellow oil (1.3 g, 59% yield) by alkylation of 4-methoxybenzyl piperazine (1.3 g, 6.3 mmol) 
with 3-nitrophenethyl bromide (1.5 g, 6.9 mmol) following general method A. 
1
H NMR (400 
MHz, CDCl3): δ 8.07 – 7.95 (m, 2H), 7.48 (t, J = 8.3, 1H), 7.37 (dd, J = 16.5, 8.6, 1H), 7.23 – 
7.15 (m, 2H), 6.86 – 6.78 (m, 2H), 3.79 – 3.69 (m, 3H), 3.46 – 3.37 (m, 2H), 2.92 – 2.78 (m, 
2H), 2.59 (dd, J = 9.0, 6.7, 2H), 2.48 (d, J = 22.1, 8H). 
13
C NMR (101 MHz, CDCl3): δ 158.68, 
148.21, 142.47, 135.00, 130.32, 130.01, 129.12, 123.51, 121.14, 113.53, 77.49, 77.17, 76.85, 
62.37, 59.52, 55.17, 53.10, 52.91, 33.09. 
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3-(2-(4-phenylpiperazin-1-yl)ethyl)aniline (3.5al): A nitro reduction reaction (500 mg, 1.6 
mmol) following method B resulted in the title compound as orange yellow semi-solid (450 mg, 
99% yield). 
1
H NMR (400 MHz, CDCl3): δ 7.30 – 7.24 (m, 2H), 7.08 (t, J = 7.7 Hz, 1H), 6.97 – 
6.92 (m, 2H), 6.88 – 6.84 (m, 1H), 6.63 (dt, J = 7.6, 1.2 Hz, 1H), 6.56 – 6.52 (m, 2H), 3.60 (bs, 
2H), 3.26 – 3.22 (m, 4H), 2.79 – 2.74 (m, 2H), 2.71 – 2.62 (m, 6H). 13C NMR (101 MHz, 
CDCl3): δ 151.26, 146.41, 141.42, 129.28, 129.05 (2C), 119.65, 118.97, 116.00, 115.43 (2C), 
112.92, 60.41, 53.20 (2C), 49.11 (2C), 33.56. 
 
3-(2-(4-benzylpiperazin-1-yl)ethyl)aniline (3.5am): A nitro reduction reaction (700 mg, 2.1 
mmol) following general method B resulted in the title compound as yellow oil (550 mg, 86% 
yield). 
1
H NMR (400 MHz, CDCl3): δ 7.32 – 7.29 (m, 4H), 7.28 – 7.20 (m, 1H), 7.04 (td, J = 
7.3, 1.4 Hz, 1H), 6.58 (dt, J = 7.3, 1.3 Hz, 1H), 6.50 (dd, J = 7.1, 1.1 Hz, 2H), 3.91 (s, 2H), 3.52 
(s, 2H), 2.76 – 2.66 (m, 2H), 2.57 (ddd, J = 23.4, 12.1, 4.9 Hz, 10H). 13C NMR (101 MHz, 
CDCl3): δ 146.38, 141.27, 137.78, 129.21, 129.17 (2C), 128.13 (2C), 127.00, 118.87, 115.36, 
112.86, 62.89, 60.21, 52.91, 52.90, 52.72, 33.29. 
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3-(2-(4-(4-methoxybenzyl)piperazin-1-yl)ethyl)aniline (3.5an): A nitro reduction reaction (1.0 
g, 3.0 mmol) following general method B resulted in the title compound as orange yellow semi-
solid (820 mg, 90% yield). 
1
H NMR (400 MHz, CDCl3): δ 7.20 (t, J = 8.4 Hz, 3H), 7.03 (t, J = 
7.7 Hz, 1H), 6.83 (dd, J = 8.4, 5.8 Hz, 3H), 6.57 (d, J = 7.6 Hz, 1H), 6.49 (d, J = 7.0 Hz, 2H), 
3.77 (s, 3H), 3.43 (s, 2H), 2.69 (dd, J = 10.6, 5.7 Hz, 2H), 2.64 – 2.39 (m, 10H). 13C NMR (101 
MHz, CDCl3): δ 158.60, 146.35, 141.42, 130.31 (2C), 129.90, 129.17, 118.84, 115.34, 113.46 
(2C), 112.79, 62.32, 60.33, 55.13, 53.03 (2C), 52.81 (2C), 33.45. 
 
 
1-(4-Fluorophenyl)-4-(3-nitrobenzyl)piperazine (3.4u): was obtained as white solid (8.5 g, 
97% yield) by alkylation of 4-florophenyl piperazine (5.0 g, 27.7 mmol) with 3-nitrobenzyl 
bromide (6.6 g, 30.5 mmol) following general method A. White solid, 97% yield. 
1
H NMR (400 
MHz, CDCl3): δ 8.21 (t, J = 2.0 Hz, 1H), 8.09 (ddd, J = 8.2, 2.4, 1.1 Hz, 1H), 7.68 (dt, J = 7.7, 
1.3 Hz, 1H), 7.47 (t, J = 7.9 Hz, 1H), 6.95 – 6.89 (m, 2H), 6.87 – 6.81 (m, 2H), 3.63 (s, 2H), 3.16 
– 3.05 (m, 4H), 2.65 – 2.56 (m, 4H). 13C NMR (101 MHz, CDCl3): δ 158.20, 155.82, 148.26, 
147.81, 147.79, 140.45, 134.92, 129.11, 123.58, 122.14, 117.74, 117.66, 115.47, 115.25, 61.81, 
52.96 (2C), 49.98 (2C). 
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3-((4-(4-Fluorophenyl)piperazin-1-yl)methyl)aniline (3.6u): A nitro reduction reaction (8.4 g, 
26.6 mmol) following general method B resulted in the title compound as a pale yellow solid 
(7.3 g, 96% yield). 
1
H NMR (400 MHz, methanol-d4): δ 7.04 (t, J = 7.7 Hz, 1H), 6.92 – 6.82 (m, 
4H), 6.68 (t, J = 2.0 Hz, 1H), 6.65 (dt, J = 7.5, 1.3 Hz, 1H), 6.60 (ddd, J = 8.0, 2.3, 1.0 Hz, 1H), 
3.40 (s, 2H), 3.06 – 3.01 (m, 4H), 2.58 – 2.52 (m, 4H). 13C NMR (101 MHz, methanol-d4) δ 
159.46, 157.09, 148.88, 148.86, 148.17, 138.65, 129.85, 120.43, 118.92, 118.85, 117.42, 116.22, 
116.00, 115.43, 63.89, 53.75 (2C), 50.69 (2C). 
 
Dimethyl 2-(((3-(hydroxymethyl)phenyl)amino)methylene)malonate (3.12a): (Pale yellow 
solid, 6.4 g, quantitative yield) was prepared from 3-aminobenzyl alcohol (3 g, 24.4mmol) 
according to the procedure described in general method C. 
1
H NMR (400 MHz, CDCl3): δ 10.93 
(d, J = 13.8 Hz, 1H), 8.44 (d, J = 13.8 Hz, 1H), 7.26 (t, J = 7.8 Hz, 1H), 7.11 – 7.04 (m, 2H), 
6.97 – 6.93 (m, 1H), 4.63 (s, 2H), 3.77 (s, 3H), 3.70 (s, 3H), 2.83 (bs, 1H). 13C NMR (101 MHz, 
CDCl3): δ 169.10, 165.98, 151.94, 143.23, 139.05, 129.74, 123.20, 116.03, 115.17, 92.62, 64.29, 
51.45, 51.39. 
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Dimethyl 2-(((3-(hydroxymethyl)-4-methoxyphenyl)amino)methylene)malonate (3.12c): 
(violet red semi-solid, 5.3 g, 92% yield) was prepared from 5-amino-2-methoxybenzyl alcohol 
(3.0 g, 19.6 mmol) according to the procedure described in general method C. 
1
H NMR (400 
MHz, CDCl3) δ 10.96 (d, J = 13.8 Hz, 1H), 8.40 (d, J = 13.9 Hz, 1H), 7.13 (d, J = 2.9 Hz, 1H), 
7.01 – 6.95 (m, 1H), 6.83 – 6.78 (m, 1H), 4.65 (s, 1H), 3.81 (s, 3H), 3.80 (s, 2H), 3.73 (s, 2H). 
13
C NMR (101 MHz, CDCl3): δ 169.40, 166.06, 154.60, 152.75, 132.42, 130.89, 117.62, 117.46, 
110.98, 91.78, 60.95, 55.59, 51.43, 51.32. 
 
Dimethyl 2-(((3-(hydroxymethyl)-4-methylphenyl)amino)methylene)malonate (3.12b): 
(pale white solid, 5.5 g, 95% yield.) was prepared from 5-amino-2-methoxybenzyl alcohol (3.0 
g, 21.9 mmol) according to the procedure described in general method C. 
1
H NMR (400 MHz, 
CDCl3): δ 10.94 (d, J = 13.9 Hz, 1H), 8.44 (dd, J = 13.9, 0.7 Hz, 1H), 7.15 (d, J = 2.5 Hz, 1H), 
7.07 (d, J = 8.1 Hz, 1H), 6.88 (dd, J = 8.0, 2.6 Hz, 1H), 4.62 (s, 2H), 3.76 (s, 3H), 3.71 (s, 3H), 
2.21 (s, 3H).  
13
C NMR (101 MHz, CDCl3): δ 169.19, 166.09, 152.11, 140.79, 136.99, 132.24, 
131.18, 115.72, 115.57, 92.01, 62.42, 51.39, 51.34, 17.87. 
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Dimethyl 2-(((3-((4-phenylpiperazin-1-yl)methyl)phenyl)amino)methylene)malonate (3.7p): 
A direct reductive amination (DRA) reaction between aldehyde-145 (1.0 g, 3.8 mmol) and 
piperazine (740 mg, 4.6 mmol) following general method E afforded the title compound as a 
brown yellow semi-solid (1.1 g, 72% yield). 
1
H NMR (400 MHz, CDCl3): δ 11.02 (d, J = 13.6 
Hz, 1H), 8.52 (dd, J = 13.7, 2.1 Hz, 1H), 7.31 – 6.96 (m, 6H), 6.90 – 6.75 (m, 3H), 3.79 (d, J = 
2.5 Hz, 3H), 3.73 (d, J = 2.2 Hz, 3H), 3.51 (d, J = 2.8 Hz, 2H), 3.16 (t, J = 4.9 Hz, 4H), 2.57 (t, J 
= 5.0 Hz, 4H). 
13
C NMR (101 MHz, CDCl3): δ 168.96, 165.63, 151.85, 150.91, 139.83, 138.92, 
129.43, 128.78 (2C), 125.52, 119.37, 117.55, 115.74 (2C), 115.64, 92.57, 62.25, 52.80 (2C), 
51.26, 51.15, 48.68 (2C). 
 
Dimethyl 2-(((3-((4-benzylpiperazin-1-yl)methyl)phenyl)amino)methylene)malonate (3.7q): 
A direct reductive amination (DRA) reaction between aldehyde-145 (500 mg, 1.9 mmol) and 
piperazine (400 mg, 2.3 mmol) following general method E afforded the title compound as a 
yellow oil (600 mg, 75% yield). 
1
H NMR (400 MHz, CDCl3): δ 11.00 (d, J = 13.8 Hz, 1H), 8.52 
(dd, J = 13.8, 1.2 Hz, 1H), 7.30 – 7.24 (m, 5H), 7.20 (ddt, J = 5.9, 4.8, 2.4 Hz, 1H), 7.11 (t, J = 
1.8 Hz, 1H), 7.06 (dt, J = 7.6, 1.2 Hz, 1H), 7.02 – 6.98 (m, 1H), 3.83 (d, J = 1.4 Hz, 3H), 3.76 (d, 
J = 1.3 Hz, 3H), 3.49 (d, J = 1.2 Hz, 2H), 3.46 (s, 2H), 2.55 – 2.36 (m, 8H). 13C NMR (101 MHz, 
CDCl3): δ 169.22, 165.92, 152.16, 140.51, 139.03, 137.91, 129.50, 129.09 (2C), 128.07 (2C), 
126.91, 125.74, 117.76, 115.64, 92.62, 62.91, 62.53, 53.03 (2C), 52.87 (2C), 51.47, 51.35. 
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Dimethyl 2-(((3-((4-(4-methoxybenzyl)piperazin-1-yl)methyl)phenyl)amino) 
methylene)malonate (3.7r): A DRA reaction between aldehyde-145 (1.0 g, 3.8 mmol) and 4-
methoxybenzyl piperazine (940 mg, 4.6 mmol) following general method E afforded the title 
compound as a yellow oil (1.2 g, 70% yield). 
1
H NMR (400 MHz, CDCl3): δ 10.99 (d, J = 13.8 
Hz, 1H), 8.51 (d, J = 13.8 Hz, 1H), 7.27 – 7.23 (m, 1H), 7.19 – 7.15 (m, 2H), 7.10 (t, J = 1.9 Hz, 
1H), 7.05 (dt, J = 7.6, 1.2 Hz, 1H), 6.99 (ddd, J = 8.1, 2.5, 1.0 Hz, 1H), 6.82 – 6.78 (m, 2H), 3.81 
(s, 3H), 3.74 (s, 4H), 3.74 (s, 4H), 3.45 (s, 2H), 3.41 (s, 2H), 2.43 (s, 8H). 
13
C NMR (101 MHz, 
CDCl3): δ 169.20, 165.89, 158.56, 152.14, 140.51, 139.01, 130.26 (2C), 129.84, 129.47, 125.71, 
117.73, 115.61, 113.42 (2C), 92.59, 62.50, 62.25, 55.08, 52.99 (2C), 52.73 (2C), 51.45, 51.33. 
 
Dimethyl 2-(((3-((4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)methyl)phenyl) 
amino)methylene)malonate (3.7s): A DRA reaction between aldehyde-145 (500 mg, 1.9 mmol) 
and piperonyl piperazine (500 mg, 2.3 mmol) following general method E afforded the title 
compound as a yellow oil (600 mg, 67% yield). 
1
H NMR (400 MHz, CDCl3): δ 11.01 (d, J = 
13.7 Hz, 1H), 8.53 (d, J = 13.9 Hz, 1H), 7.32 – 7.23 (m, 2H), 7.12 (t, J = 1.9 Hz, 1H), 7.07 (dt, J 
= 7.7, 1.1 Hz, 1H), 7.01 (ddd, J = 8.0, 2.5, 0.9 Hz, 1H), 6.82 (d, J = 1.1 Hz, 1H), 6.75 – 6.68 (m, 
2H), 5.90 (d, J = 0.6 Hz, 2H), 3.83 (d, J = 0.6 Hz, 4H), 3.76 (d, J = 0.5 Hz, 3H), 3.48 (s, 2H), 
3.41 (s, 2H), 2.46 (s, 8H).  
13
C NMR (101 MHz, CDCl3): δ 169.29, 165.99, 152.23, 147.53, 
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146.54, 140.50, 139.10, 131.71, 129.56, 125.80, 122.24, 117.82, 115.71, 109.50, 107.77, 100.80, 
92.68, 62.63, 62.55, 53.01 (2C), 52.75 (2C), 51.53, 51.42. 
 
 
Dimethyl 2-(((4-methoxy-3-((4-phenylpiperazin-1-yl)methyl)phenyl)amino) 
methylene)malonate (3.7ae):  A DRA reaction between aldehyde-157 (300 mg, 1.0 mmol) and 
phenyl piperazine (200 mg, 1.22 mmol) following Method-E afforded the title compound as a 
pale yellow semi-solid (305 mg, 68% yield). 
1
H NMR (400 MHz, CDCl3): δ 11.00 (d, J = 13.9 
Hz, 1H), 8.46 (d, J = 14.0 Hz, 1H), 7.27 – 7.18 (m, 3H), 7.01 (dd, J = 8.7, 2.9 Hz, 1H), 6.94 – 
6.88 (m, 2H), 6.85 – 6.78 (m, 2H), 3.82 (s, 3H), 3.80 (s, 3H), 3.74 (s, 3H), 3.58 (s, 2H), 3.22 – 
3.19 (m, 4H), 2.66 – 2.62 (m, 4H). 13C NMR (101 MHz, CDCl3): δ 169.46, 166.14, 155.40, 
152.90, 151.27, 132.36, 129.00 (2C), 128.02, 119.79, 119.54, 116.74, 115.97 (2C), 111.40, 
91.65, 55.76, 55.58, 53.13 (2C), 51.43, 51.32, 49.09 (2C). 
 
Dimethyl 2-(((3-((4-benzylpiperazin-1-yl)methyl)-4-methoxyphenyl)amino)methylene) 
malonate (3.7af): A DRA reaction between aldehyde-157 (500 mg, 1.7 mmol) and benzyl 
piperazine (360 mg, 2.0 mmol) following Method-E afforded the title compound as a pale yellow 
semi-solid (500 mg, 65% yield). 
1
H NMR (400 MHz, CDCl3): δ 10.97 (d, J = 14.0 Hz, 1H), 8.44 
(d, J = 13.9 Hz, 1H), 7.30 – 7.26 (m, J = 2.6 Hz, 4H), 7.23 – 7.18 (m, 2H), 6.97 (dd, J = 8.7, 2.9 
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Hz, 1H), 6.80 (d, J = 8.7 Hz, 1H), 3.83 (s, 3H), 3.77 (s, 3H), 3.75 (s, 3H), 3.52 (s, 2H), 3.49 (s, 
2H), 2.50 (s, 8H).  
13
C NMR (101 MHz, CDCl3): δ 169.45, 166.11, 155.38, 152.91, 138.04, 
132.29, 129.15 (2C), 128.19, 128.10 (2C), 126.92, 119.78, 116.59, 111.29, 91.57, 63.00, 55.69, 
55.48, 53.06 (2C), 53.02 (2C), 51.41, 51.28. 
 
Dimethyl 2-(((4-methoxy-3-((4-(4-methoxyphenyl)piperazin-1-yl)methyl)phenyl)amino) 
methylene)malonate (3.7ag): A DRA reaction between aldehyde-157 (350 mg, 1.2 mmol) and 
4-methoxybenzyl piperazine (295 mg, 1.4 mmol) following Method-E afforded the title 
compound as pale yellow semi-solid (350 mg, 61%). 
1
H NMR (400 MHz, CDCl3) δ 11.02 – 
10.91 (m, 1H), 8.44 (d, J = 14.0 Hz, 1H), 7.25 – 7.17 (m, 3H), 6.98 (dd, J = 8.7, 2.9 Hz, 1H), 
6.85 – 6.77 (m, 3H), 3.83 (s, 3H), 3.77 (s, 3H), 3.76 (s, 3H), 3.75 (s, 2H), 3.54 (s, 2H), 3.46 (s, 
2H), 2.52 (s, 8H). 
13
C NMR (101 MHz, CDCl3) δ 169.50, 166.16, 158.76, 155.42, 152.97 (2C), 
132.35 (2C), 130.50 (2C), 119.90, 116.77, 113.57 (2C), 111.35, 91.64, 62.28, 55.71, 55.44, 
55.23, 55.17, 52.88, 52.78, 51.50, 51.43, 51.37. 
 
Dimethyl 2-(2-(3-((4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)methyl)-4-
methoxyphenyl)ethylidene)malonate (3.7ah): A DRA reaction between aldehyde-157 (500 
mg, 1.7 mmol) and piperonyl piperazine (450 mg, 2.0 mmol) following Method-E afforded the 
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title compound as pale yellow oil (630 mg, 75%). 
1
H NMR (400 MHz, CDCl3): δ 10.97 (d, J = 
13.9 Hz, 1H), 8.45 (d, J = 13.9 Hz, 1H), 7.28 – 7.17 (m, 1H), 6.99 (dd, J = 8.7, 2.9 Hz, 1H), 6.82 
(d, J = 8.8 Hz, 2H), 6.71 (s, 2H), 5.90 (d, J = 1.4 Hz, 2H), 3.83 (s, 3H), 3.78 (s, 3H), 3.76 (s, 3H), 
3.53 (s, 2H), 3.41 (s, 2H), 2.50 (bs, 8H). 
13
C NMR (101 MHz, CDCl3) δ 169.51, 166.17, 155.43, 
152.98, 147.55, 146.53, 132.35, 131.91, 128.13, 122.26, 119.87, 116.68, 111.34, 109.53, 107.79, 
100.82, 91.63, 62.71, 55.75, 55.50, 53.06 (2C), 52.88 (2C), 51.47, 51.34. 
 
Dimethyl 2-(((4-methyl-3-((4-phenylpiperazin-1-yl)methyl)phenyl)amino) 
methylene)malonate (3.7x): A DRA reaction between aldehyde-152 (600 mg, 2.2 mmol) and 
phenyl piperazine (430 mg, 2.6 mmol) following Method-E afforded the title compound as white 
semi solid (700 mg, 77%). 
1
H NMR (400 MHz, CDCl3): δ 11.02 (1H), 8.52 (d, J = 13.9 Hz, 1H), 
7.23 – 7.20 (m, 2H), 7.15 – 7.12 (m, 2H), 6.95 (d, J = 8.2 Hz, 2H), 6.91 – 6.88 (dd, J = 8.8, 1.1 
Hz, 2H), 6.84 – 6.80 (m, 1H), 3.83 (s, 3H), 3.75 (s, 3H), 3.47 (s, 2H), 3.19 – 3.13 (m, 4H), 2.62 – 
2.55 (m, 4H), 2.32 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 169.21, 165.88, 152.18, 151.11, 
138.03, 136.70, 134.14, 131.33, 128.86 (2C), 119.41, 118.48, 115.82 (2C), 115.27, 92.04, 60.16, 
53.04 (2C), 51.32, 51.21, 48.98 (2C), 18.55. 
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Dimethyl 2-(((3-((4-benzylpiperazin-1-yl)methyl)-4-methylphenyl)amino) 
methylene)malonate (3.7y): A DRA reaction between aldehyde-152 (650 mg, 2.3 mmol) and 
benzyl piperazine (500 mg, 2.8 mmol) following Method-E afforded the title compound as pale 
yellow semi solid (630 mg, 63%). 
1
H NMR (400 MHz, CDCl3): δ 10.98 (d, J = 13.8 Hz, 1H), 
8.50 (dd, J = 13.9, 0.9 Hz, 1H), 7.32 – 7.20 (m, 5H), 7.13 – 7.07 (m, 2H), 6.92 (dd, J = 8.1, 2.5 
Hz, 1H), 3.83 (s, 3H), 3.76 (s, 3H), 3.50 (s, 2H), 3.41 (s, 2H), 2.47 (s, 8H), 2.28 (s, 3H). 
13
C 
NMR (101 MHz, CDCl3): δ 169.30, 165.96, 152.32, 138.38, 137.90, 136.73, 134.11, 131.28, 
129.07 (2C), 128.06 (2C), 126.90, 118.46, 115.17, 92.01, 62.90, 60.05, 53.09 (2C), 53.00 (2C), 
51.39, 51.27, 18.58. 
 
Dimethyl 2-(((3-((4-(4-methoxybenzyl)piperazin-1-yl)methyl)-4-methylphenyl)amino) 
methylene)malonate (3.7z): A DRA reaction between aldehyde-152 (200 mg, 1.4 mmol) and 4-
methoxybenzyl piperazine (350 mg, 1.7 mmol) following Method-E afforded the title compound 
as pale yellow semi-solid (430 mg, 70%). 
1
H NMR (400 MHz, CDCl3): δ 10.95 (d, J = 13.9 Hz, 
1H), 8.46 (d, J = 13.9 Hz, 1H), 7.19 – 7.12 (m, 2H), 7.07 – 7.01 (m, 2H), 6.87 (dd, J = 8.1, 2.5 
Hz, 1H), 6.79 – 6.75 (m, 2H), 3.78 (s, 3H), 3.71 (s, 3H), 3.70 (s, 3H), 3.38 (s, 2H), 3.36 (s, 2H), 
2.40 (s, 8H), 2.23 (s, 3H). 
13
C NMR (101 MHz, CDCl3): δ 169.09, 165.75, 158.39, 152.10, 
138.25, 136.57, 133.91, 131.11, 130.04 (2C), 129.80, 118.26, 114.99, 113.25 (2C), 91.86, 62.12, 
59.90, 54.86, 52.97 (2C), 52.73 (2C), 51.19, 51.07, 18.41. 
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Dimethyl 2-(((3-((4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)methyl)-4-methyl 
phenyl)amino)methylene)malonate (3.7aa): A DRA reaction between aldehyde-152 (600 mg, 
2.2 mmol) and piperonyl piperazine (572 mg, 2.6 mmol) following Method-E afforded the title 
compound as pale yellow semi-solid (800 mg, 77% yield). 
1
H NMR (400 MHz, CDCl3): δ 11.01 
– 10.93 (m, 1H), 8.50 (d, J = 13.9 Hz, 1H), 7.13 – 7.07 (m, 2H), 6.92 (dd, J = 8.2, 2.6 Hz, 1H), 
6.82 (d, J = 1.0 Hz, 1H), 6.70 (d, J = 1.0 Hz, 2H), 5.89 (s, 2H), 3.83 (s, 2H), 3.76 (s, 3H), 3.76 (s, 
4H),  2.44 – 2.41  (m, 8H), 2.27 (s, 3H).  13C NMR (101 MHz, CDCl3) δ 169.41, 166.10, 152.45, 
147.55, 146.51, 138.50, 136.83, 134.22, 131.97, 131.36, 122.20, 118.57, 115.27, 109.49, 107.78, 
100.81, 92.09, 62.72, 60.13, 53.21 (2C), 52.96 (2C), 51.49, 51.38, 26.87. 
 
Dimethyl 2-(((3-((4-(4-methoxyphenyl)piperazin-1-yl)methyl)phenyl)amino) 
methylene)malonate (3.7t): A DRA reaction between aldehyde-145 (500 mg, 1.9 mmol) and 4-
methoxyphenylpiperazine hydrochloride (604 mg, 2.3 mmol) following Method-E afforded the 
title compound as pale yellow semi-solid (565 mg, 68% yield). 
1
H NMR (400 MHz, CDCl3): δ 
11.03 (d, J = 13.8 Hz, 1H), 8.54 (d, J = 13.8 Hz, 1H), 7.30 (t, J = 7.8 Hz, 1H), 7.16 (t, J = 1.9 Hz, 
1H), 7.11 (dt, J = 7.6, 1.2 Hz, 1H), 7.05 – 7.01 (m, 1H), 6.89 – 6.84 (m, 2H), 6.82 – 6.78 (m, 
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2H), 3.83 (s, 3H), 3.76 (s, 3H), 3.73 (s, 3H), 3.53 (s, 2H), 3.10 – 3.05 (m, 4H), 2.59 (dd, J = 6.0, 
3.8 Hz, 4H). 
13
C NMR (101 MHz, CDCl3): δ 169.28, 165.99, 153.73, 152.20, 145.62, 140.36, 
139.14, 129.64, 125.81, 118.16 (2C), 117.85, 115.81, 114.34 (2C), 92.73, 62.58, 55.47, 53.21, 
51.53 (2C), 51.43, 50.53 (2C). 
 
Dimethyl 2-(((3-((4-(4-fluorophenyl)piperazin-1-yl)methyl)phenyl)amino) 
methylene)malonate (3.7u): A direct reductive amination (DRA) reaction between aldehyde-
145 (500 mg, 1.9 mmol) and 4-florophenyl piperazine (410 mg, 2.3 mmol) following Method-E 
afforded the title compound as pale yellow semi-solid (580 mg, 72%). 
1
H NMR (400 MHz, 
CDCl3): δ 11.04 (d, J = 13.6 Hz, 1H), 8.54 (dd, J = 13.9, 3.6 Hz, 1H), 7.30 (td, J = 7.8, 3.5 Hz, 
1H), 7.16 (s, 1H), 7.12 (d, J = 7.5 Hz, 1H), 7.06 – 7.01 (m, 1H), 6.92 (td, J = 8.6, 3.5 Hz, 2H), 
6.84 (dt, J = 9.0, 4.3 Hz, 2H), 3.83 (d, J = 3.2 Hz, 3H), 3.76 (d, J = 3.2 Hz, 3H), 3.53 (bs, 2H), 
3.11 – 3.08 (m, Hz, 4H), 2.60 – 2.58 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 169.17, 165.88, 
158.15, 155.77, 152.07, 147.83, 147.81, 140.26, 139.08, 129.57, 125.64, 117.68, 117.60, 115.72, 
115.43, 115.21, 92.70, 62.44, 53.00 (2C), 51.43, 51.33, 49.95 (2C). 
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Dimethyl 2-(((3-((4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)methyl)phenyl)amino) 
methylene)malonate (3.7v): A direct reductive amination (DRA) reaction between aldehyde-
145 (500 mg, 1.9 mmol) and 4-trifloromethylphenyl piperazine (840 mg, 2.3 mmol) following 
Method-E afforded the title compound as pale yellow semi-solid (980 mg, 68% yield).
 1
H NMR 
(400 MHz, CDCl3): δ 11.03 (d, J = 13.8 Hz, 1H), 8.53 (dd, J = 13.8, 1.0 Hz, 1H), 7.41 (d, J = 8.7 
Hz, 2H), 7.28 (t, J = 7.8 Hz, 1H), 7.14 (t, J = 1.8 Hz, 1H), 7.09 (dd, J = 7.7, 1.3 Hz, 1H), 7.04 – 
7.00 (m, 1H), 6.85 (d, J = 8.6 Hz, 2H), 3.81 (s, 3H), 3.74 (s, 3H), 3.50 (s, 2H), 3.23 (t, J = 5.1 
Hz, 4H), 2.54 (dd, J = 6.1, 3.9 Hz, 4H). 
13
C NMR (101 MHz, CDCl3) δ 169.13, 165.83, 153.09, 
151.99, 140.11, 139.08, 129.58, 126.21, 126.17, 126.13, 126.10, 125.55, 117.59, 115.73, 114.25 
(2C), 92.72, 62.37, 52.63 (2C), 51.38, 51.28, 47.70 (2C). 
 
Dimethyl 2-(((4-methoxy-3-((4-(4-methoxyphenyl)piperazin-1-yl)methyl)phenyl)amino) 
methylene)malonate (3.7ai): A DRA reaction between aldehyde-157 (200 mg, 0.7 mmol) and 
4-methoxypiperazine hydrochloride (220 mg, 0.82 mmol) following Method-E afforded the title 
compound as pale yellow semi-solid (250 mg, 78%). 
1
H NMR (400 MHz, CDCl3): δ 11.00 (d, J 
= 13.9 Hz, 1H), 8.47 (d, J = 13.9 Hz, 1H), 7.28 – 7.24 (m, 1H), 7.02 (dd, J = 8.7, 2.9 Hz, 1H), 
6.92 – 6.77 (m, 5H), 3.83 (s, 4H), 3.82 (s, 3H), 3.75 (s, 3H), 3.74 (s, 3H), 3.61 (s, 2H), 3.14 – 
3.08 (m, 4H), 2.67 (t, J = 5.0 Hz, 4H).  
13
C NMR (101 MHz, CDCl3) δ 169.51, 166.18, 155.45, 
153.75, 152.96 (2C), 145.70, 132.41, 119.93, 118.21 (2C), 116.84, 114.38 (2C), 111.45, 91.71, 
55.81, 55.57, 55.52, 53.24, 51.48, 51.37, 50.59. 
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Dimethyl 2-(((3-((4-(4-fluorophenyl)piperazin-1-yl)methyl)-4-methoxyphenyl)amino) 
methylene)malonate (3.7aj): A DRA reaction between aldehyde-157 (500 mg, 1.7 mmol) and 
4-florophenyl piperazine (220 mg, 2.0 mmol) following Method-E afforded the title compound 
as pale yellow semi-solid (550 mg, 71%). 
1
H NMR (400 MHz, CDCl3): δ 11.03 – 10.94 (m, 1H), 
8.44 (dd, J = 13.9, 12.3 Hz, 1H), 7.25 – 7.14 (m, 1H), 7.03 – 6.97 (m, 1H), 6.96 – 6.89 (m, 2H), 
6.87 – 6.82 (m, 3H), 3.82 (s, 3H), 3.80 (s, 3H), 3.74 (s, 3H), 3.59 (s, 2H), 3.15 – 3.10 (m, 4H), 
2.68 – 2.61 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 169.49, 166.21, 158.28, 155.91, 155.44, 
154.60, 152.94, 152.79, 147.96, 132.48, 132.40, 130.98, 127.84, 119.88, 117.82, 117.74, 117.64, 
117.46, 116.84, 115.54, 115.32, 111.46, 111.00, 91.71, 77.37, 77.05, 76.73, 60.90, 55.79, 55.61, 
55.54, 53.12 (2C), 51.47, 51.37, 51.34, 50.10 (2C). 
 
Dimethyl 2-(((4-methoxy-3-((4-(4-(trifluoromethyl)phenyl)piperazin-1-
yl)methyl)phenyl)amino)methylene)malonate (3.7ak): A DRA reaction between aldehyde-157 
(1.0 g, 3.4 mmol) and 4-trifloromethylphenyl piperazine (950 mg, 4.1 mmol) following Method-
E afforded the title compound as pale yellow semi-solid (1.2 g, 70% yield).
 1
H NMR (400 MHz, 
CDCl3): δ 11.00 (d, J = 13.9 Hz, 1H), 8.48 – 8.42 (m, 1H), 7.46 – 7.40 (m, 2H), 7.22 (d, J = 2.9 
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Hz, 1H), 7.00 (dd, J = 8.8, 2.9 Hz, 1H), 6.89 – 6.81 (s, 3H), 3.81 (m, 3H), 3.79 (s, 3H), 3.73 (S, 
3H), 3.57 (s, 2H), 3.27 (t, J = 5.0 Hz, 3H), 2.61 (t, J = 5.0 Hz, 3H).  
13
C NMR (101 MHz, 
CDCl3) δ 169.48, 166.18, 155.42, 153.27, 152.89, 132.40, 127.85, 126.34, 126.31, 126.27, 
126.23, 119.78, 116.83, 114.37 (2C), 111.46, 91.74, 55.76, 55.55, 52.82 (2C), 51.44, 51.35, 
47.89 (2C). 
 
Dimethyl 2-(((3-((4-(4-fluorophenyl)piperazin-1-yl)methyl)-4-methylphenyl)amino) 
methylene)malonate (3.7ac) A DRA reaction between aldehyde-152 (600 mg, 2.16 mmol) and 
4-florophenyl piperazine (470 mg, 2.6 mmol) following Method-E afforded the title compound 
as yellow semi-solid (800 mg, 84% yield).
 1
H NMR (400 MHz, CDCl3): δ 11.00 (d, J = 13.9 Hz, 
1H), 8.49 – 8.42 (m, 1H), 7.46 – 7.39 (m, 2H), 7.22 (d, J = 2.9 Hz, 1H), 7.00 (dd, J = 8.8, 2.9 Hz, 
1H), 6.89 – 6.82 (m, 3H), 3.81 (s, 3H), 3.79 (s, 3H), 3.73 (s, 3H), 3.57 (s, 2H), 3.27 (t, J = 5.0 
Hz, 4H), 2.61 (t, J = 5.0 Hz, 4H). 
13
C NMR (101 MHz, CDCl3) δ 169.42, 166.12, 158.28, 
155.90, 152.41, 147.95, 138.14, 136.89, 134.34, 131.52, 118.70, 117.80, 117.73, 115.55, 115.47, 
115.33, 92.22, 60.26, 53.20 (2C), 51.52, 51.42, 50.18 (2C), 18.71. 
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Dimethyl 2-(((3-((4-(4-methoxyphenyl)piperazin-1-yl)methyl)-4-methylphenyl)amino) 
methylene)malonate (3.7ab) A DRA reaction between aldehyde-152 (600 mg, 2.16 mmol) and 
4-methoxyphenylpiperazine hydrochloride (690 mg, 2.6 mmol) following Method-E afforded the 
title compound as pale yellow semi-solid (685 mg, 70%). 
1
H NMR (400 MHz, CDCl3): δ 11.00 
(d, J = 13.9 Hz, 1H), 8.52 (d, J = 13.9 Hz, 1H), 7.15 – 7.11 (m, 2H), 6.95 (dd, J = 8.2, 2.5 Hz, 
1H), 6.90 – 6.85 (m, 2H), 6.83 – 6.78 (m, 2H), 3.83 (s, 3H), 3.75 (s, 3H), 3.73 (s, 3H), 3.48 (s, 
2H), 3.09 – 3.05 (m, 4H), 2.60 (dd, J = 6.1, 3.7 Hz, 4H), 2.32 (s, 3H). 13C NMR (101 MHz, 
CDCl3): δ 169.41, 166.10, 153.71, 152.42, 145.69, 138.26, 136.84, 134.34, 131.46, 118.69, 
118.14 (2C), 115.40, 114.36 (2C), 92.15, 60.28, 55.50, 53.32 (2C), 51.50, 51.40, 50.65 (2C), 
18.70. 
 
Dimethyl 2-(((4-methyl-3-((4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)methyl)phenyl) 
amino)methylene)malonate (3.7ad): A DRA reaction between aldehyde-152 (1.0 g, 3.6 mmol) 
and 4-trifloromethylphenyl piperazine (1.0 g, 4.4 mmol) following Method-E afforded the title 
compound as pale yellow semi-solid (1.17 g, 66% yield). 
1
H NMR (400 MHz, CDCl3): δ 10.98 
(d, J = 13.8 Hz, 1H), 8.47 (d, J = 13.9 Hz, 1H), 7.37 (d, J = 8.6 Hz, 2H), 7.09 – 7.05 (m, 2H), 
6.89 (dd, J = 8.2, 2.5 Hz, 1H), 6.80 (d, J = 8.6 Hz, 2H), 3.76 (s, 3H), 3.70 (s, 3H), 3.40 (s, 2H), 
3.17 (dd, J = 6.2, 3.7 Hz, 4H), 2.51 (t, J = 5.0 Hz, 4H), 2.26 (s, 3H).  
13
C NMR (101 MHz, 
CDCl3): δ 169.02, 165.68, 152.96, 151.90, 137.68, 136.59, 133.97, 131.24, 126.01, 125.98, 
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125.94, 125.90, 118.25, 115.15, 114.01 (2C), 92.00, 59.93, 52.50 (2C), 51.09, 50.99, 47.55 (2C), 
18.30. 
 
 
Dimethyl 2-(((4-((4-phenylpiperazin-1-yl)methyl)phenyl)amino)methylene)malonate 
(3.7al): A DRA reaction of aldehyde-209b (500 mg, 1.89 mmol) with 4-
methoxyphenylpiperazine hydrochloride (370 mg, 2.3 mmol) following Method-E furnished the 
title compound as pale yellow semi-solid (520 mg, 67% yield). 
1
H NMR (400 MHz, CDCl3): δ 
11.04 (d, J = 13.9 Hz, 1H), 8.52 (d, J = 13.7 Hz, 1H), 7.34 (d, J = 8.0 Hz, 2H), 7.23 (t, J = 7.7 
Hz, 2H), 7.09 (d, J = 8.0 Hz, 2H), 6.90 (d, J = 8.1 Hz, 2H), 6.82 (t, J = 7.3 Hz, 1H), 3.84 (s, 3H), 
3.76 (s, 3H), 3.52 (s, 2H), 3.17 (t, J = 4.8 Hz, 4H), 2.58 (t, J = 4.8 Hz, 4H). 
13
C NMR (101 MHz, 
CDCl3): δ 169.31, 165.89, 152.22, 151.23, 138.07, 135.11, 130.48 (2C), 129.00 (2C), 119.57, 
117.10 (2C), 115.95 (2C), 92.65, 62.21, 53.01 (2C), 51.52, 51.38, 49.05 (2C). 
 
 
Dimethyl 2-(((4-((4-(4-methoxyphenyl)piperazin-1-yl)methyl)phenyl)amino)methylene) 
malonate (3.7am): A DRA reaction of aldehyde-209b (850 mg, 3.2 mmol) with 4-
methoxyphenylpiperazine hydrochloride (1.0 g, 3.86 mmol) following Method-E furnished the 
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title compound as pale yellow solid (1.0 g, 71% yield). 
1
H NMR (400 MHz, CDCl3): δ 11.01 (d, 
J = 13.8 Hz, 1H), 8.49 (dd, J = 13.7, 1.1 Hz, 1H), 7.31 (d, J = 8.0 Hz, 2H), 7.07 (d, J = 8.1 Hz, 
2H), 6.84 (d, J = 9.1 Hz, 2H), 6.80 – 6.76 (m, 2H), 3.81 (s, 3H), 3.73 (s, 3H), 3.70 (s, 2H), 3.49 
(s, 2H), 3.04 (t, J = 4.8 Hz, 4H), 2.55 (t, J = 4.8 Hz, 4H). 
13
C NMR (101 MHz, CDCl3): δ 169.18, 
165.78, 153.58, 152.10, 145.52, 137.95, 135.01, 130.40 (2C), 117.97 (2C), 117.02, 116.99, 
114.23 (2C), 92.53, 62.10, 55.34, 53.00 (2C), 51.40, 51.28, 50.41 (2C). 
 
 
Dimethyl 2-(((4-((4-(4-fluorophenyl)piperazin-1-yl)methyl)phenyl)amino)methylene) 
malonate (3.7an): A DRA reaction of aldehyde-209b (850 mg, 3.2 mmol) with 4-florophenyl 
piperazine (695 mg, 3.86 mmol) following Method-E furnished the title compound as pale white 
solid (900 mg, 66% yield). 
1
H NMR (400 MHz, CDCl3): δ 11.01 (d, J = 13.7 Hz, 1H), 8.49 (d, J 
= 13.8 Hz, 1H), 7.33 – 7.29 (m, 2H), 7.07 (dd, J = 9.0, 2.5 Hz, 2H), 6.92 – 6.87 (m, 2H), 6.84 – 
6.79 (m, 2H), 3.81 (s, 3H), 3.73 (s, 3H), 3.49 (s, 2H), 3.06 (t, J = 5.0 Hz, 4H), 2.54 (dd, J = 6.1, 
3.9 Hz, 4H). 
13
C NMR (101 MHz, CDCl3): δ 169.19, 165.79, 158.11, 155.74, 152.09, 147.83, 
147.81, 138.00, 134.96, 130.38, 117.61, 117.54, 117.01, 115.41, 115.19, 92.58, 62.06, 52.89, 
51.42, 51.29, 49.95. 
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Dimethyl 2-(((4-((4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)methyl)phenyl)amino) 
methylene)malonate (3.7ao): A DRA reaction of aldehyde-209b (500 mg, 1.9 mmol) with 4-
trifloromethylphenyl piperazine (523 mg, 2.3 mmol) following Method-E furnished the title 
compound as pale yellow solid (570 mg, 63% yield). 
1
H NMR (400 MHz, CDCl3): δ 11.03 (d, J 
= 13.7 Hz, 1H), 8.52 (dd, J = 13.7, 1.1 Hz, 1H), 7.43 (d, J = 1.2 Hz, 2H), 7.34 (d, J = 7.4 Hz, 
2H), 7.12 – 7.08 (m, 2H), 6.90 – 6.86 (m, 2H), 3.83 (s, 3H), 3.76 (s, 3H), 3.51 (s, 2H), 3.27 – 
3.23 (m, 4H), 2.56 (dd, J = 6.1, 4.1 Hz, 4H). 
13
C NMR (101 MHz, CDCl3): δ 169.35, 165.94, 
153.25, 152.23, 138.20, 134.94, 130.49 (2C), 126.37, 126.33, 126.29, 126.26, 117.17 (2C), 
114.41 (2C), 92.77, 62.18, 52.70 (2C), 51.56, 51.43, 47.92 (2C). 
 
Methyl 4-oxo-7-((4-phenylpiperazin-1-yl)methyl)-1,4-dihydroquinoline-3-carboxylate 
(3.8p): 
1
H NMR (400 MHz, DMSO-d6): δ 12.58 (s, 1H), 8.57 (d, J = 6.4, 1H), 8.22 (d, J = 7.9, 
1H), 7.69 (s, 1H), 7.51 (d, J = 8.0, 1H), 7.22 (t, J = 7.9, 2H), 6.94 (d, J = 8.1, 2H), 6.82 (t, J = 
7.2, 1H), 3.78 (s, 2H), 3.72 (s, 3H), 3.53 (m, 4H), 3.21 (s, 4H). 
13
C NMR (101 MHz, DMSO-d6): 
δ 173.74, 165.89, 151.43, 145.72, 143.76, 139.77, 129.34 (2C), 126.83, 126.12, 125.79, 119.25, 
118.74, 115.80 (2C), 109.81, 61.87, 53.10 (2C), 51.52, 48.69 (2C). 
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Methyl 4-oxo-7-(2-(4-phenylpiperazin-1-yl)ethyl)-1,4-dihydroquinoline-3-carboxylate 
(3.8al): 
1
H NMR (400 MHz, DMSO-d6): δ 12.59 (s, 1H), 8.55 (s, 1H), 8.25 (m, 1H), 7.49 (s, 
1H), 7.35 (d, J = 10.5, 2H), 7.26 (t, J = 7.9, 2H), 7.01 (d, J = 8.1, 2H), 6.86 (t, J = 7.3, 1H), 3.85 
(m, 2H), 3.73 (s, 3H), 3.51 – 3.43 (m, 4H), 3.19 (dd, J = 9.9, 6.6, 4H), 3.02 (m, 2H).  
 
Methyl 7-((4-benzylpiperazin-1-yl)methyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 
compound (3.8q): 
1
H NMR (400 MHz, methanol-d6):  δ 8.67 (s, 1H), 7.95 (d, J = 8.3, 1H), 7.61 
(s, 1H), 7.47 – 7.34 (m, 6H), 4.41 (s, 2H), 4.30 (s, 2H), 3.83 (s, 3H), 3.61 (s, 4H), 3.49 (s, 4H). 
 
Methyl 7-(2-(4-benzylpiperazin-1-yl)ethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(3.8am): 
1
H NMR (400 MHz, DMSO-d6): δ 12.22 (s, 1H), 8.50 (s, 1H), 8.04 (s, 1H), 7.41 (s, 
1H), 7.28 (m, 6H), 3.72 (s, 3H), 3.44 (s, 2H), 3.31 (s, 2H), 2.84 (s, 2H), 2.48 – 2.37 (m, 8H). 
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Methyl 7-((4-benzylpiperazin-1-yl)methyl)-6-methoxy-4-oxo-1,4-dihydroquinoline-3-
carboxylate (3.8af): 
1
H NMR (500 MHz, DMSO-d6): 12.30 (bs, 1H), δ 8.48 (s, 1H), 7.67 (s, 
1H), 7.53 (s, 1H), 7.33 – 7.23 (m, 5H), 3.85 (s, 3H), 3.72 (s, 3H), 3.55 (s, 2H), 3.47 (s, 2H), 2.44 
(m, 8H). 
 
Methyl 7-((4-benzylpiperazin-1-yl)methyl)-6-methyl-4-oxo-1,4-dihydroquinoline-3-
carboxylate (3.8y): 
1
H NMR (400 MHz, DMSO-d6): δ 12.20 (s, 1H), 8.47 (s, 1H), 7.89 (d, J = 
1.0 Hz, 1H), 7.52 (s, 1H), 7.33 – 7.17 (m, 5H), 3.72 (s, 3H), 3.51 (s, 2H), 3.46 (s, 2H), 2.44 (s, 
8H), 2.37 (s, 3H). 
 
Methyl 7-((4-(4-methoxybenzyl)piperazin-1-yl)methyl)-4-oxo-1,4-dihydroquinoline-3-
carboxylate (3.8r): 
1
H NMR (400 MHz, DMSO-d6): δ 12.27 (s, 1H), 8.52 (s, 1H), 8.08 (d, J = 
8.0, 1H), 7.52 (s, 1H), 7.32  (d, J = 8.1, 1H), 7.17 (d, J = 7.0, 3H), 6.85 (d, J = 6.8, 3H), 3.74 (d, 
J = 20.2, 9H), 3.57 (s, 3H), 3.36 (d, J = 17.5, 3H), 2.38 (s, 9H). 
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Methyl 7-(2-(4-(4-methoxybenzyl)piperazin-1-yl)ethyl)-4-oxo-1,4-dihydroquinoline-3-
carboxylate (3.8an): 
1
H NMR (400 MHz, DMSO-d6): δ 12.47 – 11.99 (m, 0H), 8.52 (d, J = 
33.3, 1H), 8.10 (s, 1H), 7.46 (s, 1H), 7.33 (s, 1H), 7.23 (s, 2H), 6.92 (s, 2H), 3.77 (s, 10H), 2.89 
(s, 3H), 2.55 (s, 17H), 2.40 (s, 4H). 
 
Methyl 6-methoxy-7-((4-(4-methoxybenzyl)piperazin-1-yl)methyl)-4-oxo-1,4-
dihydroquinoline-3-carboxylate (3.8ag): 
1
H NMR (400 MHz, DMSO-d6): δ 12.43 (s, 1H), 8.51 
(s, 1H), 7.60 (d, J = 12.7 Hz, 2H), 7.44 – 7.34 (m, 2H), 7.04 – 6.96 (m, 2H), 4.20 (s, 2H), 4.15 – 
3.90 (m, 0H), 3.87 (s, 3H), 3.77 (d, J = 0.7 Hz, 3H), 3.74 – 3.71 (m, 3H), 3.49 – 2.80 (m, 6H). 
 
Methyl 7-((4-(4-methoxybenzyl)piperazin-1-yl)methyl)-6-methyl-4-oxo-1,4-
dihydroquinoline-3-carboxylate (3.8z): 
1
H NMR (400 MHz, DMSO-d6): δ 12.27 (s, 1H), 8.51 
(s, 1H), 7.91 (s, 1H), 7.56 (s, 1H), 7.20 (d, J = 7.8 Hz, 2H), 6.88 (d, J = 8.0 Hz, 2H), 3.74 (s, 6H), 
3.52 (s, 2H), 3.41 (s, 2H), 2.45 (s, 8H), 2.38 (s, 3H). 
13
C NMR (101 MHz, DMSO-d6) δ 173.56, 
165.92, 158.72, 144.98, 142.63, 137.63, 134.24, 130.56 (2C), 126.46, 118.68, 113.98 (2C), 
109.60, 61.87, 59.78, 55.44 (2C), 53.32, 52.95 (2C), 51.50, 19.11. 
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Methyl 7-((4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)methyl)-4-oxo-1,4-
dihydroquinoline-3-carboxylate (3.8s): 
1
H NMR (400 MHz, DMSO-d6): δ 12.33 (bs, 1H), 8.51 
(s, 1H), 8.10 (s, 1H), 7.52 (s, 1H), 7.35 (s, 1H), 6.98– 6.89 (m, 3H), 6.00 (s, 2H), 3.92 (m, 4H), 
3.70 (s, 3H), 2.82 (m, 8H). 
 
Methyl 7-((4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)methyl)-6-methoxy-4-oxo-1,4-
dihydroquinoline-3-carboxylate (3.8ah): 
1
H NMR (500 MHz, CDCl3 + methanol-d6): δ 8.43 
(s, 1H), 7.71 (s, 1H), 7.47 (s, 1H), 6.77 (s, 1H), 6.68 (s, 2H), 5.88 (s, 2H), 3.86 (s, 3H), 3.84 (s, 
3H), 3.66 (s, 2H), 3.40 (s, 2H), 2.58 – 2.49 (m, 8H).  
 
Methyl 7-((4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)methyl)-6-methyl-4-oxo-1,4-
dihydroquinoline-3-carboxylate (3.8aa): 
 1
H NMR (400 MHz, DMSO-d6) δ 12.22 (s, 1H), 8.48 
(s, 1H), 7.89 (s, 1H), 7.54 (s, 1H), 6.82 (d, J = 7.5 Hz, 2H), 6.72 (d, J = 7.9 Hz, 1H), 5.97 (s, 2H), 
3.71 (s, 3H), 3.51 (s, 2H), 3.37 (s, 2H), 2.42 (s, 8H), 2.36 (s, 4H). 
13
C NMR (101 MHz, DMSO-
d6): δ 173.65, 165.95, 147.60, 146.58, 145.00, 142.70, 137.61, 134.33, 126.45, 126.33, 122.51, 
118.68, 109.99, 109.58, 108.28, 101.20, 62.13, 59.75, 53.29 (2C), 52.90 (2C), 51.54, 19.11. 
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Methyl 6-methoxy-4-oxo-7-((4-phenylpiperazin-1-yl)methyl)-1,4-dihydroquinoline-3-
carboxylate(3.8ae): 
1
H NMR (400 MHz, DMSO-d6): δ 12.29 (s, 1H), 8.52 – 8.42 (m, 1H), 7.72 
(d, J = 14.8 Hz, 1H), 7.59 – 7.51 (m, 1H), 7.25 – 7.12 (m, 2H), 6.93 (d, J = 8.3 Hz, 2H), 6.76 (t, 
J = 7.2 Hz, 1H), 3.87 (s, 3H), 3.70 (m, 3H), 3.61 (d, J = 13.9 Hz, 2H), 3.21 – 3.12 (m, 4H), 2.61 
(t, J = 5.0 Hz, 4H). 
 
 
Methyl 6-methyl-4-oxo-7-((4-phenylpiperazin-1-yl)methyl)-1,4-dihydroquinoline-3-
carboxylate (3.8x): 
1
H NMR (400 MHz, DMSO-d6): δ 12.22 (s, 1H), 8.48 (s, 1H), 7.89 (s, 1H), 
7.58 (s, 1H), 7.16 (t, J = 7.8 Hz, 2H), 6.89 (d, J = 8.1 Hz, 2H), 6.73 (t, J = 7.3 Hz, 1H), 3.69 (s, 
3H), 3.56 (s, 2H), 3.11 (m, 4H), 2.55 (t, J = 5.0 Hz, 4H), 2.37 (s, 3H). 
13
C NMR (101 MHz, 
DMSO-d6): δ 173.58, 165.91, 151.41, 145.03, 137.63, 134.32, 129.36 (2C), 126.48, 119.28, 
118.82, 115.80 (2C), 109.63, 59.74, 53.25 (2C), 51.50, 48.75 (2C), 19.18. 
 
Methyl 7-((4-(4-methoxyphenyl)piperazin-1-yl)methyl)-4-oxo-1,4-dihydroquinoline-3-
carboxylate (3.8t): 
1
H NMR (400 MHz, DMSO-d6): δ 12.31 (s, 1H), 8.55 (s, 1H), 8.12 (d, J = 
8.2 Hz, 1H), 7.60 (s, 1H), 7.38 (d, J = 8.3 Hz, 1H), 6.88 (d, J = 8.7 Hz, 2H), 6.81 (d, J = 9.1 Hz, 
2H), 3.74 (s, 3H), 3.68 (s, 3H), 3.65 (s, 2H), 3.03 (t, J = 4.6 Hz, 4H), 2.58 – 2.53 (m, 4H). 13C 
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NMR (101 MHz, DMSO-d6): δ 173.70, 165.85, 153.33, 145.83, 145.50, 143.91, 139.53, 126.79, 
126.14, 125.83, 118.50, 117.78, 114.68, 109.93, 61.86, 55.62, 53.23, 51.55, 50.11.  
 
Methyl 6-methoxy-7-((4-(4-methoxyphenyl)piperazin-1-yl)methyl)-4-oxo-1,4-
dihydroquinoline-3-carboxylate (3.8ai): 
1
H NMR (400 MHz, DMSO-d6): δ 12.29 (s, 1H), 8.48 
(s, 1H), 7.72 (s, 1H), 7.55 (s, 1H), 6.91 – 6.85 (m, 2H), 6.80 (d, J = 9.0 Hz, 2H), 3.87 (s, 3H), 
3.71 (s, 4H), 3.66 (s, 3H), 3.62 (s, 2H), 3.05 (t, J = 4.7 Hz, 4H), 2.60 (t, J = 4.8 Hz, 5H). 
13
C 
NMR (101 MHz, DMSO-d6): δ 173.15, 165.94, 155.22, 153.31, 145.82, 144.07, 133.68, 127.54, 
119.46, 117.71 (2C), 114.68 (2C), 108.75, 104.48, 56.06, 55.59, 53.43 (2C), 51.45, 50.16 (2C).  
 
Methyl 7-((4-(4-methoxyphenyl)piperazin-1-yl)methyl)-6-methyl-4-oxo-1,4-
dihydroquinoline-3-carboxylate (3.8ab): 
1
H NMR (400 MHz, DMSO-d6): δ 12.26 (s, 1H), 8.55 
– 8.45 (m, 1H), 7.93 (d, J = 4.8 Hz, 1H), 7.59 (d, J = 4.8 Hz, 1H), 6.82 (ddd, J = 29.5, 8.9, 4.9 
Hz, 4H), 3.73 (s, 4H), 3.67 (s, 3H), 3.04 (m, 4H), 2.66 (m, 4H), 2.41 (s, 3H). 
13
C NMR (101 
MHz, DMSO): δ 173.24, 165.35, 152.97, 144.55, 137.12, 133.89, 126.18, 117.39 (2C), 114.17 
(2C), 114.18 (2C), 109.12, 79.20, 78.87, 78.54, 55.09, 52.81 (2C), 50.97, 49.63 (2C), 18.79. 
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Methyl 7-((4-(4-fluorophenyl)piperazin-1-yl)methyl)-4-oxo-1,4-dihydroquinoline-3-
carboxylate (3.8u): 
1
H NMR (400 MHz, DMSO-d6): δ 12.29 (s, 1H), 8.53 (s, 1H), 8.10 (d, J = 
8.3 Hz, 1H), 7.57 (d, J = 1.4 Hz, 1H), 7.35 (dd, J = 8.2, 1.5 Hz, 1H), 7.04 – 6.98 (m, 2H), 6.93 – 
6.89 (m, 2H), 3.72 (s, 3H), 3.63 (s, 2H), 3.07 (t, J = 4.9 Hz, 4H), 2.53 (t, J = 4.9 Hz, 5H).  
13
C 
NMR (101 MHz, DMSO-d6): δ 173.69, 165.83, 157.59, 155.25, 148.33, 145.51, 143.83, 139.53, 
126.79, 126.14, 125.83, 118.52, 117.56, 117.48, 115.79, 115.57, 109.93, 61.81, 53.07 (2C), 
51.54, 49.47 (2C). 
 
Methyl 7-((4-(4-fluorophenyl)piperazin-1-yl)methyl)-6-methoxy-4-oxo-1,4-
dihydroquinoline-3-carboxylate (3.8aj): 
1
H NMR (400 MHz, DMSO-d6): δ 12.29 (s, 1H), 8.49 
(s, 1H), 7.73 (s, 1H), 7.56 (s, 1H), 7.03 (t, J = 8.7 Hz, 2H), 6.94 (dd, J = 9.2, 4.7 Hz, 2H), 3.88 (s, 
3H), 3.72 (s, 3H), 3.63 (s, 2H), 3.12 (t, J = 4.6 Hz, 4H), 2.61 (t, J = 4.8 Hz, 4H). 
13
C NMR (101 
MHz, DMSO-d6): δ 173.16, 165.96, 157.60, 155.24, 148.37, 144.11, 133.71, 133.63, 127.56, 
119.51, 117.50, 117.43, 115.82, 115.60, 108.77, 104.50, 56.08, 55.59, 53.32, 51.48, 49.57. 
 
Methyl 7-((4-(4-fluorophenyl)piperazin-1-yl)methyl)-6-methyl-4-oxo-1,4-dihydroquinoline-
3-carboxylate (3.8ac): 
1
H NMR (400 MHz, DMSO-d6): δ 12.23 (s, 1H), 8.50 (s, 1H), 7.92 (s, 
1H), 7.59 (s, 1H), 7.03 (t, J = 8.7 Hz, 2H), 6.93 (dd, J = 9.2, 4.6 Hz, 2H), 3.72 (s, 3H), 3.59 (s, 
2H), 3.10 (t, J = 4.8 Hz, 4H), 2.58 (t, J = 4.7 Hz, 4H), 2.41 (s, 3H). 
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Methyl 4-oxo-7-((4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)methyl)-1,4-
dihydroquinoline-3-carboxylate (3.8v): 
1
H NMR (400 MHz, DMSO-d6): δ 12.30 (s, 1H), 8.54 
(s, 1H), 8.12 (d, J = 8.2 Hz, 1H), 7.58 (s, 1H), 7.48 (d, J = 8.5 Hz, 2H), 7.37 (dd, J = 8.2, 1.5 Hz, 
1H), 7.04 (d, J = 8.6 Hz, 2H), 3.73 (s, 3H), 3.65 (s, 2H), 3.32 – 3.27 (m, 4H), 2.54 (t, J = 5.0 Hz, 
4H). 
 
Methyl 6-methoxy-4-oxo-7-((4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)methyl)-1,4-
dihydroquinoline-3-carboxylate (3.8ak): 
1
H NMR (400 MHz, DMSO-d6): δ 12.29 (s, 1H), 8.49 
(s, 1H), 7.73 (s, 1H), 7.56 (s, 1H), 7.49 (d, J = 8.5 Hz, 2H), 7.06 (d, J = 8.6 Hz, 2H), 3.88 (s, 3H), 
3.72 (s, 3H), 3.63 (s, 2H), 3.32 (m, 4H), 2.61 (t, J = 4.8 Hz, 4H).  
 
Methyl 6-methyl-4-oxo-7-((4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)methyl)-1,4-
dihydroquinoline-3-carboxylate (3.8ad): 
1
H NMR (400 MHz, DMSO-d6): δ 12.25 (s, 1H), 8.51 
(s, 1H), 7.92 (s, 1H), 7.60 (s, 1H), 7.49 (d, J = 8.5 Hz, 2H), 7.05 (d, J = 8.6 Hz, 2H), 3.72 (s, 3H), 
3.59 (s, 2H), 3.29 (m, 4H), 2.62 – 2.54 (m, 4H), 2.40 (s, 3H). 
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3-Bromo-7-((4-(4-fluorophenyl)piperazin-1-yl)methyl)-2-methylquinolin-4(1H)-one 
(3.8aw): The bromination reaction was carried out on quinolone RN-246-I (50.0 mg, 0.14 
mmol) using NBS (30.0 mg, 0.17 mmol) according to the general method G. The reaction 
mixture was filtered, and the solid was washed with EtOAc followed by MeOH to give the 
purest the title compound as pale white solid (25 mg, 42% yield).  
1
H NMR (400 MHz, DMSO-
d6): δ 12.07 (s, 1H), 8.04 (d, J = 8.3 Hz, 1H), 7.54 (s, 1H), 7.31 (d, J = 8.3 Hz, 1H), 7.03 (t, J = 
8.7 Hz, 2H), 6.93 (dd, J = 9.3, 4.6 Hz, 2H), 3.65 (s, 2H), 3.10 (d, J = 4.9 Hz, 4H), 2.55 (d, J = 6.1 
Hz, 7H). 
 
3-Chloro-7-((4-(4-fluorophenyl)piperazin-1-yl)methyl)-2-methylquinolin-4(1H)-one (3.8ax): 
The chlorination reaction was carried out on quinolone RN-246-I (50.0 mg, 0.14 mmol) using 
NCS (23.0 mg, 0.17 mmol) according to the general method G. The reaction mixture was 
concentrated under reduced pressure and the residue was purified by preparative HPLC to give 
the purest RN-250-I as white solid (30 mg, 55% yield). 
1
H NMR (400 MHz, DMSO-d6): δ 12.03 
(s, 1H), 8.05 (d, J = 8.2 Hz, 1H), 7.54 (s, 1H), 7.30 (d, J = 8.3 Hz, 1H), 7.03 (t, J = 8.9 Hz, 2H), 
6.97 – 6.85 (m, 2H), 3.65 (s, 2H), 3.09 (t, J = 4.7 Hz, 4H), 2.55 (t, J = 4.6 Hz, 4H), 2.50 (s, 3H). 
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3-Bromo-7-((4-(4-fluorophenyl)piperazin-1-yl)methyl)quinolin-4(1H)-one (3.8at): An 
inseparable mixture of quinolone regioisomers RN-252 (200.0 mg, 0.60 mmol) was subjected to 
bromination reaction using NBS (127.0 mg, 0.71 mmol) according to the general method G. The 
reaction mixture was concentrated under reduced pressure and the residue was purified by 
preparative HPLC to give the desired the title compound as pale yellow solid (40 mg, 16% yield 
for single isomer).  
1
H NMR (400 MHz, DMSO-d6): δ 12.50 (d, J = 6.4 Hz, 1H), 8.53 (d, J = 6.3 
Hz, 1H), 8.24 (d, J = 8.3 Hz, 1H), 7.73 (s, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.13 – 7.06 (m, 2H), 
7.02 – 6.97 (m, 2H), 3.74 (d, J = 13.3 Hz, 2H), 3.44 (d, J = 12.2 Hz, 3H), 3.25 (d, J = 11.1 Hz, 
3H), 2.97 (d, J = 12.6 Hz, 2H). 
 
3-Chloro-7-((4-(4-fluorophenyl)piperazin-1-yl)methyl)quinolin-4(1H)-one (3.8au): An 
inseparable mixture of quinolone regioisomers RN-252 (200.0 mg, 0.60 mmol) was subjected to 
chlorination reaction using NCS (94.0 mg, 0.71 mmol) according to the general method G. The 
reaction mixture was concentrated under reduced pressure and the residue was purified by 
preparative HPLC to give the desired the title compound as pale yellow solid (34 mg, 15% yield 
for single isomer). 
1
H NMR (400 MHz, DMSO-d6): δ 12.71 (s, 1H), 8.39 (d, J = 4.8 Hz, 1H), 
8.20 (d, J = 8.3 Hz, 1H), 7.86 (d, J = 1.5 Hz, 1H), 7.65 (dd, J = 8.4, 1.5 Hz, 1H), 7.08 (dd, J = 
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9.9, 7.8 Hz, 2H), 7.01 – 6.94 (m, 2H), 3.70 (d, J = 12.5 Hz, 2H), 3.37 (d, J = 11.5 Hz, 2H), 3.26 
– 3.03 (m, 6H). 
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Chapter 4: Summary and Future Directions 
Many scaffolds have been reoccurring themes in malaria drugs. These include some of 
the before mentioned 4(1H)-quinolones and acridones, including dihydroacridinediones, 
acridines and 1,2,3,4-tetrahydroacridones. With respect to the rate that malaria resistance 
emerged and spread, new drug entities are needed now to help combat this disease.
1, 2, 5, 33, 34
 
Furthermore, due to the cost and resources it takes to develop new antimalarial drugs, there are 
legitimate reasons to attempt to recycle discarded or historical antimalarial agents, provided that 
these can be rescued due to technological advances and/or new insights.
35
 Not surprisingly, 
abandoned entities have been resurrected with promising results due to recent advances in 
parasitology, validation of new biochemical pathways, or the drug discovery process in general.  
Commonly, historical scaffolds hold much potential for optimization provided that the 
potential advantages for their use outweigh the current shortcomings. Primarily, the initial 
screening for activity is not needed because the core is already known to be active. Investments 
in the development of synthetic routes are not needed as previous attempts have been well 
probed and documented.
35
 Similarly, liabilities related to physicochemical properties, activity, 
toxicity, and others are usually well documented providing a clear goal for future improvements. 
The Manetsch and Kyle laboratories have demonstrated track records of such a strategy based on 
endochin, a 4(1H)-quinolone, which was reported for the first time in 1945. Endochin’s drug 
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development failed for over 40 years, but the use of modern parasitology and drug design 
approaches yielded orally bioavailable 4(1H)-quinolones ELQ-300 and P4Q-391, of which ELQ-
300 entered preclinical development.
6, 7, 9
 Although both compounds were superior to endochin, 
especially in terms of physicochemical properties, pharmacokinetic profiles, in vitro and in vivo 
efficacy, and selectivity thus propelling the class of 4(1H)-quinolones among the compounds 
entering preclinical development, the Manetsch and Kyle laboratories initiated to work on 
different 4(1H)-quinolone classes which failed in previous optimization studies or drug 
development attempts. Similar to endochin, the optimization of floxacrine as well as ICI 56,780, 
two historical 4(1H)-quinolones, was attempted. However, poor physicochemical properties, 
poor bioavailability, toxicity, or potential to induce resistance hindered its further 
development.
10, 11
  
Initial structural-activity relationships (SAR) were initially performed on both the 
floxacrine and ICI 56,780 analogues.
11, 19
 From these SARs, ICI 56,780 seemed to have more 
potential and therefore was chosen for further optimization. An initial set of compounds were 
synthesized in order to first assess how each functionality affected the activity of this historical 
compound. Next, replacement functionalities were probed for each of the substituents on the 
scaffold with the goal of maintaining the activities, especially the potent liver stage activity, 
while lowering the RI values of the class. Replacing the 3-ester substituent with a 3-halo 
substituent gave the lead compound more acceptable values with 3-bromo-6-butyl-2-methyl-7-
(2-phenoxyethoxy)quinolin-4(1H)-one showing improved in vivo activity over the original 
compound.  
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Next, a set of compounds were synthesized to improve the solubility while maintaining 
activity. Amines in the form of piperazines were introduced in the 7-position for that purpose. 
The carbon spacers on both ends of the piperazine were probed in order to tune the aromatic and 
aliphatic character of the nitrogen, with the C1 linker being most preferred. The electronics were 
then tuned on the 6-position of the quinolone and on the phenyl and benzyl substituents of the 
piperazine. Although the piperazine containing quinolones displayed enhanced solubilities, they 
suffered from the unacceptable RI values like their quinolone ester predecessors. Therefore, the 
previously employed strategy of introducing a 3-halo replacement of the 3-ester substituent was 
performed with similar results, although the 4-trifluoromethyl phenyl piperazinyl quinolones 
were most active in vivo, with the 6-methyl and 6-methoxy versions giving cures. 
The introduction of the piperazine moiety into the poorly soluble quinolone esters was a 
breakthrough in increasing the 4(1H)-quinolone’s solubility. However, there is chemical space 
that can still be explored in this scaffold. The piperazine moiety has largely been unexplored 
although a large number of compounds have been prepared and tested. From our SAR data, it 
appears that modifications to the piperazine ring could possibly enhance the antimalarial efficacy 
without compromising the superb physicochemical properties. Furthermore, the benzenoid 
piperazine substituent also remained largely unprobed. While there has been a seemingly clear 
trend of potency improvements as the four-position becomes increasingly electron deficient, all 
other positions on the benzyl ring have not been investigated at all. Finally, the ester in the 
4(1H)-quinolone’s 3-position is probably one of the most important groups that need to be 
balanced in order to obtain the most broad range antimalarial activity. Removal of the 3-ester 
moiety dramatically improved the RI, however when compared to the original compound, ICI 
56,780, the overall potency decreased by more than 8,000 fold. The 3-position has been probed 
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with esters, amides, nitriles, ketones, akyl and further with the Guy laboratories’ introduction of 
amines at the end of their ester substituents.
17, 18
 When aromatic functionalities replaced these 
groups, as with the 3-aryl substituents used in the Manetsch laboratory’s publication19 and when 
replaced with alkyl and halo substituents, the RI rapidly converged towards 1. There are other 
bio-isosteres of esters which may be able to maintain the boost in activity the ester brings, while 
preserving the RI decrease provided by the loss of the ester. The insights from the ICI 56,780 
analogues could be extrapolated fully into the piperazines creating fusion molecules. The 6-butyl 
group enhanced activity and could be used to fine tune activities in these quinolones. Lastly, the 
two methyl substituted quinolones were much more active than compounds that were not 
substituted showing the importance and potential of that position.  
Up to this point the potential of the quinolones and quinolone esters have been discussed, 
however nothing has been mentioned of the 1,2,3,4 tetrahydroacridones (THAs) and 
acridinediones. The story of the acridones and their analogues has always been a big 
brother/little brother relationship with the acridones always being discarded over the more active 
recently discovered quinolone.
4, 35
  
The bioavailability of the poorly soluble 4(1H)-quinolone antimalarials can also be 
manipulated by the use of a prodrug approach which was developed in the Manetsch 
laboratory.
36
 Substantial work in the Manetsch and Kyle laboratories resulted in the development 
of a highly soluble prodrug moiety, which can be installed in any 4(1H)-pyridone, 4(1H)-
quinolone, or 1,2,3,4-tetrahydroacridin-9(10H)-one scaffold. The prodrug moiety is detached 
from the parent molecules via a pH-triggered mechanism in vivo. Based on P4Q-391, ICI 
56,780, and floxacrine we demonstrated the utility and versatility of our prodrug approach 
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affording their prodrugs significantly improved in vivo efficacies over the parent compounds. 
Follow-up pharmacokinetic studies demonstrated improvements in bioavailabilies with up to 70-
fold increases in the maximal serum concentration Cmax. 
At this point, no antimalarial 4(1H)-quinolones have achieved the milestone of preclinical 
development However, recent studies, including those presented in this thesis, clearly underscore 
the value of 4(1H)-quinolones as potent and broad spectrum antimalarials with strong potential 
to enter preclinical and clinical development.  
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’ INTRODUCTION
Malaria’s origin, recently estimated to be over 30 million years
old,1 predates mankind and has plagued civilization since the
dawn of agriculture.2 This devastating disease has become one of
the most widespread infectious diseases3 with approximately 243
million cases resulting in approximately 863 000 deaths in 2008.4
It is believed that∼40% of the world’s population is at risk3 with
the greatest representation of this number being young children.
With the widespread emergence of parasite resistance to drug
mainstays such as atovaquone, sulfadoxinepyrimethamine, me-
ﬂoquine, and even more recently artemisinin,5,6 the development
of new antimalarials has been invigorated and supported by the
recent call-to-arms from the Bill and Melinda Gates Foundation
and other initiatives.7 In an eﬀort to curb artemisinin resistance,
the World Health Organization (WHO) promoted the use of
artemisinin-combination therapies (ACTs)8 by which two or
more antimalarials with diﬀerent modes of action are taken at
the same time.9 Unfortunately, disturbing reports of emerging
resistance to ACTs, which originally have been considered to be
reliable treatments for malaria, have emanated in recent studies.
Historically, once resistance has manifested itself to one com-
pound, the resistance is conferred to the entire chemotype class.
Therefore, much eﬀort has been taken to modify existing drugs to
counteract the induced resistance through structural changes.10,11
Alternatively, new pharmacophores are extremely desirable as
platforms for new possibilities in malaria therapy.
Advances in library screening, hit-to-lead optimization, physico-
chemical understanding of biologically active compounds, and
reﬁned understanding in mechanisms of action can lead to
overcoming hurdles in previously discovered lead candidates.12,13
One such example recently arose with the optimization of the
4(1H)-quinolone endochin (3) into a more robust 3-phenyl-
4(1H)-quinolone (4) that possessed higher solubility, greater
microsomal stability, and no cross-resistance with atovaquone.14
A similarly related example is ﬂoxacrine (1) and its analogue WR
243251 (2a) (Figure 1). The dihydroacridinedione 1 was ﬁrst
discovered by Durckheimer and co-workers in 1975.15 Though
compound 1 had promising characteristics including causal
prophylactic activity,1618 it suﬀered from poor solubility,19
parasite drug-resistance,20 and dose-dependent chronic
periarteritis.20 Shortly after, a new synthetic analogue 2a with
superior properties devoid of the aforementioned disadvantages
of 1 emerged.19 However, during late preclinical development,
compound 2a was abandoned because of suboptimal stability,
cross-resistance with atovaquone,21 and lingering toxicity.
Received: January 7, 2011
ABSTRACT: Antimalarial activity of 1,2,3,4-tetrahydroacridin-
9(10H)-ones (THAs) has been known since the 1940s and has
garnered more attention with the development of the acridine-
dione ﬂoxacrine (1) in the 1970s and analogues thereof such as
WR 243251 (2a) in the 1990s. These compounds failed just
prior to clinical development because of suboptimal activity,
poor solubility, and rapid induction of parasite resistance. More-
over, detailed structureactivity relationship (SAR) studies of
the THA core scaﬀold were lacking and SPR studies were
nonexistent. To improve upon initial ﬁndings, several series of
1,2,3,4-tetrahydroacridin-9(10H)-ones were synthesized and
tested in a systematic fashion, examining each compound for antimalarial activity, solubility, and permeability. Furthermore, a
select set of compounds was chosen for microsomal stability testing to identify physicochemical liabilities of the THA scaﬀold.
Several potent compounds (EC50 < 100 nM) were identiﬁed to be active against the clinically relevant isolates W2 and TM90-C2B
while possessing good physicochemical properties and little to no cross-resistance.
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Even though 1,2,3,4-tetrahydroacridin-9(10H)-ones (THAs)
with antimalarial activity were reported initially by Stephen and co-
workers in 1947, follow-up optimization studies were relatively
limited in comparison to optimizations of other historical
antimalarials.22 Riscoe et al. recently examined acridone analogues
as antimalarials, which, however, diﬀer from the THAs with
respect to the structure and aromaticity.23,24 With limited explora-
tion of THA analogues such as 1 and 2a, as well as recent studies
on antimalarial 4(1H)-quinolones,14,25 we were prompted to
examine the THA series (Figure 1) for antimalarial eﬃcacy by
conducting detailed structureactivity and structureproperty
relationship (SAR and SPR) studies in parallel. In the past decade,
drug discovery and optimization programs focusing on biological
activity and physicochemical property data at the early develop-
mental stages have been shown to minimize the risks to fail later.
Our synthetic strategy was based in part upon the Topliss
operational schemes26,27 to design THA analogues for routine in
vitro testing against P. falciparum multidrug resistant strains W2
(resistant to chloroquine and pyrimethamine) and TM90-C2B
(resistant to chloroquine, meﬂoquine, pyrimethamine, and
atovaquone). All THAs have undergone in vitro testing for
cytotoxicity in mammalian J774 macrophage cells. Furthermore,
all compounds have routinely been evaluated for aqueous solubi-
lity at pH 2.4, 4.0, and 7.4, permeability at pH 4.0 and 7.4, and
logD at pH 7.4 to determine which compounds have potential to
be advanced into in vivo eﬃcacy experiments. Herein, we report
the preparation and thorough examination of a library of 118
THAs as antimalarial agents.
’RESULTS AND DISCUSSION
Synthetic Chemistry.Previous optimization studies leading to
acridinedione compounds 1 and 2a demonstrated that a 7-chloro
substituent in the benzenoid ring of the acridinedione core was
important for antimalarial activity, as well as the imine moiety at
the carbonyl carbon C1 in N10-H analogues. Over 200 com-
pounds were prepared and tested; however, the main investiga-
tion focused on analogues varying the nature of the aryl ring at the
3 position and analogues possessing various alkylamino imines at
the 1-position. Of these aforementioned analogues, the majority
of them possessed a 7-chloro substituent with very limited
attention paid to benzenoid ring substitution.19 It is possible that
access to a single synthetic route for generating various benzenoid
substituents in the acridinedione core was a key factor in the
limited scope of compounds tested. For the current optimization
study, THAs varying in their substituents at the, 2-, 3-, 5-, 6-, 7-,
and/or 8-position have been designed to obtain detailed SAR and
SPR data, which complements previous studies potentially over-
coming the liabilities of compounds 1 and 2a.
First, a set of THAs was synthesized to determine the optimal
size of the saturated ring. On the basis of 3-aryl-substituted 4(1H)-
quinolones previously developed in our laboratory,14 ﬁve- to eight-
membered ring sizes were examined with THAs containing
either an electron poor or an electron rich substituent at the
6-position. Structures shown in Figure 1 with aliphatic ring sizes
of 5, 7, and 8 are not tetrahydroacridone according to the
IUPAC nomenclature. Nevertheless, the inclusive acronym
THA (tetrahydroacridone) was used for all analogues based on
a six-membered aliphatic ring. These compounds were prepared
using 4-methoxyanthranillic acid or 4-triﬂuoromethylanthranillic
acid with POCl3 and the appropriate cycloalkanone to yield
9-chloro-1,2,3,4-tetrahydroacridines. These intermediates were
subsequently hydrolyzed using acetic acid in a sealed tube at
200 C to generate compounds 512 (Scheme 1). The two-step
synthetic sequence proved to be superior over themore frequently
reported direct condensation reactions of anthranillic acids and
cyclohexanones via azeotropic distillation of water.2830 It was
observed that these one-step condensationswere often incomplete
and overall problematic especially those starting from electron rich
anthranillic acids. Recently, Elguero and co-workers utilized
microwave irradiation to improve the yields through the one-step
condensation.31 Another hurdle of the one-step condensations is
the puriﬁcation of the THA products, as unreacted anthranillic
acid and resultant polar side products are very diﬃcult to remove.
In contrast, the two-step reaction sequence cleanly provided THA
compounds upon precipitation from water which were further
recrystallized from either pyridine or DMF. Generally, the use of
pyridine provided neutral THA products as opposed to DMF
which could yield the corresponding salt forms. It was observed
that the hydrolysis undergoes a nucleophilic displacement at the
9-position, providing the 1,2,3,4-tetrahydroacridin-9-yl acetate,
which is subsequently hydrolyzed. This observation is in accor-
dance with the known electrophilicity of these 9-chloro-1,2,3,4-
tetrahydroacridines, since these intermediates are commonly
found in literature to prepare 4-aminoquinolines.32,33
Next, a set of compounds was designed to probe the benzenoid
ring positions according to the Topliss operational schemes,
which are based upon physicochemical parameters related to
hydrophobicity, electronics, and sterics.26,27 Upon determination
that the THAs containing the six-membered aliphatic ring
were the most potent analogues, chloro-, methyl-, or methoxy-
substituted anthranillic acids were combined with cyclohexanone,
3,3-dimethylcyclohexanone, and 4,4,-dimethylcyclohexanone to
yield THAs 1350. Furthermore, a series of monosubstituted
THAs 5163 with more electronegative or sterically encumber-
ing benzenoid ring substituents were prepared either by the two-
step sequence starting from anthranillic acids and cyclohexanones
(Scheme 2, route A) or by a ConradLimpach cyclization
reactions (Scheme 2, route B).34 The decision of which route
to use for the preparation of a particular THA was based on
commercial availability and cost of starting materials as well as the
ease in puriﬁcation of the ﬁnal product.35 The preparation of
THAs via the ConradLimpach synthetic route starting from
meta-substituted anilines yields a mixture of 6- and 8-substituted
regioisomers, which are diﬃcult to separate. In contrast, the two-step
Figure 1. Structures of several antimalarials 14 and the core 1,2,3,4-
tetrahydroacridin-9(10H)-one.
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reaction sequence with 4-substituted anthranillic acids cleanly
produces the desired THA regioisomer. Nevertheless, the Con-
radLimpach reaction is more suitable for THAs that cannot
withstand the acetic acid hydrolysis such as compound 63.
Overall, the commercial availability of various anilines compared
to anthranillic acids is much greater, making this synthetic route
very desirable and valuable.
Investigations then focused onTHAs equally disubstituted at the
benzenoid ring to probe potential synergistic eﬀects derived
from these monosubstituents. By use of the same pair of synthetic
routes in Scheme 2, compounds 6483 were prepared from
commercially available anilines (Figure 2, route B). Via route B,
some anilines generated regioisomeric THAs, whose individual
isomers were puriﬁed via preparative HPLC and recrystallization
as noted in Scheme 2. Furthermore, THAs substituted with two
diﬀerent groups at the 6- and 7-positions were synthesized to
test whether a particular benzenoid ring substituent combina-
tion exhibits a potency enhancement similar to that observed
for the 6-chloro-7-methoxy-4(1H)-quinolone antimalarial series
(Scheme 3). Simultaneously, THAs containing one heteroatom in
the saturated ring were prepared with the intent to increase the
solubility, the metabolic stability, or both.
Scheme 1. Synthesis of Varying Ring-Sized 1,2,3,4-Tetrahydroacridin-9(10H)-ones 550a
aReaction conditions: (a) POCl3, cycloalkanone, reﬂux, 18 h; (b) AcOH, sealed tube, 200 C, 2448 h; (i) yield over two steps after recrystallization
from either DMF or pyridine.
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Starting materials, which are commercially unavailable, have
been synthesized prior to the THA syntheses. 4-Chloro-3-meth-
oxyaniline 84 was prepared using sodium amide in liquid
ammonia,36 while 4-chloro-3-isopropoxyaniline 85 was obtained
by acetylating 5-amino-2-chlorophenol followed by an alkylation
with isopropyl iodide in Cs2CO3. Interestingly, K2CO3 generated
lower yields through a deprotective hydrolysis of the acetamido
group. The amide was subsequently hydrolyzed with KOH in
EtOH and water (9:1) to provide aniline 85. 4-Methyl-3-meth-
oxyaniline 86 was generated starting from a solution of 2-meth-
oxy-1-methyl-4-nitrobenzene inMeOH and hydrogenated for 3 h
in the presence of 10% Pd/C.37 The cyclic β-ketoester 87 was
prepared by esterifying 3,30-thiodipropanoic acid to the ethyl
ester. Subsequently, this intermediate was intramolecularly
cyclized via sodium hydride by reﬂuxing in THF. Ethyl 5,5-
diﬂuoro-2-oxocyclohexanecarboxylate 88 was prepared from 4,4-
diﬂuorocyclohexanone using NaH and diethyl carbonate.
Compounds 89100 were prepared using the Conrad
Limpach reaction conditions used in route B (Scheme 4).
THA 100 was synthesized from a commercially available anili-
noether to examine whether an aryl ether directly attached to
the THA core would improve biological activity. Similarly, this
compound provides a diﬀerent class of ethers as opposed to
THAs 62, 70, 73, and 8993, which contain alkyl ether
Scheme 2. Synthesis of 1,2,3,4-Tetrahydroacridin-9(10H)-ones 5163 Using Route A or Route Ba
aReaction conditions: (a) POCl3, cyclohexanone, reﬂux, 18 h; (b) AcOH, sealed tube, 200 C, 2448 h; (c) ethyl 2-oxocyclohexanecarboxylate,
AcOH, benzene, DeanStark trap, reﬂux, overnight, then Ph2O, reﬂux, 15min. i Route A - yield over two steps after recrystallization from either DMF or
pyridine. Route B - yield is reported as the standard ConradLimpach conditions described in the experimental section. Some compounds were further
puriﬁed either via Preparative HPLC or recrystallization, see experimental section.
Figure 2. Compounds 6483 via routes A and B. i Route A - yield over two steps after recrystallization from either DMF or pyridine. Route B - yield is
reported as the standard ConradLimpach conditions described in the experimental section. Some compounds were further puriﬁed either via
Preparative HPLC or recrystallization, see experimental section.
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substituents. Sulfoxide 101 and sulfone 102 were oxidized from
THA 92 using aqueous hydrogen peroxide at 40 C andm-CPBA
in CHCl3 at 0 C, respectively.38 Finally, a small set of THAs was
prepared in which the 2-position possessed a diﬂuoromethylene
unit. Compound 93 was prepared using route B from the
chloromethoxyaniline 84 and cyclic β-ketoester 88, while com-
pounds 94 and 95 were generated using route A with 4,4-
diﬂuorocyclohexanone.
Finally, a small series of SuzukiMiyaura coupled THAs
(103118) was prepared to probe the similarity between the
Scheme 4. Synthesis of THAs 89102a
aReaction conditions: (a) various ethyl 2-oxo-4-substituted cyclohexanecarboxylates, AcOH, benzene, DeanStark trap, reﬂux, overnight, then Ph2O,
reﬂux, 15 min; (b) H2O2 (aq), 40 C; (c) m-CPBA in CHCl3, 0 C, 4 h. i Route A using corresponding anthranillic acid was used.
Scheme 3. Synthesis of Intermediate Anilines 8486 and β-Ketoesters 8788a
aReaction conditions: (a)Na, NH3(l); (b) Ac2O, AcOH, reﬂux, 5min; (c) Cs2CO3,
iPrI, DMF, 45 C, 18 h; (d) KOH, EtOH/H2O (9:1), reﬂux, 8 h; (e)
Pd/C, H2(g), MeOH, 3 h; (f) conc H2SO4, EtOH, reﬂux, 4 h; (g) NaH, THF, EtOH (cat.), reﬂux, 8 h; (h) NaH, diethylcarbonate, benzene, 80 C, 8 h.
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THAs and the 4(1H)-quinolone chemotype (Scheme 5).14 No-
tably, THA 100 was promising in terms of activity, prompting the
investigation of the position and nature of several aryl moieties at
the benzenoid ring. A variety of monosubstituted and biaryl 6- or
7-substituted THAs were prepared. Moreover, recent results from
GSK’s pyridone project39,40 and preliminary data generated in our
laboratory motivated us to synthesize boronic acids 119121
used in the preparation of 109, 110, and 118 (Scheme 6). Of all
the SuzukiMiyaura compounds, the diﬂuoro and pyridyl sub-
strates 103, 105, and 116 demonstrated the most sluggish
reactivity, requiring long reaction times and providing low yields.
Starting from 1-bromo-4-(chloromethyl)benzene, boronic
acid 119 was prepared using 60% NaH in anhydrous DMF at
80 C. This benzyl intermediate was lithiated using n-BuLi
Scheme 5. Synthesis of THAs 100118 via SuzukiMiyaura Cross-Couplinga
aReaction conditions: (a) Pd2(dba)3, SPHOS, Na2CO3 (aq), ArB(OH)2, DMF, 80 C, 436 h.
Scheme 6. Synthesis of Boronic Acids 119121a
aReaction conditions: (a) NaH, DMF (anhyd), 80 C; (b) B(OiPr)3, THF (anhyd),78 C, then n-BuLi (1.6M), 3 h, then 6MHCl, rt, 18 h; (c) CuCl,
NMP (anhyd), Cs2CO3, 2,2,6,6-tetramethylheptane-3,5-dione (22 mol %), 110 C, 46 h.
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at 78 C in anhydrous THF and stirred in the presence of-
B(OiPr)3 for 3 h at 78 C. The boronate ester was hydro-
lyzed via the addition of 6 M HCl and subsequently warmed
to room temperature and stirred overnight. Boronic acids
120 and 121 were prepared similarly; however, an Ullman cross-
coupling was used to generate the halobiaryl intermediate
that was subsequently hydrolyzed to the boronic acid as
in 119.
AntimalarialActivity.All synthesized compounds were tested,
as previously reported, against the clinically relevant multidrug
resistant malarial strains W2 (chloroquine and pyrimethamine
resistant) and TM90-C2B (chloroquine, mefloquine, pyrimetha-
mine, and atovaquone resistant).14 The humanmalaria parasite P.
falciparum was grown in vitro in dilute human erythrocytes in
RPMI 1640medium containing 10% heat inactivated plasma, and
the potency for each 1,2,3,4-tetrahydroacridin-9(10H)-one
against the individual strains has been calculated as the 50%
effective concentration (EC50).
41 The emergence of resistance
and cross-resistance with atovaquone is a concern for new
antimalarials that target the parasite mitochondria (e.g.,
atovaquone), and the resistance index (RI) of each compound
was calculated as the ratio of the effective concentrations for W2
and TM90-C2B (RI = EC50(TM90-C2B)/EC50(W2)).
14 Com-
pounds with RI = 0.33.0 are considered acceptable in regards to
risk of cross-resistance with atovaquone, whereas compounds
with RI > 10 or RI < 0.1 are likely to have clinically relevant levels
of cross-resistance with atovaquone and are not candidates for
additional preclinical studies.42,43
StructureActivity Studies. THA 1 has been reported to
display EC50 of 478 nM forW2 (chloroquine and pyrimethamine
resistant) and 270 nM for D6 (drug susceptible strain), while the
EC50 of compound 2a (racemic mixture) for W2 is 25 nM, EC50
for D6 is 11 nM, EC50 for TM91 (chloroquine, quinine, and
mefloquine resistant) is 51 nM, and EC50 for TM90-C2B is
300 nM.21,44 Great strides were taken to improve the efficacy of
compound 1. Hundreds of analogues were prepared and tested,
culminating in compound 2a, a prodrug of 2b.19,45,46 Though
these optimization attempts resulted in several compounds with
single digit nanomolar activities to as low as 730 pM, these efforts
were lacking in a systematic SAR and accompanying SPR studies.
In the end, the development of compound 2a and analogues
thereof were abandoned, since these compounds suffered from
drug resistance,21 poor aqueous solubility, and lingering toxicity
issues.18,47 Similarly, in 1947 Stephen and co-workers examined
THAs for antimalarial activity using an in vivo assay against
P. gallinaceum infections in chickens without determining key
physicochemical properties.22 Sixmonosubstituted THAs and one
disubstituted compound, which for confirmatory purposes have
also been reevaluated by us, were tested, and compound 14 was
identified by Kesten and co-workers to be the most potent
compound. Interestingly, at the time that Stephen and co-workers
initiated their studies onTHAs, endochin had just been discovered
and its in vivo antimalarial activity against P. gallinaceum was
superior to that of most of the THAs.
The majority of the analogues of 1 and 2a that were previously
screened contained a 7-chloro substituent. Kesten and co-work-
ers reported that the monochloro substituent was a necessity to
achieve the highest levels of activity, while an unsubstituted or a
disubstituted benzenoid ring resulted in greatly reduced anti-
malarial activities. In contrast, recent work by our laboratory
demonstrates a substantial increase of potency in endochin
analogues that are disubstituted at the benzenoid ring with a
6-chloro-7-methoxy substituent pair.14 Just as important, this
synergistic pair of substituents also improved the RI for W2 and
TM90-C2B and the aqueous solubility. Furthermore, in the past,
the aliphatic THA ring was moderately evaluated. Thus, a
systematic approach to investigate the benzenoid ring and the
saturated ring simultaneously was considered to be of highest
priority to initiate our studies expanding upon the ﬁndings of
Stephen and Kesten. A small series of THAs containing saturated
ring sizes with ﬁve to eight carbons was prepared utilizing the
appropriate commercially available cycloalkanones (Table 1).
THAs 58 contained one electron rich methoxy substituent
at the benzenoid ring, while 912 were substituted with one
Table 1. SAR Focusing on the Aliphatic Ring Size of the 1,2,3,4-Tetrahydroacridin-9(10H)-onesa
compd R n
EC50
W2 (nM)
EC50
TM90-C2B (nM) RI
EC50
J774 (μM)
solubility,
pH 7.4 (μM)
Pe, pH 7.4
(106 cm/s)
logD,
pH 7.4
1 478 270b
2a 25.0 300 12.0
2b 8.71 27.8 3.19 1 20 3.1
5 OMe 1 1130 610 0.54 >40 91 11 1.5
6 OMe 2 89.9 99.9 1.11 >40 82 25 1.9
7 OMe 3 171 153 0.89 >20 30 39 2.1
8 OMe 4 146 230 1.58 >40 98 73 2.4
9 CF3 1 2320 438 0.19 >40 98 60 2.3
10 CF3 2 120 19.0 0.16 >20 158 73 2.7
11 CF3 3 4890 >4340 >0.88 >10 17 131 3.0
12 CF3 4 4740 4230 0.89 >10 13 252 3.2
aDihydroartemisinin (DHA), chloroquine (CQ), and atovaquone (ATO) are internal controls for each in vitro assay: DHA (1.8 nM W2 and 0.9 nM
TM90-C2B) and CQ (162 nM W2 and 131 nM TM90-C2B) and ATO (0.53 nM W2 and >170 nM TM90-C2B). bEC50 vs D6.
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electron-poor triﬂuoromethyl group. Regardless of the benze-
noid ring substituent, THAs 6 and 10 containing a six-membered
saturated ring were the most potent compounds against bothW2
and TM90-C2B. Compounds 5 and 9 with the ﬁve-membered
aliphatic ring and THAs 7, 8, 11, and 12 with ring sizes of seven
or larger were less potent than 6 and 10. Furthermore, the RI
value was not found to signiﬁcantly depend on the aliphatic ring
size. With the exception of compounds 9 and 10, acceptable RI
values have been calculated for all other THAs 58, 11, and 12.
In fact, the signiﬁcant potency diﬀerences related to the two
diﬀerent benzenoid ring substitutents were determined to be of
greater importance than the size of the saturated ring. Thus, the
results of the subset of the methoxy-substituted THAs 58
urged us to focus on the further optimization of compounds
containing six-membered saturated rings exclusively.
Next, an investigation was designed to explore the THA’s
benzenoid ring with various substituents at the 5-, 6-, 7-, and
8-positions. Following the Topliss operational scheme for aro-
matic substituents, the ﬁrst compound set focused on groups
probing electronic and steric factors. Monosubstituted THAs
6, 1324 containing amethyl, a methoxy, or a chloro substituent
were tested (Table 2).
The unsubstituted THA 13 was used as a reference compound
to assess whether a particular substituent of 1424 has a favorable
or an adverse eﬀect on the antimalarial activity. Furthermore, two
additional compound series were designed in which the 2- or
3-position of the saturated ring possesses gem-dimethyl substitu-
tion in combination with a methyl, a methoxy, or a chloro
substituent on the benzenoid ring. These analogues not only
probe the 2- and 3-position for sterics but also provide informa-
tion on the saturated ring, since the methyl substituents inﬂuence
the ring conformation. All possible combinations of 2,2-dimethyl
substituted THAs 2537 (Table 3) and 3,3-dimethyl-substituted
compounds 3850 (Table 4) have been tested against W2 and
TM90-C2B. Analogues 25 and 38 have been prepared as
reference compounds to reliably concludewhether the 2-position,
the 3-position, or both are suitable for structural modiﬁcations.
Of compounds 6, 1324, the 7-chloro-THA 23 exhibiting
EC50 of 99.4 nM for W2 and 63.4 nM for TM90-C2B is the most
active analogue, which is closely followed in activity by 6-meth-
oxy- and 6-methyl-substituted THAs, 6 and 18, respectively.
Compound 6 with a methoxy group at the 6-position was the
most potent compound of all the methoxy-substituted THAs, 6
and 1416 with EC50 values of 89.9 nM for W2 and 99.9 nM for
TM90-C2B. Thus, depending on the tested strain, THA 6 is
approximately 3- to 7-fold more potent compared to the
unsubstituted reference compound 13. In contrast, methoxy
substitution at the 5-, 7-, or 8-position provides THAs 14, 15,
and 16 with diminished antimalarial activities in the micromolar
range. Testing of THAs 1724 identiﬁed that the 6- and
7-positions, when populated with a methyl or chloro substituent,
improve the antimalarial activity by a factor of 27. The
6-methyl-THA 18 was approximately 2 to 4-fold more potent
than the 7-methyl-substituted analogue 19, while the 7-chloro-
substituted THA 23 was twice as active as the 6-chloro-THA 22.
The 2,2-dimethyl- or the 3,3-dimethyl-substituted THAs
2550 were overall less active than the THA series 1324
containing an unsubstituted saturated ring. The methyl groups
appear to be less tolerated at the 3-position than at the 2-position
with an average of a 4-fold diﬀerence in antimalarial activity.
Furthermore, the 2,2-dimethyl- and 3,3-dimethyl-THAs 2550
display a more pronounced strain selectivity with less favorable
RI values in comparison to THAs 1324 with an unsubstituted
saturated ring. Especially THA 31, which was shown to be potent
against W2 with an EC50 of 166 nM and fairly inactive against
TM90-C2B, and its analogues 18 and 44 are striking examples
demonstrating that a small variance in structure can signiﬁcantly
impact the strain dependence. Regarding the benzenoid ring
substituents of the 2,2-dimethyl- or the 3,3-dimethyl-substituted
THAs 2550, potency trends were observed that are similar to
Table 2. SAR Focusing on Monosubstituted Benzenoid Ring Containing Unsubstituted Aliphatic Ringa
compd R
EC50
W2 (nM)
EC50
TM90-C2B (nM) RI
EC50
J774 (μM)
solubility,
pH 7.4 (μM)
Pe, pH 7.4
(106 cm/s)
logD,
pH 7.4
13 H 719 325 0.45 >40 24 10 3.0
14 5-OMe 4770 4560 0.95 >20 99 16 1.7
6 6-OMe 89.9 99.9 1.11 >40 82 25 1.9
15 7-OMe 2440 2530 1.03 >40 78 16 1.5
16 8-OMe 8970 5940 0.66 >20 76 17 1.2
17 5-Me 2200 888 0.40 >40 47 26 1.9
18 6-Me 150 152 1.01 >40 89 27 2.0
19 7-Me 449 656 1.46 >40 44 19 1.7
20 8-Me 6250 4570 0.73 >20 99 87 2.1
21 5-Cl 1350 >9000 >7.9 >20 107 107 2.2
22 6-Cl 137 122 0.89 >10 15 75 2.2
23 7-Cl 99.4 63.4 0.63 >2 4 57 2.0
24 8-Cl 368 447 1.22 >5 99 47 1.8
aDihydroartemisinin (DHA), chloroquine (CQ), and atovaquone (ATO) are internal controls for each in vitro assay: DHA (1.8 nM W2 and 0.9 nM
TM90-C2B) and CQ (162 nM W2 and 131 nM TM90-C2B) and ATO (0.53 nM W2 and >170 nM TM90-C2B).
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those of the THA analogues 1324. The 6-methoxy- or
7-chloro-containing compounds 27, 36, 40, and 49 were con-
siderably more potent compared to the nonsubstituted reference
compounds 25 and 38, while methyl or chloro substituents in the
5- or 8-position resulted in compounds with poor activity with
EC50 in the micromolar range.
The loss in potency and the adverse eﬀect on the RI observed
with the gem-dimethyl-THAs 2550motivated us to restrict the
compound design to THAs possessing an unsubstituted aliphatic
ring only. A selection of THAs 5163 was prepared with the
intent of exploring additional benzenoid ring substituents of
distinct steric or electronic withdrawing nature (Table 5). Most
compounds of this series displayed poor antimalarial activity with
EC50 in the high-nanomolar or micromolar range. The 6-ﬂuoro
and the 6-bromo THAs 54 and 56 were the best analogues
inhibiting the drug-susceptible strain W2 and the resistant strain
Table 3. SAR Focusing on Monosubstituted Benzenoid Ring Containing 2-gem-Dimethyl Aliphatic Ringa
compd R
EC50
W2 (nM)
EC50
TM90-C2B (nM) RI
EC50
J774 (μM)
solubility,
pH 7.4 (μM)
Pe, pH 7.4
(106 cm/s)
logD,
pH 7.4
25 H 421 295 0.70 >20 35 43 1.8
26 5-OMe 1990 620 0.31 >40 91 95 2.4
27 6-OMe 54.3 175 3.22 >40 61 88 2.2
28 7-OMe 8400 >9720 >1.16 >20 38 73 2.0
29 8-OMe 5240 3500 0.67 >20 83 54 1.9
30 5-Me 791 531 0.67 >40 38 90 2.3
31 6-Me 166 1980 11.9 >40 75 82 2.4
32 7-Me 474 2180 4.60 >40 52 84 2.4
33 8-Me 3020 4130 1.37 >40 45 269 2.7
34 5-Cl 4670 4730 1.01 >20 62 427 2.9
35 6-Cl 240 829 3.45 >40 1 62 2.8
36 7-Cl 256 118 0.46 >40 1 63 2.6
37 8-Cl 373 599 1.61 >40 23 117 2.4
aDihydroartemisinin (DHA), chloroquine (CQ), and atovaquone (ATO) are internal controls for each in vitro assay: DHA (1.8 nM W2 and 0.9 nM
TM90-C2B) and CQ (162 nM W2 and 131 nM TM90-C2B) and ATO (0.53 nM W2 and >170 nM TM90-C2B).
Table 4. SAR Focusing on Monosubstituted Benzenoid Ring Containing 3-gem-Dimethyl Aliphatic Ringa
compd R
EC50
W2 (nM)
EC50
TM90-C2B (nM) RI
EC50
J774 (μM)
solubility,
pH 7.4 (μM)
Pe, pH 7.4
(106 cm/s)
logD,
pH 7.4
38 H 1870 335 0.18 >40 64 43 1.9
39 5-OMe 6540 2490 0.38 >20 91 114 2.4
40 6-OMe 355 112 0.32 >40 92 64 2.2
41 7-OMe >9720 >9720 ND >5 9.2 128 2.3
42 8-OMe >9720 4100 <0.42 >20 64 43 1.7
43 5-Me 2370 1750 0.74 >40 60 88 2.3
44 6-Me 1460 965 0.66 >10 17 53 2.49
45 7-Me 587 319 0.54 >2 4 78 2.4
46 8-Me >9990 >9990 ND >5 9 240 2.8
47 5-Cl 6700 >9550 >1.42 >20 20 407 3.0
48 6-Cl 1080 645 0.60 >1 1 0 2.9
49 7-Cl 215 538 2.50 >1 2 96 2.7
50 8-Cl 2990 5330 1.78 >5 6 103 2.5
aDihydroartemisinin (DHA), chloroquine (CQ), and atovaquone (ATO) are internal controls for each in vitro assay: DHA (1.8 nM W2 and 0.9 nM
TM90-C2B) and CQ (162 nM W2 and 131 nM TM90-C2B) and ATO (0.53 nM W2 and >170 nM TM90-C2B).
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TM90-C2B at 100 nM or lower concentrations. Compound 63
containing an ethyl ester moiety at the 7-position was potent
against TM90-C2B with an EC50 of 58.3 nM, which is consistent
with previous observations that an electron-withdrawing group at
the 7-position enhances activity. Analogues 58 and 60 containing
substitutions at the 5-position were both devoid of activity.
7-Ethoxy-THA 62 was approximately 5-fold more potent when
compared to the 7-methoxy analogues 15, 28, and 41, suggesting
that THAs with substituents at the 7-position may have potential
to occupy a hydrophobic pocket of the biological target.21,47,48
Subsequently, amethodical approach to test the benzenoid ring
positions, which are substituted with two identical groups, was
devised to explore the synergistic potential of 6483 (Table 6).
This study was accompanied by a second THA series having two
diﬀerent groups at the benzenoid ring or containing one hetero-
atom in the aliphatic ring, 89102 (Table 7). Themajority of the
dimethyl-, dimethoxy-, dichloro-, and diﬂuoro-substituted THAs
6483 lacked submicromolar antimalarial activity. Nevertheless,
ﬁve compounds with EC50 lower than 300 nM suggested that
disubstitution patterns could be eﬀective. The dimethyl and the
dichloro analogues 68 and 78 substituted at the 6- and 7-positions
were moderately potent with EC50 of 216341 nM, whereas the
6,7-diﬂuoro analogue 83 exhibited slightly better activities with
EC50 in the 100 nM range for W2 and TM90-C2B. In contrast,
the 6,8-dichloro analog 76 with EC50 of 87.896.2 nM and
especially the 6,8-diﬂuoro analog 81 with EC50 of 16.545.0 nM
were approximately 5-fold more potent than their congeners 78
and 83. However, compound 81 has an RI of 2.72, which just falls
into the acceptable range for a resistance index ﬁgure but is still
much more active in the drug susceptible strain. Eight disubsti-
tuted THA analogues containing an R4 substituent possessed
activities between 1 and 10 μM, except compounds 76 and 81
which also maintained a 6-substituent. The 6,7-disubstituted
benzenoid moiety was manifested in terms of potency while
maintaining excellent RIs of 0.82, 1.06, and 0.91 in compounds
68, 78, and 83, respectively. Antimalarial activities of THAs 68,
81, and 83 are further evidence that a particular combination of
substituents can provide not only a potent compound but one
that could perhaps be free of multidrug resistance.
On the basis of the SAR of compounds 583, a series was
developed with the majority of the analogues containing a
6-methoxy-7-substituted THA core, with various substitutions
on the aliphatic chain, 89102 (Table 7). Compound 91was the
most potent against W2 (21.3 nM) but displayed a RI of 4.88,
well above the desired range. Compounds 90, 92, 96, and 97
were all 113 nM or less in activity against W2, with 92 having a
26.3 nM activity. These analogues support the observation that
the 6-methoxy-7-substituted (generally chloro) substitution pat-
tern is very important for potency. The RIs of these compounds
are all in the acceptable range with exception of compound 92,
which has a good activity with the drug-susceptible strain.
Compound 100 is interesting in that it has an RI just out of
the acceptable range of 0.28 but an aﬃnity for the drug-resistant
line of 47 nM (TM90-C2B) and 169 (W2). ThisO-aryl ether was
one of a possible series that we decided to pursue. These
compounds can be assembled using a number of synthetic
pathways. However, their synthesis is outside the scope of this
manuscript. Nonetheless, this analogue highlights the potential
for aryl-substituted scaﬀolds on the THA core. Compounds
90 and 96 were the most potent analogs against TM90-C2B
with 24.1 and 16.2 nM, respectively. Compound 90 displayed an
acceptable RI as observed with other analogues possessing this
substitution pattern.14
3-Aryl substitution was shown to improve potency in the
4(1H)-quinolone series.14 Analogous to the 4(1H)-quinolones, a
small THA series was prepared to examine whether substitutions
at the 6- and 7-positions of the benzenoid ring have potential to
improve antimalarial activity, solubility, or both (Table 8).
The electronic nature of the aryl ring has been shown to be
important for overall eﬃcacy. All of the benzenoid positions in
Table 5. SAR Focusing on Benzenoid Ring Substituted with Various Electronegative and/or Bulky Substituentsa
compd R
EC50
W2 (nM)
EC50
TM90-C2B (nM) RI
EC50
J774 (μM)
solubility,
pH 7.4 (μM)
Pe, pH 7.4
(106 cm/s)
logD,
pH 7.4
51 6-NO2 1050 959 0.91 >2 3 63 1.5
52 7-NO2 3160 379 0.12 >5 8 6.9 1.5
53 5-F 536 2910 5.43 >40 109 17 1.5
54 6-F 67.7 119 1.76 >20 46 21 1.7
55 7-I 378 167 0.44 >20 4 96 2.3
56 6-Br 77.7 115 1.48 >10 14 70 2.8
57 7-Br 197 64.7 0.32 >2 2 63 2.1
58 5-tBu >9790 >9790 ND >10 90 553 3.3
59 7-tBu 78.7 325 4.13 >5 5 165 2.8
60 5-CF3 >9350 >9350 ND >20 116 246 2.6
61 7-iPr 879 732 0.83 >40 30 100 2.2
62 7-OEt 265 226 0.85 >5 5 52 1.9
63 7-CO2Et 153 58.3 0.38 >5 8 63 2.1
aDihydroartemisinin (DHA), chloroquine (CQ), and atovaquone (ATO) are internal controls for each in vitro assay: DHA (1.8 nM W2 and 0.9 nM
TM90-C2B) and CQ (162 nM W2 and 131 nM TM90-C2B) and ATO (0.53 nM W2 and >170 nM TM90-C2B).
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the THA scaﬀold could be decorated with an appropriate halide
to be used as a Suzuki coupling precursor; however, the focus
would be on the 6- and 7-position because of the preliminary
SAR emerging from Tables 17. Choice of boronic acid was
based on the desire to probe a broad chemical space with
electronic diﬀerences in the rings. 7-Pyridyl analogues 103 and
104 displayed poor activities in the micromolar range. 7-Sub-
stituted aromatic analogues, especially 106, which has a 34.6 nM
activity against W2 and a 23.2 nM activity against TM90-C2B,
displayed good potencies. Next, 7-biaryl ether and 7-benzylaryl
ether substituted analogues were tested. Compounds 108112
showed good activities against W2 but a pronounced decline
against TM90-C2B, suggesting the presence of resistance in
these extended biaryl ethers. Alternatively, compound 118 dis-
played excellent activities against both strains with EC50 of 12.2
and 9.1 nM against W2 and TM90-C2B, respectively. The
6-dimethylaminobenzene substituted analogue 117 displayed
activities of 99.2 and 161 nM against W2 and TM90-C2B. As a
direct comparison of analogues substituted at the 6- and 7-posi-
tion and the necessity of a sulfur containing aliphatic ring,
analogues 113115 were prepared. These three compounds
were all active in the lower nanomolar range with the 6-triﬂuor-
omethylphenyl substituent being the most potent at 34.9 and
8.70 nM against W2 and TM90-C2B, respectively. This high-
lights the slight increase in activity of a strictly carbon aliphatic
ring versus a heteroatom containing ring; however, the solubi-
lities and half-lives of these analogues varied (see below). Overall,
the aryl analogues exhibit increased activities in comparison to
the mono- and disubstituted THAs. These analogues make for a
large area of opportunity for diversiﬁcation and improvements of
the THA chemotype.
Resistance Index and Cytotoxicity. Through in vitro studies
one can determine the strain dependence of individual com-
pounds, which in turn can generate a proportion known as the
resistance index (RI). As previously mentioned, RI > 3 has been
linked to chemical resistance in atovaquone and chloroquine,42,43
while a THA with an RI between 3 and 0.3 is desired (Figure 3).
The initial SAR probing aliphatic ring size revealed an inter-
esting trend showing that electron withdrawing substituents at
the 6-position were more potent against TM90-C2B, the che-
mically resistant strain, while the 6-methoxy substituted with six-
membered rings showed an RI very close to 1. Generally the aryl-
substituted THA series (Table 8) is more potent against W2 in
comparison to TM90-C2B with a few of the compounds
displaying RIs close to 1. This stands in contrast to the rest of
the THA library (Tables 17) whose analogues are slightly more
potent against the TM90-C2B strain than W2. Compound 90 is
one of the most active THAs with EC50(W2) of 30.6 nM and
EC50(TM90-C2B) of 24.1 nM with an RI of 0.79. Nevertheless,
the RI is sensitive to structural changes among analogues similar
to THA 90. For example, THA 92 containing a sulfur in the
aliphatic ring has an RI of almost 5, while replacement of the
methoxy substituent by an isopropoxy group shifts the RI to
almost 5 as well. Alternatively, for analogues 96 and 97, in which
Table 6. SAR of Disubstituted THAsa
compd R1 R2 R3 R4
EC50
W2 (nM)
EC50
TM90-C2B (nM) RI
EC50
J774 (μM)
solubility,
pH 7.4 (μM)
Pe, pH 7.4
(106 cm/s)
logD,
pH 7.4
64 Me H H Me 3070 2390 0.78 >20 122 263 2.6
65 Me H Me H 1070 768 0.72 >40 108 58 2.2
66 H Me H Me 3130 4830 1.54 ND 17 218 2.4
67 Me Me H H 3920 2280 0.58 >5 8 42 2.2
68 H Me Me H 262 216 0.82 >20 41 46 2.1
69 OMe H H OMe >9640 >9640 ND >20 105 9 1.5
70 OMe H OMe H >9640 7980 <0.83 >20 152 51 1.9
71 H OMe H OMe >7290 2590 <0.36 >40 188 13 1.4
72 OMe OMe H H 6340 3460 0.55 >20 175 19 1.8
73 H OMe OMe H 8970 3390 0.38 >20 88 1 1.3
74 Cl H H Cl >9320 >9320 ND >20 108 288 2.6
75 Cl H Cl H >9320 >9320 ND >1 1 252 3.0
76 H Cl H Cl 87.8 96.2 1.10 >5 8 134 2.5
77 Cl Cl H H 6330 >9330 >1.47 >20 41 348 2.9
78 H Cl Cl H 321 341 1.06 >1 1 180 2.6
79 F H H F 804 1320 1.64 >40 159 12 1.3
80 F H F H 2690 405 0.15 >40 66 29 1.7
81 H F H F 16.5 45.0 2.72 >2 3 13 1.5
82 F F H H 1050 378 0.36 >40 93 38 1.9
83 H F F H 129 118 0.91 >10 18 28 1.9
aDihydroartemisinin (DHA), chloroquine (CQ), and atovaquone (ATO) are internal controls for each in vitro assay: DHA (1.8 nM W2 and 0.9 nM
TM90-C2B) and CQ (162 nM W2 and 131 nM TM90-C2B) and ATO (0.53 nM W2 and >170 nM TM90-C2B).
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the 7-chloro has been replaced with a 7-methyl substituent, the
RIs revert back to 0.46 and 0.86, respectively. Interestingly, the
6-chloro and 7-methoxy analogues 94 and 95, respectively, which
contain aCF2 group in the aliphatic ring, display acceptable RIs
while compound 93 combining the two benzenoid ring substit-
uents with the CF2 unit yields a RI of less than 0.1. Ultimately, the
placement of benzenoid substituents in conjunction with the
other favorable aliphatic ring features is critical for developing a
molecule with an acceptable RI. All compounds were ﬁnally
tested for cytotoxicity against J774 mammalian cells in a 96-well
plate format, which has been previously reported (see Experi-
mental Section for details). Generally, the THAs do not display
signs of cytotoxicity at concentrations lower than 20 μM,
rendering cytotoxicity indices (CI = EC50(J774)/EC50(TM90-
C2B)) of 100 or more. These results indicate that most of the
THAs are selective and nontoxic agents.14
StructureProperty Studies. In parallel to the antimalarial
activity testing, standard physicochemical properties were deter-
mined to identify potential compound liabilities prior to the
time-consuming and costly development and optimization of
analogues that will ultimately fail within in vivo efficacy experi-
ments. Compound 2b was prepared, using the procedure of
Kesten et al., as a reference compound for comparison of
solubility, permeability, and logD7.4 (Table 1).
19 Analogue 2b
does not possess the imine moiety of prodrug 2a and hence is
structurally more similar to THAs 5118. Interestingly, com-
pound 2b displayed poor solubility and a logD7.4 just out of the
acceptable range. Compounds 5118 were routinely assessed in
parallel for aqueous solubility, partition coefficient (logD7.4),
and permeability (Pe) at various pH (Tables 18). Protein and
plasma binding assays were regarded as redundant, since the in
vitro antimalarial activity assay is conducted in 10% heat in-
activated plasma. Furthermore, a selection of promising THAs
has also been tested for murinemicrosomal stability to determine
potential metabolic liabilities (Table 9).
The determination of aqueous solubility and logD7.4 was
conducted using HPLC-based protocols, which were previously
utilized for the 3-substituted 4(1H)-quinolone series (see Ex-
perimental Section for details).14,49 The distribution coeﬃcients
of all THAs are in the acceptable range (1 < logD7.4 < 4),
whereby a plot of in vitro activity against logD7.4 implies that
potency against both strains weakly correlates with lipophilicity
(Figure 4). The most potent compound 118 also possess the
greatest lipophilicity with a logD7.4 of 3.6.
Overall, for the majority of the THAs, the solubilities are in the
acceptable range of 40 μM or higher and no signiﬁcant pH
dependence on the aqueous solubility has been observed
(Tables 18). Comparison of the solubility of compounds
5118 suggests that THAs containing a ﬁve- or six-membered
aliphatic ring exhibit greater solubility than the analogues with a
Table 7. SAR of Various THAs Including Heteroatom Containing Aliphatic Ringa
aDihydroartemisinin (DHA), chloroquine (CQ), and atovaquone (ATO) are internal controls for each in vitro assay: DHA (1.8 nM W2 and 0.9 nM
TM90-C2B) and CQ (162 nM W2 and 131 nM TM90-C2B) and ATO (0.53 nM W2 and >170 nM TM90-C2B).
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Table 8. SAR of SuzukiMiyaura Cross-Coupled THAsa
aDihydroartemisinin (DHA), chloroquine (CQ), and atovaquone (ATO) are internal controls for each in vitro assay: DHA (1.8 nM W2 and 0.9 nM
TM90-C2B) and CQ (162 nM W2 and 131 nM TM90-C2B) and ATO (0.53 nM W2 and >170 nM TM90-C2B).
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seven- or eight-membered saturated ring. The solubility also
depends on the nature and position of substituents on the
benzenoid ring. For example, the 5-chloro-THAs 21, 34, 47
and the 8-chloro-THAs 24, 37, 50 possess signiﬁcantly increased
solubility in comparison to the 6- or 7-chloro-substituted analo-
gues 22, 23, 35, 36, 48, and 49. A more pronounced diﬀerence in
solubility is observed for the compound pair 58 and 59, which is
monosubstituted with one tert-butyl group at the 5- or 7-position.
Though THAs 58 and 59 are similar in electronics, the diver-
gence in solubility is purely derived by the position of the bulky
alkyl group. A similar observation can be made by analyzing the
THAs disubstituted on the benzenoid ring, 6483, and espe-
cially the dichloro compounds 7478, in which the 5,8-dichloro
analogue 74 is much more soluble than compounds 7578.
Strikingly, the extent of the solubility increase for the 5- or
8-substituted analogues stands in contrast to the distribution
coeﬃcient logD7.4 determined to be in the range of 2.43.0 for
all monochloro- or dichloro-THAs 2124, 3437, 4750, and
7478 (see Supporting Information, Figure S1).
Analogous solubility trends for the dimethyl- or the dimethoxy-
substituted THAs 6473were determined; however, these results
are less pronounced in comparison to the dichloro compounds
7478. These data support the notion that the THA’s solubility is
strongly inﬂuenced by a tight crystal packing. A chloro group at the
5- or 8-position or both positions creates steric hindrance that
presumably weakens the strength of the intermolecular hydrogen
bonding between the carbonyl and the amino groups of the THA
scaﬀold. 1HNMRNHchemical shift trends also seem to support
such a weakening of hydrogen bonding with respect to DMSO in
solution. The unsubstituted THA 13 (NH δ 11.3 ppm) is
similarly shifted as 5-chloro-THA 21 (NH δ 10.4 ppm),
5-ﬂuoro-THA 53 (NH δ 11.2 ppm), and 5-methoxy-THA 14
(NH δ 10.7 ppm). However, the 5-methyl-THA 17 (NH δ
10.0 ppm) shows a large upﬁeld shift while the 5-tert-butyl-THA 58
(NH δ 8.7 ppm) is even further shifted, almost 3 ppm compared
to the unsubstituted THA 13. This trend suggests the THANH
chemical shift is much more dependent on the local steric
environment than electronics/σ-eﬀect, especially when considering
that either electron poor or electron rich analogues have chemical
shifts similar to those of the unsubstituted THA 13. This conclu-
sion is further supported by the increased solubility and dramatic
loss of antimalarial activity as seen in THAs 14, 17, 21, 58, 64, 69,
and 74 possessing a sterically encumbered substituent at the 5- or
8-positions (see Supporting Information, Figure S1).
The crucial role of the benzenoid ring substituents at the 6-
and 7-positions on antimalarial activity alsomotivated us to study
Figure 3. Plot of pEC50 (TM90-C2B) versus pEC50 (W2).
Table 9. In Vitro Metabolic Stability Using Murine Liver
Microsomes
compd t1/2 (min) compd t1/2 (min)
6 6.8 95 15.8
13 18.2 101 990
17 6.4 102 CNCa
18 20.1 106 8.4
27 77 109 15.1
40 24.8 113 11.2
81 3.6 114 C.N.C.a
93 8.5 115 C.N.C.a
94 40.8 118 173.3
aC.N.C. compounds that underwent such a minimal degradation that
half-lives could not be calculated.
Figure 4. Plots of activities of W2 and TM90-C2B versus logD (pH 7.4).
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their eﬀect on solubility. In comparison to the unsubstituted
compound 13, the presence of a 6- methoxy group as in analogue
6 increases the solubility by a factor of 3, while 7-chloro-THA 23
is 6-fold less soluble. The combination of both substituents in the
same compound (90) not only improves the antimalarial activity
but also restores the compound’s solubility to that similar to 13.
Replacement of the 7-chloro group in 90 by a 7-methyl group
yields analogue 96 and restores the aqueous solubility to a range
similar to that of analogue 13. The 7-chloro substituent improves
the hydrogen bond donor capacity of the THA’s amine, while the
6-methoxy group enhances the carbonyl’s ability as a hydrogen
bond acceptor, which possibly strengthens the intramolecular
hydrogen bonding in the crystal packing.
Compounds substituted at the benzenoid ring with an aro-
matic residue at the 6- or 7-position belong to another major
compound series that in general displayed poor solubility with a
few exceptions. Nevertheless, the solubility of biaryl ether 108 is
improved by the out-of-plane o-methylaryl group in 109, de-
pending on the pH in which the aqueous solubility has been
determined, by a factor 6 or higher. Furthermore, the pyridyl
analogues 103 and 104 were extremely soluble at low pH
(>80 μM each) and at pH 7.4 (>40 μM each); unfortunately,
they were devoid of activity.
Finally, the aliphatic ring has been considered to be a suitable
site for improving the aqueous solubility by perturbing the crystal
packing and/or increasing the compound polarity. In comparison
to the THAs 1324, the 2,2-dimethyl-THAs 2537 and the 3,3-
dimethyl-substituted analogues 3850 have been designed with
the idea of introducing subtle steric entities while minimally
increasing the distribution coeﬃcients. Overall, the 2,2-dimethyl-
THAs 2537 are similar or less soluble than the THAs 1324,
while the 3,3-dimethyl-substituted compounds are less soluble.
The strategy to improve the solubility by steric diﬀerences at the
aliphatic ring was abandoned given that the 2,2-dimethyl- and 3,3-
dimethyl-THAs 2550 did not improve the aqueous solubility.
However, replacement of amethylene unit in the aliphatic ring by a
nitrogen or a sulfur yielded analogues varying in solubility and
potency. The tertiary amine in THA 99 signiﬁcantly enhances the
solubility across all pHs, while the antimalarial activity is comple-
tely abolished. In contrast, the solubility of thioether compounds
varies depending on the benzenoid ring substituents. 7-Aryl-
substituted thioether 113 is approximately 5-fold more soluble
than its methylene congener 114, while 6-methoxy-substituted
thioethers 92 and 97 are less soluble than the aliphatic THAs 90
and 96. Nevertheless, oxidation of the sulfur atom of 92, leading to
sulfoxide 101 and sulfone 102, restores the aqueous solubility of
20 μM or higher. Replacement of the same methylene by a CF2
unit was synthesized mainly as a probe for examining microsomal
stability; however, upon comparison of the solubility of these three
analogues 93, 94, and 95, an interesting trend emerged. The
7-chloro is the least soluble while the 6-methoxy is the most
soluble at all three pHs. The 6-chloro-7-methoxy compound’s
solubility is comparable to the 6-methoxy compound but with an
approximate 63-fold increase in potency against TM90-C2B.
The permeabilities of the majority of the compounds have
been determined and are not considered to be amajor liability for
the THA compound series. A plot of the permeability against
solubility at pH 4.0 and pH 7.4 demonstrates an insigniﬁcant pH
dependence (see Supporting Information, Figure S2). Further-
more, it also shows that most of the tested THAs possess
acceptable solubilities (20100 μM) and acceptable permeabil-
ities (10  106 to 100  106 cm/s).
Microsomal stability was determined for a select set of
compounds to systematically determine the structural features
of the THA core that are most susceptible to microsomal
degradation (Table 9). Compounds that underwent such a
minimal degradation that half-lives could not be calculated are
listed as CNC.
The unsubstituted THA 13 had a half-life of 18 min, while
substitution at the 5-position with a methyl as in 17 or disub-
stitution at the 6- and 8- position as in 81 with a ﬂuorine
decreased the half-lives to less than 7 min. Comparison of
geminally disubstituted methoxy analogues 27 and 40 revealed
that the 2,2-dimethyl analogue had a half-life of 77 min, which
corresponds to a 3-fold increase of stability over the 3,3-dimethyl
congener. Sulfoxide containing THA 101 had a half-life of 990
min, while the sulfone 102 was minimally degraded. Next, the
aryl substituted analogues were tested, showing that THAs 106,
109, and 113 with sulfur containing aliphatic rings displayed the
poorest half-lives of 8.3, 15.1, and 11.2 min, respectively. The
THA 118 substituted at the 6-position with a biaryl ether
demonstrated an improved half-life of 173 min, while the 6-
and 7-triﬂuoromethylphenyl substituted analogues 115 and 114
showed minimal degradation. Finally, three compounds were
prepared in which the methylene at the 2-position was replaced
by a CF2 unit with intentions of gaining a contrasting result to the
sulfur containing aliphatic ring. Themost stable analogue was 94,
which is monosubstituted with a chloro at the 7-position. The
half-life of the 6-methoxy analogue 95 was decreased by a factor
of 3, whereas the half-life of the 7-chloro-6-methoxy-THA was
less. The ﬂuoromethylene compound 93, which was shown to
increase potency while slightly decreasing solubility, maintained
a similar microsomal stability as the reference THA 13. The
aryl-substituted analogues 106, 109, 113115, and 118 vary in
half-lives from 8 min to minimally detectable degradation. The
triﬂuoromethylphenyl was shown to be the superior substituent
in terms of stability compared to the other aryl analogues, and
substitution at the 6-position appeared to be slightly more stable
compared to the 7-substituted analogue.
’CONCLUSIONS
Upon examination of the shortcomings of compounds 1, 2a,
and 2b, a set of compounds was prepared to probe the ring size of
the aliphatic ring of the THA core and to examine whether
heteroatoms in the aliphatic ring are tolerated. In addition, a
library of THA analogues was prepared to systematically identify
the key positions and substitutions of the benzenoid ring by
loosely following the Topliss operational schemes. Generally, the
best antimalarial activities with acceptable RI values were ob-
tained if (a) the 5-position was unsubstituted, (b) the 6-position
was substituted with an electron donating or electron with-
drawing group, (c) the 7-position was substituted with an
electron donating group, (d) the 8-position was ﬂuorinated or
unsubstituted, and (e) the THA core contained a six-membered
aliphatic ring. Furthermore, it was shown that replacement of the
C-2methylene unit by oneCF2 group or one sulfur was tolerated,
while introduction of other heteroatoms in the aliphatic ring
signiﬁcantly reduced the THA’s antimalarial activity. The best
substituents were combined in follow-up optimization studies
leading to the identiﬁcation of several THAs with improved
antimalarial activity against multidrug resistant strains W2 and
the TM90-C2B. THAs 89 and 90, which are disubstituted in 6-
and 7-positions with one electron withdrawing and one electron
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donating group, and 6,8-diﬂuoro-substitued THA 81 are among
the most potent compounds with EC50 of 45 nM or lower.
Furthermore, THAs such as 106, 114, 115, and 118, substituted
with an aryl ring either in the 6- or 7-position, demonstrated
comparable or improved antimalarial activity. Of all THAs tested,
biaryl ether 118 with EC50 of 12.2 nM for W2 and 9.1 nM for
TM90-C2B was the most potent compound, also possessing an
acceptable resistance index (RI) of 0.75. Overall, this SAR study
demonstrated that most of the THA compounds possess RI
values in the acceptable range and thus lack, in contrast to
atovaquone or chloroquine, any cross-resistance. Furthermore,
the entire THA series did not show any cytotoxicity to J774
mammalian cells at 20 μM, yielding cytotoxicity indices (CIs) of
100 or more for the most potent antimalarial THAs 89, 90, 106,
114, 115, and 118.
All THAs have also been examined for aqueous solubility,
logD7.4, and permeability. In general, the permeability, the
logD7.4, and the aqueous solubility of most of the THAs have
been determined to be in the acceptable ranges. Nevertheless, the
more potent THAs tend to possess increased logD7.4 values and
decreased aqueous solubility, which is consistent with the pre-
vious report on antimalarial 4(1H)-quinolones.14 Importantly, in
comparison to reference compound 2b, THAs such as 89, 90,
114, and 115 are similar in antimalarial activity; however, they
possess a better solubility or an improved permeability or both.
Furthermore, a selection of THAs has been tested for murine
microsomal stability and most of the tested THAs suﬀer from
short half-lives of 320 min. The aliphatic ring and several
groups of the benzenoid ring have been identiﬁed to be the major
sites for metabolism. Nevertheless, THAs 114, 115, and 118,
which are substituted with an aryl group in the 6- or 7-position,
possess excellent half-lives of 3 h or longer.
The improved physicochemical properties in conjunction
with the potent antimalarial activity and lack of cross-resistance
make the aryl-substituted THAs attractive for further optimiza-
tion and development. Even though no THA with optimal
antimalarial activity and optimal physicochemical properties
has been identiﬁed, the herein presented study strongly suggests
that THAs 114, 115, and possibly 89, 90, and 118 are well suited
for further development. Studies are currently ongoing to assess
whether these frontrunner compounds demonstrate in vivo
eﬃcacy in rodent malaria models as well as exoerythrocytic stage
activity. The discovery that the 6- or 7-position of the THA
scaﬀold tolerates aryl substituents provides opportunities for
next generation designs. The herein presented ease of the
palladium catalyzed cross-coupling conditions to prepare 6- or
7-aryl-substituted THAs in combination with the large number
of commercially available boronic acids is attractive for future
lead optimization.
’EXPERIMENTAL SECTION
All anhydrous solvents were obtained from Aldrich Chemical Co. and
used without further puriﬁcation unless otherwise noted. 2,5-Dichloro-
anisole, 4,4-dimethylcyclohexanone, and 3,3-dimethylcyclohexanone
were bought from Alfa Aesar. 4-Fluoro-3-methoxyaniline was bought
from Oakwood Products, Inc., while 4-bromo-3-methoxyaniline was
bought from TCI America. Anthranillic acids were purchased from
Oakwood Products, Inc. or Aldrich. POCl3, 2-methoxy-1-methyl-4-nitro-
benzene, 3,30-thiodipropanoic acid, cycloalkanones, and all other anilines
were purchased from Aldrich. 1-Bromo-4-(chloromethyl)benzene,
1-iodo-4-(triﬂuoromethoxy)benzene, and all phenols were purchased
fromMatrix Scientiﬁc. All palladium catalysts and ligands were purchased
from Strem. All boronic acids were purchased from Frontier Scientiﬁc.
The identity of all title compounds were veriﬁed via 1H NMR, 13C NMR,
and HPLC/HRMS. The chemical purity of the titled compounds was
determined using the following conditions: an Agilent 1100 series
LC/MSDwith an Eclipse XDB-C18 (4.6 mm 100mm, 5 μm) reversed
phase column; method, 10% (v/v) of acetonitrile (þ0.05% TFA) in 90%
(v/v) of H2O (þ0.05% TFA), ramped to 100% acetonitrile (þ0.05%
TFA) over 9 min, and holding at 100% acetonitrile for 4 min with a ﬂow
rate of 0.7 mL/min; UV detector, 254 nm. The purity of each compound
was g95% in this analysis. NMR spectra were recorded at ambient
temperature on a 400 or 500 MHz Varian NMR spectrometer in the
solvent indicated. All 1H NMR experiments are reported in δ units, parts
per million (ppm) downﬁeld of TMS, and were measured relative to the
signals for chloroform (7.26 ppm) and dimethylsulfoxide (2.50 ppm). All
13C NMR spectra were reported in ppm relative to the signals for
chloroform (77 ppm) and dimethylsulfoxide (39.5 ppm) with 1H
decoupled observation. Data for 1H NMR are reported as follows:
chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet,
q = quartet, m =multiplet, br = broad), integration, and coupling constant
(Hz). 13C NMR analyses were obtained at 101 MHz and reported in
terms of chemical shift. NMR data were analyzed by using MestReNova
software, version 5.3.2-4936. High resolution mass spectrometry
(HRMS) was performed on an Agilent LC/MSD TOF system
G3250AA. Isomers were separated by reverse phase HPLC system
(Waters Prep LC 4000 system with Waters 996 photodiode array
detector, Agilent column Eclipse XDB-C18, 5 μm, 9.4 mm  250 mm).
Compounds were eluted using a gradient elution of 70/30 to 50/50 A/B
over 30 min at a ﬂow rate of 5.0 mL/min, where solvent A was water and
solvent B was acetonitrile. Analytical thin layer chromatography (TLC)
was performed on silica gel 60 F254 precoated plates (0.25 mm) from
EMD Chemical Inc., and components were visualized by ultraviolet light
(254 nm). Silicycle silica gel 230400 (particle size 4063μm)meshwas
used for all ﬂash column chromatography experiments.
General Procedure A: POCl3 Cyclization of Anthranillic
Acids. Anthranillic acid (0.25 g, 1.7 mmol) is added to a dried flask,
followed by cycloalkanone (0.23 g, 1.87 mmol). This flask is cooled to
0 C, and POCl3 (1.4 mL) is added. The mixture is allowed to reflux for
18 h. Upon completion the mixture is poured onto ice and water. The
solution is brought to pH 10 using saturated K2CO3 . Next ethyl acetate
or chloroform is added and the organic layer is removed andwashed with
brine (50mL) followed bywater (50mL). Next the organic layer is dried
over Na2SO4 and concentrated in vacuo. The crude oil is purified further
via flash chromatography (hexane/EtOAc). A few representative exam-
ples of these compounds were characterized by NMR; however, most
were considered as intermediates and were taken on to acetic acid
hydrolysis upon identification using LCMS.
General Procedure B: Hydrolysis of 9-Chloro-1,2,3,4-tetra-
hydroacridine. 9-Chloro-1,2,3,4-tetrahydroacridine (0.15 g, 0.69
mmol) was dissolved in AcOH (1.5 mL) and heated in a sealed tube
at 200 C for 2448 h. Upon completion via LCMSanalysis, the crude
material is poured onto ice and water. The mixture is filtered, and the
solid is recrystallized from either pyridine or DMF.
General Procedure C: ConradLimpach Cyclization Using
Ethyl 2-Oxocyclohexanecarboxylate. An oven-dried 100 mL
round-bottom flask attached to a DeanStark trap equipped with a
reflux condenser was charged with an aniline (0.025 mol), correspond-
ing cyclohexanone carboxylate (0.0250.05 mol), benzene (25 mL),
and glacial acidic acid (1mL). Themixture was heated at 100 C until no
more water was separated (324 h). The benzene was distilled under
reduced pressure, and the resulting crude intermediate was then used in
the next step without further purification. Biphenyl ether (30 mL) was
stirred and heated at reflux, while the crude intermediate was added
rapidly through the dropping funnel. Stirring and refluxing continued for
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1015 min until no more ethanol separated within the DeanStark
trap. The mixture was then allowed to cool to room temperature while
precipitation arose. The solid was filtered off and washed with hexane
and acetone. Ice cold methanol washing may be necessary in some cases.
In most cases no further purification was needed, however in some cases
recrystallization from DMF was employed. Furthermore, compounds
68, 78, and 89 which produced regioisomers were isolated using
preparative HPLC as previously described.
General Procedure D: Suzuki Coupling of Halotetrahy-
droacridone. An oven-dried Schlenk tube was flame-dried and back-
filled with argon (3). The tube was then charged with 6-bromo-1,2,3,4-
tetrahydroacridin-9(10H)-one (0.1 g, 0.36 mmol), Pd2(dba)3 (0.01 g,
7 mol %), SPHOS (0.013 g, 14 mol %), and boronic acid (0.102 g,
0.54 mmol). A rubber septum was then placed on the tube, and 1 M
Na2CO3 (1 mL) and DMF (5 mL) were added. The tube was then
purged of air by argon for about 1 min while the mixture was stirred and
then heated at 80 Cuntil reaction completion byHPLCanalysis (324 h).
After completion, the mixture was boiled with 1:1 MeOH/CHCl3 and
filtered over Celite. The Celite was then rinsed with boiling hot DMF. The
filtrate was then evaporated on silica gel purified via flash chromatography.
6-Methoxy-2,3-dihydro-1H-cyclopenta[b]quinolin-9(4H)-
one (5). Following general procedures A and B, the title compound was
prepared to provide 54% yield as a brown powder. 1H NMR (400 MHz,
DMSO) δ 7.92 (s, 1H), 6.83 (d, J = 32.8 Hz, 2H), 3.76 (s, 3H), 2.87
(br s, 2H), 2.44 (br s, 2H), 1.95 (br s, 2H). 13C NMR (101 MHz,
DMSO) δ 161.58, 153.93, 142.55, 126.95, 119.35, 112.52, 99.65, 55.40,
32.13, 28.09, 21.72. HRMS (ESI) calcd for C13H14NO2 [M þ H]þ,
216.1019; found, 216.1018.
6-Methoxy-1,2,3,4-tetrahydroacridin-9(10H)-one (6). Fol-
lowing general procedures A and B, the title compound was prepared to
provide 43% yield as an off-white powder, mp = 283287 C. 1H NMR
(400MHz, DMSO) δ 11.38 (s, 1H), 7.97 (d, J = 8.7Hz, 1H), 6.85 (d, J =
10.0 Hz, 2H), 3.83 (s, 3H), 2.66 (d, J = 5.8 Hz, 2H), 2.41 (t, J = 5.4 Hz,
2H), 1.761.65 (m, 4H). 13C NMR (101 MHz, DMSO) δ 175.74,
162.10, 147.41, 141.57, 127.25, 118.14, 115.67, 113.14, 98.86, 55.97,
27.79, 22.55, 22.24, 22.13. HRMS (ESI) calcd for C14H16NO2[M þ
H]þ, 230.1176; found, 230.1171.
3-Methoxy-7,8,9,10-tetrahydro-5H-cyclohepta[b]quinolin-
11(6H)-one (7). Following general procedures A and B, the title
compound was prepared to provide 38% yield as a brown crystal, mp =
284285 C. 1HNMR (400MHz, DMSO) δ 11.98 (s, 1H), 8.04 (d, J =
8.6Hz, 1H), 7.036.86 (m, 2H), 3.84 (s, 3H), 2.88 (br s, 2H), 2.79 (br s,
2H), 1.79 (br s, 2H), 1.66 (br s, 2H), 1.46 (br s, 2H). 13C NMR (101
MHz, DMSO) δ 172.38, 161.53, 154.31, 140.25, 126.79, 120.02, 117.02,
113.92, 98.63, 55.45, 33.51, 31.70, 27.00, 25.66, 23.06. HRMS (ESI)
calcd for C15H18NO2 [M þ H]þ, 244.1332; found, 244.1330.
3-Methoxy-6,7,8,9,10,11-hexahydrocycloocta[b]quinolin-
12(5H)-one (8). Following general procedures A and B, the title
compound was prepared to provide 32% yield as a brown powder, mp =
266268 C. 1HNMR (400MHz, DMSO) δ 12.66 (s, 1H), 8.12 (d, J =
8.3 Hz, 1H), 7.12 (s, 1H), 6.99 (d, J = 8.0 Hz, 1H), 3.85 (s, 3H), 2.91 (br
s, 2H), 2.74 (br s, 2H), 1.75 (br s, 2H), 1.55 (br s, 2H), 1.35 (br s, 4H).
13CNMR (101MHz, DMSO) δ 171.34, 161.68, 152.63, 140.83, 126.34,
117.78, 116.29, 114.60, 98.50, 55.48, 30.12, 29.72, 29.15, 25.85, 25.45,
22.57. HRMS (ESI) calcd for C16H20NO2 [MþH]þ, 258.1489; found,
258.1490.
6-Trifluoromethyl-2,3-dihydro-1H-cyclopenta[b]quinolin-
9(4H)-one (9). Following general procedures A and B, the title
compound was prepared to provide 65% yield as a gray powder, mp =
283284 C. 1HNMR (400MHz, DMSO) δ 12.57 (s, 1H), 8.29 (d, J =
8.0 Hz, 1H), 7.87 (s, 1H), 7.57 (d, J = 7.8 Hz, 1H), 3.03 (s, 2H), 2.73 (s,
2H), 2.07 (d, J = 6.2 Hz, 2H). 19F NMR (376 MHz, DMSO) δ61.82.
13C NMR (101 MHz, DMSO) δ 172.41, 155.98, 139.50, 130.55 (q, J =
31.3 Hz), 126.54, 123.74 (q, J = 273.1Hz),120.94, 118.28, 115.44, 31.83,
27.49, 21.26. HRMS (ESI) calcd for C13H11F3NO [M þ H]þ,
254.0787; found, 254.0785.
6-Trifluoromethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (10).
Following general procedures A and B, the title compound was prepared
to provide 62% yield as a brown crystal, mp = 324328 C. 1H NMR
(400 MHz, DMSO) δ 12.09 (s, 1H), 8.26 (d, J = 8.4 Hz, 1H), 7.88 (s,
1H), 7.52 (d, J = 8.4 Hz, 1H), 2.75 (t, J = 5.7 Hz, 2H), 2.46 (t, J = 5.8 Hz,
2H), 1.801.66 (m, 4H). 19F NMR (376 MHz, DMSO) δ62.16. 13C
NMR (101 MHz, DMSO) δ 175.00, 164.60, 161.89, 149.63, 141.41,
139.16, 133.55, 131.50 (q, J = 32.3 Hz), 130.08, 127.25, 125.26, 124.47
(q, J = 273.7 Hz,), 118.57, 117.76, 115.76, 27.92, 22.32, 22.20, 21.85.
HRMS (ESI) calcd for C14H13F3NO [M þ H]þ, 268.0944; found,
268.0943.
3-Trifluoromethyl-7,8,9,10-tetrahydro-5H-cyclohepta[b]
quinolin-11(6H)-one (11). Following general procedures A and B,
the title compoundwas prepared to provide 57% yield as a brown crystal,
mp = 332333 C. 1H NMR (500 MHz, DMSO) δ 8.27 (d, J = 8.8 Hz,
1H), 8.23 (s, 1H), 7.88 (d, J = 7.6 Hz, 1H), 3.19 (dd, J = 15.4, 8.5 Hz,
4H), 1.83 (dd, J = 11.1, 5.7 Hz, 2H), 1.69 (dd, J = 11.2, 5.4 Hz, 4H). 13C
NMR (126 MHz, DMSO) δ 167.07, 145.26, 138.64, 136.72, 130.0 (q, J
= 25 Hz), 127.01, 126.65 (q, J = 12.5 Hz), 126.49, 124.3 (q, J = 275 Hz),
122.88 (q, J = 3.75 Hz), 39.79, 31.38, 30.22, 27.27, 26.69. HRMS (ESI)
calcd for C15H15F3NO [M þ H]þ, 282.1100; found, 282.1099.
3-Trifluoromethyl-6,7,8,9,10,11-hexahydrocycloocta[b]
quinolin-12(5H)-one (12). Following general procedures A and B,
the title compound was prepared to provide 31% yield as a brown
powder, mp = 241242 C. 1H NMR (400 MHz, DMSO) δ 11.94 (s,
1H), 8.25 (d, J = 6.3 Hz, 1H), 7.88 (s, 1H), 7.52 (d, J = 6.4 Hz, 1H), 2.84
(s, 2H), 2.70 (s, 2H), 1.55 (s, 2H), 1.37 (s, 4H). 19F NMR (376 MHz,
DMSO) δ 61.51. 13C NMR (101 MHz, DMSO) δ 174.50, 151.87,
139.20, 131.09 (q, J = 27.3 Hz), 127.43, 125.53, 124.28 (q, J = 273.7 Hz),
120.52, 118.32, 115.75, 30.70, 29.96, 29.57, 26.43, 25.97, 23.21.
1,2,3,4-Tetrahydroacridin-9(10H)-one (13). Following gener-
al procedures A and B, the title compound was prepared to provide 72%
yield as an off-white powder, mp = 341343 C. 1H NMR (400 MHz,
DMSO) δ 11.30 (s, 1H), 8.05 (d, J = 7.9 Hz, 1H), 7.55 (dd, J = 11.1, 4.0
Hz, 1H), 7.45 (d, J = 8.3 Hz, 1H), 7.21 (t, J = 7.4 Hz, 1H), 2.69 (t, J = 6.0
Hz, 2H), 2.43 (t, J = 6.0 Hz, 2H), 1.771.67 (m, 4H). 13C NMR (101
MHz, DMSO) δ 176.60, 147.41, 139.92, 131.57, 125.49, 123.88, 122.60,
118.00, 116.18, 27.79, 22.56, 22.34, 22.18. HRMS (ESI) calcd for
C13H14NO [M þ H]þ, 200.1070; found, 200.1073.
5-Methoxy-1,2,3,4-tetrahydroacridin-9(10H)-one (14). Fol-
lowing general procedures A and B, the title compound was prepared to
provide 27% yield as a light yellow powder, mp = 273276 C. 1HNMR
(400MHz, DMSO) δ 10.69 (s, 1H), 7.647.58 (m, 1H), 7.15 (d, J = 5.0
Hz, 2H), 3.97 (s, 3H), 2.76 (t, J = 5.8 Hz, 2H), 2.42 (t, J = 6.0 Hz, 2H),
1.741.65 (m, 4H). 13C NMR (101 MHz, DMSO) δ 175.66, 147.91,
146.72, 130.09, 124.02, 121.64, 116.19, 116.01, 110.28, 56.00, 27.12,
21.80, 21.78, 21.51. HRMS (ESI) calcd for C14H16NO2 [M þ H]þ,
230.1176; found, 230.1171.
7-Methoxy-1,2,3,4-tetrahydroacridin-9(10H)-one (15).
Following general procedure A, the title compound was prepared to
provide 46% yield as a brown crystal, mp = 299301 C. 1H NMR (400
MHz, DMSO) δ 11.29 (s, 1H), 7.45 (d, J = 2.8 Hz, 1H), 7.42 (d, J = 9.0
Hz, 1H), 7.21 (dd, J = 9.0, 2.8 Hz, 1H), 3.80 (s, 3H), 2.68 (t, J = 5.8 Hz,
2H), 2.44 (t, J = 5.9 Hz, 2H), 1.771.67 (m, 4H). 13C NMR (101MHz,
DMSO) δ 175.23, 154.64, 145.85, 133.95, 123.99, 121.41, 119.06,
114.48, 104.05, 55.19, 27.05, 21.95, 21.79, 21.54. HRMS (ESI) calcd
for C14H16NO2 [M þ H]þ, 230.1176; found, 230.1179.
8-Methoxy-1,2,3,4-tetrahydroacridin-9(10H)-one (16).
Following general procedures A and B, the title compound was prepared
to provide 15% yield as a brown powder. 1H NMR (400 MHz, DMSO)
δ 11.1 (s, 1H), 7.377.30 (m, 1H), 7.16 (d, J = 8.0, 1H), 6.78 (d, J = 6.8,
1H), 2.82 (s, 3H), 2.60 (t, J = 5.1, 2H), 2.43 (t, J = 5.0, 2H), 1.701.60
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(m, 4H). HRMS (ESI) calcd for C14H16NO2 [M þ H]þ, 230.1176;
found, 230.1167.
5-Methyl-1,2,3,4-tetrahydroacridin-9(10H)-one (17). Fol-
lowing general procedure and B, the title compound was prepared to
provide 29% yield as a brown powder, mp = 314317 C. 1HNMR (400
MHz, DMSO) δ 10.16 (s, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.41 (d, J = 6.8
Hz, 1H), 7.13 (t, J = 7.5 Hz, 1H), 2.80 (t, J = 5.6 Hz, 2H), 2.5 (s, 3H),
2.462.42 (m, 2H), 1.72 (br m, J = 23.1, 5.0 Hz, 4H). 13C NMR (101
MHz, DMSO) δ 176.00, 147.35, 137.91, 131.89, 125.43, 123.28, 122.78,
121.81, 115.66, 27.32, 21.78, 21.76, 21.57, 17.49. HRMS (ESI) calcd for
C14H16NO [M þ H]þ, 214.1226; found, 214.1229.
6-Methyl-1,2,3,4-tetrahydroacridin-9(10H)-one (18). Fol-
lowing general procedures A and B, the title compound was prepared
to provide 51% yield as a tan crystal, mp = 330332 C. 1H NMR (250
MHz, DMSO) δ 11.17 (s, 1H), 7.92 (d, J = 8.2 Hz, 1H), 7.21 (s, 1H),
7.03 (dd, J = 8.3, 1.1 Hz, 1H), 2.67 (t, J = 5.8 Hz, 2H), 2.452.35 (m,
5H), 1.781.62 (m, 4H). 13C NMR (63 MHz, DMSO) δ 175.83,
146.44, 140.87, 139.45, 124.85, 123.74, 121.29, 116.57, 115.26, 27.11,
21.91, 21.65, 21.53, 21.33. HRMS (ESI) calcd for C14H16NO [M þ
H]þ, 214.1226; found, 214.1226.
7-Methyl-1,2,3,4-tetrahydroacridin-9(10H)-one (19). Fol-
lowing general procedures A and B, the title compound was prepared
to provide 55% yield as a beige crystal, mp = 352356 C. 1H NMR
(250MHz, DMSO) δ 11.24 (s, 1H), 7.84 (s, 1H), 7.37 (s, 2H), 2.67 (t, J
= 5.4 Hz, 2H), 2.42 (t, J = 5.7 Hz, 2H), 2.37 (s, 3H), 1.831.61 (m, 4H).
13C NMR (63 MHz, DMSO) δ 175.75, 146.37, 137.37, 132.36, 130.97,
124.02, 123.15, 117.30, 115.20, 27.11, 21.95, 21.74, 21.54, 20.75. HRMS
(ESI) calcd for C14H16NO [M þ H]þ, 214.1226; found, 214.1219.
8-Methyl-1,2,3,4-tetrahydroacridin-9(10H)-one (20). Fol-
lowing general procedures A and B, the title compound was prepared
to provide 43% yield as an off-white powder, mp = 340342 C. 1H
NMR (250MHz, DMSO) δ 11.06 (s, 1H), 7.397.32 (m, 1H), 7.26 (d,
J = 8.0, 1H), 6.88 (d, J = 6.8, 1H), 2.79 (s, 3H), 2.62 (t, J = 5.1, 2H), 2.36
(t, J = 5.0, 2H), 1.751.65 (m, 4H). 13C NMR (63 MHz, DMSO) δ
178.44, 145.16, 140.85, 138.90, 130.01, 124.31, 121.55, 116.67, 115.53,
26.70, 23.34, 21.99, 21.76, 21.48. HRMS (ESI) calcd for C14H16NO [M
þ H]þ, 214.1226; found, 214.1222.
5-Chloro-1,2,3,4-tetrahydroacridin-9(10H)-one (21). Fol-
lowing general procedures A and B, the title compound was prepared
to provide 60% yield as a light yellow powder, mp = 265266 C. 1H
NMR (400MHz, DMSO) δ 10.46 (s, 1H), 8.05 (d, J = 8.0 Hz, 1H), 7.74
(d, J = 7.6 Hz, 1H), 7.24 (t, J = 7.8 Hz, 1H), 2.82 (t, J = 5.9 Hz, 2H), 2.43
(t, J = 6.0Hz, 2H), 1.751.67 (m, 4H). 13CNMR (101MHz, DMSO) δ
175.44, 148.06, 135.79, 131.26, 124.69, 124.25, 122.38, 120.54, 116.59,
27.28, 21.71, 21.56, 21.39. HRMS (ESI) calcd for C13H13ClNO [M þ
H]þ, 234.0680; found, 234.0681.
6-Chloro-1,2,3,4-tetrahydroacridin-9(10H)-one (22). Fol-
lowing general procedures A and B, the title compound was prepared
to provide 65% yield as an off-white crystal, mp = 362365 C. 1HNMR
(250 MHz, DMSO) δ 11.38 (s, 1H), 8.03 (d, J = 8.6 Hz, 1H), 7.46 (s,
1H), 7.22 (dd, J = 8.6, 1.8 Hz, 1H), 2.68 (t, J = 5.6 Hz, 2H), 2.41 (t, J =
5.7 Hz, 2H), 1.791.66 (m, 4H). 13C NMR (101 MHz, DMSO) δ
175.38, 147.31, 139.92, 135.51, 127.22, 122.37, 121.77, 116.39, 116.30,
27.11, 21.70, 21.55, 21.36. HRMS (ESI) calcd for C13H13ClNO [M þ
H]þ, 234.0680; found, 234.0683.
7-Chloro-1,2,3,4-tetrahydroacridin-9(10H)-one (23). Fol-
lowing general procedures A and B, the title compound was prepared
to provide 68% yield as an off-white powder, mp = 359361 C. 1H
NMR (400MHz, DMSO) δ 11.51 (s, 1H), 7.97 (d, J = 2.2 Hz, 1H), 7.59
(dd, J = 8.8, 2.2Hz, 1H), 7.50 (d, J = 8.8Hz, 1H), 2.70 (t, J = 5.8Hz, 2H),
2.43 (t, J = 5.9 Hz, 2H), 1.76 (d, J = 5.1 Hz, 2H), 1.70 (d, J = 5.2 Hz, 2H).
13CNMR (101MHz, DMSO) δ 174.70, 147.32, 137.77, 131.04, 126.51,
124.07, 123.68, 119.83, 116.01, 27.10, 21.71, 21.63, 21.37. HRMS (ESI)
calcd for C13H13ClNO [M þ H]þ, 234.0680; found, 234.0677.
8-Chloro-1,2,3,4-tetrahydroacridin-9(10H)-one (24). Fol-
lowing general procedures A and B, the title compound was prepared
to provide 43% yield as a tan powder, mp = 329330 C. 1HNMR (400
MHz, DMSO) δ 11.35 (s, 1H), 7.487.38 (m, 2H), 7.16 (d, J = 7.3,
1H), 2.65 (t, J = 5.9, 2H), 2.36 (t, J = 5.8, 2H), 1.781.66 (m, 4H). 13C
NMR (101 MHz, DMSO) δ 175.16, 145.67, 141.72, 131.74, 130.65,
124.56, 119.07, 117.36, 116.94, 26.71, 21.77, 21.31. HRMS (ESI) calcd
for C13H13ClNO [M þ H]þ, 234.0680; found, 234.0680.
2,2-Dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (25).
Following general procedures A and B, the title compound was prepared
to provide 59% yield as a white crystal. 1H NMR (400 MHz, DMSO) δ
11.34 (s, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.56 (t, J = 8.1 Hz, 1H), 7.45 (d, J
= 8.2 Hz, 1H), 7.21 (t, J = 7.4 Hz, 1H), 2.71 (t, J = 6.5 Hz, 2H), 2.25 (s,
2H), 1.55 (t, J = 6.6 Hz, 2H), 0.97 (s, 6H). 13C NMR (101 MHz,
DMSO) δ 176.17, 145.59, 139.23, 130.91, 124.80, 123.11, 121.87,
117.30, 114.54, 35.42, 33.89, 28.51, 27.93, 24.60. HRMS (ESI) calcd
for C15H18NO [M þ H]þ, 228.1383; found, 228.1376.
5-Methoxy-2,2-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-
one (26). Following general procedure A and B, the title compound
was prepared to provide 56% yield as a yellow powder solid. 1H NMR
(400 MHz, DMSO) δ 10.75 (s, 1H), 7.677.58 (m, 1H), 7.15 (s, 2H),
3.97 (s, 3H), 2.78 (s, 2H), 2.24 (t, J = 6.1 Hz, 2H), 1.51 (t, J = 6.1 Hz,
2H), 0.95 (s, 6H). 13C NMR (101 MHz, DMSO) δ 175.91, 147.92,
145.58, 130.11, 123.94, 121.61, 116.20, 115.09, 110.29, 56.02, 35.56,
33.93, 28.35, 27.91, 24.63. HRMS (ESI) calcd for C16H20NO2 [M þ
H]þ, 258.1487; found, 258.1478.
6-Methoxy-2,2-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-
one (27). Following general procedures A and B, the title compound
was prepared to provide 37% yield as a yellow powder solid, mp =
301303.5C. 1H NMR (400 MHz, DMSO) δ 11.17 (s, 1H), 7.94 (d, J
= 8.6 Hz, 1H), 6.82 (d, J = 9.9 Hz, 2H), 3.82 (s, 3H), 2.66 (t, J = 6.1 Hz,
2H), 2.22 (s, 2H), 1.52 (t, J = 6.2 Hz, 2H), 0.95 (s, 6H). 13C NMR (101
MHz, DMSO) δ 175.81, 161.34, 145.04, 140.91, 126.65, 117.66, 114.06,
112.00, 98.15, 55.23, 35.30, 33.89, 28.51, 27.92, 24.55. HRMS (ESI)
calcd for C16H20NO2 [M þ H]þ, 258.1489; found, 258.1484.
7-Methoxy-2,2-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-
one (28). Following general procedures A and B, the title compound
was prepared to provide 61% yield as a yellow powder, mp =
206208 C. 1H NMR (400 MHz, DMSO) δ 11.34 (s, 1H),
7.467.40 (m, 2H), 7.22 (dt, J = 8.9, 3.2 Hz, 1H), 3.80 (s, 3H), 2.71
(s, 2H), 2.26 (s, 2H), 1.54 (t, J = 6.1 Hz, 2H), 0.96 (s, 6H). 13C
NMR (101 MHz, DMSO) δ 175.51, 154.64, 144.74, 133.98, 123.92,
121.50, 119.08, 113.58, 104.03, 55.22, 35.60, 33.95, 28.56, 27.97,
24.52. HRMS (ESI) calcd C16H20NO2 [M þ H]þ, 258.1489; found,
258.1492.
8-Methoxy-2,2-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-
one (29). Following general procedures A and B, the title compound
was prepared to provide 45% yield as a white powder. 1H NMR (400
MHz, DMSO) δ 11.04 (s, 1H), 7.39 (t, J = 8.2 Hz, 1H), 6.96 (d, J = 8.3
Hz, 1H), 6.62 (d, J = 8.0 Hz, 1H), 3.76 (s, 3H), 2.62 (t, J = 6.4 Hz, 2H),
2.14 (s, 2H), 1.50 (t, J = 6.5 Hz, 2H), 0.94 (s, 6H). 13CNMR (101MHz,
DMSO) δ 176.72, 159.92, 143.99, 142.68, 131.75, 116.82, 114.31,
110.11, 103.72, 56.10, 36.33, 34.54, 29.28, 28.68, 24.86. HRMS (ESI)
calcd for C16H20NO2 [M þ H]þ, 258.1489; found, 258.1500.
2,2,5-Trimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (30).
Following general procedures A and B, the title compound was prepared
to provide 34% yield as a yellow crystal. 1H NMR (400MHz, DMSO) δ
10.15 (s, 1H), 7.93 (d, J = 7.9 Hz, 1H), 7.41 (d, J = 6.8 Hz, 1H), 7.12 (t,
J = 7.4 Hz, 1H), 2.81 (t, J = 6.0 Hz, 2H), 2.50 (s, 3H), 2.25 (s, 2H), 1.54
(t, J = 6.0 Hz, 2H), 0.96 (s, 6H). 13C NMR (101 MHz, DMSO) δ
176.47, 145.99, 137.95, 131.86, 125.39, 123.31, 122.83, 121.68, 114.72,
35.51, 34.02, 28.37, 27.93, 24.79, 17.53. HRMS (ESI) calcd for
C16H20NO [M þ H]þ, 242.1539; found, 242.1537.
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2,2,6-Trimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (31).
Following general procedures A and B, the title compound was prepared
to provide 37% yield as a white crystal, mp = 329330 C. 1HNMR (250
MHz,DMSO)δ 11.22 (s, 1H), 7.92 (d, J= 8.2Hz, 1H), 7.21 (s, 1H), 7.03
(dd, J = 8.3, 1.3 Hz, 1H), 2.69 (t, J = 6.5 Hz, 2H), 2.39 (s, 3H), 2.23 (s,
2H), 1.53 (t, J = 6.6 Hz, 2H), 0.96 (s, 6H). 13CNMR (101MHz, DMSO)
δ 176.07, 145.26, 140.84, 139.43, 124.82, 123.65, 121.20, 116.53, 114.28,
35.40, 33.91, 28.51, 27.94, 24.60, 21.30.HRMS (ESI) calcd forC16H20NO
[M þ H]þ, 242.1539; found, 242.1533.
2,2,7-Trimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (32).
Following general procedures A and B, the title compound was prepared
to provide 39% yield as a yellow crystal,mp= 334335 C. 1HNMR(400
MHz, DMSO) δ 11.28 (s, 1H), 7.83 (s, 1H), 7.427.33 (m, 2H), 2.70 (t,
J= 6.5Hz, 2H), 2.37 (s, 3H), 2.25 (s, 2H), 1.54 (t, J= 6.5Hz, 2H), 0.96 (s,
6H). 13C NMR (101 MHz, DMSO) δ 175.93, 145.22, 137.34, 132.34,
130.92, 123.97, 123.02, 117.26, 114.23, 35.49, 33.91, 28.52, 27.95, 24.57,
20.71. HRMS (ESI) calcd for C16H20NO [M þ H]þ, 242.1539; found,
242.1547.
2,2,8-Trimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (33).
Following general procedures A and B, the title compound was prepared
to provide 44% yield as a yellow crystal,mp= 308309 C. 1HNMR(400
MHz,DMSO)δ 11.10 (s, 1H), 7.35 (t, J=7.7Hz, 1H), 7.26 (d, J= 8.2Hz,
1H), 6.88 (d, J= 7.0Hz, 1H), 2.79 (s, 3H), 2.65 (t, J= 6.3Hz, 2H), 2.18 (s,
2H), 1.51 (t, J = 6.4Hz, 2H), 0.95 (s, 6H). 13CNMR (101MHz, DMSO)
δ 178.64, 143.98, 140.84, 138.88, 130.00, 124.24, 121.48, 115.72, 115.50,
35.54, 33.87, 28.57, 27.99, 24.24, 23.31. HRMS (ESI) calcd for
C16H20NO [M þ H]þ, 242.1539; found, 242.1531.
5-Chloro-2,2-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-
one (34). Following general procedures A and B, the title compound
was prepared to provide 51% yield as a light yellow crystal, mp =
244246 C. 1H NMR (400 MHz, DMSO) δ 10.52 (s, 1H), 8.05 (s,
1H), 7.75 (s, 1H), 7.24 (s, 1H), 2.84 (s, 2H), 2.25 (s, 2H), 1.53 (s, 2H),
0.96 (s, 6H). 13C NMR (101 MHz, DMSO) δ 175.69, 146.96, 135.81,
131.29, 124.63, 124.28, 122.36, 120.54, 115.65, 35.42, 33.83, 28.25,
27.85, 24.82. HRMS (ESI) calcd for C15H17ClNO [M þ H]þ,
262.0993; found, 262.0998.
6-Chloro-2,2-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-
one (35). Following general procedures A and B, the title compound
was prepared to provide 45% yield as a off-white crystal, mp =
341343 C. 1H NMR (400 MHz, DMSO) δ 11.43 (s, 1H), 8.03 (d,
J = 8.6 Hz, 1H), 7.48 (d, J = 1.6 Hz, 1H), 7.23 (dd, J = 8.6, 1.7 Hz, 1H),
2.70 (t, J = 6.4 Hz, 2H), 2.23 (s, 2H), 1.54 (t, J = 6.5 Hz, 2H), 0.96 (s,
6H). 13C NMR (101 MHz, DMSO) δ 176.29, 146.87, 140.60, 136.19,
127.90, 122.99, 122.37, 117.07, 116.00, 35.96, 34.44, 29.15, 28.58, 25.33.
HRMS (ESI) calcd for C15H17ClNO [M þ H]þ, 262.0993; found,
262.0996.
7-Chloro-2,2-dimethyl-1,2,3,4-tetrahydroacridin-9(10H-
one (36). Following general procedures A and B, the title compound
was prepared to provide 60% yield as an off-white powder, mp =
324325 C. 1H NMR (400 MHz, DMSO) δ 11.55 (s, 1H), 7.97 (s,
1H), 7.59 (dd, J = 8.7, 1.8 Hz, 1H), 7.50 (d, J = 8.8 Hz, 1H), 2.72 (t, J =
6.2 Hz, 2H), 2.25 (s, 2H), 1.54 (t, J = 6.3 Hz, 2H), 0.96 (s, 6H). 13C
NMR (101 MHz, DMSO) δ 174.98, 146.24, 137.78, 131.07, 126.48,
123.99, 123.70, 119.83, 115.07, 35.37, 33.77, 28.47, 27.90, 24.62.
HRMS (ESI) calcd for C15H16ClNONa [MþNa]þ, 284.0813; found,
284.0810.
8-Chloro-2,2-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-
one (37). Following general procedures A and B, the title compound
was prepared to provide 42% yield as a tan crystal. 1H NMR (400 MHz,
DMSO) δ 11.38 (s, 1H), 7.477.38 (m, 2H), 7.16 (d, J = 7.2 Hz, 1H),
2.67 (t, J= 6.2Hz, 2H), 2.18 (s, 2H), 1.52 (t, J= 6.4Hz, 2H), 0.96 (s, 6H).
13C NMR (101MHz, DMSO) δ 175.38, 144.55, 141.73, 131.75, 130.66,
124.51, 119.01, 116.93, 116.41, 35.49, 33.70, 28.54, 27.94, 24.28. HRMS
(ESI) calcd for C15H17ClNO [M þ H]þ, 262.0993; found, 262.0987.
3,3-Dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (38).
Following general procedures A and B, the title compound was prepared
to provide 43% yield as a white crystal, mp = 301302 C. 1H NMR
(400MHz, DMSO) δ 11.27 (s, 1H), 8.05 (d, J = 7.3 Hz, 1H), 7.56 (t, J =
7.6 Hz, 1H), 7.45 (d, J = 8.2 Hz, 1H), 7.22 (t, J = 7.5 Hz, 1H), 2.482.43
(m, 4H), 1.50 (t, J = 6.6 Hz, 2H), 0.98 (s, 6H). 13C NMR (101 MHz,
DMSO) δ 175.77, 145.97, 139.39, 130.89, 124.77, 123.23, 121.98,
117.33, 114.04, 40.57, 34.48, 28.99, 27.55, 19.48. HRMS (ESI) calcd
for C15H18NO [M þ H]þ, 228.1383; found, 228.1386.
5-Methoxy-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-
one (39). Following general procedures A and B, the title compound
was prepared to provide 21% yield as a tan powder, mp = 317 C, dec. 1H
NMR (400MHz, DMSO) δ 10.65 (s, 1H), 7.63 (t, J = 4.5 Hz, 1H), 7.16
(d, J = 3.3 Hz, 2H), 3.97 (s, 3H), 2.57 (s, 2H), 2.45 (t, J = 6.1 Hz, 2H),
1.48 (t, J = 6.1 Hz, 2H), 0.96 (s, 6H). 13C NMR (101 MHz, DMSO) δ
175.54, 147.94, 145.99, 130.28, 124.05, 121.74, 116.14, 114.59, 110.28,
56.00, 40.54, 34.40, 28.95, 27.63, 19.65. HRMS (ESI) calcd for
C16H20NO2 [M þ H]þ, 258.1489; found, 258.1495.
6-Methoxy-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-
one (40). Following general procedures A and B, the title compound
was prepared to provide 39% yield as a tan crystal, mp = 309311 C. 1H
NMR (400MHz, DMSO) δ 11.10 (s, 1H), 7.94 (d, J = 9.3Hz, 1H), 6.83
(s, 2H), 3.82 (s, 3H), 2.42 (d, J = 9.5 Hz, 4H), 1.48 (t, J = 6.0 Hz, 2H),
0.98 (s, 6H). 13C NMR (101 MHz, DMSO) δ 175.43, 161.32, 145.42,
141.07, 126.62, 117.76, 113.57, 112.13, 98.20, 55.25, 40.52, 34.53, 28.98,
27.56, 19.36. HRMS (ESI) calcd for C16H20NO2 [MþH]þ, 258.1489;
found, 258.1483.
7-Methoxy-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-
one (41). Following general procedures A and B, the title compound
was prepared to provide 21% yield as a yellow crystal, mp = 318320 C.
1H NMR (400 MHz, DMSO) δ 11.27 (s, 1H), 7.477.38 (m, 2H),
7.247.17 (m, 1H), 3.81 (s, 3H), 2.47 (s, 4H), 1.49 (t, J = 5.9 Hz, 2H),
0.98 (s, 6H). 13C NMR (101 MHz, DMSO) δ 175.11, 154.71, 145.12,
134.12, 124.05, 121.40, 119.09, 113.03, 104.04, 55.21, 40.54, 34.55,
29.00, 27.55, 19.60. HRMS (ESI) calcd for C16H19NO2 [M þ H]þ,
258.1489; found, 258.1485.
8-Methoxy-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-
one (42). Following general procedures A and B, the title compound
was prepared to provide 46% yield as a white powder, mp = 365 C, dec.
1H NMR (400 MHz, DMSO) δ 10.95 (s, 1H), 7.40 (t, J = 7.9 Hz, 1H),
6.96 (d, J= 8.0Hz, 1H), 6.63 (d, J= 7.6Hz, 1H), 3.76 (s, 3H), 2.37 (d, J=
16.8 Hz, 4H), 1.46 (s, 2H), 0.97 (s, 6H). 13C NMR (101 MHz, DMSO)
δ 175.81, 159.43, 143.63, 142.16, 131.17, 115.64, 113.95, 109.43, 103.15,
55.55, 40.44, 34.63, 28.96, 27.58, 19.62. HRMS (ESI) calcd for
C16H20NO2 [M þ H]þ, 258.1489; found, 258.1493.
3,3,5-Trimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (43).
Following general procedures A and B, the title compound was prepared
to provide 32% yield as a white powder, mp = 280 C, dec. 1HNMR (400
MHz, DMSO) δ 10.15 (s, 1H), 7.93 (d, J = 8.0 Hz, 1H), 7.41 (d, J = 6.8
Hz, 1H), 7.12 (t, J = 7.2 Hz, 1H), 2.81 (t, J = 6.0 Hz, 2H), 2.25 (s, 3H),
1.54 (t, J = 6.0 Hz, 2H), 0.96 (s, 6H). 13C NMR (101 MHz, DMSO) δ
176.74, 147.02, 138.78, 132.48, 126.10, 124.10, 123.45, 122.43, 114.85,
41.43, 35.06, 29.70, 28.33, 20.23, 18.11. HRMS (ESI) calcd for
C16H20NO [M þ H]þ, 242.1539; found, 242.1530.
3,3,6-Trimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (44).
Following general procedures A and B, the title compound was prepared
to provide 41% yield as a tan crystal, mp = 339341 C. 1H NMR (400
MHz,DMSO)δ 11.13 (s, 1H), 7.93 (d, J= 8.2Hz, 1H), 7.21 (s, 1H), 7.04
(d, J = 8.2 Hz, 1H), 2.472.41 (m, 4H), 2.39 (s, 3H), 1.49 (t, J = 6.5 Hz,
2H), 0.98 (s, 6H). 13C NMR (101 MHz, DMSO) δ 175.48, 145.99,
141.02, 139.58, 124.78, 123.97, 121.21, 116.65, 113.83, 40.62, 34.50,
29.03, 27.60, 21.34, 19.49. HRMS (ESI) calcd for C16H20NO [MþH]þ,
242.1539; found, 242.1531.
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3,3,7-Trimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (45).
Following general procedures A and B, the title compound was prepared
to provide 38% yield as a white crystal, mp = 342344 C. 1H NMR (400
MHz, DMSO) δ 11.20 (s, 1H), 7.84 (s, 1H), 7.38 (q, J = 8.3 Hz, 2H),
2.442.48 (m, 4H), 2.38 (s, 3H), 1.49 (t, J= 6.0Hz, 2H), 0.98 (s, 6H). 13C
NMR (101 MHz, DMSO) δ 175.57, 145.56, 137.49, 132.30, 131.01,
123.94, 123.16, 117.28, 113.69, 40.55, 34.52, 28.98, 27.56, 20.71, 19.51.
HRMS (ESI) calcd for C16H20NO [MþH]þ, 242.1539; found, 242.1530.
3,3,8-Trimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (46).
Following general procedures A and B, the title compound was prepared
to provide 75% yield as a white crystal, mp = 327329 C. 1HNMR (400
MHz,DMSO)δ 11.03 (s, 1H), 7.36 (t, J=7.7Hz, 1H), 7.26 (d, J= 8.2Hz,
1H), 6.89 (d, J = 7.0Hz, 1H), 2.80 (s, 3H), 2.39 (dd, J = 13.1, 6.4 Hz, 4H),
1.47 (t, J = 6.5 Hz, 2H), 0.97 (s, 6H). 13C NMR (101 MHz, DMSO) δ
178.31, 144.39, 141.02, 138.92, 129.99, 124.35, 121.58, 115.54, 115.21,
40.21, 34.64, 28.95, 27.56, 23.29, 19.60. HRMS (ESI) calcd for
C16H20NO [M þ H]þ, 242.1539; found, 242.1529.
5-Chloro-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-
one (47). Following general procedures A and B, the title compound
was prepared to provide 26% yield as an off-white powder, mp =
255256 C. 1H NMR (400 MHz, DMSO) δ 10.52 (s, 1H), 8.05 (s,
1H), 7.75 (s, 1H), 7.24 (s, 1H), 2.84 (s, 2H), 2.25 (s, 2H), 1.53 (s, 2H),
0.96 (s, 6H). 13C NMR (101 MHz, DMSO) δ 175.32, 147.30, 135.97,
131.26, 124.73, 124.22, 122.47, 120.61, 115.17, 40.64, 34.15, 28.96,
27.60, 19.55. HRMS (ESI) calcd for C15H17ClNO [M þ H]þ,
262.0993; found, 262.0993.
6-Chloro-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-
one (48). Following general procedures A and B, the title compound
was prepared to provide 52% yield as a white powder, mp =
346349 C. 1H NMR (400 MHz, DMSO) δ 11.36 (s, 1H), 8.04
(d, J = 8.6 Hz, 1H), 7.47 (d, J = 1.7 Hz, 1H), 7.24 (dd, J = 8.6, 1.7 Hz,
1H), 3.17 (s, 2H), 2.43 (d, J = 6.5 Hz, 2H), 1.49 (t, J = 6.5 Hz, 2H), 0.98
(s, 6H). 13C NMR (101 MHz, DMSO) δ 175.26, 146.54, 140.09,
135.52, 127.20, 122.44, 121.82, 116.44, 114.87, 48.58, 34.34, 28.99,
27.54, 19.40. HRMS (ESI) calcd for C15H17ClNO [M þ H]þ,
262.0993; found, 262.0998.
7-Chloro-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-
one (49). Following general procedures A and B, the title compound
was prepared to provide 53% yield as a white crystal, mp = 337339 C.
1H NMR (400 MHz, DMSO) δ 11.48 (s, 1H), 7.98 (d, J = 2.1 Hz, 1H),
7.60 (dd, J = 8.8, 2.1 Hz, 1H), 7.50 (d, J = 8.8 Hz, 1H), 2.482.44 (m,
4H), 1.49 (t, J = 6.4 Hz, 2H), 0.98 (s, 6H). 13C NMR (101 MHz,
DMSO) δ 174.61, 146.61, 137.95, 131.07, 126.61, 124.13, 123.68,
119.88, 114.61, 40.54, 34.33, 28.99, 27.54, 19.48. HRMS (ESI) calcd for
C15H17ClNO [M þ H]þ, 262.0993; found, 262.0989.
8-Chloro-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-
one (50). Following general procedures A and B, the title compound
was prepared to provide 45% yield as an off-white powder, mp =
339341 C. 1HNMR (400MHz, DMSO)δ 11.30 (s, 1H), 7.487.38
(m, 2H), 7.17 (d, J = 7.0 Hz, 1H), 2.43 (s, 2H), 2.39 (t, J = 6.2 Hz, 2H),
1.48 (t, J = 6.4 Hz, 2H), 0.97 (s, 6H). 13C NMR (101 MHz, DMSO) δ
175.05, 144.91, 141.90, 131.76, 130.64, 124.62, 119.10, 116.97, 115.95,
40.16, 34.43, 28.90, 27.52, 19.62. HRMS (ESI) calcd for C15H17ClNO
[M þ H]þ, 262.0993; found, 262.0995.
6-Nitro-1,2,3,4-tetrahydroacridin-9(10H)-one (51). Follow-
ing general procedures A and B, the title compound was prepared to
provide 54% yield as a yellow powder, mp = 330331 C. 1HNMR (400
MHz, DMSO) δ 11.74 (s, 1H), 8.29 (s, 1H), 8.22 (d, J = 8.7 Hz, 1H),
7.93 (d, J = 8.6 Hz, 1H), 2.71 (br s, 2H), 2.43 (br s, 2H), 1.74 (dd, J =
25.7, 5.0 Hz, 4H). HRMS (ESI) calcd for C13H13N2O3 [M þ H]þ,
245.0921; found, 245.0925.
7-Nitro-1,2,3,4-tetrahydroacridin-9(10H)-one (52). Follow-
ing general procedures A and B, the title compound was prepared to
provide 61% yield as a yellow powder, mp = 358359 C. 1HNMR (400
MHz, DMSO) δ 11.82 (s, 1H), 8.77 (s, 1H), 8.31 (d, J = 8.8 Hz, 1H),
7.56 (d, J = 9.0 Hz, 1H), 2.69 (s, 2H), 2.42 (s, 2H), 1.73 (dd, J = 26.3, 4.1
Hz, 4H). 13C NMR (101 MHz, DMSO) δ 175.49, 148.16, 142.76,
141.74, 125.15, 121.86, 121.70, 119.06, 117.53, 27.08, 21.46, 21.20.
HRMS (ESI) calcd for C13H13N2O3 [M þ H]þ, 245.0921; found,
245.0926.
5-Fluoro-1,3,4,10-tetrahydro-2H-acridin-9-one (53). Fol-
lowing general procedure C, the title compoundwas prepared to provide
25% yield as an off-white powder, mp = 308310 C. 1H NMR (400
MHz, DMSO) δ 11.21 (s, 1H), 7.82 (d, J = 8.1 Hz, 1H), 7.44 (dd,
J = 11.4, 7.9 Hz, 1H), 7.177.12 (m, 1H), 2.70 (t, J = 5.7 Hz, 2H), 2.39
(t, J = 5.7 Hz, 2H), 1.711.62 (m, 4H). 19F NMR (376 MHz, DMSO)
δ131.26. 13CNMR (101MHz, DMSO)δ 175.09, 151.14 (d, J= 248.5
Hz), 147.40, 128.54 (d, J = 13.13 Hz), 125.24, 121.40 (d, J = 6.1 Hz),
120.53, 116.45, 115.45 (d, J = 17.2 Hz), 27.08, 21.68, 21.65, 21.34.
HRMS (ESI) calcd for C13H13FNO [M þ H]þ, 218.0976; found,
218.0969.
6-Fluoro-1,2,3,4-tetrahydroacridin-9(10H)-one (54). Fol-
lowing general procedures A and B, the title compound was prepared
to provide 55% yield as a white powder, mp = 359 C, dec. 1H NMR
(400 MHz, DMSO) δ 11.35 (s, 1H), 8.08 (dd, J = 8.8, 6.6 Hz, 1H), 7.15
(dd, J = 10.3, 2.2 Hz, 1H), 7.06 (td, J = 8.8, 2.2 Hz, 1H), 2.67 (t, J = 6.0
Hz, 2H), 2.40 (t, J = 6.0 Hz, 2H), 1.761.66 (m, 4H). 19F NMR (376
MHz, DMSO) δ 109.41. 13C NMR (101 MHz, DMSO) δ 175.38,
163.46 (d, J = 247.5 Hz), 147.24, 140.45 (d, J = 12.12 Hz), 128.12 (d, J =
10.1 Hz), 120.27, 115.78, 110.79 (d, J = 24.24 Hz), 102.22 (d, J = 25.25
Hz), 27.05, 21.75, 21.49, 21.38. HRMS (ESI) calcd for C13H13FNO [M
þ H]þ, 218.0976; found, 218.0967.
7-Iodo-1,2,3,4-tetrahydroacridin-9(10H)-one (55). Follow-
ing general procedures A and B, the title compound was prepared to
provide 49% yield as a white powder. 1H NMR (400 MHz, DMSO) δ
11.45 (s, 1H), 8.32 (s, 1H), 7.82 (d, J = 8.5 Hz, 1H), 7.28 (d, J = 8.7 Hz,
1H), 2.68 (s, 2H), 2.41 (s, 2H), 1.72 (d, J= 18.6Hz, 4H). 13CNMR (101
MHz, DMSO) δ 174.39, 147.29, 138.89, 138.36, 133.30, 124.99, 119.94,
116.22, 86.02, 27.12, 21.70, 21.65, 21.35. HRMS (ESI) calcd for
C13H12INONa [M þ Na]þ, 347.9856; found, 347.9851
6-Bromo-1,2,3,4-tetrahydroacridin-9(10H)-one (56). Fol-
lowing general procedures A and B, the title compound was prepared
to provide 51% yield as a yellow powder. 1H NMR (400 MHz, DMSO)
δ 11.37 (s, 1H), 7.96 (d, J = 8.4Hz, 1H), 7.63 (s, 1H), 7.35 (d, J = 8.3Hz,
1H), 2.68 (s, 2H), 2.41 (s, 2H), 1.72 (d, J= 20.6Hz, 4H). 13CNMR (101
MHz, DMSO) δ 175.36, 147.34, 140.08, 127.23, 125.09, 124.32, 121.95,
119.48, 116.32, 27.13, 21.69, 21.57, 21.35. HRMS (ESI) calcd for
C13H13BrNO [M þ H]þ, 278.0175; found, 287.0179.
7-Bromo-1,2,3,4-tetrahydroacridin-9(10H)-one (57). Fol-
lowing general procedure C, the title compoundwas prepared to provide
48% yield as a yellow crystal, mp = 252253 C. 1H NMR (400 MHz,
DMSO) δ 11.50 (s, 1H), 8.12 (s, 1H), 7.70 (d, J = 8.8 Hz, 1H), 7.43 (d, J
= 8.7Hz, 1H), 2.69 (t, J = 6.0Hz, 2H), 2.42 (t, J = 6.1Hz, 2H), 1.72 (dd, J
= 24.8, 5.7 Hz, 4H). 13C NMR (101 MHz, DMSO) δ 174.53, 147.39,
138.04, 133.64, 126.90, 124.47, 120.05, 116.13, 114.45, 27.12, 21.70,
21.65, 21.36. HRMS (ESI) calcd for C13H13BrNO [M þ H]þ,
278.0175; found, 287.0167.
5-tert-Butyl-1,2,3,4-tetrahydroacridin-9(10H)-one (58).
Following general procedure C, the title compound was prepared to
provide 49% yield as an off-white crystal, mp = 176177 C. 1H NMR
(400 MHz, DMSO) δ 8.74 (s, 1H), 8.05 (d, J = 7.9 Hz, 1H), 7.55 (d, J =
7.0 Hz, 1H), 7.17 (d, J = 7.4 Hz, 1H), 2.87 (d, J = 5.4 Hz, 2H), 2.44 (s,
2H), 1.781.66 (m, 4H), 1.50 (s, 9H). 13CNMR (101MHz, DMSO) δ
177.11, 147.11, 137.58, 136.90, 128.98, 125.30, 124.44, 122.61, 115.94,
34.81, 31.16, 28.56, 22.40, 22.25, 22.20. HRMS (ESI) calcd for
C17H22NO [M þ H]þ, 256.1696; found, 256.1703.
7-tert-Butyl-1,2,3,4-tetrahydroacridin-9(10H)-one (59).
Following general procedure C, the title compound was prepared to
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provide 84% yield as a white crystal, mp = 316319 C. 1H NMR (400
MHz, DMSO) δ 11.25 (s, 1H), 8.047.97 (m, 1H), 7.66 (ddd, J = 8.7,
2.3, 1.4 Hz, 1H), 7.40 (dd, J = 8.7, 0.8 Hz, 1H), 2.67 (t, J = 5.9 Hz, 2H),
2.43 (t, J = 6.0 Hz, 2H), 1.771.67 (m, 4H), 1.32 (s, 9H). 13C NMR
(101 MHz, DMSO) δ 175.97, 146.32, 144.25, 137.30, 129.03, 122.64,
119.78, 117.19, 115.17, 34.27, 31.14, 27.07, 21.93, 21.72, 21.53. HRMS
(ESI) calcd for C17H22NO [M þ H]þ, 256.1696; found, 256.1700.
5-(Trifluoromethyl)-1,2,3,4-tetrahydroacridin-9(10H)-one
(60). Following general procedure C, the title compound was prepared
to provide 39% yield as a yellow powder, mp = 226230 C. 1H NMR
(400MHz, DMSO) δ 10.00 (s, 1H), 8.40 (d, J = 7.9Hz, 1H), 7.99 (d, J =
7.3 Hz, 1H), 7.39 (t, J = 7.6 Hz, 1H), 2.84 (s, 2H), 2.44 (s, 2H), 1.72 (dd,
J = 14.8, 6.6 Hz, 4H). 19F NMR (376 MHz, DMSO) δ 59.13. 13C
NMR (101MHz, DMSO) δ 175.18, 148.45, 135.21, 130.51, 129.57 (d, J
= 5.05 Hz), 124.41, 123.79 (d, J = 276.7 Hz), 121.42, 117.16, 27.61,
21.59, 21.43. HRMS (ESI) calcd for C14H13F3NO [M þ H]þ,
268.0944; found, 268.0940.
7-Isopropyl-1,2,3,4-tetrahydroacridin-9(10H)-one (61).
Following general procedure C, the title compound was prepared to
provide 11% yield as a tan powder, mp = 275277 C. 1H NMR (400
MHz, DMSO) δ 11.24 (s, 1H), 7.88 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H),
7.39 (d, J = 8.0 Hz, 1H), 2.96 (d, J = 6.0 Hz, 1H), 2.68 (s, 2H), 2.43 (s,
2H), 1.72 (d, J = 19.1 Hz, 4H), 1.23 (d, J = 5.9 Hz, 6H). 13C NMR (101
MHz, DMSO) δ 176.54, 147.00, 142.62, 138.31, 130.68, 123.74, 121.75,
118.06, 115.81, 33.69, 27.76, 24.59, 22.61, 22.40, 22.21. HRMS (ESI)
calcd for C16H20NO [M þ H]þ, 242.1539; found, 242.1540.
7-Ethoxy-1,2,3,4-tetrahydroacridin-9(10H)-one (62). Fol-
lowing general procedure C, the title compound was prepared to provide
51% yield as a yellow powder, mp = 291292 C. 1H NMR (400 MHz,
DMSO) δ 11.28 (s, 1H), 7.42 (dd, J = 11.0, 5.8Hz, 2H), 7.19 (dd, J = 8.9,
2.8 Hz, 1H), 4.05 (q, J = 6.9 Hz, 2H), 2.68 (t, J = 5.7Hz, 2H), 2.43 (d, J =
5.5Hz, 2H), 1.751.63 (m, 4H), 1.35 (t, J = 6.9Hz, 3H). 13CNMR(101
MHz, DMSO) δ 175.93, 154.57, 146.51, 134.56, 124.69, 122.41, 119.72,
115.13, 105.38, 63.87, 27.74, 22.65, 22.49, 22.24, 15.29. HRMS (ESI)
calcd for C15H18NO2 [M þ H]þ, 244.1332; found, 244.1323.
9-Oxo-5,6,7,8,9,10-hexahydroacridine-2-carboxylic Acid
Ethyl Ester (63). Following general procedure C, the title compound
was prepared to provide 32% yield as an off-white crystal, mp =
325326 C. 1H NMR (400 MHz, DMSO) δ 11.60 (s, 1H), 8.68 (d,
J = 1.3 Hz, 1H), 8.06 (dd, J = 8.6, 1.5 Hz, 1H), 7.52 (d, J = 8.7 Hz, 1H),
4.33 (q, J = 7.0Hz, 2H), 2.69 (d, J = 5.9Hz, 2H), 2.42 (d, J = 5.4Hz, 2H),
1.73 (dd, J = 25.3, 4.9 Hz, 4H), 1.34 (t, J = 7.0 Hz, 3H). 13C NMR (101
MHz, DMSO) δ 176.57, 166.08, 148.25, 142.67, 131.42, 128.12, 123.83,
122.98, 118.58, 117.55, 61.31, 27.77, 22.31, 22.25, 22.02, 14.90. HRMS
(ESI) calcd C16H18NO3 [M þ H]þ, 272.1281; found, 272.1275.
5,8-Dimethyl-1,3,4,10-tetrahydro-2H-acridin-9-one (64).
Following general procedure C, the title compound was prepared to
provide 74% yield as a yellow crystal, mp = 246248 C. 1H NMR (400
MHz, DMSO) δ 9.66 (s, 1H), 7.20 (d, J = 7.3 Hz, 1H), 6.80 (d, J = 7.3
Hz, 1H), 2.74 (br m, 5H), 2.41 (s, 3H), 2.37 (t, J = 5.9 Hz, 2H), 1.69 (br
m, 4H). 13C NMR (101 MHz, DMSO) δ 178.77, 145.46, 139.30,
136.53, 130.96, 124.10, 122.78, 121.68, 116.94, 26.92, 23.49, 21.93,
21.81, 21.57, 17.56. HRMS (ESI) calcd C15H18NO [M þ H]þ,
228.1383; found, 228.1376.
5,7-Dimethyl-1,3,4,10-tetrahydro-2H-acridin-9-one (65).
Following general procedure C, the title compound was prepared to
provide 78% yield as an off-white crystal, mp = 323326 C. 1H NMR
(400 MHz, DMSO) δ 10.97 (s, 1H), 7.06 (s, 1H), 6.74 (s, 1H), 2.79 (s,
3H), 2.64 (s, 2H), 2.38 (s, 2H), 2.34 (s, 3H), 1.72 (br d, J = 15.4 Hz, 4H).
13C NMR (101 MHz, DMSO) δ 178.28, 144.84, 141.08, 139.66, 138.73,
126.06, 119.63, 116.40, 114.83, 26.72, 23.18, 22.04, 21.74, 21.52, 21.01.
HRMS (ESI) calcd for C15H18NO [MþH]þ, 228.1383; found, 228.1377.
6,8-Dimethyl-1,3,4,10-tetrahydro-2H-acridin-9-one (66).
Following general procedure C, the title compound was prepared to
provide 31% yield as a white powder, mp = 292294 C. 1HNMR (400
MHz, DMSO) δ 10.97 (s, 1H), 7.06 (s, 1H), 6.74 (s, 1H), 2.79 (s, 3H),
2.64 (s, 2H), 2.38 (s, 2H), 2.34 (s, 3H), 1.72 (br d, J = 15.4 Hz, 4H). 13C
NMR (101 MHz, DMSO) δ 178.28, 144.84, 141.08, 139.66, 138.73,
126.06, 119.63, 116.40, 114.83, 26.72, 23.18, 22.04, 21.74, 21.52, 21.01.
HRMS (ESI) calcd for C15H18NO [M þ H]þ, 228.1383; found,
228.1381.
5,6-Dimethyl-1,3,4,10-tetrahydro-2H-acridin-9-one (67).
Following general procedure C, the title compound was prepared to
provide 27% yield as a white crystal, mp = 340343 C. 1H NMR (400
MHz, DMSO) δ 9.93 (s, 1H), 7.83 (d, J = 8.2 Hz, 1H), 7.06 (d, J = 8.2
Hz, 1H), 3.32 (d, J = 0.9 Hz, 3H), 2.78 (t, J = 5.9 Hz, 2H), 2.42 (t, J = 5.5
Hz, 2H), 2.39 (s, 2H), 2.36 (s, 2H), 1.72 (dd, J = 23.8, 5.9 Hz, 4H). 13C
NMR (101 MHz, DMSO) δ 176.21, 146.99, 138.82, 138.00, 124.46,
122.77, 122.05, 121.91, 114.99, 27.33, 21.84, 21.66, 21.63, 20.39, 12.94.
HRMS (ESI) calcd for C15H17NONa [M þ Na]þ, 250.1202; found,
250.1195.
6,7-Dimethyl-1,3,4,10-tetrahydro-2H-acridin-9-one (68).
Following general procedure C, the title compound was prepared to
provide 34% yield as a white powder. 1H NMR (400 MHz, DMSO) δ
11.13 (s, 1H), 7.78 (s, 1H), 7.20 (s, 1H), 2.66 (s, 2H), 2.41 (s, 2H), 2.29
(d, J = 9.1 Hz, 6H), 1.751.67 (m, 4H). 13C NMR (101 MHz, DMSO)
δ 146.69, 141.04, 138.51, 131.36, 125.19, 122.28, 117.82, 115.62, 27.77,
22.64, 22.38, 22.23, 20.57, 19.86. HRMS (ESI) calcd for C15H18NO [M
þ H]þ, 228.1383; found, 228.1379.
5,8-Dimethoxy-1,3,4,10-tetrahydro-2H-acridin-9-one (69).
Following general procedure C, the title compound was prepared to
provide 84% yield as a yellow-green powder, mp = 215219 C. 1H
NMR (400MHz, DMSO) δ 10.25 (s, 1H), 7.03 (d, J = 8.6 Hz, 1H), 6.55
(d, J = 8.6 Hz, 1H), 3.89 (s, 3H), 3.71 (s, 3H), 2.70 (s, 2H), 2.34 (s, 2H),
1.66 (br d, 4H). 13CNMR (101MHz, DMSO) δ 175.66, 152.65, 144.61,
141.47, 132.17, 117.75, 114.67, 110.58, 102.85, 56.16, 26.71, 21.90, 21.47.
HRMS (ESI) calcd for C15H18NO3 [M þ H]þ, 260.1281; found,
260.1272.
5,7-Dimethoxy-1,3,4,10-tetrahydro-2H-acridin-9-one (70).
Following general procedure C, the title compound was prepared to
provide 23% yield as a tan powder, mp = 226230 C. 1H NMR (400
MHz, DMSO) δ 10.67 (s, 1H), 7.04 (s, 1H), 6.79 (s, 1H), 3.95 (s, 3H),
3.80 (s, 3H), 2.74 (t, J = 5.3 Hz, 2H), 2.43 (t, J = 5.3 Hz, 2H), 1.68 (d, J =
3.6 Hz, 4H). 13C NMR (101 MHz, DMSO) δ 174.94, 154.78, 149.16,
145.77, 125.34, 124.31, 115.14, 101.88, 95.19, 56.16, 55.21, 27.04, 21.92,
21.89, 21.54. HRMS (ESI) calcd for C15H18NO3 [Mþ H]þ, 260.1281;
found, 260.1283.
6,8-Dimethoxy-1,3,4,10-tetrahydro-2H-acridin-9-one (71).
Following general procedure C, the title compound was prepared to
provide 11% yield as a white powder, mp = 267270 C. 1H NMR (400
MHz, DMSO) δ 10.89 (s, 1H), 6.44 (s, 1H), 6.24 (s, 1H), 3.82 (s, 3H),
3.77 (s, 3H), 2.59 (s, 2H), 2.33 (s, 2H), 1.71 (br d, J = 15.8 Hz, 4H). 13C
NMR (101 MHz, DMSO) δ 175.40, 161.27, 160.78, 143.77, 143.25,
116.56, 109.04, 93.46, 90.60, 55.46, 55.05, 26.49, 21.99, 21.58, 21.45.
HRMS (ESI) calcd for C15H18NO3 [M þ H]þ, 260.1281; found,
260.1273.
5,6-Dimethoxy-1,3,4,10-tetrahydro-2H-acridin-9-one (72).
Following general procedure C, the title compound was prepared to
provide 35% yield as a light yellow powder, mp = 206207 C. 1HNMR
(400MHz, DMSO) δ 10.59 (s, 1H), 7.82 (d, J = 9.0Hz, 1H), 7.10 (d, J =
9.0 Hz, 1H), 3.95 (s, 3H), 3.87 (s, 3H), 2.79 (s, 2H), 2.44 (s, 2H), 1.73
(br d, J = 14.5 Hz, 4H). 13C NMR (101MHz, DMSO) δ 175.70, 152.76,
147.14, 134.98, 134.04, 120.67, 118.58, 114.75, 108.68, 60.57, 56.08,
27.22, 21.84, 21.67, 21.53. HRMS (ESI) calcd for C15H18NO3 [M þ
H]þ, 260.1281; found, 260.1280.
6,7-Dimethoxy-1,2,3,4-tetrahydroacridin-9(10H)-one (73).
Following general procedures A and B, the title compound was prepared
to provide 40% yield as a yellow powder, mp = 252254 C. 1H NMR
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(400MHz, DMSO) δ 11.15 (s, 1H), 7.40 (s, 1H), 6.88 (s, 1H), 3.82 (d, J
= 14.2Hz, 6H), 2.65 (t, J = 5.5Hz, 2H), 2.41 (t, J = 5.8Hz, 2H), 1.71 (dd,
J = 21.9, 5.1 Hz, 4H). 13C NMR (101 MHz, DMSO) δ 175.51, 153.13,
146.48, 145.85, 135.57, 117.71, 115.03, 104.89, 99.12, 56.20, 56.07, 27.68,
22.68, 22.41, 22.23. HRMS (ESI) calcd for C15H18NO3 [M þ H]þ,
260.1281; found, 260.1284.
5,8-Dichloro-1,3,4,10-tetrahydro-2H-acridin-9-one (74).
Following general procedure C, the title compound was prepared to
provide 15% yield as a off-white powder, mp = 229231 C. 1H NMR
(400MHz, DMSO) δ 10.23 (s, 1H), 7.65 (d, J = 8.3Hz, 1H), 7.18 (d, J =
8.3 Hz, 1H), 2.76 (d, J = 5.7 Hz, 2H), 2.36 (t, J = 5.3 Hz, 2H), 1.69 (dd,
J = 11.3, 5.3 Hz, 4H). 13C NMR (101 MHz, DMSO) δ 174.77, 146.66,
137.78, 131.09, 130.81, 124.67, 120.09, 119.61, 118.45, 26.92, 21.77,
21.48, 21.21. HRMS (ESI) calcd for C13H12Cl2NO [M þ H]þ,
268.0291; found, 268.0281.
5,7-Dichloro-1,3,4,10-tetrahydro-2H-acridin-9-one (75).
Following general procedure C, the title compound was prepared to
provide 39% yield as a yellow crystalline powder, mp = 302305 C. 1H
NMR (400 MHz, DMSO) δ 10.68 (s, 1H), 7.96 (d, J = 24.3 Hz, 2H),
2.84 (s, 2H), 2.44 (s, 2H), 1.73 (d, J = 16.2 Hz, 4H). 13C NMR (101
MHz, DMSO) δ 174.89, 149.30, 135.41, 131.50, 126.92, 125.65, 123.97,
122.87, 117.70, 27.97, 22.40, 22.10, 21.98. HRMS (ESI) calcd for
C19H12Cl2NO [M þ H]þ, 268.0291; found, 268.0286.
6,8-Dichloro-1,3,4,10-tetrahydro-2H-acridin-9-one (76). Fol-
lowing general procedure C, the title compound was prepared to provide
47% yield as a white powder. 1H NMR (400 MHz, DMSO) δ 11.38 (s,
1H), 7.41 (s, 1H), 7.23 (s, 1H), 2.63 (s, 2H), 2.34 (s, 2H), 1.70 (d, J = 17.9
Hz, 4H). 13CNMR (101MHz, DMSO) δ 203.73, 175.33, 146.66, 142.67,
135.02, 134.25, 124.69, 118.78, 116.66, 27.39, 22.32, 21.88. HRMS (ESI)
calcd for C13H12Cl2NO [M þ H]þ, 268.0290; found, 268.0278.
5,6-Dichloro-1,3,4,10-tetrahydro-2H-acridin-9-one (77).
Following general procedure C, the title compound was prepared to
provide 36% yield as a white powder, mp = 320322 C. 1HNMR (400
MHz, DMSO) δ 10.56 (s, 1H), 8.05 (d, J = 8.7 Hz, 1H), 7.47 (d, J = 8.7
Hz, 1H), 2.85 (s, 2H), 2.45 (s, 2H), 1.75 (br d, J = 17.2 Hz, 4H). 13C
NMR (101 MHz, DMSO) δ 175.02, 148.58, 136.99, 134.43, 125.14,
125.06, 123.15, 122.89, 117.09, 27.28, 21.58, 21.40, 21.29. HRMS (ESI)
calcd for C13H12Cl2NO [M þ H]þ, 268.0290; found, 268.0286.
6,7-Dichloro-1,3,4,10-tetrahydro-2H-acridin-9-one (78).
Following general procedure C, the title compound was prepared to
provide 21% yield as a brown powder. 1H NMR (400 MHz, DMSO) δ
9.93 (s, 1H), 7.83 (1H), 7.06 (1H), 2.78 (d, J = 5.8 Hz, 2H), 2.34 (d, J =
4.9 Hz, 2H), 1.781.66 (m, 4H). HRMS (ESI) calcd for C13H12Cl2NO
[M þ H]þ, 268.0290; found, 268.0296.
5,8-Difluoro-1,3,4,10-tetrahydro-2H-acridin-9-one (79).
Following general procedure C, the title compound was prepared to
provide 19% yield as a yellow powder, mp = 304.4306.3 C. 1H NMR
(400 MHz, DMSO) δ 11.20 (s, 1H), 7.567.39 (m, 1H), 6.946.79
(m, 1H), 2.71 (t, J = 5.8 Hz, 2H), 2.36 (t, J = 5.8 Hz, 2H), 1.731.64 (m,
4H). 19F NMR (376 MHz, DMSO) δ 119.28, 134.70. 13C NMR
(101 MHz, DMSO) δ 174.02, 156.28 (d, J = 256.5 Hz), 147.04 (dd, J =
245.4, 5.05 Hz), 146.72, 118.22, 115.47 (dd, J = 19.19, 10.1 Hz), 106.64
(dd, J = 24.24, 7.07 Hz), 26.83, 21.56, 21.22. HRMS (ESI) calcd for
C13H12F2NO [M þ H]þ, 236.0882; found, 236.0880.
5,7-Difluoro-1,3,4,10-tetrahydro-2H-acridin-9-one (80).
Following general procedure C, the title compound was prepared to
provide 97% yield as a white powder, mp = 328331 C. 1HNMR (400
MHz, DMSO) δ 11.38 (s, 1H), 7.667.58 (m, 1H), 7.53 (dd, J = 9.1, 0.9
Hz, 1H), 2.73 (t, J = 5.8 Hz, 2H), 2.42 (t, J = 5.8 Hz, 2H), 1.761.64 (m,
4H). 19F NMR (376 MHz, DMSO) δ 117.71, 125.75. 13C NMR
(101 MHz, DMSO) δ 174.15, 156.13 (dd, J = 244.4, 11.11 Hz), 151.42
(dd, J = 252.5, 12.12 Hz), 147.70, 125.66 (d, J = 12.12Hz), 124.94 (d, J =
6.06 Hz), 116.00, 106.07 (dd, J = 29.3, 20.0 Hz), 106.5 (d, J = 22.2 Hz),
27.06, 21.68, 21.57, 21.27. HRMS (ESI) calcd for C13H12F2NO [M þ
H]þ, 236.0882; found, 236.0874.
6,8-Difluoro-1,3,4,10-tetrahydro-2H-acridin-9-one (81).
Following general procedure C, the title compound was prepared to
provide 30% yield as an off-white powder, mp = 315 C, dec. 1H NMR
(400 MHz, DMSO) δ 11.45 (s, 1H), 6.99 (dd, J = 24.9, 10.2 Hz, 2H),
2.67 (s, 2H), 2.38 (s, 2H), 1.74 (d, J = 19.6 Hz, 2H), 0.00 (dd, J = 24.9,
10.2 Hz, 2H). 19F NMR (376 MHz, DMSO) δ 106.67, 109.20.
HRMS (ESI) calcd for C13H12F2NO [M þ H]þ, 236.0882; found,
236.0871.
5,6-Difluoro-1,3,4,10-tetrahydro-2H-acridin-9-one (82).
Following general procedure C, the title compound was prepared to
provide 51% yield as an off-white powder, mp = 327331 C. 1H NMR
(400 MHz, DMSO) δ 11.42 (s, 1H), 7.957.85 (m, 1H), 7.28 (dd, J =
16.9, 9.0 Hz, 1H), 2.76 (s, 2H), 2.44 (s, 2H), 1.74 (br d, J = 15.9Hz, 4H).
13CNMR (101MHz, DMSO) δ 174.64, 150.21 (dd, J = 248.5, 9.09Hz),
147.97, 138.51 (dd, J = 250.5, 15.15 Hz), 129.97, 121.45, 121.04, 116.47,
110.94 (d, J = 19.19 Hz), 27.05, 21.52, 21.23. HRMS (ESI) calcd for
C13H11F2NONa (M þ Na)þ, 258.0701; found, 258.0700.
6,7-Difluoro-1,2,3,4-tetrahydroacridin-9(10H)-one (83).
Following general procedures A and B, the title compound was prepared
to provide 42% yield as a tan powder, mp = 357358 C. 1HNMR (400
MHz, DMSO) δ 11.47 (s, 1H), 7.86 (t, J = 9.7 Hz, 1H), 7.37 (dd, J =
10.6, 6.8 Hz, 1H), 2.67 (s, 2H), 2.40 (s, 2H), 1.71 (d, J = 19.1 Hz, 5H).
19F NMR (376 MHz, DMSO) δ 133.05, 144.44. 13C NMR (101
MHz, DMSO) δ 174.55, 151.68 (dd, J = 255.53, 15.15 Hz), 147.54,
146.08 (dd, J = 245.43, 14.14 Hz), 136.08 (d, J = 11.11 Hz), 119.93,
115.38, 111.77 (d, J = 16.16 Hz), 105.26 (d, J = 20.2 Hz), 27.03, 21.65,
21.50, 21.29. HRMS (ESI) calcd for C13H12F2NO [M þ H]þ,
236.0882; found, 236.0885.
4-Chloro-3-methoxyaniline (84). An amount of 900 mL of
ammonia is condensed at 78 C. Then 1 g of thinly shaven strips of
sodium was added followed by 1.0 g of iron(III) nitrate nonahydrate.
Upon disappearance of the deep blue color 25 g of thinly shaven strips of
sodium was added. After the mixture is stirred for 30 min at78 C, 50 g
of 2,5-dichloroanisole is added as a solution in hexane (70 mL) dropwise
and the mixture is warmed to 45 C for 2 h. Upon completion the
ammonia is allowed to evaporate. The crude pot is then diluted in
chloroform, and 100 g of NH4Cl is added slowly. The combines are taken
up in a separatory funnel and washed with H2O (3) followed by brine
(1). The organic layer is dried over Na2SO4 and concentrated in vacuo.
The resulting solid can be usedwithout further purification. Yield: 99%. 1H
NMR (400 MHz, DMSO) δ 6.98 (d, J = 8.4, 1H), 6.34 (d, J = 1.8, 1H),
6.16 (dd, J= 8.4, 1.9, 1H), 5.23 (s, 2H), 3.74 (s, 3H). 13CNMR(101MHz,
DMSO) δ 154.90, 149.16, 129.68, 107.02, 106.74, 98.66, 55.38. HRMS
(ESI) calcd for C7H8ClNO [M þ H]þ, 157.0367; found, 157.0361.
4-Chloro-3-isopropoxyaniline (85).To13.9mmol of 5-amino-2-
chlorophenol, 1.3 mL of acetic anhydride and 8 mL of acetic acid were
added. After 5 min at reflux, the mixture was allowed to cool. Product was
filtered and used without purification. To the product described above
were added 25.6 mmol of isopropyl iodide, 25.6 mmol of Cs2CO3, and
65 mL of DMF. After 18 h of reflux, the product was purified via flash
chromatography. This product was refluxed with 121.5 mmol of KOH,
15 mL of water, and 135 mL of ethanol overnight. Flash chromatography
afforded 4-chloro-3-isopropoxyaniline in 75% yield over three steps. 1H
NMR (250 MHz, CDCl3) δ 7.07 (d, J = 8.4, 1H), 6.28 (d, J = 2.5, 1H),
6.21 (dd, J= 8.4, 2.6, 1H), 4.45 (dt, J= 12.2, 6.1, 1H), 3.62 (s, 2H), 1.34 (d,
J = 6.1, 3H).
3-Methoxy-4-methylaniline (86). A solution of 2-methoxy-1-
methyl-4-nitrobenzene (12 mmol) in 30 mL of ethyl acetate was stirred
with 75 mg of 10% palladium on carbon under 1.4 atm of hydrogen for 5
h. The catalyst was filtered and the solutionwas concentrated to afford 86
in 93% yield. 1H NMR (400 MHz, CDCl3) δ 6.91 (d, J = 8.0 Hz, 1H),
6.296.16 (m, 2H), 3.79 (s, 3H), 3.57 (s, 2H), 2.12 (s, 3H). 13C NMR
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(101 MHz, DMSO) δ 158.54, 145.66, 131.08, 116.62, 106.91, 98.66,
55.27, 15.44.
Ethyl 4-Oxotetrahydro-2H-thiopyran-3-carboxylate (87).
To 15 mmol of 3-(2-carboxyethylsulfanyl)propionic acid, 5 mL of
concentrated sulfuric acid in 900 mL of ethanol was added. The mixture
was allowed to reflux for 4 h. After cooling, the mixture was concentrated
to∼20% of its initial concentration followed by the addition of 600mL of
EA. The solution was extracted using 50% sodium bicarbonate twice and
once with brine. After flash chromatography, the resulting compound was
added in 30 mL of Et2O to a flamed dried flask containing 193 mmol of
60% NaH, 350 mL of Et2O, and catalytic ethanol. After the mixture was
refluxed for 8 h, the reaction was quenched with 200 mL of 3.1 N aqueous
AcOH. After extraction with ether 3 times, the organic layers were washed
with sodium bicarbonate, dried, and concentrated. After purification via
flash chromatography, the titled compoundwas afforded in 68%yield over
two steps as a mixture of keto and enol forms. 1H NMR (400 MHz,
CDCl3) δ 12.51 (d, J = 3.6 Hz, 2H), 4.16 (qd, J = 7.0, 3.4 Hz, 8H), 3.59
(ddd, J = 7.7, 3.8, 3.1 Hz, 1H), 3.283.25 (m, 4H), 3.253.16 (m, 1H),
3.022.92 (m, 1H), 2.922.73 (m, 4H), 2.70 (td, J = 6.0, 3.5 Hz, 6H),
2.532.48 (m, 4H), 1.281.12 (m, 15H). 13CNMR (101MHz, CDCl3)
δ 172.27, 171.46, 168.54, 97.29, 61.42, 60.66, 60.58, 60.53, 58.59, 43.50,
37.42, 32.50, 32.44, 30.76, 30.31, 29.61, 25.17, 24.63, 23.44, 14.17, 14.05.
Ethyl 5,5-Difluoro-2-oxocyclohexanecarboxylate (88). To
a flamed-dried flask, 7.5 mmol of 4,4-difluorocyclohexanone in 3 mL of
benzene was added along with 22.3 mmol of NaH in 30 mL of benzene
and 18.6 mmol of diethyl carbonate. After the mixture was refluxed for 2
h, the reaction was quenched by the addition of crushed ice, brine, and
6 mL of acetic acid. The mixture was washed with DCM twice, and the
organic layers were dried and concentrated. The oil was purified via
column chromatography to afford the titled compound in 22% yield.
6-Chloro-7-methoxy-1,3,4,10-tetrahydro-2H-acridin-9-
one (89). Following general procedure C, the title compound was
prepared to provide 36% yield as a mixture of isomers. The desired
compound was further purified by preparative HPLC. 1H NMR (400
MHz, DMSO) δ 11.19 (s, 1H), 7.497.39 (m, 2H), 3.86 (s, 3H), 2.62
(d, J = 5.6 Hz, 3H), 2.35 (t, J = 5.6 Hz, 2H), 1.741.64 (m, 4H). 13C
NMR (101 MHz, DMSO) δ 175.90, 150.85, 145.83, 136.52, 120.60,
118.85, 118.10, 117.77, 116.81, 57.48, 27.39, 22.60, 22.57, 22.04. HRMS
(ESI) calcd for C14H15ClNO2 (M þ H)þ, 264.0786; found, 264.0777.
7-Chloro-6-methoxy-1,3,4,10-tetrahydro-2H-acridin-9-
one (90). Following general procedure C, the title compound was
prepared to provide 42% yield as a mixture of isomers. The desired
compound was further purified by preparative HPLC to afford an off-
white powder, mp = 316317 C. 1H NMR (400 MHz, DMSO) δ
11.31 (s, 1H), 7.96 (s, 1H), 6.99 (s, 1H), 3.93 (s, 1H), 2.66 (s, 2H), 2.40
(s, 2H), 1.72 (br d, J = 20.3 Hz, 4H). 13C NMR (101 MHz, DMSO) δ
174.46, 156.27, 146.66, 139.43, 125.63, 117.69, 117.22, 115.41, 99.07,
56.20, 27.03, 21.75, 21.49, 21.37. HRMS (ESI) calcd for C14H15ClNO2
[M þ H]þ, 264.0786; found, 264.0781.
7-Chloro-6-isopropoxy-1,3,4,10-tetrahydro-2H-acridin-9-
one (91). Following general procedure C, the title compound was
prepared to provide 35% yield as a white powder, mp = 345346 C. 1H
NMR (400 MHz, DMSO) δ 11.22 (s, 1H), 7.95 (s, 1H), 7.01 (s, 1H),
4.66 (s, 1H), 2.65 (s, 2H), 2.39 (s, 2H), 1.751.68 (m, 4H), 1.38 (d, J =
5.7 Hz, 6H). 13C NMR (101 MHz, DMSO) δ 175.19, 155.24, 147.37,
140.10, 126.50, 118.85, 118.26, 115.98, 101.48, 72.16, 40.83, 40.62,
40.41, 40.20, 39.99, 39.78, 39.57, 27.74, 22.49, 22.15. HRMS (ESI) calcd
for C16H19ClNO2 [M þ H]þ, 292.1099; found, 292.1097.
7-Chloro-6-methoxy-1,3,4,10-tetrahydro-2-thia-10-aza-
anthracen-9-one (92). Following general procedure C, the title
compound was prepared to provide 16% yield as a brown powder, mp
= 324 C, dec. 1H NMR (400 MHz, DMSO) δ 11.46 (s, 1H), 7.96 (s,
1H), 6.98 (s, 1H), 3.93 (s, 3H), 3.54 (s, 2H), 2.91 (dd, J = 13.5, 4.5 Hz,
4H). 13C NMR (101 MHz, DMSO) δ 174.02, 157.29, 147.38, 140.03,
126.42, 118.45, 118.28, 114.49, 99.86, 56.98, 29.27, 24.25, 23.01.
7-Chloro-2,2-difluoro-6-methoxy-1,3,4,10-tetrahydro-
2H-acridin-9-one (93). Following general procedure C, the title
compoundwas prepared to provide 4% yield as a dark brown powder. 1H
NMR (400 MHz, DMSO) δ 11.66 (s, 1H), 7.97 (s, 1H), 7.00 (s, 1H),
3.93 (s, 3H), 2.90 (d, J = 15.6 Hz, 4H), 2.29 (s, 2H). 19F NMR (376
MHz, DMSO) δ 94.75. 13C NMR (101 MHz, DMSO) δ 174.01,
157.13, 144.74, 139.80, 126.03, 124.13, 118.42, 117.67, 99.64, 56.84,
31.67 (t, J = 25.3 Hz), 29.08 (t, J = 25.3 Hz), 25.74. HRMS (ESI) calcd
for C14H13ClF2NO2 [M þ H]þ, 300.060 29; found, 300.060 24.
7-Chloro-2,2-difluoro-1,3,4,10-tetrahydro-2H-acridin-9-
one (94). Following general procedures A and B, the title compound
was prepared to provide 55% yield as a brown powder, mp = 351 C,
dec. 1H NMR (400 MHz, DMSO) δ 11.83 (s, 1H), 7.98 (d, J = 2.1 Hz,
1H), 7.64 (dd, J = 8.8, 2.1 Hz, 1H), 7.52 (d, J = 8.8 Hz, 1H), 2.96 (d, J =
5.9 Hz, 4H), 2.342.27 (m, 2H). 19F NMR (376 MHz, DMSO) δ
94.75. 13C NMR (101 MHz, DMSO) δ 174.69, 145.68, 138.34,
132.14, 127.63, 124.22, 124.03, 120.52, 111.66, 31.75 (t, J = 25.3 Hz),
29.25 (t, J = 25.3 Hz), 25.70 (t, J = 5 Hz). HRMS (ESI) calcd for
C13H11ClF2NO [M þ H]þ, 270.04972; found, 270.04968.
2,2-Difluoro-6-methoxy-1,3,4,10-tetrahydro-2H-acridin-
9-one (95). Following general procedures A and B, the title compound
was prepared to provide 36% yield as a light brown powder, mp =
327 C, dec. 1H NMR (400 MHz, DMSO) δ 11.48 (s, 1H), 7.96 (d, J =
8.8 Hz, 1H), 6.86 (dt, J = 6.8, 2.3 Hz, 2H), 3.84 (s, 3H), 2.962.87 (m,
4H), 2.27 (dt, J = 20.6, 7.0 Hz, 2H). 19F NMR (376 MHz, DMSO) δ
94.73. 13C NMR (101 MHz, DMSO) δ 175.05, 161.78, 144.18,
141.11, 126.58, 117.24, 112.74, 110.36, 98.40, 55.35, 31.25 (t, J = 25.3
Hz), 28.50 (t, J = 25.2 Hz), 25.23. HRMS (ESI) calcd for C14H14F2NO2
[M þ H]þ, 266.09926; found, 266.09933.
6-Methoxy-7-methyl-1,3,4,10-tetrahydro-2H-acridin-9-
one (96). Following general procedure C, the title compound was
prepared to provide 38% yield as a white powder. 1H NMR (400 MHz,
DMSO) δ 11.09 (s, 1H), 7.77 (s, 1H), 6.81 (s, 1H), 3.85 (s, 3H), 2.64
(s, 2H), 2.39 (s, 2H), 2.20 (s, 3H), 1.71 (d, J = 19.9 Hz, 4H). 13C NMR
(101 MHz, DMSO) δ 175.33, 159.92, 145.62, 139.46, 125.89, 121.81,
117.16, 114.86, 96.44, 55.39, 27.03, 21.98, 21.60, 21.53, 16.00.
HRMS (ESI) calcd for C15H18NO2 [M þ H]þ, 244.1332; found,
244.1326.
6-Methoxy-7-methyl-1,3,4,10-tetrahydro-2-thia-10-aza-
anthracen-9-one (97). Following general procedure C, the title
compound was prepared to provide 9% yield as a pink crystalline
powder, mp = 328 C, dec. 1H NMR (400 MHz, DMSO) δ 11.27 (s,
1H), 7.79 (s, 1H), 6.83 (s, 1H), 3.87 (s, 3H), 3.52 (d, J = 19.9 Hz, 2H),
2.90 (dd, J = 14.6, 5.0 Hz, 4H), 2.21 (s, 3H). 13C NMR (101 MHz,
DMSO) δ 174.12, 160.25, 145.68, 139.37, 125.97, 122.48, 117.07,
113.24, 96.54, 55.47, 28.54, 23.67, 22.43, 15.98. HRMS (ESI) calcd
for C14H16NO2S [M þ H]þ, 262.0896; found, 262.0895.
7-Bromo-3,4-dihydro-1H-thiopyrano[4,3-b]quinolin-10(5H)-
one (98). Following general procedure C, the title compound was
prepared to provide 34% yield as a yellow crystal, mp = 298 C, dec. 1H
NMR (400MHz, DMSO) δ 11.66 (s, 1H), 8.13 (d, J = 2.2Hz, 1H), 7.74
(dd, J = 8.8, 2.3 Hz, 1H), 7.45 (d, J = 8.8 Hz, 1H), 3.57 (s, 2H), 2.97 (d,
J = 5.6Hz, 2H), 2.90 (t, J= 5.8Hz, 2H). 13CNMR (101MHz, DMSO)δ
173.45, 147.35, 137.90, 134.11, 127.00, 124.48, 120.16, 114.94, 114.44,
28.66, 23.57, 22.40. HRMS (ESI) calcd for C12H10BrNOSNa [M þ
Na]þ, 317.9556; found, 317.9571.
2-Methyl-1,3,4,5-tetrahydro-2H-benzo[b][1,6]naphthyridin-
10-one (99). Following general procedure C, the title compound was
prepared to provide 26% yield as a yellow powder. 1H NMR (400 MHz,
DMSO) δ 12.31 (s, 1H), 8.07 (d, J = 7.9 Hz, 1H), 7.66 (dd, J = 11.0,
4.0 Hz, 1H), 7.60 (d, J = 8.1 Hz, 1H), 7.31 (t, J = 7.2 Hz, 1H), 4.07
(s, 2H), 3.48 (s, 2H), 3.16 (s, 2H), 2.93 (s, 3H). 13C NMR (101 MHz,
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DMSO) δ 174.24, 143.62, 139.38, 124.62, 124.54, 123.22, 122.86,
118.11, 109.49, 49.65, 49.13, 42.76, 24.79. HRMS (ESI) calcd for
C13H15N2O [M þ H]þ, 215.1179; found, 215.1170.
7-(4-Fluorophenoxy)-1,3,4,10-tetrahydro-2H-acridin-9-one
(100). Following general procedure C, the title compound was prepared
to provide 55% yield as an off-white powder, mp = 306308 C. 1HNMR
(400MHz, DMSO) δ 11.42 (s, 1H), 7.51 (s, 1H), 7.44 (s, 1H), 7.36 (dd,
J = 8.7, 2.0Hz, 1H), 7.23 (t, J = 8.5 Hz, 2H), 7.08 (dd, J = 8.5, 4.4 Hz, 2H),
2.67 (d, J = 5.7 Hz, 2H), 2.40 (s, 2H), 1.70 (dd, J = 24.6, 5.0 Hz, 4H). 13C
NMR (101 MHz, DMSO) δ 175.12, 158.19 (d, J = 249.47 Hz), 152.80,
152.31, 146.61, 135.49, 123.98, 123.30, 120.64, 119.72, 116.57 (d, J= 24.24
Hz), 114.90, 111.09, 27.08, 21.83, 21.67, 21.47. HRMS (ESI) calcd for
C19H17FNO2 [M þ H]þ, 310.1238; found, 310.1232.
7-Chloro-6-methoxy-2-oxo-1,3,4,10-tetrahydro-2H-2l4-
thia-10-aza-anthracen-9-one (101). A flame-dried 5 mL round-
bottom flask was charged with 2 mL of 27% aq H2O2 and 7-chloro-6-
methoxy-1,3,4,10-tetrahydro-2-thia-10-aza-anthracen-9-one (0.142
mmol). The mixture was heated at 40 C for 10 h and the resulting
solid was filtered and purified by preparatory HPLC to give a white
crystal. 1HNMR (400MHz, DMSO) δ 11.80 (s, 1H), 7.97 (s, 1H), 7.05
(s, 1H), 3.95 (s, 3H), 3.84 (d, J = 16.0 Hz, 2H), 3.65 (d, J = 16.6 Hz, 2H),
3.20 (d, J = 12.1 Hz, 2H). 13C NMR (101 MHz, DMSO) δ 174.36,
156.85, 145.41, 139.42, 125.66, 118.12, 117.54, 105.92, 99.39, 56.40,
42.86, 41.15, 19.64. HRMS (ESI) calcd for C13H13ClNO3S [MþH]þ,
298.0299; found, 298.0295.
7-Chloro-6-methoxy-2,2-dioxo-1,3,4,10-tetrahydro-2H-
2l6-thia-10-aza-anthracen-9-one (102). A flame-dried 25 mL
round-bottom flask was charged with m-CPBA (0.553 mmol), 4.7 mL
of anhydrous CHCl3, and 7-chloro-6-methoxy-1,3,4,10-tetrahydro-2-
thia-10-aza-anthracen-9-one (0.142 mmol). The reaction slurry was
allowed to stir at room temperature for 22 h. It was then quenched by
adding a few drops of water and filtered. The resulting solid was then
purified by preparatory HPLC to give a white crystal. 1H NMR (400
MHz, DMSO)δ 11.92 (s, 1H), 7.99 (s, 1H), 7.05 (s, 1H), 4.06 (s, 2H),
3.95 (s, 3H), 3.49 (d, J = 6.5 Hz, 2H), 3.30 (d, J = 6.3 Hz, 2H). 13C
NMR (101 MHz, DMSO) δ 173.23, 157.05, 144.24, 139.76, 125.60,
118.51, 117.05, 108.82, 99.60, 56.44, 46.71, 45.62, 28.02. HRMS
(ESI) calcd for C13H13ClNO4S [M þ H]þ, 314.0248; found,
314.0244.
7-Pyridin-4-yl-1,3,4,10-tetrahydro-2-thia-10-aza-anthra-
cen-9-one (103). Following general procedure D, the title compound
was prepared to provide 31% yield as a yellow powder, mp = 348 C, dec.
1H NMR (400 MHz, DMSO) δ 11.66 (s, 1H), 8.65 (s, 2H), 8.44 (s,
1H), 8.05 (d, J = 8.2 Hz, 1H), 7.76 (s, 2H), 7.61 (d, J = 8.5 Hz, 1H), 3.61
(s, 2H), 3.00 (s, 2H), 2.92 (d, J = 5.1 Hz, 2H). 13C NMR (101 MHz,
DMSO) δ 175.15, 150.56, 147.58, 140.06, 140.03, 131.41, 130.27,
123.70, 123.59, 121.43, 119.13, 114.97, 29.12, 24.08, 22.92. HRMS
(ESI) calcd for C17H15N2OS [M þ H]þ, 295.0900; found, 295.0904.
7-Pyridin-3-yl-1,3,4,10-tetrahydro-2-thia-10-aza-anthra-
cen-9-one (104). Following general procedure D, the title compound
was prepared to provide 82% yield as a yellow powder, mp = 327 C, dec.
1H NMR (400 MHz, DMSO) δ 11.64 (s, 1H), 8.94 (s, 1H), 8.58 (s,
1H), 8.33 (s, 1H), 8.13 (d, J = 7.1 Hz, 1H), 8.00 (d, J = 8.6 Hz, 1H), 7.61
(d, J = 8.8 Hz, 1H), 7.587.30 (m, 1H), 3.61 (s, 2H), 3.01 (d, J = 5.2 Hz,
2H), 2.93 (d, J = 5.3 Hz, 2H). 13C NMR (101 MHz, DMSO) δ 174.67,
148.29, 147.42, 146.99, 138.87, 135.00, 134.02, 131.17, 130.12, 123.97,
123.40, 122.80, 118.62, 114.29, 28.68, 23.66, 22.49. HRMS (ESI) calcd
for C17H15N2OS [M þ H]þ, 295.0900; found, 295.0889.
8-(2,4-Difluorophenyl)-3,4-dihydro-1H-thiopyrano[4,3-b]
quinolin-10(5H)-one (105). Following general procedure D, the
title compound was prepared to provide 74% yield as a yellow powder,
mp = 341 C, dec. 1HNMR (400MHz, DMSO)δ 11.64 (s, 1H), 8.19 (s,
1H), 7.827.74 (m, 1H), 7.65 (td, J = 8.9, 6.7 Hz, 1H), 7.59 (d, J = 8.6
Hz, 1H), 7.427.35 (m, 1H), 7.21 (td, J = 8.5, 2.7 Hz, 1H), 3.61 (s, 2H),
3.02 (t, J = 5.5 Hz, 2H), 2.92 (t, J = 5.6 Hz, 2H). 13C NMR (101 MHz,
DMSO) δ 174.60, 161.62 (dd, J = 241.9, 6.8 Hz), 159.09 (dd, J = 242.9,
7.3 Hz), 147.03, 138.56, 133.05130.30 129.10127.80 (m), 124.90
(d, J = 3.3 Hz), 124.24 (dd, J = 13.1, 3.6 Hz), 123.05, 118.04, 114.24,
112.15 (dd, J = 21.2, 3.7Hz), 104.56 (dd, J = 26.9, 25.9Hz), 28.65, 23.67,
22.46. HRMS (ESI) calcd for C18H14F2NOS [M þ H]þ, 330.0759;
found, 330.0749.
7-(4-Chloro-2-methylphenyl)-1,3,4,10-tetrahydro-2-thia-
10-aza-anthracen-9-one (106). Following general procedure D,
the title compound was prepared to provide 70% yield as an orange
powder, mp = 329 C, dec. 1H NMR (400 MHz, DMSO) δ 11.62
(s, 1H), 7.96 (s, 1H), 7.657.58 (m, 1H), 7.56 (d, J = 8.6 Hz, 1H), 7.41
(s, 1H), 7.33 (d, J = 8.1 Hz, 1H), 7.26 (d, J = 8.2 Hz, 1H), 3.60 (s, 2H),
3.00 (d, J = 5.4 Hz, 2H), 2.92 (d, J = 5.2 Hz, 2H), 2.23 (s, 3H). 13CNMR
(101 MHz, DMSO) δ 174.64, 146.94, 139.51, 138.20, 137.39, 134.10,
132.35, 131.81, 131.30, 129.91, 125.92, 124.78, 122.91, 117.61, 114.11,
28.67, 23.69, 22.45, 19.97. HRMS (ESI) calcd for C19H16ClNOSNa
[M þ Na]þ, 364.0533; found, 364.0532.
8-(4-(Trifluoromethoxy)phenyl)-3,4-dihydro-1H-thiopyrano
[4,3-b]quinolin-10(5H)-one (107). Following general procedure
D, the title compound was prepared to provide 72% yield as a yellow
powder, mp = 319 C, dec. 1H NMR (400 MHz, DMSO) δ 11.63 (s,
1H), 8.31 (s, 1H), 7.95 (d, J = 8.6 Hz, 1H), 7.84 (d, J = 8.1 Hz, 2H), 7.59
(d, J = 8.6 Hz, 1H), 7.46 (d, J = 8.2 Hz, 2H), 3.61 (s, 2H), 3.00 (d, J = 5.2
Hz, 2H), 2.92 (t, J = 5.5 Hz, 2H). 19F NMR (376 MHz, DMSO) δ
56.96. 13C NMR (101 MHz, DMSO) δ 174.67, 147.70, 146.95,
138.77, 138.69, 132.80, 130.10, 128.35, 123.30, 122.56, 121.50, 120.10
(q, J= 256.2Hz), 118.48, 114.19, 28.67, 23.65, 22.47. HRMS (ESI) calcd
for C19H15F3NO2S [M þ H]þ, 378.0770; found, 378.0764.
8-(3-(4-Fluorophenoxy)phenyl)-3,4-dihydro-1H-thiopyrano
[4,3-b]quinolin-10(5H)-one (108). Following general procedure
D, the title compound was prepared to provide 79% yield as an off-white
powder, mp = 338 C, dec. 1H NMR (400 MHz, DMSO) δ 11.61 (s,
1H), 8.26 (d, J = 2.1 Hz, 1H), 7.92 (dd, J = 8.7, 2.1 Hz, 1H), 7.57 (d, J =
8.7 Hz, 1H), 7.557.44 (m, 2H), 7.347.21 (m, 3H), 7.217.11 (m,
2H), 7.116.83 (m, 2H), 3.60 (s, 2H), 3.132.91 (m, 4H), 2.90 (s, 1H).
19F NMR (376 MHz, DMSO) δ 119.90. 13C NMR (101 MHz,
DMSO) δ 174.69, 157.81, 158.27 (d, J = 239.4 Hz), 152.43, 146.89,
141.51, 138.68, 133.44, 130.72, 130.09, 123.26, 122.39, 121.50, 120.85
(d, J = 8.5 Hz), 118.42, 116.80 (d, J = 13.4 Hz), 116.50, 115.93, 114.13,
28.65, 23.64, 22.46. HRMS (ESI) calcd for C24H19FNO2S [M þ H]þ,
404.1115; found, 404.1122.
7-[2-Methyl-4-(4-trifluoromethoxyphenoxy)phenyl]-1,3,4,
10-tetrahydro-2-thia-10-aza-anthracen-9-one (109). Follow-
ing general procedure D, the title compound was prepared to provide
56% yield as an off-white powder, mp = 350 C, dec. 1H NMR (400
MHz, DMSO) δ 11.61 (s, 1H), 7.97 (s, 1H), 7.63 (d, J = 8.2, 1H), 7.56
(d, J = 8.6, 1H), 7.40 (d, J= 8.4, 2H), 7.29 (d, J = 8.2, 1H), 7.17 (d, J = 9.0,
2H), 7.05 (s, 1H), 6.96 (d, J = 8.0, 1H), 3.60 (s, 2H), 2.97 (d, J = 37.9,
4H), 2.23 (s, 3H). 13C NMR (101 MHz, DMSO) δ 174.67, 155.73,
155.23, 146.87, 143.58, 138.02, 137.21, 136.57, 134.66, 132.55, 131.33,
124.81, 122.93, 120.71, 119.73, 117.51, 116.54, 114.02, 28.67, 23.69,
22.45, 20.26. HRMS (ESI) calcd for C26H21F3NO3S [M þ H]þ,
484.1189; found, 484.1173.
8-(4-((4-(Trifluoromethoxy)phenoxy)methyl)phenyl)-3,4-
dihydro-1H-thiopyrano[4,3-b]quinolin-10(5H)-one (110).
Following general procedure D, the title compound was prepared to
provide 68% yield as a light yellow powder, mp = 301 C, dec. 1H NMR
(400 MHz, DMSO) δ 11.60 (s, 1H), 8.33 (s, 1H), 7.96 (d, J = 8.5 Hz,
1H), 7.75 (d, J = 7.8 Hz, 2H), 7.57 (dd, J = 12.5, 8.6 Hz, 3H), 7.31 (d, J =
8.7 Hz, 2H), 7.13 (d, J = 8.9 Hz, 2H), 5.18 (s, 2H), 3.62 (s, 2H), 3.00 (d,
J = 5.2 Hz, 2H), 2.92 (d, J = 5.2 Hz, 2H). 19F NMR (376 MHz, DMSO)
δ 57.38. 13C NMR (101 MHz, DMSO) δ 174.76, 157.16, 146.82,
141.85, 139.08, 138.54, 135.75, 133.86, 130.09, 128.44, 126.57, 123.36,
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122.50, 122.26, 120.15 (d, J = 255.2 Hz), 118.38, 116.00, 114.08, 69.35,
28.67, 23.67, 22.50.
7-(4-Phenoxymethyl-phenyl)-1,3,4,10-tetrahydro-2-thia-
10-aza-anthracen-9-one (111). Following general procedure D,
the title compound was prepared to provide 68% yield as a off-white
powder, mp = 323 C, dec. 1H NMR (400 MHz, DMSO) δ 11.60 (s,
1H), 8.32 (d, J = 2.0 Hz, 1H), 7.96 (dd, J = 8.7, 2.1 Hz, 1H), 7.74 (d, J =
8.1 Hz, 2H), 7.57 (dd, J = 12.9, 8.5 Hz, 3H), 7.30 (t, J = 7.9 Hz, 2H), 7.03
(d, J = 8.0 Hz, 2H), 6.95 (s, 1H), 5.16 (s, 2H), 3.61 (s, 2H), 3.00 (d, J =
5.2 Hz, 2H), 2.92 (t, J = 5.6 Hz, 2H). 13C NMR (101 MHz, DMSO) δ
174.74, 158.28, 146.82, 138.92, 138.51, 136.23, 133.91, 130.10, 129.47,
128.35, 126.52, 123.36, 122.23, 120.70, 118.37, 114.77, 114.07, 68.72,
28.67, 23.67, 22.49. HRMS (ESI) calcd for C25H22NO2S [M þ H]þ,
400.1366; found, 400.1357.
8-(4-(Benzyloxy)phenyl)-3,4-dihydro-1H-thiopyrano[4,3-
b]quinolin-10(5H)-one (112). Following general procedure D, the
title compoundwas prepared to provide 62% yield as a yellow powder, mp
= 310 C, dec. 1H NMR (400 MHz, DMSO) δ 11.57 (s, 1H), 8.25 (s,
1H), 7.90 (d, J = 8.1 Hz, 1H), 7.65 (d, J = 8.1Hz, 2H), 7.56 (d, J = 8.7 Hz,
1H), 7.48 (d, J = 7.0 Hz, 2H), 7.427.39 (m, 2H), 7.35 (d, J = 6.9 Hz,
1H), 7.12 (d, J = 7.7Hz, 2H), 5.16 (s, 2H), 3.61 (s, 2H), 3.00 (s, 2H), 2.91
(s, 2H). 13C NMR (101MHz, DMSO) δ 174.54, 157.91, 146.81, 138.02,
137.02, 134.10, 132.04, 129.89, 128.41, 127.80, 127.63, 127.61, 123.30,
121.41, 118.29, 115.38, 113.90, 69.25, 28.68, 23.66, 22.49. HRMS (ESI)
calcd for C25H22NO2S [M þ H]þ, 400.1366; found, 400.1377.
7-(4-Trifluoromethylphenyl)-1,3,4,10-tetrahydro-2-thia-
10-aza-anthracen-9-one (113). Following general procedure D,
the title compound was prepared to provide 71% yield as a dark green
powder, mp = 304 C, dec. 1H NMR (400 MHz, DMSO) δ 8.38 (d, J =
2.2 Hz, 1H), 8.00 (dd, J = 8.7, 2.2 Hz, 1H), 7.94 (d, J = 8.2 Hz, 2H), 7.82
(d, J = 8.4 Hz, 2H), 7.62 (d, J = 8.7 Hz, 1H), 3.62 (s, 2H), 3.01 (t, J = 5.5
Hz, 2H), 2.92 (t, J = 5.7 Hz, 2H). 19F NMR (376 MHz, DMSO) δ
61.09. 13C NMR (101 MHz, DMSO) δ 174.57, 147.44, 143.49,
139.47, 132.39, 129.98, 127.18, 125.88, 125.84, 123.43, 123.02,
118.96, 114.28, 28.91, 23.73, 22.52.
7-(4-(Trifluoromethyl)phenyl)-1,2,3,4-tetrahydroacridin-
9(10H)-one (114). Following general procedure D, the title com-
pound was prepared to provide 78% yield as a white solid, mp > 364 C.
1H NMR (400 MHz, DMSO) δ 11.48 (s, 1H), 8.37 (d, J = 2.2 Hz, 1H),
7.97 (dd, J = 8.7, 2.3 Hz, 1H), 7.94 (d, J= 8.2Hz, 2H), 7.82 (d, J = 8.3Hz,
2H), 7.59 (d, J = 8.7 Hz, 1H), 2.72 (t, J = 6.0 Hz, 2H), 2.46 (t, J = 6.1 Hz,
2H), 1.811.69 (m, 4H). 13C NMR (101 MHz, DMSO) δ 175.86,
147.06, 143.61, 139.24, 132.08, 129.72, 127.15, 125.86, 123.32, 122.95,
118.48, 116.05, 109.55, 27.15, 21.81, 21.71, 21.46. 19F NMR (376 MHz,
DMSO) δ 60.89. HRMS (ESI) calcd for C20H16F3NONa [M þ
Na]þ, 366.1076; found, 366.1076.
6-(4-(Trifluoromethyl)phenyl)-1,2,3,4-tetrahydroacridin-
9(10H)-one (115). Following general procedure D, the title com-
pound was prepared to provide 81% yield as a yellow powder, mp =
352354 C. 1HNMR (400MHz, DMSO)δ 11.43 (s, 1H), 8.15 (d, J =
8.5 Hz, 1H), 7.90 (dd, J = 19.8, 8.3 Hz, 4H), 7.73 (s, 1H), 7.57 (d, J = 8.4
Hz, 1H), 2.72 (t, J = 5.9 Hz, 2H), 2.45 (t, J = 6.0 Hz, 2H), 1.74 (dd, J =
25.2, 6.0 Hz, 4H). 19F NMR (376 MHz, DMSO) δ 61.09. HRMS
(ESI) calcd for C20H17F3NO[M þ H]þ, 344.1257; found, 344.1251.
6-(2,6-Difluorophenyl)-1,2,3,4-tetrahydroacridin-9(10H)-
one (116). Following general procedure D, the title compound was
prepared to provide 10% yield as a yellow powder, mp = 318320 C.
1H NMR (400 MHz, DMSO) δ 11.42 (s, 1H), 8.14 (d, J = 8.3 Hz, 1H),
7.53 (dd, J = 9.9, 3.1 Hz, 2H), 7.28 (t, J = 8.2 Hz, 3H), 2.71 (d, J = 6.2 Hz,
2H), 2.46 (t, J = 5.9 Hz, 2H), 1.75 (dd, J = 23.2, 4.8 Hz, 4H). 19F NMR
(376 MHz, DMSO) δ 114.70. 13C NMR (101 MHz, DMSO) δ
176.01, 160.88, 147.69, 139.46, 131.37, 131.03, 125.48, 124.26, 123.16,
119.38, 116.52, 112.76, 112.51, 27.61, 22.26, 22.11, 21.90. HRMS (ESI)
calcd for C19H16F2NO [M þ H]þ, 312.1195; found, 312.1183.
6-(4-(Dimethylamino)phenyl)-1,2,3,4-tetrahydroacridin-
9(10H)-one (117). Following general procedure D, the title compound
was prepared to provide 33% yield as a light brown powder, mp > 364 C.
1H NMR (400 MHz, DMSO) δ 11.24 (s, 1H), 8.04 (d, J = 8.5 Hz, 1H),
7.58 (d, J = 1.9 Hz, 2H), 7.56 (s, 1H), 7.47 (dd, J = 8.5, 1.7 Hz, 1H), 6.84
(d, J = 8.9 Hz, 2H), 2.96 (s, 6H), 2.70 (t, J = 6.0 Hz, 2H), 2.44 (t, J = 5.9
Hz, 2H), 1.73 (dd, J = 25.6, 4.8 Hz, 4H). 13CNMR (101MHz, DMSO) δ
175.74, 150.30, 146.68, 142.67, 139.86, 127.35, 126.32, 125.45, 121.32,
120.18, 115.45, 112.78, 112.60, 27.16, 21.92, 21.67, 21.52. HRMS (ESI)
calcd for C21H23N2O [M þ H]þ, 319.1805; found, 319.1795.
6-(4-(4-(Trifluoromethoxy)phenoxy)phenyl)-1,2,3,4-tet-
rahydroacridin-9(10H)-one (118). Following general procedure
D, the title compound was prepared to provide 37% yield as a yellow
powder, mp = 311313 C. 1H NMR (400 MHz, DMSO) δ 11.39 (s,
1H), 8.11 (d, J = 8.4 Hz, 1H), 7.76 (s, 1H), 7.74 (s, 1H), 7.66 (s, 1H),
7.52 (d, J = 8.5 Hz, 1H), 7.44 (s, 1H), 7.41 (s, 1H), 7.247.17 (m, 4H),
2.72 (t, J= 5.9Hz, 2H), 2.45 (t, J= 5.9Hz, 2H), 1.74 (dd, J= 25.5, 6.1Hz,
4H). 13C NMR (101 MHz, DMSO) δ 175.62, 156.49, 155.29, 147.09,
143.92, 141.73, 139.67, 134.92, 128.70, 125.71, 123.04, 122.07, 120.87,
120.24, 119.30, 115.82, 114.55, 27.20, 21.86, 21.68, 21.48. HRMS (ESI)
calcd for C26H21F3NO3 [M þ H]þ, 452.1468; found, 452.1467.
4-((4-(Trifluoromethoxy)phenoxy)methyl)phenylboronic
Acid (119). To a flame-dried flask back-filled with argon (2) are added
4-(trifluoromethoxy)phenol (20 mmol, 3.64 g), anhydrous DMF (3 mL),
andNaH (32.3mmol, 0.77 g) at 0 C.This suspension is allowed to stir for
30 min, at which time a solution of 1-bromo-4-(chloromethyl)benzene
(19mmol, 4 g) dissolved in 3mL of DMF is added dropwise. Themixture
is stirred overnight at 80 C and quenched by pouring onto ice and water.
The resulting slurry is extracted by EtOAc (3) and washed with water
followed by brine and subsequently dried over Na2SO4. The crude
bromide is purified further via flash chromatography (hexane/EtOAc
10:1) to afford 1-bromo-4-((4-(trifluoromethoxy)phenoxy)methyl)-
benzene as a colorless oil in 90% yield. To a solution of 1-bromo-
4-((4-(trifluoromethoxy)phenoxy)methyl)benzene (7.2 mmol, 2.5 g)
and triisopropyl borate (9.4 mmol, 2.15 mL) in dry THF (65 mL) at
78 Cwas added dropwise 1.6MBuLi (5.4mL) in hexanes over 10min.
The mixture was stirred for 3 h at78 C, at which point 10 mL of 6 M
HCl is added and the solution is allowed towarm to room temperature and
stir overnight. The reactionmixturewas dilutedwithEtOAc (150mL) and
water (150 mL). The organic layer is taken separately and rinsed with
water (150mL), followed by brine (150mL) and then dried overNa2SO4.
The EtOAc is then concentrated in vacuo to afford a waxy solid which is
then treated with 2 M NaOH (40 mL). The mixutre is stirred for 15 min,
diluted with water (300 mL), and stirred for 20 min. The solution is then
filtered and the filtrate washed with hexane (3  100 mL). The aqueous
layer was carefully acidified to pH 1 with 6 M HCl. The resulting white
solid was filtered and dried on a high vacuum overnight to afford the titled
compound in 67% yield.
4-(4-(Trifluoromethoxy)phenoxy)phenylboronic Acid (120).
The titled compound was prepared exactly as Yeates et al.39 described.
A flame-dried 25 mL Schlenk tube was back-filled with argon (3). To
a solution of 4-bromophenol (0.346 g, 2 mmol) inN-methylpyrrolidine
(8 mL) under an argon atmosphere were added 4-(trifluoromethoxy)-
iodobenzene (0.626 mL, 4 mmol), 2,2,6,6-tetramethylheptane-3,5-
dione (0.092 mL, 0.44 mmol), and cesium carbonate (1.30 g, 4 mmol).
The slurry was degassed by bubbling argon for 15 min, and CuCl (0.099
g, 1 mmol) was then added. The reaction mixture was again degassed
and then warmed to 100 C for 7 h. After the mixture was cooled to
room temperature, Et2O (75 mL) was added slowly. The resulting
slurry was filtered and the solid washed with Et2O (3  50 mL). The
combined filtrates were washed with 2 M NaOH (100 mL), water
(100 mL), 1 M aq HCl (100 mL), water (100 mL), and saturated brine
(100 mL), then subsequently dried over Na2SO4 and concentrated
under reduced pressure. The residue was purified via flash
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chromatography with 100% hexane. This column chromatography was
repeated three times, combining the purest fractions each column elution
to obtain pure material due to similarly eluting 4-(trifluoromethoxy)-
iodobenzene to afford 1-bromo-4-(4-(trifluoromethoxy)phenoxy)-
benzene (0.15 g, 45%) as a colorless liquid. 1H NMR (300MHz, CDCl3)
δ 7.45 (m, 2H), 7.20 (m 2H), 6.99 (m 2H), 6.90 (m 2H). To a solution of
1-bromo-4-(4-(trifluoromethoxy)phenoxy)benzene (2.1 mmol, 0.7 g)
and triisopropyl borate (2.7 mmol, 0.63 mL) in dry THF (15 mL) at
78 Cwas added dropwise 2.5M BuLi (6.5 mL) in hexanes over 5 min.
The mixture was stirred for 3 h at78 C, at which point 10 mL of 6 M
HCl is added and the solution is allowed to warm to room temperature
and stir overnight. The reaction mixture was diluted with EtOAc
(150 mL) and water (150 mL). The organic layer is taken separately
and rinsed with water (150 mL) followed by brine (150 mL) and then
dried over Na2SO4. The EtOAc is then concentrated in vacuo to afford a
waxy solid which is then treated with 2MNaOH (40mL). The mixture is
stirred for 15 min, diluted with water (300 mL), and stirred for 20 min.
The solution is then filtered and the filtrate washed with hexane (3 
100mL). The aqueous layer was carefully acidified to pH 1 with 6MHCl.
The resulting white solid was filtered and dried on a high vacuum
overnight to afford the titled compound in 67% yield. 1H NMR (300
MHz, CDCl3) δ 8.01 (bs, 2H), 7.857.78 (m, 2H), 7.437.33 (m, 2H),
7.157.07 (m, 2H), 7.026.94 (m, 2H).
2-Methyl-4-(4-(trifluoromethoxy)phenoxy)phenylboronic
Acid (121). The titled compound is prepared similarly to 120 in 36%
yield over two steps as an off-white solid. 1H NMR (400 MHz, DMSO)
δ 7.92 (d, J = 7.9 Hz, 1H), 7.36 (d, J = 8.9 Hz, 2H), 7.127.07 (m, 2H),
6.82 (d, J = 9.0 Hz, 2H), 2.64 (s, 3H). 13C NMR (101 MHz, DMSO) δ
156.91, 155.63, 146.05, 143.50, 136.70, 135.43, 122.82, 120.03, 119.75,
119.57, 114.87, 21.97.
J774 Cytotoxicity Assay. Mouse macrophage cell line J774 was
cultured in RPMI 1640 medium with phenol red containing L-glutamine
and then supplemented with 10% fetal bovine serum, penicillin (50
U/mL), and streptomycin (50 μg/mL). For seeding into 96-well plates
the J774 cells were diluted to 5 105 cells/mL. Cells were dispensed into
96-well plates at a volume of 100 μL/well, giving a final concentration of
5 104 cells/well. Plates were incubated for 24 h at 37 C and 5%CO2 to
allow the attachment of J774 to the bottom of the plate wells. Test
compounds were prepared by diluting to 10 μg/mL or 20 nM followed by
1:2 serial dilutions over 11 concentrations. After 24 h the medium was
removed from the wells and serially diluted test compounds were added to
each well. Positive and negative control wells were included on each assay
plate. Plates containing cells and test compounds were then incubated for
72 h at 37 C and 5% CO2. After the incubation period, cell proliferation
was assessed using CellTiter 96 Aqueous One solution cell proliferation
assay reagent (Promega). To each well 20 μL of reagent was added
followed by incubation for 4 h at 37 C and 5% CO2. A Spectramax M2e
(Molecular Devices) plate reader was used to read absorbance at 490 nM.
IC50 values were determined using a custom database manager
(Dataspects, Inc.). Nonlinear regression analysis was used to calculate IC50.
In Vitro Parasite Culturing. P. falciparum clone W2/Indochina
and TM90C2B/Thailand were grown in continuous culture using RPMI
1640 medium containing 10% heat-inactivated type Aþ human plasma,
sodium bicarbonate (2.4 g/L), HEPES (5.94 g/L), and 4% washed
human type Aþ erythrocytes. Cultures were gassed with a 90% N2, 5%
O2, and 5%CO2 mixture followed by incubation at 37 C.
Assay Preparation. Test compounds at 5 mg/mL in DMSO were
diluted at least 1:400 and then serially diluted in duplicate over 11
concentrations. P. falciparum cultures with >70% ring stage parasites
were diluted to 0.50.7% parasitemia and 1.5% hematocrit in RPMI
1640 medium. In 96-well plates a volume of 90 μL/well of parasitized
erythrocytes was added on top of 10 μL/well of the test compound. A
separate plate containing chloroquine, dihydroartemisinin, and atova-
quone was added to each set of assay plates as control drugs. A Beckman
Coulter Biomek 3000 was used to dispense test compounds, control
drugs, and parasitized erythrocytes into the microtiter plates. Positive
and negative controls were included in each plate. Positive controls
consisted of drug-free parasitized erythrocytes, and negative controls
consisted of parasitized erythrocytes dosed with a high concentration of
chloroquine or dihydroartemisinin that ensured 100% parasite death.
Assay plates were placed into a plastic gassing chamber and equilibrated
with 90% N2, 5% O2, and 5%CO2 mixture and then incubated at 37 C
for 72 h. After 72 h of incubation the assay plates were frozen at80 C
until later processed for parasite growth determinations.
SYBR Green I Processing. Assay plates were removed from
80 C and allowed to thaw at room temperature. By use of the
Beckman Biomek 3000, 100 μL was transferred from the assay plates
into 96-well black assay plates. Next, 100 μL of SYBR green I
(Invitrogen) in 2 lysis buffer (0.2 μL of SYBR green I/mL of 2 lysis
buffer [0.008% saponin, 0.08% Triton X-100, 20 mM Tris, and 5 mM
EDTA]) was dispensed into each well of the 96-well black assay plate
using the Beckman Coulter Biomek 3000. Upon addition of SYBR green
I the microtiter plates were incubated for 1 h in the dark. Relative
fluorescence units (RFU) were read using a Molecular Devices Spec-
tramax microplate reader.
Data Analysis. Data analysis was performed using a custom
database manager (Dataspects, Inc.). Nonlinear regression analysis
was used to calculate EC50.
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4-(1H)-Quinolones and 1,2,3,4-Tetrahydroacridin-9(10H)-Ones
Prevent the Transmission of Plasmodium falciparum to Anopheles
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Malaria kills approximately 1 million people a year, mainly in sub-Saharan Africa. Essential steps in the life cycle of the parasite
are the development of gametocytes, as well as the formation of oocysts and sporozoites, in the Anophelesmosquito vector. Pre-
venting transmission of malaria through the mosquito is necessary for the control of the disease; nevertheless, the vast majority
of drugs in use act primarily against the blood stages. The study described herein focuses on the assessment of the transmission-
blocking activities of potent antierythrocytic stage agents derived from the 4(1H)-quinolone scaffold. In particular, three 3-alkyl-
or 3-phenyl-4(1H)-quinolones (P4Qs), one 7-(2-phenoxyethoxy)-4(1H)-quinolone (PEQ), and one 1,2,3,4-tetrahydroacridin-
9(10H)-one (THA) were assessed for their transmission-blocking activity against the mosquito stages of the humanmalaria
parasite (Plasmodium falciparum) and the rodent parasite (P. berghei). Results showed that all of the experimental compounds
reduced or prevented the exflagellation of male gametocytes and, more importantly, prevented parasite transmission to the mos-
quito vector. Additionally, treatment with ICI 56,780 reduced the number of sporozoites that reached the Anopheles salivary
glands. These findings suggest that 4(1H)-quinolones, which have activity against the blood stages, can also prevent the trans-
mission of Plasmodium to the mosquito and, hence, are potentially important drug candidates to eradicate malaria.
There were an estimated 154 million to 289 million cases and610,000 to 971,000 deaths from malaria in 2010 (1). Plasmo-
dium falciparum, the deadliest of the five malaria species that in-
fect humans, mainly affects children under the age of 5 years in
Africa (2–6). In areas where malaria is endemic, such as Africa,
Southeast Asia, and South America, P. falciparum has developed
resistance to many commercially available antimalarials, such as
chloroquine (CQ), mefloquine (MFQ), and sulfadoxine-pyrim-
ethamine (SP) (7). Currently, artemisinin derivatives, which have
potent activity against blood stages and early-stage gametocytes,
are the only drugs that are effective for treating drug-resistant P.
falciparum (8, 9). However, recent evidence suggests that parasite
resistance to artemisinin and its derivatives is emerging in South-
east Asia (4, 10), thus indicating the need for new drugs to combat
this disease.
Development of new antimalarials has traditionally been fo-
cused on the asexual blood stages, which are responsible for the
proliferation of the parasite in the human host and for the clinical
symptoms of the disease (11). However, gametocytes (i.e., the sex-
ual stages), as well as the mosquito stages (i.e., ookinetes, oocysts,
and salivary gland sporozoites), are important drug targets, be-
cause they are necessary for disease transmission (12). Currently,
there are a limited number of antimalarials that are effective
against the sexual and the vector stages ofmalaria parasites. There-
fore, we investigated the transmission-blocking activity of 4(1H)-
quinolones that have activity against the blood and liver stages of
parasites in the avian, rodent, and rhesus monkey malaria models
(13–15). Recent studies have demonstrated that 4(1H)-quinolo-
nes are active against P. falciparum blood and liver stages in vitro
(16–25), as well as against P. berghei rodent malaria liver stages in
vitro and in vivo (26).
In this work, we tested three 3-alkyl- or 3-phenyl-4(1H)-quin-
olones (P4Qs; P4Q-95, P4Q-105, P4Q-146), one 7-(2-phenoxy-
ethoxy)-4(1H)-quinolone (PEQ; ICI 56,780), and one 1,2,3,4-tet-
rahydroacridin-9(10H)-one (THA-93) (16, 17, 23) for their ga-
metocytocidal, gametocidal, and sporozontocidal activity against
P. falciparum as well as their transmission activities in vivo against
P. berghei. These compounds were chosen because of their strong
efficacy against blood stages in vitro (16, 17, 23). We found that
most of the compounds were not effective in killing early- and
late-stage gametocytes, although they reduced or prevented male
gametocyte exflagellation and subsequent vector infection in vitro
and in vivo. Additionally, when administered to infected mosqui-
toes, ICI 56,780 inhibited sporozoite infection of mosquito sali-
vary glands. Our results show that members of the class of 4(1H)-
quinolones not only have blood-stage activity but also have potent
transmission-blocking activity.
MATERIALS AND METHODS
Chemicals.The experimental compounds used in this studywere P4Q-95
(16), P4Q-105 (16), P4Q-146 (26), ICI 56,780 (23), and THA-93 (17),
whose structures are shown in Fig. 1. The compounds were synthesized
and purified by the laboratory of R. Manetsch, Department of Chemistry,
University of South Florida. Dihydroartemisinin (DHA; AVA Scientific
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Chemicals, Mumbai, India) and the 8-aminoquinoline primaquine
(PMQ; Sigma, St. Louis, MO) were used as controls. For the in vitro
studies, compounds were reconstituted in dimethyl sulfoxide (DMSO;
Sigma) and then diluted to appropriate concentrations in RPMI 1640
(Life Technologies, Grand Island, NY) before use. For the in vivo studies,
compounds were reconstituted in polyethylene glycol 400 (Sigma).
Parasites. In these studies, we used P. falciparum and P. berghei para-
sites. For in vitro studies, we used P. falciparum NF54 (27), which was
cultured in type A-positive red blood cells (RBCs) at 5% hematocrit in
RPMI 1640 medium containing 0.5% AlbuMAX at 37°C in the presence
of 90% N2, 5% O2, and 5% CO2, as previously described (28). For in vivo
studies, we used a transgenic P. berghei ANKA line (GFPcon 259cl2) ob-
tained through the Malaria Research and Reference Reagent Resource
Center (MR4; Manassas, VA), supported by the National Institute of Al-
lergy and Infectious Diseases: Plasmodium berghei (ANKA) GFPcon
259cl2 (MRA-865; deposited byC. J. Janse andA. P.Waters). This linewas
designed to constitutively express a green fluorescent protein (GFP) fu-
sion protein under the control of the eef1 promoter (29).
In vitro P. falciparum gametocyte production. Asexual and mature
gametocytes ofNF54 parasiteswere cultivated as previously described (30,
31) in six-well plates.We used the CQ-sensitive strain NF54 because of its
ability to form viable male and female gametocytes and to infect mosqui-
toes. In brief, gametocyte production was induced by use of a low parasite
inoculum (0.1%) and a high hematocrit (7.5%) in 2.5 ml of culture (day
0), and gametocytes were grown for 3 days. On day 4 postinoculation
(p.i.) the volume of medium was doubled. The medium was changed
every day until day 15, when the gametocytes were mature (stage V). The
plates weremaintained in a gassing incubator in 90%N2, 5%O2, 5%CO2
at 37°C.
Assessment of gametocytocidal activity. All drugs were dissolved in
DMSO at a concentration of 5 mg/ml and then diluted to the desired
concentrations in culture medium before use. To determine the effect of
the compounds against gametocytes, cultureswere treatedwith 0.1, 1.0, or
10 M experimental or control compound at the early stage (I, II, III) on
days 7, 8, and 9 p.i. or at the late stage (III, IV, V) on days 11, 12, and 13 p.i.
Blood smears were prepared daily starting on day 7 p.i. to document the
progression of asexual-stage as well as sexual-stage parasitemia, and a
minimum of 1,000 cells was counted per treatment group. Finally, on
day 15 p.i., gametocytes were checked for exflagellation using previ-
ously described methods (30). All experiments were conducted in du-
plicate (Fig. 2A).
Assessment of gametocidal activity of tested compounds in vitro.
Female Anopheles freeborni mosquitoes (4 to 5 days old), obtained from
MR4 (MRA-130; Manassas, VA), were used for P. falciparum infection.
Red blood cells infectedwithmaturemale and female gametocytes at 37°C
were fed to mosquitoes by membrane feeds by the method previously
described (31, 32). The blood meal was provided to mosquitoes with
artificial feeders (Hemotek membrane feeding system; Accrington, Lan-
cashire, United Kingdom). Briefly, infected RBCs with mature gameto-
cytes (day 15 p.i.) previously treated in early or late stages weremixedwith
fresh RBCs and type AB human serum. The mixture was placed on the
Hemotek feeders, and 50 A. freeborni females were allowed to feed for 20
min. Following the blood meal, the mosquitoes were kept at 26°C and
80% humidity with sucrose ad libitum. Midguts (n 10) were dissected
on day 25 p.i. and stainedwith 0.5%mercurochrome for 5min to enhance
the identification of oocysts. The oocyst number for each mosquito was
determined by light microscopy (Fig. 2A). This study was conducted in
duplicate.
Assessment of sporozontocidal activity of tested compounds.Tode-
termine the sporozontocidal effect of the compounds against P. falcipa-
rum in vitro, blood containing untreatedmature gametocyteswas fed toA.
freeborni females as described above, and on day 8 postexposure (PE) the
presence of oocysts in the midguts was confirmed. Later, noninfected
blood containing the test compounds (1.0M)was fed to themosquitoes.
On day 18 postfeeding (day 35 p.i.), 10 mosquitoes (i.e., 20 salivary
glands) were dissected and the presence of sporozoites was recorded. The
number of infected glands was determined by light microscopy as previ-
ously described (32) (Fig. 2B). This study was conducted in duplicate.
Evaluation of effect of drug treatment on vertebrate host transmis-
sion tomosquitoes.To determine if treating infectedmice would prevent
parasite transmission to A. stephensimosquitoes, experimental mice were
infected with 1  106 P. berghei GFP-ANKA parasites (MRA-865; MR4,
Manassas, VA). On day 4 PE, when levels of parasitemia were 3.0%,
Giemsa-stained blood smears were prepared and the presence of gameto-
cytes was verified prior to treatment. Six groups consisting of two mice
each (n 2) were treated with ICI 56,780, THA-93, or P4Q-95 (0.1, 0.3,
1.0, 3.0, and 10.0mg/kg of body weight) or 10mg/kg of the control drugs,
PMQ and DHA (Fig. 3). Untreated mice were included as an infection
control. At 1 h posttreatment (PT), the mice were anesthetized and ex-
posed to 100 naiveA. stephensimosquitoes for 20min, as described above.
Following the blood feed, unfedmosquitoes were removed. On day 10 PE,
midguts (n  40) from mosquitoes in each treatment group were dis-
sected to assess oocyst prevalence and numbers using light microscopy, as
previously described (31, 33, 34).
In another study, infected mice were treated with 1.0 mg/kg of ICI
56,780 (the minimal transmission-blocking concentration) and then ex-
FIG 1 Structures of the compounds tested in this study.
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posed to noninfected mosquitoes at 1, 6, 12, and 24 h PT. Untreated
noninfected and infected mice were included as controls.
Ethics statement. All mice used in these experiments were female
BALB/c mice (average weight, approximately 18 g) obtained fromHarlan
(Fredrick, MD). This study was conducted in compliance with the Guide
for the Care andUse of Laboratory Animals of theNational ResearchCoun-
cil of the National Academies (35). The protocol was approved by the
University of South Florida Institutional Animal Care and Use Commit-
tee. The numbers of animals usedwere theminimum required for obtain-
ing scientifically valid data. Experimental procedures were designed to
minimize harm and included predefined parasitological endpoints to
avoid unnecessary suffering.
Statistical analysis. All statistical analyses were performed using
GraphPad Prism, version 5, software (GraphPad Software Inc., La Jolla,
CA). A P value of0.05 was considered statistically significant. Data were
analyzed using one-way analysis of variance with Dunnett’s post hoc test,
comparing treated groups to untreated controls.
RESULTS
Assessment of gametocytocidal activity. To assess the gametocy-
tocidal activity of the 4(1H)-quinolones, we tested the com-
pounds against early- and late-stage gametocytes and determined
the total number of gametocytes as well as the number of stage V
gametocytes on day 14 p.i. We observed 88%, 58%, and 89% re-
ductions in stage V gametocytemia when 0.1 M P4Q-95, ICI
56,780, and P4Q-146, respectively, were added to early-stage ga-
metocytes. We found 78%, 67%, 83%, and 73% reductions when
1.0MTHA-93, P4Q-105, ICI 56,780, and P4Q-146, respectively,
were added. Furthermore, we saw 83%, 89%, 79%, 80%, and 91%
reductionswhen 10.0MTHA-93, P4Q-95, P4Q-105, ICI 56,780,
and P4Q-146, respectively, were added. However, we found that,
compared to the untreated control, therewas no significant reduc-
tion in total or in stage V gametocytemia (Dunnett’s test). In con-
trast, DHA completely suppressed the formation of gametocytes
at all concentrations (Fig. 4). When late-stage gametocytes were
treated with these compounds, no compound produced a signif-
icant reduction in stageV gametocytemia compared to that for the
untreated control. PMQ did not affect gametocytemia when
added to late-stage gametocytes (Fig. 4).
Assessment of gametocidal effect. In order to assess the game-
tocidal effects of the P4Q, PEQ, and THA compounds, we tested
the exflagellation of treated male gametocytes and the capacity of
these gametes to form oocysts in the mosquito midgut. We found
that most of the tested compounds had an effect on the exflagel-
lation of male gametocytes when the drug was added to stages I to
III. Early stages treated with THA-93 at 0.1 and 1.0 M had 93%
FIG 2 Summary of the methods used in this study. (A) Assessment of gametocytocidal and gametocidal activity of experimental compounds. To test the
gametocytocidal activity of the compounds, early-stage (stages I, II, and III) and late-stage (stages III, IV, and V) gametocytes were treated with the compounds
in duplicate for three consecutive days at 0.1, 1.0, and 10.0 M concentrations. The gametocytemia on day 14 p.i. was used as a measure of the effect of the
experimental compounds on gametocyte development. Gametocidal activity was determined by assessing the effect of the test compounds (1.0 M) on male
gamete exflagellation on day 15 p.i. and subsequent oocyst development in the mosquito midgut. The number of oocysts per midgut on day 25 p.i. was used as
a measure of gametocidal activity. (B) Assessment of sporozontocidal activity of the test compounds. On day 15 p.i., untreated gametocyte cultures were fed to
noninfectedA. freeborni females. On day 25 p.i., mosquitoes were exposed to a noninfected bloodmeal containing 1.0Mthe test compound, and on day 35 p.i.,
salivary glands were checked for infections.
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and 90% reductions in exflagellation, respectively. P4Q-95 pro-
duced no reduction of exflagellation at 0.1 M but a 96% reduc-
tion of exflagellation at 1.0 M. Early-stage gametocytes treated
with P4Q-105 had a 69% reduction of exflagellation at 0.1Mand
a 100% reduction at 1.0M.Treatment with ICI 56,780 and P4Q-
146 eliminated exflagellation at all tested concentrations. It is im-
portant to note that at 10.0 M treatment concentrations, all of
the tested compounds completely prevented exflagellation ofmale
gametocytes (Fig. 5).
The treatment of late-stage gametocytes also showed a reduc-
tion in exflagellation. In fact, P4Q-105, P4Q-146, and ICI 56,780
reduced exflagellation at all treatment concentrations. P4Q-105
produced decreases of 93%, 72%, and 100% at 0.1, 1.0, and 10.0
M, respectively. ICI 56,780 produced reductions of 99%, 83%,
and 98% at 0.1, 1.0, and 10.0 M, respectively. P4Q-146 reduced
exflagellation by 99%, 69%, and 100% at 0.1, 1.0, and 10.0 M,
respectively (Fig. 5). In comparison with the untreated control,
these reductions were significantly different (Dunnett’s multiple-
comparison test, P0.001). It is important to note that PMQ did
not prevent the exflagellation of male gametocytes at 0.1Mor at
1.0 M (Fig. 5).
To determine the transmission-blocking activity of the P4Q,
PEQ, and THA compounds, the treated gametocytes were fed to
noninfected mosquitoes and the numbers of infected mosquitoes
and oocysts in the midguts were evaluated on day 8 postexposure.
The total number of infected mosquitoes in each treatment was
significantly affected by the tested compounds (Dunnett’s multi-
ple-comparison test, P  0.05). In particular, treatment of early
gametocyte stages with 1.0MTHA-93, ICI 56,780, and P4Q-146
completely prevented the infection in 100% of the mosquitoes,
while treatment with P4Q-95 and P4Q-105 reduced the number
of infected mosquitoes by 90% (Table 1). Treatment of late-stage
gametocytes with 1.0 M ICI 56,780 and P4Q-146 prevented in-
fection in 100% of mosquitoes, while only 80% of the mosquitoes
were infected after treatment with 1.0 M THA-93. Treatment
with 1.0 M P4Q-95 and P4Q-105 reduced the number of in-
fected mosquitoes by 95% (Table 1).
When early- and late-stage gametocytes treated with 1.0 M
THA-93, P4Q-95, P4Q-105, P4Q-146, and ICI 56,780, were ex-
posed tomosquitoes, a significant reduction in the oocyst number
per midgut was observed in comparison to that for the untreated
control (Dunnett’s multiple-comparison test, P 0.001). In fact,
when added to early-stage gametocytes, THA-93, ICI 56,780, and
P4Q-146 reduced oocyst numbers by 100%, while both P4Q-95
and P4Q-105 reduced them by 99%.When late-stage gametocytes
were treated with P4Q-146 and ICI 56,780 and then fed to nonin-
fected mosquitoes, there was no formation of oocysts in the mos-
quito midgut, while THA-93, P4Q-95, and P4Q-105 reduced the
oocyst numbers by 96.6%, 99.8%, and 99.4%, respectively (Dun-
FIG 3 Transmission-blocking technique. PEG400, polyethylene glycol 400.
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nett’s multiple-comparison test, P  0.001). As expected, PMQ
did not decrease the number of oocysts (Table 2).
Evaluation of effect of drug treatment on vertebrate host
transmission to mosquitoes. Transmission-blocking studies
were conducted to determine if THA-93, P4Q-95, P4Q-146, and
ICI 56,780 block P. berghei transmission from the vertebrate host
(e.g., mouse) to the mosquito vector. In this study, a range of
concentrations was tested, and the results showed that infected
mice treated with 10.0, 3.0, and 1.0 mg/kg of ICI 56,780 and P4Q-
146were unable to transmit infection tomosquitoes (Fig. 6).Mice
treatedwith 0.3 and 0.1mg/kg of ICI 56,780 remained infective for
mosquitoes, which had an average of 128 and 68 oocysts per
midgut, respectively. Compared to the untreated group, the num-
ber of oocysts in treated animals was significantly lower (Dun-
nett’s multiple-comparison test, P  0.01; Fig. 6). Unlike ICI
56,780 and P4Q-146, when positive-control compounds PMQ
and DHA were administered at 10 mg/kg, they did not prevent
mosquito infection. However, the average numbers of 12 and 101
oocysts permidgut, respectively, were also significantly lower than
those for the untreated group (Dunnett’s multiple-comparison
test, P 0.01; Fig. 3). Conversely, THA-93 and P4Q-95 were not
able to prevent the transmission of P. berghei to Anopheles mos-
quitoes.
Subsequently, we evaluated the effectiveness of ICI 56,780 (1
mg/kg) at different exposure times. Mosquitoes were exposed to
mice at 1 h, 6 h, 12 h, and 24 h following treatment with a single
dose of drug (1 mg/kg). ICI 56,780 blocked transmission up to 12
h posttreatment; however, 24 h later, themosquitoes developed an
infection (Fig. 7).
Assessment of sporozontocidal activity.We tested the sporo-
zontocidal activity of the P4Q, PEQ, and THA compounds in P.
falciparum-infectedmosquitoes by feedingmosquitoes with 1M
drug-treated blood. We found that ICI 56,780 was the only com-
pound to significantly reduce salivary gland infections (80%)
compared to the results for the untreated control (Dunnett’s mul-
tiple-comparison test, P 0.05). The sporozontocidal activity of
ICI 56,780 was greater than the effect of pyrimethamine (Table 3).
DISCUSSION
An antimalarial drug effective against more than one stage of the
parasite life cycle is advantageous. To date, the vast majority of
commercially available drugs are effective against only erythro-
cytic stages, and only a small number of antimalarials in use have
activity against liver and transmission stages. More than 60 years
ago, endochin, a 3-heptyl-substituted 4(1H)-quinolone, showed
promising in vivo antimalarial activity, in addition to prophylactic
activity, against liver stages of avian malaria and activity against
male gametocyte exflagellation of the apicomplexan Haemopro-
teus in finches (14, 15, 36, 37). However, clinical tests with endo-
chin were a failure. Nevertheless, more recently, it was shown that
4(1H)-quinolones derived from endochin are potent in vitro
against atovaquone-resistant strains (16, 21, 22) and warranted
further investigation.
Consequently, in this work we tested several compounds de-
rived from endochin for their gametocytocidal, gametocidal, and
sporozontocidal activity against P. falciparum. Although most of
the compounds did not significantly block the gross morpholog-
ical development of early- or late-stage gametocytes into mature
FIG 4 Stage V gametocytemia on day 14 p.i. following treatment with 0.1, 1.0, and 10.0 M compound. Treatment of early-stage (ES; stages I to III) and
late-stage (LS; stages III to V) gametocytes with 0.1, 1.0, or 10.0 M compound did not significantly affect gametocyte development compared to that for the
untreated controls. Only the control drug DHA significantly diminished the number of stage V gametocytes compared to that for the untreated controls (P
0.05). Interestingly, primaquine did not have a significant effect on the number of stage V gametocytes. *, statistically significant difference.
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stage V forms, the three 4(1H)-quinolones (P4Q-95, P4Q-105,
and P4Q-146), THA-93, and the PEQ ICI 56,780 completely in-
hibited exflagellation of gametocytes and subsequent mosquito
salivary gland infections. In addition, we showed that P4Q-146
and the PEQ ICI 56,780 completely inhibited P. berghei transmis-
sion to mosquitoes.
Themeasure of drug effects on exflagellation has been reported
for both commercially available and experimental compounds.
For example, pyronaridine, tert-butyl isoquine, NPC-1161B,
OZ277, and cycloheximide completely inhibited exflagellation at
10M(38). Additionally, protease inhibitors such as the cysteine/
serine protease inhibitors N-p-tosyl-L-lysine chloromethyl ke-
tone and tosylsulfonyl phenylalanyl chloromethyl ketone block
microgamete formation at 100 M (39, 40). More recently, it was
reported that 4-quinolones also have activity against different
stages of the life cycle of P. falciparum; however, the activity
against exflagellation was only modest (50% inhibitory concen-
tration,10 M) (19). In contrast, the 4(1H)-quinolones tested
in our studies, particularly ICI 56,780 and P4Q-146, were able to
almost completely inhibit exflagellation at lower concentrations
(0.1 M) compared with the activity of previously tested com-
pounds (38).
FIG 5 Effect of test compounds on exflagellation when gametocytes were treated during the early stage (ES; stages I to III) and late stage (LS; stages III to IV).
Treatment of early-stage gametocytes with 0.1 M THA-93, P4Q-105, P4Q-146, and ICI 56,780 significantly reduced male gamete exflagellation compared to
that for the untreated control (Dunnett’s multiple-comparison test, P  0.001). Treatment of early-stage gametocytes with 1.0 M and 10.0 M all test
compounds significantly reduced exflagellation compared to that for the untreated control (Dunnett’s multiple-comparison test, P  0.001). Late-stage
gametocyte treatment with 0.1 M and 1.0 M P4Q-105, P4Q-146, and ICI 56,780 significantly reduced male gamete exflagellation compared to that for the
untreated control (Dunnett’s multiple-comparison test, P 0.05). Treatment of late-stage gametocytes with 10.0 M all test compounds significantly reduced
exflagellation compared to that for the untreated control (Dunnett’s multiple-comparison test, P 0.001). *, statistically significant difference.
TABLE 1 Average number of infected mosquitoes on day 8 PE
following treatment of early- or late-stage gametocytes with 1.0 M
compound
Compound
No. of infected mosquitoesa
Stages I to III Stages III to V
Untreated 9 1.41 8 0.00
THA-93 0 0.00 4 2.83
P4Q-95 1 0.00 0.5 0.70
P4Q-105 1 1.41 0.5 0.70
P4Q-146 0 0.00 0 0.00
ICI 56,780 0 0.00 0 0.00
PMQ Not tested 9 0.00
a Data are means SDs (n 10). , means significantly different from those for
untreated parasites (Dunnett’s multiple-comparison test, P 0.05).
TABLE 2 Average number of oocysts per mosquito midgut on day 8 PE
following treatment of early- or late-stage gametocytes with 1.0 M
compound
Compound
No. of oocysts per midguta
Stages I to III Stages III to V
Untreated 15.25 12.74 17.7 13.22
THA-93 0.00 0.00 0.60 0.88
P4Q-95 0.10 0.31 0.05 0.22
P4Q-105 0.15 0.49 0.10 0.45
P4Q-146 0.00 0.00 0.00 0.00
ICI 56,780 0.00 0.00 0.00 0.00
PMQ Not tested 16.80 14.16
a Data are means SDs (n 10). , means significantly different from those for
untreated gametocytes (Dunnett’s multiple-comparison test, P 0.001).
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All of the P4Q, PEQ, and THA compounds reported on herein
showed robust transmission-blocking activity in vitro by prevent-
ing the development of oocysts in the mosquito at a 1.0M treat-
ment concentration. Although when late-stage gametocytes were
treated with 1.0 M the test compounds there was modest or no
activity in reducing exflagellation (Fig. 5),most of the compounds
did reduce oocyst production by 95% (Table 2). Several com-
pounds have previously been reported to inhibit the development
of oocysts in mosquitoes, but at concentrations much higher than
whatwe report here. In particular, several endoperoxides aswell as
lumefantrine, halofantrine, and mefloquine prevent the develop-
ment of oocysts at 10.0 M (38). The transmission-blocking po-
tential of these compounds was confirmed by in vivo studies,
where we show that treatment of P. bergheiwith P4Q-146 and ICI
56,780 at 1.0mg/kg inhibited the development of oocysts and that
ICI 56,780 activity was retained for up to 12 h posttreatment. The
FIG 6 P4Q-146 and ICI 56,780 block the transmission of P. berghei to A. stephensi in vivo. (A) ICI 56,780 blocks the transmission at 1, 3, and 10 mg/kg; (B)
THA-93 and P4Q-95 do not prevent P. berghei transmission to A. stephensi; (C) P4Q-146 blocks transmission at 1, 3, and 10 mg/kg.
FIG 7 ICI 56,780 blocks transmission for up to 12 h posttreatment in P. berghei-
infectedmice. Animals with3%parasitemia were treatedwith a single dose of 1
mg/kg ICI 56,780 (per os), and then adult female A. stephensi mosquitoes were
allowed to feed at 1, 6, 12, or 24 h posttreatment. ICI 56,780 completely blocked
transmissionup to12hposttreatment, as assessedby a lackof oocyst development
in mosquitoes 8 days after feeding on treated animals.
TABLE 3 Average number of infected mosquito salivary glands on day
16 PE following treatment of oocyst-positive mosquitoes with 1.0 M
compound
Compound
No. of infected
salivary glanda
Untreated 5.0 1.41
THA-93 3.0 2.83
PEQ-95 3.5 2.12
PEQ-105 5.5 0.71
PEQ-146 4.0 1.41
ICI 56,780 1.0 0.00
Pyrimethamine 3.5 2.12
a Data are means SDs (n 20 pairs). , mean significantly different from that for the
untreated mosquitoes (Dunnett’s multiple-comparison test, P 0.05).
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ability of the P4Q and PEQ compounds to prevent mosquito in-
fection and reduce sporozoite viability may give the 4(1H)-quin-
olones an advantage over first-line therapies, such as artemisinin-
based combination therapies, which have a minimal impact on
mosquito infectivity in zones of intensemalaria transmission (41).
The sporozontocidal activity of the P4Q, PEQ, and THA
4(1H)-quinolones was also tested, indicating that the PEQ ICI
56,780 significantly inhibited the development of sporozoite in-
fections of mosquito salivary glands at 1.0 M. Sporozontocidal
activity has been previously reported in a small number of com-
pounds. In particular, it was found that pyrimethamine, tafeno-
quine, the THA floxacrine, and other experimental compounds
have an effect on sporogonic development in P. berghei and P.
falciparum (42). Interestingly, in our study, pyrimethamine de-
creased the number of infected salivary glands by only 30%,
whereas ICI 56,780 decreased the number by 80%. The ability of
ICI 56,780 to limit the number of sporozoites that reach the sali-
vary glands demonstrates the potential utility of PEQ derivatives
as transmission-blocking drugs.
The mechanism of action by P4Qs, PEQs, and THAs in pre-
venting the transmission of parasites to the mosquito and affect-
ing the development of sporozoites is unknown; however, the
structural similarities of these compounds to atovaquone and the
GlaxoSmithKline pyridones, as well as oxygen consumption tests,
indicate that the parasite cytochrome bc1 may be the target for
these compounds (16, 21, 22). Early studies noted that the mito-
chondria of P. falciparum are morphologically different between
the asexual erythrocytic stages and the sexual blood stages (game-
tocytes) (43). The asexual stages have tubule-like cristate mito-
chondria, whereas the gametocyte mitochondria have higher
numbers of cristae and contain electron-dense tubular cristae
(43). These differences suggest that gametocytes have more met-
abolically active mitochondria that may be required for survival
during transmission. Biochemical evidence supports the hypoth-
esis thatmitochondrial function ismore active in gametocytes and
mosquito stages of the malaria parasite (44–46). In P. berghei,
complex II is essential for oocyst formation, suggesting that the
parasite switches energy metabolism from glycolysis to oxidative
phosphorylation in the mosquito (47). Further studies with
NDH2 knockouts in P. berghei demonstrated arrested develop-
ment of oocyst maturation, which is consistent with the hypoth-
esis that parasite stages in mosquitoes are dependent upon an
active mitochondrial electron transport chain (48). Our observa-
tions of the inhibitory effect of the 4(1H)-quinolones on transmis-
sion stages support the hypothesis that mitochondrial function is
crucial for the transmission stages of Plasmodium, validating that
mitochondria are an important target for transmission-blocking
drugs.
In previous studies, it was reported that THA-93, P4Q-95,
P4Q-105, P4Q-146, and ICI 56,780 have potent erythrocytic stage
activity in vitro (16, 17, 23). Moreover, we recently described that
P4Q-146 and ICI 56,780 have activity against liver stages in vivo
and in vitro (26). Herein, we show not only that these compounds
are potent against blood stages and liver stages but also that they
have transmission-blocking activity in vitro and in vivo. Together,
these results indicate that these compounds havemultistage activ-
ity and show that P4Q, PEQ, and THA 4(1H)-quinolones are im-
portant drug candidates with the potential to prevent transmis-
sion of malaria and have potential for supporting the malaria
eradication campaign.
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ABSTRACT: The continued proliferation of malaria throughout temperate and tropical regions of the world has promoted a
push for more eﬃcacious treatments to combat the disease. Unfortunately, more recent remedies such as artemisinin
combination therapies have been rendered less eﬀective due to developing parasite resistance, and new drugs are required that
target the parasite in the liver to support the disease elimination eﬀorts. Research was initiated to revisit antimalarials developed
in the 1940s and 1960s that were deemed unsuitable for use as therapeutic agents as a result of poor understanding of both
physicochemical properties and parasitology. Structure−activity and structure−property relationship studies were conducted to
generate a set of compounds with the general 6-chloro-7-methoxy-2-methyl-4(1H)-quinolone scaﬀold which were substituted at
the 3-position with a variety of phenyl moieties possessing various properties. Extensive physicochemical evaluation of the
quinolone series was carried out to downselect the most promising 4(1H)-quinolones, 7, 62, 66, and 67, which possessed low-
nanomolar EC50 values against W2 and TM90-C2B as well as improved microsomal stability. Additionally, in vivo Thompson
test results using Plasmodium berghei in mice showed that these 4(1H)-quinolones were eﬃcacious for the reduction of
parasitemia at >99% after 6 days.
■ INTRODUCTION
Malaria continues its devastating impact on the health of human
populations in tropical regions, with over 200 million cases of
malaria and over 600 000 deaths from malaria each year.1−3 The
most impacted region is sub-Saharan Africa, which accounts for
an estimated 90% of all deaths, occurring primarily in children
less than 5 years old. Of the ﬁve Plasmodium species which cause
human disease, the two most prevalent are P. falciparum and P.
vivax. These strains have become increasingly more diﬃcult to
control and treat due to the emergence of multi-drug resistance
as well as a lack of preventative drugs for the populations at
highest risk, in particular children and pregnant women. During
the past three decades, P. falciparum has developed resistance to
every commonly available antimalarial, including the most recent
ﬁndings of reduced parasite clearance with the artemisinin
combination therapies (ACTs).4−8 The rapid spread of these
resistant parasites has signiﬁcantly hindered the successful
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treatment of patients to the point that some drugs have been
rendered virtually useless in many parts of the world.
In an eﬀort to curb artemisinin resistance, the World Health
Organization promoted the use of ACTs within endemic
countries, by which two or more antimalarials with diﬀerent
modes of action are taken simultaneously.5 Unfortunately,
disturbing reports of parasite resistance to the ACTs, which
were originally considered to be reliable treatments for malaria,
have emanated in recent studies. History has shown that once
resistance has manifested itself to one compound, the resistance
usually is conferred to the entire chemotype class. Therefore,
much eﬀort has been taken tomodify existing drugs to counteract
the induced resistance through structural modiﬁcations.9,10
Recent understanding of the mechanism of action and
resistance to current drugs suggests that previously discovered
leads remain viable candidates, provided renewed eﬀorts
overcome chemotype-speciﬁc hurdles.11,12 Eﬀorts to surmount
these hurdles have been supplemented by advances in library
screening, hit-to-lead optimization, physicochemical under-
standing of biologically active compounds, and reﬁned under-
standing of mechanisms of action. One speciﬁc example of this
challenge is endochin (1), which in the 1940s was identiﬁed to be
a causal prophylactic (kills growing liver-stage parasites) and
potent erythrocytic-stage agent in avian malaria models. Despite
its promise as an antimalarial agent, the further development of
endochin-like agents languished because of inadequate preclin-
ical models and a poor understanding of parasite biochemistry
(Figure 1).13 Approximately 25 years later, Casey tested a
focused series of 3-alkenyl- and 3-alkyl-2-methyl-4(1H)-
quinolones, but no antimalarial activity was observed in the
utilized preclinical screen (Rane single-dose rodent malaria
model).14,15 Evaluation of the coccidiostat quinolone ester
identiﬁed as ICI 56,780 (2), a 4(1H)-quinolone structurally
related to 1, displayed causal prophylactic (single dose of 30 mg/
kg subcutaneous) and blood schizonticidal activity (ED50 = 0.05
mg/kg) in rodent malaria models (Figure 1). Compound 2 was
later found to have anti-relapse activity in P. cynomolgi-infected
rhesus monkeys (10−30mg/kg subcutaneous).16 Unfortunately,
a high degree of resistance to this compound was obtained after
one passage in P. berghei-infected mice. This, in conjunction with
a lack of oral bioavailability, led to the abandonment of the
quinolone ester series.17
Since the aforementioned studies were conducted over 20
years ago without adequate evaluation in current preclinical
eﬃcacy models and without assessment of drug-like properties,
several laboratories recently revisited the optimization and
development of 4(1H)-quinolone-based antimalarials.18−29
Starting from compound 1, detailed SAR and structure−
property relationship (SPR) studies conducted in our laboratory
identiﬁed the substituent at the 3-position to be of highest
priority for in vitro activity. Furthermore, a remarkable
synergistic eﬀect, improving the antimalarial activity by a factor
of 30 and eliminating the cross-resistance to atovaquone, was
identiﬁed for compounds substituted with a chloro substituent at
the 6-position and a methoxy group at the 7-position. 3-Ethyl-
and 3-phenyl-substituted 6-chloro-7-methoxy-2-methyl-4(1H)-
quinolones (3 and 4) were among the most promising
compounds, as both not only displayed low-nanomolar EC50
values against the multi-drug-resistant isolates W2 and TM90-
C2B of P. falciparum but also possessed acceptable phys-
icochemical properties.20
Independent optimization of 1 by Riscoe and co-workers led
to the development of the polyethylene glycol carbonate prodrug
5, which was orally bioavailable with an ED50 value of 11 mg/kg
against P. yoelii infections.21 Our combined eﬀorts to further
optimize the 4(1H)-quinolone compound series yielded ELQ-
300 (6) and P4Q-391 (7), of which the translational team from
Medicines for Malaria Venture selected compound 6 to undergo
preclinical development.22,30 Both compounds 6 and 7 were
highly eﬃcacious against both the blood and the liver stages of
the malaria parasite, as well as active against the forms critical for
disease transmission. Both compounds were shown to selectively
inhibit Plasmodium cytochrome bc1 complex over mammalian bc1
due to the 6-chloro-7-methoxy substitution pattern of the 4(1H)-
quinolone’s benzenoid ring.22 Herein, we report the design,
synthesis, physicochemical and pharmacokinetic evaluation, and
testing for in vitro and in vivo antimalarial activity of a 3-aryl-6-
chloro-7-methoxy-4(1H)-quinolone library (12−67) that lead
the way to the identiﬁcation of frontrunner compounds 6 and 7.
Figure 1. Common antimalarials and 4(1H)-quinolone scaﬀolds.
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■ RESULTS AND DISCUSSION
Synthetic Chemistry. In our eﬀorts to optimize the
antimalarial 4(1H)-quinolones, 3-ethyl- and 3-phenyl-substi-
tuted analogues 3 and 4were initially prepared with the intention
of evaluating their in vitro and in vivo eﬃcacy. According to
previous reports, the β-keto esters 2-ethyl- and 2-phenyl-
substituted ethyl acetoacetate were reacted with 4-chloro-3-
methoxyaniline (8) via Conrad−Limpach cyclization, providing
compounds 3 and 4, respectively, in good yields (Scheme 1).
Further optimization focused on 3-aryl-substituted compounds
due to the favorable antimalarial activity and physiochemical
properties as well as the synthetic tractability of 3-phenyl-4(1H)-
quinolone 4 as opposed to 3-ethyl-4(1H)-quinolone 3. These
investigations were conducted with four initial sub-series of
compounds probing the 3-position with alkylphenyl, heteroaryl,
para-substituted aryl, and ﬂuoroaryl moieties followed by a ﬁfth
sub-series focusing on the optimization of these most promising
3-aryl moieties. Syntheses of these analogues were carried out in
a linear fashion beginning with 4(1H)-quinolone 9 (Scheme 2).
Regioselective iodination produced intermediate 3-iodo-4(1H)-
quinolone 10. Upon Suzuki−Miyaura cross-coupling of the iodo
intermediate 10 with the corresponding boronic acid, 4(1H)-
quinolones 7 and 12−67 could be prepared.31 Since a broad
range of Suzuki adducts was desired, myriad changes in cross-
coupling conditions were employed (see the Supporting
Information for details). As previously reported, intermediate
11 was also used in the synthesis of analogues 7 and 12−67,
when progress was halted due to sluggish reaction times, poor
yields, and/or diﬃcult puriﬁcation schemes.22
Antimalarial Activity. All synthesized compounds were
tested, as previously reported, against the clinically relevant
multi-drug-resistant P. falciparum strains W2 (chloroquine and
pyrimethamine resistant) and TM90-C2B (chloroquine, me-
ﬂoquine, pyrimethamine, and atovaquone resistant).20,31,32 The
human malaria parasites are grown in vitro in dilute human
erythrocytes in RPMI 1640 media containing 10% heat-
inactivated plasma, and the potency for each 4(1H)-quinolone
has been calculated against the individual strains as the 50%
eﬀective concentration (EC50).
32 The emergence of resistance
and cross-resistance with atovaquone is a concern for new
antimalarials that target the parasite mitochondria (e.g.,
atovaquone), thus the resistance index (RI) of each compound
was calculated as the ratio of the eﬀective concentrations for W2
and TM90-C2B (RI = EC50(TM90-C2B)/EC50(W2)) (see the
Supporting Information for details). Compounds with RI = 0.3−
3.0 were considered acceptable with regard to risk of cross-
resistance with atovaquone, whereas compounds with RI > 10 or
RI < 0.1 are likely to have clinically relevant levels of cross-
resistance, thus making them unsuitable for development as new
antimalarials.33,34
Structure−Activity Relationship (SAR) Studies. Initial
SAR studies were carried out to determine the best-suited
benzenoid ring substituents resulting in compounds containing
the 6-chloro-7-methoxy substituent pattern that not only
provided a synergistic eﬀect on antimalarial activity but also
narrowed the RI and improved the solubility in select
analogues.20 Furthermore, despite 3-phenyl-4(1H)-quinolone
(4) being approximately 20-fold less potent as compared to 3-
alkyl and 3-alkenyl analogues, it was considered to be a more
robust platform for development due to improved hepatic
microsomal stability and slightly increased aqueous solubility.
Several sub-series of 4(1H)-quinolones were designed to cover a
wide chemical space, improving antimalarial potency and
addressing physicochemical liabilities such as aqueous solubility
and microsomal stability in parallel.
The ﬁrst sub-series of analogues, consisting of 3-alkylphenyl-
4(1H)-quinolones (12−18, Table 1), was designed to test for
steric eﬀects. While 3-phenyl-4(1H)-quinolone 4 displayed an
approximately 2-fold improvement in antimalarial activity against
W2 and TM90-C2B when compared to the 3-ethyl-substituted
congener 3, additional gains in potency were observed with
compounds modiﬁed at the 4(1H)-quinolone’s 3-position with
simple ortho-alkyl- or para-alkyl-substituted phenyl moieties. In
comparison to reference compound 4, the addition of a methyl
substituent to the ortho- or para-position of 4(1H)-quinolones,
as in 12 and 13, improved the potency against TM90-C2B by at
least 2-fold. In contrast, for the strain W2, only compound 12
displayed an improvement in potency. Combining multiple
Scheme 1. Synthesis of 6-Chloro-7-methoxy-2-methyl-3-
substituted 4(1H)-Quinolonesa
aReagents and conditions: (a) corresponding β-keto-ester, HOAc,
PhH, reﬂux, 18 h, then Ph2O, reﬂux, 12 min.
Scheme 2. Synthesis of 6-Chloro-7-methoxy-2-methyl-3-aryl-4(1H)-quinolonesa
aReagents and conditions: (a) I2, Na2CO3, MeOH, rt. (b) ArB(OH)2, SPHOS, K3PO4, toluene or DMF, 80−100 °C, 0.5−48 h. (c) EtI, Cs2CO3,
DMF, 5 h, rt. (d) HBr, reﬂux, 15 min.
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methyl groups such as 3-(2,4-dimethylphenyl)- and 3-mesityl-
substituted 4(1H)-quinolones (14 and 15, respectively) did not
show any further improvements in potency. Increasing the steric
eﬀects with groups such as ethyl-, isopropyl-, and tert-butyl
provided compounds 16−18, of which only 3-(4-isopropyl)-
phenyl-4(1H)-quinolone (17) turned out to be equipotent to the
most potent 4(1H)-quinolone 12. In summary, compounds 12
and 17 were the most potent analogues in this sub-series, with
EC50 values of 5.83 and 6.65 nM against W2 and 4.03 and 2.67
nM against TM90-C2B, respectively, thus yielding acceptable RI
values.
We next synthesized and tested a sub-series of 3-heteroaryl-
4(1H)-quinolones (19−32, Table 2), probing both steric and
electronic factors. We anticipated that the incorporation of a
heteroaromatic residue would elicit an enhancement of
solubility. 3-Pyridyl analogues 19−21 possessed EC50 values of
128−928 nM against W2 and 120−219 nM against TM90-C2B.
Of the three compounds, 4(1H)-quinolone 20, possessing a
nitrogen at the meta-position, proved to be most active against
TM90-C2B, whereas the best activity against W2 was shown by
analogue 21, with the nitrogen at the para-position. Pyrimidine
analogue 22, containing two nitrogens both at the meta-
positions, lacked antimalarial activity altogether. Alteration of
pyridine 20 with a para-N,N-dimethylamino group yielded
4(1H)-quinolone 23, which showed slightly improved activity
against TM90-C2B; however, the potency against W2 remained
unaﬀected. Similar results were obtained with the N-methyl-
piperazino-substituted pyridine 24, a contiguous extension of
Table 1. 3-Alkylphenyl-4(1H)-quinolonesa
aDihydroartemisinin (DHA), chloroquine (CQ), and atovaquone
(ATO) are internal controls for each in vitro assay: DHA, 5.5 nM W2
and 5.9 nM TM90-C2B; CQ, 229 nM for TM90-C2B and 421 nM for
W2; and ATO, 1.4 nM W2 and 18.4 μM TM90-C2B.
Table 2. 3-Heteroaryl-4(1H)-quinolonesa
aDihydroartemisinin (DHA), chloroquine (CQ), and atovaquone
(ATO) are internal controls for each in vitro assay: DHA, 5.5 nM W2
and 5.9 nM TM90-C2B; CQ, 229 nM for TM90-C2B and 421 nM for
W2; and ATO, 1.4 nM W2 and 18.4 μM TM90-C2B.
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analogue 23, displaying poor activities with EC50 values no lower
than 536 nM for TM90-C2B. 3-Furanyl analogues 25 and 26
displayed excellent EC50 values of 8.43 and 1.85 nM against
TM90-C2B and 34.2 and 13.3 nM for W2, respectively, with 26
being the most potent analogue in the sub-series. These two
analogues highlight the breadth of design opportunities, given
the considerable improvement in antimalarial activity despite a
relatively minor structural modiﬁcation over reference com-
pound 4. Isoxazole 27 was prepared next and shown to be
inactive, with poor EC50 values of 1060 nM against W2 and 629
nM against TM90-C2B. Finally, a selection of 4(1H)-quinolones
substituted with bicyclic systems at the 3-position were tested.
Benzo-oxadiazole 28 had poor activity against W2 and an
unacceptable RI value of 0.04, yet it had decent activity against
TM90-C2B, with an EC50 of 80.6 nM. Benzofuran 29 and
benzothiophene 30 possessed EC50 values of 24.8−138 nM
against TM90-C2B, with analogue 29 displaying nearly
equipotent activity against both strains W2 and TM90-C2B
and, thus, an RI of nearly 1.0. Similarly, favorable RI values were
determined for 4(1H)-quinolones 31 and 32, although both
compounds were less potent than reference compound 4.
As compounds 12 and 17 have shown to be slightly more
potent than reference compound 4, a sub-series of 3-phenyl-
substituted 4(1H)-quinolones was prepared, in which the phenyl
ring has been mono-substituted with the intent of identifying
structural modiﬁcations that improve the aqueous solubility or
the metabolic stability while increasing or maintaining the
antimalarial activity (Table 3). Analogous to GSK’s successful
development of their pyridone prodrug, this sub-series was also
designed with the secondary objective of identifying a chemical
handle to potentially develop a 4(1H)-quinolone phosphate
prodrug.35
A set of compounds (33−48, Table 3) with hydrogen bond-
accepting potential, containing various functional groups,
including ethers, carbonyls, amines, and sulfonyls, was prepared
and tested. Methyl ether 33 and isopropyl ether 34, with EC50
values of 11.3 and 12.6 nM, respectively, against TM90-C2B,
were slightly more potent than reference 4, whereas their
potency against W2 dropped by a factor of 2. While carbonyl
analogues 35−38 showed no improvement over 4 in activity,
methyl ester 38 appeared to be equipotent with 4 and possessed
an excellent RI value approaching 1. Similar to the ethers 33 and
34, the antimalarial activity of N,N-dimethylaniline 39 was
unaﬀected for TM90-C2B and W2. N,N-Dimethylsulfonamide
40 was nearly inactive, with EC50 values in the lower micromolar
range. Noting that analogues 33, 34, and 39 all possessed similar
activities against bothW2 and TM90-C2B and all possessed non-
hydrogen-bearing heteroatoms at the para-position of the 3-
phenyl substituent, curiosity arose as to the eﬃcacy of analogue
41 with hydrogen-bonding potential. Thus, synthesis and testing
of phenol 41 resulted in a compound that was 50 times less
potent against W2 and on average 35 times less potent against
TM90-C2B. An interesting trend was realized with carbinol-
bearing 3-phenyl-4(1H)-quinolones. Analogues 42−44, with
carbinol appendages at the ortho-, meta-, and para-positions of
the 3-phenyl ring, possessed EC50 values ranging from 93.9 nM
to 5.40 μM. The general trend that resulted was that the para-
substituted 3-phenyl-4(1H)-quinolone (44) was much more
active than the ortho-substituted isomer (42), while the meta-
isomer (43) exhibited low activities.
Finally, a set of 4(1H)-quinolones was prepared whose 3-
substituent consisted of two aromatic rings. Several of these
analogues were inspired by results obtained with GSK’s pyridone
Table 3. 3-(4-Substituted)aryl-4(1H)-quinolonesa
aDihydroartemisinin (DHA), chloroquine (CQ), and atovaquone
(ATO) are internal controls for each in vitro assay: DHA, 5.5 nM W2
and 5.9 nM TM90-C2B; CQ, 229 nM for TM90-C2B and 421 nM for
W2; and ATO, 1.4 nM W2 and 18.4 μM TM90-C2B.
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm500942v | J. Med. Chem. 2014, 57, 8860−88798864
series (Table 3).19 Strikingly, the EC50 values of these analogues
were in the low single digit nanomolar ranges, with most of the
analogues also possessing acceptable RI values. Biaryl 45 and
biaryl ether 46 were very potent, displaying EC50 values of 1.78
and 2.40 nM for W2 and 4.33 and 1.31 nM for TM90-C2B,
respectively. Replacement of the terminal phenyl ring of
compound 46 by a benzyl substituent provided phenoxybenzyl
ether 47, which was approximately equipotent against TM90-
C2B and approximately 5-fold less potent against W2.
Benzyloxyphenyl ether 48, an isomer of compound 47 diﬀering
only in the position of the ether oxygen, was even more active,
with EC50 values of 0.638 nM for TM90-C2B and 1.30 nM for
W2.
To address possible microsomal lability within the 3-phenyl-
4(1H)-quinolones, a sub-series of ﬂuorinated analogues (49−58,
Table 4) was prepared and tested. The majority of these
analogues displayed good potency against both strains, with EC50
values in the low nanomolar ranges. Monoﬂuorophenyl-4(1H)-
quinolone 49 and bis-ﬂuoro analogues 50 and 51 were slightly
less potent than reference compound 4. Triﬂuoromethylphenyl
analogue 52 emerged as one of the most potent compounds
among the entire library, with EC50 values of 6.25 nM against W2
and 5.98 nM against TM90-C2B, while the bis-triﬂuoromethyl-
phenyl derivative 53 possessed poor activity. Combination of a
ﬂuoro and a triﬂuoromethyl moiety on the 3-phenyl substituent
of the 4(1H)-quinolone (54) did not signiﬁcantly improve the
activity over compound 4. In contrast, compounds 55 and 56,
with a 3-phenyl moiety substituted with one or two ﬂuoro
substituents and one alkoxy group, demonstrated poor
antimalarial activities altogether. Finally, ortho-triﬂuoromethox-
yphenyl analogue 57was devoid of antimalarial activity, while the
para-triﬂuoromethoxyphenyl analogue 58 possessed excellent
EC50 values of 7.72 nM against W2 and 7.76 nM against TM90-
C2B. This compound was extremely promising as it exhibited not
only single-digit nanomolar activities but a nearly perfect RI of
1.0.
Physicochemical and ADME Properties. In parallel to the
in vitro antimalarial activity testing, standard physicochemical
and ADME properties were determined to identify potential
compound liabilities. All compounds were routinely assessed for
aqueous solubility and partition coeﬃcient (logD) using HPLC-
based protocols, which have been previously described and
utilized for quinolone-based antimalarials.20 Passive transcellular
permeability was determined using the standard parallel artiﬁcial
membrane permeability assay (PAMPA).20 Plasma protein
binding was determined by ultracentrifugation (see Supporting
Information for method details) for selected compounds that
were progressed to in vivo pharmacokinetic studies. Finally, a
large set of the most promising 4(1H)-quinolones was tested for
human microsomal stability following a previously reported
protocol.22 Brieﬂy, the compounds were incubated with human
liver microsomes, and the metabolic reaction was quenched at
various time points over the incubation period by the addition of
acetonitrile. The relative loss of compound was ﬁtted to an
exponential decay function to determine the ﬁrst-order rate
constant and in vitro intrinsic clearance.22 The distribution
coeﬃcients of all analogues were in the acceptable range (1 <
log D < 4). The majority of the more potent compounds also
possessed the greatest lipophilicity, with an average logD7.4 = 3.6
(see Supporting Information for more details). This represents
an improvement over the 4(1H)-quinolones of the initial
study,20 as the most promising compounds possessed log D7.4
values which are reduced by approximately 1 unit, while their
potency increased by an estimated factor of 10. The permeability
of themajority of the library was high (Pe > 50× 10
−6 cm/s), with
the exception of a few analogues, such as the pyridyl analogues 20
and 22, the isoxazole 27, the phenol 41, and the benzyl alcohol
analogues 42−44.
Despite improvement in many physiochemical properties, the
majority of the compounds possessed poor aqueous solubility. As
previously proposed,20 the poor aqueous solubility of the 4(1H)-
quinolones possibly derives from a strong lattice energy and high
melting point due to strong intermolecular hydrogen bonds
within the crystal lattice. Compounds 12 and 14, possessing an
ortho-methyl-substituted phenyl moiety at the 3-position,
displayed slightly improved aqueous solubility over reference
compound 4 while maintaining their in vivo activity. In contrast,
heteroaromatic compounds such as 21, 22, 24, and 27 with
improved aqueous solubility showed a decrease in potency,
Table 4. 3-Fluoroaryl-4(1H)-quinolonesa
aDihydroartemisinin (DHA), chloroquine (CQ), and atovaquone
(ATO) are internal controls for each in vitro assay: DHA, 5.5 nM W2
and 5.9 nM TM90-C2B; CQ, 229 nM for TM90-C2B and 421 nM for
W2; and ATO, 1.4 nM W2 and 18.4 μM TM90-C2B.
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suggesting ionizable groups to be incompatible for this
chemotype.
Human liver microsomal stability was considered to be
important for the selection of the candidates to be tested for in
vivo eﬃcacy studies. Within the ﬁrst sub-series of 4(1H)-
quinolones, the 3-ethyl analogue 3 displayed a high intrinsic
clearance (CLint) of 56 μL/(min·mg), whereas the 3-aryl-
substituted 4(1H)-quinolone 4 had a moderate CLint of 17 μL/
(min·mg). Analogues bearing a heterocyclic moiety at the 3-
position exhibited improved stability over 4. While CLint values
were less than 15 μL/(min·mg) for pyridines 20 and 21, furan
analogues 25 and 26 were signiﬁcantly less stable, making them
unattractive for in vivo eﬃcacy testing. Isoxazole 27 highlighted
the potential for a heteroaryl-substituted 4(1H)-quinolone with
minimal degradation after 250 min. Similarly, phenol 41, phenyl
ethers 33 and 34, and benzyl alcohols 43 and 44 were minimally
metabolized, indicating substitution at the para-position of the 3-
aryl group to be critical for stability. As expected, of the
ﬂuorinated analogues, triﬂuoromethylphenyl and triﬂuoro-
methoxyphenyl analogues 52 and 58 were shown to be highly
stable.
Screening for in Vivo Eﬃcacy. Nine 4(1H)-quinolones
with potent in vitro activity against P. falciparum were selected to
undergo screening for in vivo eﬃcacy using a rodent malaria
model (Table 5). Physicochemical and ADME criteria such as
aqueous solubility, microsomal stability, and compound
availability were also taken into account for the selection process.
Compounds 12 and 24 were chosen for the in vivo eﬃcacy
screening due to the increased aqueous solubility derived from
their out-of-plane or ionizable 3-substituent. Among the selected
candidates were 4(1H)-quinolones 33, 34, 45, 46, 50, and 58,
which possessed moderate to high microsomal stability. The
screen involved treating mice with a single dose of compound at a
concentration of 50 mg/kg on day 1 post-exposure (PE) and
then assessing parasitemia on days 3 and 6 PE. Compounds with
>50% inhibition of parasitemia on both days were considered to
be active. In preliminary studies, a PEG400 formulation was
shown to enhance exposure; thus, the same vehicle was
indiscriminately utilized for all the compounds tested in this
assay.22
As expected, the reference antimalarial compounds amodia-
quine (AMO), artesunate (AS), and atovaquone (ATOV) had
>95% inhibition of parasitemia on days 3 and 6 PE. Biphenyl and
biaryl ether 4(1H)-quinolones 45 and 46 were the most active
compounds, displaying over 80% inhibition on day 3 PE and over
60% inhibition on day 6 PE. Reduced in vivo eﬃcacy, averaging
52% inhibition on day 3 PE and 28% inhibition on day 6 PE, was
observed for compounds 33, 34, 50, and 58. Compounds 12 and
24, which were among the most soluble compounds in this test
series, were poorly active or not active at all.
From this initial in vivo eﬃcacy screening, it was concluded
that the four analogues 33, 34, 50, and 58 were physicochemi-
cally similar to compounds 45 and 46, and the decreased in vivo
activity was related primarily to the 10-fold reduction of in vitro
potency. On the other hand, compound 12, being nearly
equipotent to 3-(4-triﬂuoromethoxy)phenyl-4(1H)-quinolone
58 in the in vitro eﬃcacy testing, was not eﬃcacious in vivo. This
result is likely due to its drastically decreased microsomal
stability. These results prompted a signiﬁcant paradigm shift, as
microsomal stability and aqueous solubility were now considered
to be equally important in the further optimization of in vivo
eﬃcacious 4(1H)-quinolones.
Disruption of the 3-Aryl-4(1H)-quinolones’ Molecular
Planarity and Symmetry. Compound 12 was slightly more
active in vitro than 4; nevertheless, it displayedminor suppressive
antimalarial activity in vivo. This observation was attributed
primarily to the slightly better solubility of 12 by the out-of-plane
aryl moiety due to the additional ortho-methyl group. In order to
support our hit-to-lead optimization eﬀorts, we decided to
investigate why these frontrunner compounds displayed such
diﬀerences in the in vivo eﬃcacy assays. Quantum mechanics
(QM) torsional proﬁle calculations and single-crystal X-ray
diﬀraction (XRD) studies were conducted with the objective of
determining structural modiﬁcations responsible for the
improvement in solubility of 4(1H)-quinolone 12.
As the main structural diﬀerence between compounds 4 and
12 is the absence or presence of the ortho-methyl group on the 3-
phenyl ring, the rotational barriers along the C3−C12 bond of
both 3-aryl-4(1H)-quinolones 4 and 12 were ﬁrst established
using QM calculations following methodology previously
reported (Figure 2).36 Relaxed dihedral angle scans (starting
with a 0° angle when the methyl groups of the quinolone and
ortho-methyl-3-phenyl moieties are directed toward each other)
Table 5. Results of the in Vivo Eﬃcacy Screening
inhibition (%)
compd day 3 PE day 6 PE
4 0.0 0.0
12 9.0 0.0
24 0.0 0.0
33 53.6 26.9
34 41.4 26.8
45 85.7 61.0
46 83.9 69.0
50 44.3 29.1
58 60.0 28.8
amodiaquine 95.5 99.9
artesunate 97.0 81.0
atovaquone 96.3 99.8
Figure 2. Quantum mechanics energy proﬁle for 4 and 12 around the
C3−C12 bond. Relaxed dihedral angle scans with a torsional angle
increment of 15° were carried out employing a HF/6-31G** method
using the Jaguar application in the Maestro suite (version 9.2,
Schrödinger, Inc.).
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at torsion angle increments of 15° were carried out employing
the ab initio HF/6-31G** method using the Jaguar program
(version 7.9, Schrödinger, Inc.). Maestro software (version 9.2,
Schrödinger, Inc.) was used for model building and visualization
and to launch the Jaguar program. The structures were subjected
to geometry optimization prior to the torsion scan using the same
level of theory. The torsional proﬁle was then obtained by
plotting 24 energy points versus the dihedral angles. Previously,
the calculated rotational barrier ΔErot = 20 kcal/mol was
reported as a suitable threshold between atropisomers and non-
atropisomers.37 As previously reported, the accuracy of QM
calculations to predict atropisomerism is 86% relative to
experimental values; therefore, QM calculations are a practical
tool for this purpose. Based on the QM energy proﬁle obtained
for compound 4, the lowest energy barrier that allowed the C3−
C12 bond rotation was ΔErot = 11.9 kcal/mol. This result
suggests that the torsional rotation half-time at room temper-
ature was in the order of milliseconds with a free rotation of the
C3−C12 bond. In contrast, the minimal energy barrier of
compound 12 has been calculated to be ΔErot = 23.2 kcal/mol,
implying that the half-time for the same bond rotation was in the
range of hours. According to the classiﬁcation proposed by
Figure 3. Crystal structures of compounds 4 and 12. (A) Asymmetric units, conformation, and numbering schemes. (B) Hydrogen-bonding schemes.
(C) Packing schemes showing the disruption of π···π interactions through weak CH···OandCH···π interactions (dotted lines). The crystalline pocket in
12 is marked as a yellow sphere. Some of the molecules are omitted for clarity. (D) Packing schemes. Crystalline voids can be seen in the crystal structure
of 12.
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LaPlante and co-workers,36 compound 12 could be categorized
as showing Class 2 atropisomerism, as the rotation of the 3-
phenyl ring around the C3−C12 bond was signiﬁcantly slower.
Importantly, Class 2 atropisomers can be developed as a mixture
Table 6. Optimized 3-Aryl-4(1H)-quinolonesa
aDihydroartemisinin (DHA), chloroquine (CQ), and atovaquone (ATO) are internal controls for each in vitro assay: DHA, 5.5 nM W2 and 5.9 nM
TM90-C2B; CQ, 229 nM for TM90-C2B and 421 nM for W2; and ATO, 1.4 nM W2 and 18.4 μM TM90-C2B. bStandards for the solubility assay
include carbamazepine and albendazole. Solubility for carbamazepine at pH 7.4, 4.0, and 2.0 is 95 μM, 100 μM, and 100 μM, respectively. Solubility
for albendazole at pH 7.4, 4.0, and 2.0 is 6.1 μM, 12 μM, and 100 μM, respectively. cStandards for the permeability assay include verapamil HCl (Pe
= 1405 × 10−6 cm/s at pH 7.4 and 39 × 10−6 cm/s at pH 4.0), carbamazepine (Pe = 112 ×10
−6 cm/s at pH 7.4 and 108 × 10−6 cm/s at pH 4.0), and
ranitidine HCl (Pe = 0.5 × 10
−6 cm/s at pH 7.4 and 0 × 10−6 cm/s at pH 4.0). dStandards for the log D7.4 assay include cinnarizine (log D7.4 = 5.68),
hydrocortisone-21-acetate (log D7.4 = 2.19), ketoconazole (log D7.4 = 3.83), metronidazole (log D7.4 = −0.02), nadolol (log D7.4 = 0.68), pyrene
(log D7.4 = 4.88), theophyline (log D7.4 = −0.05), and tolnaftate (log D7.4 = 5.40). eC.N.C. = could not be calculated. These compounds displayed
little to no observable degradation throughout the assay duration (typically 250 min). Analogue 1 was used as a control for comparing half-lives of
4(1H)-quinolones. Compound 1 possesses half-lives of 7.9 min in mouse microsomes and 10.2 min in human microsomes.
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of stereoisomers as long as the racemization is faster relative to
the in vivo elimination rates.
Previously, it has been reported that disruption of the
molecular planarity is an eﬀective method to increase the
aqueous solubility up to 350-fold.38 The expected orthogonal
orientation of the 3-aryl substituent relative to the 4(1H)-
quinolone plane for 12 and 4 (conﬁrmed by QM calculations)
could therefore be a likely cause of the increase in aqueous
solubility. In order to explain the solubility diﬀerences between 4
and 12, XRD experiments have been conducted to study the
crystal packing for both compounds. For compound 4, an
asymmetric unit contains one molecule, whereas two diﬀerent
conformers are found in the asymmetric unit of analogue 12
(Figure 3A). In both structures, molecular chains are observed
due to the presence of hydrogen bond interactions between the
quinolone nitrogen and the quinolone oxygen (Figure 3B). The
hydrogen bond distances between the quinolone oxygen and
nitrogen atoms are 2.800 Å for compound 4, and 2.687 and 2.808
Å for compound 12 (with twomolecules in the asymmetric unit).
For 4 and 12, the 3-aryl substituents were nearly orthogonal to
the 4(1H)-quinolone plane, with torsion angles of −81.1° and
+73.3° for compound 12 and −69.96° for compound 4 (Figure
3A). In both cases, π−π interactions between quinolone planes
were signiﬁcantly disrupted, most likely because of the presence
of weak CH···O and CH···π interactions with the methyl group
as the H-bond donor (Figure 3C). For compound 12, the
additional methyl group of the 3-aryl substituent forms a weak
CH···O bond with an oxygen of the 7-methoxy group, leading to
crystalline pockets with 3.4% free space in the crystal structure
(yellow circles in Figure 3C,D) and a Kitaigorodski packing index
(KPI) of 68%. This is in stark contrast to the crystal packing of
compound 4, with a higher KPI of 71.4%, lacking any free space.
Therefore, the potentially weaker interactions between mole-
cules arising from the ortho-methyl-3-phenyl substituent, which
probably correlates with a looser packing of the molecules within
the crystal, are possibly the reason for the slightly higher aqueous
solubility of compound 12 over its analogue 4. The XRD studies
performed in conjunction with QM calculations strongly support
the notion that the disruption of dense molecular crystal packing
of 4(1H)-quinolones improves the aqueous solubility. At the
molecular level, weak and strong intermolecular interactions
have to be taken into account in order to explain and expand this
observation in detail for each case at study.
Lead Optimization.With activity data and physicochemical
results in hand for an array of compounds bearing a wide variety
of aryl substituents at the 3-position, a number of potential agents
were envisioned that would retain the solubility of compounds
similar to 12 while maintaining antimalarial potency and
microsomal stability of the para-substituted phenyls at the 3-
position (7, 59−67, Table 6). Initially, compounds 59−61 were
synthesized in eﬀorts to incorporate both the 3-substituted
phenyl with an ortho-methyl and a para-substituent. Each of the
three compounds maintained its activities against both W2 and
TM90-C2B and showed improved log D values of 2.69−2.88.
Solubility, however, plummeted in reference to compound 12.
Microsomal stability of the three analogues showed a marked
improvement over the para-ﬂuorophenyl analogue by at least 2-
fold, with analogue 60 showing virtually no degradation. An
attempt to expound on the promising results for biaryl ether 46
led to the synthesis of analogous biaryl ethers possessing both an
ortho-substituent on the proximal ring and a para-substituent on
the distal ring. Analogues 62 and 7 were synthesized and tested.
While activities for analogue 7 remained essentially unchanged,
analogue 62 showed sub-nanomolar activities against both W2
and TM90-C2B. Additionally, both analogues showed improve-
ments in solubility and log D. Microsomal stability improved
from a CLint of 19 μL/(min·mg) for compound 46 to the point
that no degradation was measured.
In an eﬀort to improve the results obtained with
benzyloxyphenyl and phenoxybenzyl analogues 47 and 48,
para-substituted analogues 63 and 64 were synthesized and
tested. Analogue 64 showed a 2-fold improvement in activity
against W2 while its activity against TM90-C2B remained the
same. The solubility with the para-ﬂuoro increased substantially
while log D remained similar. Compound 65, possessing the
ﬂuoro substituent at themeta-position of the proximal ring rather
than the para-position of the distal ring, showed a drastic
decrease in activities but a moderate increase in solubility.
Likewise, analogue 63, the para-triﬂuoromethoxy congener of
48, showed a decrease in activities while physicochemical data
remained similar.
Based on the data generated from the compounds previously
discussed, several 3-substituted 4(1H)-quinolones showed
promising results. Biaryl 45 possessed excellent activities but
poor solubility. The 3-pyridyl analogues 19−21 had enhanced
solubility yet poor EC50 values, while the 3-para-substituted
phenyl analogues 54 and 58 possessed good EC50 values coupled
with excellent microsomal stability for 58. The new focus was to
combine the desired properties of enhanced solubility and good
microsomal stability while maintaining excellent activities against
W2 and TM90-C2B strains. Analogues incorporating a pyridyl-
based biaryl with ﬂuoro substituents were envisioned; 66 and 67
were synthesized and tested. Both analogues showed excellent
EC50 values against W2 and TM90-C2B and favorable RI values.
Solubility testing rendered excellent data for 66, while 67
remained unchanged. Compound 67 also showed minimal
degradation in microsomal stability testing.
In Vivo Eﬃcacy Evaluation of Frontrunner Com-
pounds. A modiﬁed Thompson test model was used for
deﬁnitive in vivo eﬃcacy evaluation of frontrunner compounds.
Mice were infected with 1 × 106 P. berghei-GFP parasites. Mice
were treated once a day (days 3−5 PE) with 3, 10, or 50mg/kg of
test compound suspended in PEG400. On days 3, 6, 9, 13, 21,
and 30 PE, parasitemia were monitored via blood smears. The
primary evaluation was deﬁned as the reduction in parasitemia on
day 6 PE and the survival to day 30 PE, whereby a parasitemia
level at day 30 of <1% (99% inhibition) was considered to be a
cure. Animals were euthanized when >40% parasitemia was
reached. The 4(1H)-quinolones assayed in these rigorous
Thompson tests consisted of analogues that excelled in the in
vivo eﬃcacy screening assay, as well as optimized analogues
showing promising in vitro activity and physicochemical
properties.
3-Ethyl- and 3-phenyl-substituted 4(1H)-quinolones 3 and 4,
previously regarded as adequate for in vivo eﬃcacy studies, had
no in vivo activity in the more vigorous challenge of the
Thompson test assay, in which higher parasitemia is achieved
prior to starting treatment.20 In comparison to reference 4, ortho-
methylphenyl-substituted 4(1H)-quinolone 12, with a 3-fold
increased solubility and a 4-fold improved in vitro antimalarial
activity, produced a modest 17% parasitemia reduction at 10 mg/
kg dosing (Table 7). A 41% parasitemia reduction was observed
at an increased dose of 50 mg/kg for compound 12. Compounds
25 and 44, which were among the most soluble analogues, failed
to demonstrate suppressive activity, whereas aminopyridine 23
showed 22% suppression of parasitemia albeit only at a dose of 50
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mg/kg. Biphenyl and biaryl ether 4(1H)-quinolones 45 and 46,
which were the most promising compounds in the preliminary in
vivo eﬃcacy screening, eﬃciently inhibited parasite development
by day 6 at 10 and 50 mg/kg. Likewise, ﬂuorinated compounds
49 and especially 52 were potent 4(1H)-quinolones with
suppressive activities of up to 97%. These results supported
our previous ﬁndings that the triﬂuoromethylphenyl analogue
52, which was superior in terms of antimalarial activity, solubility,
and microsomal stability, was better suited for in vivo eﬃcacy
studies. Compounds 60 and 61, substituted analogues of 4(1H)-
quinolone 12, were even more eﬃcacious, increasing the survival
period of mice to 11 and 13 days PE. These results are most likely
due to the increased metabolic stability derived from the addition
of the chloro (60) and triﬂuoromethyl substituents (61).
Curative activities were obtained with 4(1H)-quinolones 7, 62,
66, and 67, which were structurally related to biphenyl 45 and
biaryl ether 46, at doses as low as 3mg/kg and 1mg/kg. Based on
results by GSK and insights gained from our own SAR studies
and physicochemical evaluation, it was believed that 4(1H)-
quinolones 7 and 62 would be among the most potent analogues
in the 4(1H)-quinolone series.19 As expected, the biological
activities of analogues 7 and 62 were excellent, with 98−99.5%
inhibition on day 6 PE. Similar results were observed for biaryl
ethers 45 and 46. Compound 67 cured all the mice at a dose of 10
mg/kg, whereas 62 was not as active, curing two out of ﬁve
animals. There was no diﬀerence in the survival curves between
the untreated group of mice and the one treated with 12 (Figure
4).
In Vivo Exposure and Pharmacokinetics of Front-
runner Compounds. The in vivo exposure of four lead
compounds (7, 52, 66 and 67) was assessed in Swiss mice
following oral administration at a dose of 10 mg/kg in the same
formulation used for eﬃcacy studies (Figure 5). The highest
exposure was observed for 7, and slightly lower exposure was
observed for 66 and 67. Interestingly, exposure of 52 was
substantially lower than those of the other three frontrunners,
which may have partly contributed to its lower in vivo eﬃcacy in
the Thompson test.
Table 7. Results of Thompson Test
eﬃcacy
compd
dose
(mg/kg)
inhibition (%),
day 6 PE
survival
(daysa)
cure (%),
n = 5
4 50 <1 0 0
12 10 17 0 0
50 41 0 0
23 10 <1 0 0
50 22 0 0
25 10 <1 0 0
50 <1 0 0
44 10 <1 0 0
50 <1 0 0
45 10 80 0 0
50 79 0 0
46 10 87 4 0
50 70 4 0
49 10 63 1 0
50 30 1 0
52 10 92 3 0
50 97 4 0
60 10 95 5 0
50 71 5 0
61 3 84 6 0
10 80 6 0
62 10 99 23 100
50 98 23 100
7 1 99.3 23 100
3 99.3 23 100
10 99.5 23 100
50 99.2 23 100
66 0.3 94.3 23 60
1 94.5 23 100
3 96.3 23 100
10 95.2 23 100
67 0.3 93.9 23 80
1 95.8 23 100
3 97.3 23 80
10 97.3 23 100
amodiaquine 30 99.8 23 100
atovaquone 50 99.1 23 100
aNumber of days animals survived beyond control, untreated animals.
Figure 4. Representative survival curves for 4(1H)-quinolones 12 (A),
62 (B), and 67 (C) that demonstrate enhanced in vivo eﬃcacy
congruent with sequential improved physiological properties of the
series.
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Compound 7 was further examined for its pharmacokinetic
properties in rats (Figure 6). Compound 7 exhibited a long in
vivo half-life (32−42 h), low plasma clearance (0.3 mL/(min·
kg)), and low volume of distribution (0.7 L/kg) following
intravenous administration. These properties are likely to be
inﬂuenced by the extensive binding to plasma proteins (>99%).
The apparent oral bioavailability of 7 after dosing in PEG400 was
approximately 14%. It is unlikely that bioavailability was limited
by extensive ﬁrst-pass metabolism or poor intestinal perme-
ability, given that in vitro studies indicated that both of these
were within acceptable ranges. Rather, the low aqueous solubility
of 7, as described above, would suggest that absorption is likely to
be limited by a combination of precipitation from the co-solvent
vehicle and incomplete dissolution within the gastrointestinal
tract.
■ CONCLUSIONS
Inspired by encouraging results from previous SAR studies on
the 6-chloro-7-methoxy-4(1H)-quinolone core, we synthesized a
library of 58 analogues bearing a variety of aryl substituents at the
3-position of the core using various Suzuki−Miyaura cross-
coupling conditions and tested for antimalarial activities against
clinically relevant W2 and TM90-C2B strains. The library of
compounds was also subjected to extensive physicochemical
testing for solubility, permeability, log D, and microsomal
stability in an eﬀort to predict their potential for in vivo eﬃcacy.
This process was done in parallel with the synthetic chemistry to
produce rapid SAR and SPR results, thus facilitating in vivo study
timelines.
Nine of the 58 compounds gave positive results in some, but
not all, of the physicochemical properties that were anticipated to
predict eﬀective in vivo activity. When the nine leads were
subjected to in vivo testing, it was realized that microsomal
stability was a key indicator for in vivo eﬃcacy of the antimalarial
4(1H)-quinolones.
An optimized sub-series of 3-substituted-4(1H)-quinolones
possessing structural features of the most active, most soluble,
and most stable compounds in preliminary SAR studies were
synthesized and subjected to a complete panel of in vitro and in
vivo testing. All compounds possessed excellent activities against
W2 and TM90-C2B strains along with desirable RI values and
favorable cytotoxicity values. Most of the compounds showed
low CLint values when tested for microsomal stability. Ultimately,
six of the optimized compound sub-series were subjected to in
vivo testing using a modiﬁed Thompson test. Four of the
compounds, 7, 62, 66, and 67, resulted in >97% suppression of
parasitemia 6 days PE, eliciting curative activities with as little as 1
mg/kg necessary for a curative dose. In conjunction with
previous studies demonstrating potent exoerythrocytic activity
and transmission blocking,22,39,40 3-substituted 4(1H)-quino-
lones have tremendous potential as antimalarial drug candidates.
■ EXPERIMENTAL SECTION
Synthetic Chemistry. All palladium catalysts and ligands were
purchased from Strem. All boronic acids were purchased from Frontier
Scientiﬁc. The identities of all title compounds were veriﬁed via 1H
NMR, 13C NMR, and HPLC/HRMS. The chemical purity of the title
compounds was determined using the following conditions: Agilent
1100 series LC/MSD with an Eclipse XDB-C18 (4.6 mm × 100 mm, 5
μm) reversed-phase column; 10% (v/v) acetonitrile (+0.05% TFA) in
90% (v/v) H2O (+0.05% TFA), ramped to 100% acetonitrile (+0.05%
TFA) over 9 min, and holding at 100% acetonitrile for 4 min with a ﬂow
rate of 0.7 mL/min; UV detector, 254 nm. The purity of each compound
was ≥95% in this analysis. NMR spectra were recorded at ambient
temperature on a 400 or 500 MHz Varian NMR spectrometer in the
solvent indicated. All 1H NMR experiments are reported in parts per
million (ppm) downﬁeld of TMS and were measured relative to the
signals for chloroform (7.26 ppm) and dimethyl sulfoxide (2.50 ppm).
All 13C NMR spectra are reported in ppm relative to the signals for
chloroform (77 ppm) and dimethyl sulfoxide (39.5 ppm) with 1H
decoupled observation. Data for 1H NMR are reported as follows:
chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q
= quartet, m = multiplet), integration, and coupling constant (Hz),
whereas 13C NMR analyses were obtained at 101 MHz and reported in
terms of chemical shift. NMR data were analyzed by using MestReNova
software version 5.3.2-4936. High-resolution mass spectrometry
(HRMS) was performed on an Agilent G3250AA LC/MSD TOF
system. Isomers were separated by reversed-phase HPLC (Waters Prep
LC 4000 system with Waters 996 photodiode array detector, Agilent
Eclipse XDB-C18 column, 5 μM, 9.4 × 250 mm). Compounds were
eluted using a gradient elution of 70/30 to 50/50 A/B over 30 min at a
ﬂow rate of 5.0 mL/min, where solvent A was water and solvent B was
acetonitrile. Analytical thin-layer chromatography (TLC) was per-
formed on silica gel 60 F254 pre-coated plates (0.25 mm) from EMD
Chemical Inc., and components were visualized by UV light (254 nm).
Silicycle silica gel 230−400 (particle size 40−63 μm) mesh was used for
all ﬂash column chromatography.
Figure 5. Abbreviated (three time-point) plasma exposure proﬁles for
four frontrunner compounds in Swiss outbred mice following oral
administration as PEG400 suspensions at 10 mg/kg: (●) 52, (△) 66,
(■) 67, and (◇) 7.
Figure 6. Plasma concentration versus time proﬁles for compound 7 in
Sprague−Dawley rats (average of n = 2): (●) concentrations following
IV administration at 0.15 mg/kg and (○) concentrations following oral
administration of a PEG400 suspension at 10 mg/kg.
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General Procedure A: Preparation of 3-Aryl-6-chloro-7-
methoxy-4(1H)-quinolones via Suzuki−Miyaura Cross-Cou-
pling. An oven-dried Schlenk tube was ﬂame-dried and backﬁlled
with argon (×3). The tube was then charged with quinolone (100 mg,
0.4 mmol), Pd2(dba)3 (14.5 mg, 0.016 mmol), SPHOS (13 mg, 0.032
mmol), boronic acid (0.6 mmol), and anhydrous powdered K3PO4 (168
mg, 0.79 mmol). The Schlenk tube was ﬁtted with a rubber septum and
then evacuated and backﬁlled with argon (this process was repeated
three times). Dry solvent (toluene, DMF, or 2-butanol, 1 mL) was
added through the septum via syringe, and the resulting solution was
stirred for 1 min while purging with argon before replacing the rubber
septum with the Teﬂon screwcap. The reaction was placed in an oil bath
at 110 °C until completion was observed via HPLC analysis. The
reaction was cooled to room temperature and then diluted with 20 mL
of chloroform and 20 mL of methanol. The mixture was heated to
boiling with a heat gun and then ﬁltered over a pad of Celite. Then, 10−
30 mL of boiling DMF was passed through the Celite pad. The eluent
was concentrated under reduced pressure, and the residual oil was
puriﬁed further via ﬂash chromatography. Some 4(1H)-quinolones
required two successive column puriﬁcations. The puriﬁed solids were
then collected, placed in a 2-mL fritted funnel, and washed with ice-cold
methanol, followed by diethyl ether; they were then dried in vacuo to
obtain the NMR-pure samples. Some 4(1H)-quinolones could be
triturated with cold ether upon in vacuo removal of the chloroform/
methanol/DMF, placed in a 2-mL frit, and washed with ∼30 mL of
diethyl ether and ∼30 mL of ice-cold methanol without any further
puriﬁcation.
General Procedure B: Preparation of 3-Aryl-6-chloro-7-
methoxy-4(1H)-quinolones via Suzuki−Miyaura Cross-Cou-
pling. An oven-dried Schlenk tube was ﬂame-dried and backﬁlled
with argon (×3). The tube was then charged with quinolone (100 mg,
0.4mmol), Pd(PPh3)4 (14.5mg, 0.016mmol), boronic acid (0.6 mmol),
and degassed 1−2 MNa2CO3 (1 mL). The Schlenk tube was ﬁtted with
a rubber septum and then evacuated and backﬁlled with argon (this
process was repeated three times). DMF (5 mL) was added through the
septum via syringe, and the resulting solution was stirred for 1 min while
purging with argon before replacing the rubber septum with the Teﬂon
screwcap. The reaction was placed in an oil bath at 110 °C until
completion was observed via HPLC analysis. The reaction was cooled to
room temperature and then diluted with 20 mL of chloroform and 20
mL of methanol. This mixture was heated to boiling with a heat gun and
then ﬁltered over a pad of Celite. Then, 10−30 mL of boiling DMF was
passed through the Celite pad. The eluent was concentrated under
reduced pressure, and the residual oil was puriﬁed further via ﬂash
chromatography. Some 4(1H)-quinolones required two successive
column puriﬁcations. The puriﬁed solids were then collected, placed in a
2-mL fritted funnel, and washed with ice-cold methanol, followed by
diethyl ether; they were then dried in vacuo to obtain the NMR-pure
samples. Some 4(1H)-quinolones could be triturated with cold ether
upon in vacuo removal of the chloroform/methanol/DMF, placed in a
2-mL fritted funnel, and washed with ∼30 mL of diethyl ether and ∼30
mL of ice-cold methanol without any further puriﬁcation.
General Procedure C: Preparation of 3-Aryl-6-chloro-7-
methoxy-4(1H)-quinolones via Suzuki−Miyaura Cross-Cou-
pling. An oven-dried Schlenk tube was ﬂame-dried and backﬁlled
with argon (×3). The tube was then charged with quinolone (100 mg,
0.4mmol), Pd(PPh3)4 (14.5mg, 0.016mmol), boronic acid (0.6 mmol),
and K3PO4 (168 mg, 0.79 mmol). The Schlenk tube was ﬁtted with a
rubber septum and then evacuated and backﬁlled with argon (this
process was repeated three times). A degassed mixture of toluene/H2O
(9:1) was added through the septum via syringe, and the resulting
solution was stirred for 1 min while purging with argon before replacing
the rubber septum with the Teﬂon screwcap. The reaction was placed in
an oil bath at 110 °C until completion was observed via HPLC analysis.
The reaction was cooled to room temperature and then diluted with 20
mL of chloroform and 20 mL of methanol. This mixture was heated to
boiling with a heat gun and then ﬁltered over a pad of Celite. Then, 10−
30 mL of boiling DMF was passed through the Celite pad. The eluent
was concentrated under reduced pressure, and the residual oil was
puriﬁed further via ﬂash chromatography. Some 4(1H)-quinolones
required two successive column puriﬁcations. The puriﬁeded solids were
then collected, placed in a 2-mL fritted funnel, and washed with ice-cold
methanol, followed by diethyl ether; they were then dried in vacuo to
obtain the NMR-pure samples. Some 4(1H)-quinolones could be
triturated with cold ether upon in vacuo removal of the chloroform/
methanol/DMF, placed in a 2-mL fritted funnel, and washed with ∼30
mL of diethyl ether and ∼30 mL of ice-cold methanol without any
further puriﬁcation.
General Procedure D: Preparation of 3-Aryl-6-chloro-7-
methoxy-4(1H)-quinolones via Suzuki−Miyaura Cross-Cou-
pling. An oven-dried Schlenk tube was ﬂame-dried and backﬁlled
with argon (×3). The tube was then charged with quinolone (100 mg,
0.4 mmol), Pd2(dba)3 (14.5 mg, 0.016 mmol), SPHOS (13 mg, 0.032
mmol), boronic acid (0.6 mmol), and anhydrous powdered K3PO4 (168
mg, 0.79 mmol). The Schlenk tube was ﬁtted with a rubber septum and
then evacuated and backﬁlled with argon (this process was repeated
three times). A degassed mixture of toluene/H2O (9:1) was added
through the septum via syringe, and the resulting solution was stirred for
1 min while purging with argon before replacing the rubber septum with
the Teﬂon screwcap. The reaction was placed in an oil bath at 110 °C
until completion was observed via HPLC analysis. The reaction was
cooled to room temperature and then diluted with 20 mL of chloroform
and 20 mL of methanol. This mixture was heated to boiling with a heat
gun and then ﬁltered over a pad of Celite. Then, 10−30 mL of boiling
DMF was passed through the Celite pad. The eluent was concentrated
under reduced pressure, and the residual oil was puriﬁed further via ﬂash
chromatography. Some 4(1H)-quinolones required two successive
column puriﬁcations. The puriﬁed solids were then collected, placed in a
2-mL frit, and washed with ice-cold methanol, followed by diethyl ether;
they were then dried in vacuo to obtain the NMR-pure samples. Some
4(1H)-quinolones could be triturated with cold ether upon in vacuo
removal of the chloroform/methanol/DMF, placed in a 2-mL fritted
funnel, and washed with ∼30 mL of diethyl ether and ∼30 mL of ice-
cold methanol without any further puriﬁcation.
General Procedure E: Preparation of 3-Aryl-6-chloro-7-
methoxy-4(1H)-quinolones via Suzuki−Miyaura Cross-Cou-
pling. An oven-dried Schlenk tube was ﬂame-dried and backﬁlled
with argon (×3). The tube was then charged with quinolone (100 mg,
0.4 mmol), Pd2(dba)3 (14.5 mg, 0.016 mmol), SPHOS (13 mg, 0.032
mmol), boronic acid (0.6 mmol), and degassed 1−2MNa2CO3 (1 mL).
The Schlenk tube was ﬁtted with a rubber septum and then evacuated
and backﬁlled with argon (this process was repeated three times). Dry
solvent (toluene, DMF, or 2-butanol, 5 mL) was added through the
septum via syringe, and the resulting solution was stirred for 1 min while
purging with argon before replacing the rubber septum with the Teﬂon
screwcap. The reaction was placed in an oil bath at 110 °C until
completion was observed via HPLC analysis. The reaction was cooled to
room temperature and then diluted with 20 mL of chloroform and 20
mL of methanol. This mixture was heated to boiling with a heat gun and
then ﬁltered over a pad of Celite. Then, 10−30 mL of boiling DMF was
passed through the Celite pad. The eluent was concentrated under
reduced pressure, and the residual oil was puriﬁed further via ﬂash
chromatography. Some 4(1H)-quinolones required two successive
column puriﬁcations. The puriﬁed solids were then collected, placed in a
2-mL frit, and washed with ice-cold methanol, followed by diethyl ether;
they were then dried in vacuo to obtain the NMR-pure samples. Some
4(1H)-quinolones could be triturated with cold ether upon in vacuo
removal of the chloroform/methanol/DMF, placed in a 2-mL fritted
funnel, and washed with ∼30 mL of diethyl ether and ∼30 mL of ice-
cold methanol without any further puriﬁcation.
General Procedure F: Preparation of 3-Aryl-6-chloro-7-
methoxy-4(1H)-quinolones via Suzuki−Miyaura Cross-Cou-
pling. An oven-dried Schlenk tube was ﬂame-dried and backﬁlled
with argon (×3). The tube was then charged with O-ethyl quinolone
(100 mg, 0.39 mmol), Pd2(dba)3 (14.5 mg, 0.016 mmol), SPHOS (13
mg, 0.032 mmol), boronic acid (0.6 mmol), and anhydrous powdered
K3PO4 (168 mg, 0.79 mmol). The Schlenk tube was ﬁtted with a rubber
septum and then evacuated and backﬁlled with argon (this process was
repeated three times). Dry solvent (toluene, DMF, or 2-butanol, 1 mL)
was added through the septum via syringe, and the resulting solution was
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stirred for 1 min while purging with argon before replacing the rubber
septum with the Teﬂon screwcap. The reaction was placed in an oil bath
at 110 °C until completion was observed via HPLC analysis. The
reaction was cooled to room temperature and then diluted with 20 mL
of chloroform and 20 mL of methanol. This mixture was heated to
boiling with a heat gun and then ﬁltered over a pad of Celite. Then, 10−
30 mL of boiling DMF was passed through the Celite pad. The eluent
was concentrated under reduced pressure, and the residual oil was
puriﬁed further via ﬂash chromatography. Some 4(1H)-quinolones
required two successive column puriﬁcations. The puriﬁed solids were
then collected, placed in a 2-mL fritted funnel, and washed with ice-cold
methanol, followed by diethyl ether; they were then dried in vacuo to
obtain the NMR-pure samples. Some 4(1H)-quinolones could be
triturated with cold ether upon in vacuo removal of the chloroform/
methanol/DMF, placed in a 2-mL frit, and washed with ∼30 mL of
diethyl ether and ∼30 mL of ice-cold methanol without any further
puriﬁcation. The resulting Suzuki adduct was then dissolved in 1:1
AcOH/HBr and reﬂuxed for 1.5 h. The solution was allowed to cool to
room temperature and poured onto ice and water. Next, the crude
compound was isolated via ﬁltration and washed with 100 mL of water.
The product was placed in a 60 °C oven, dried for 1 h, and then re-
crystallized from DMF.
General Procedure G: Preparation of 3-Aryl-6-chloro-7-
methoxy-4(1H)-quinolones via Suzuki−Miyaura Cross-Cou-
pling. An oven-dried Schlenk tube was ﬂame-dried and backﬁlled
with argon (×3). The tube was then charged with O-ethyl quinolone
(100 mg, 0.39 mmol), Pd2(dba)3 (14.5 mg, 0.016 mmol), SPHOS (13
mg, 0.032 mmol), boronic acid (0.6 mmol), and degassed 1−2 M
Na2CO3 (1 mL). The Schlenk tube was ﬁtted with a rubber septum and
then evacuated and backﬁlled with argon (this process was repeated
three times). DMF (5 mL) was added through the septum via syringe,
and the resulting solution was stirred for 1 min while purging with argon
before replacing the rubber septum with the Teﬂon screwcap. The
reaction was placed in an oil bath at 110 °C until completion was
observed via HPLC analysis. The reaction was cooled to room
temperature and then diluted with 20 mL of chloroform and 20 mL
ofmethanol. This mixture was heated to boiling with a heat gun and then
ﬁltered over a pad of Celite. Then, 10−30 mL of boiling DMF was
passed through the Celite pad. The eluent was concentrated under
reduced pressure, and the residual oil was puriﬁed further via ﬂash
chromatography. Some 4(1H)-quinolones required two successive
column puriﬁcations. The puriﬁed solids were then collected, placed in a
2-mL fritted funnel, and washed with ice-cold methanol, followed by
diethyl ether; they were then dried in vacuo to obtain the NMR-pure
samples. Some 4(1H)-quinolones could be triturated with cold ether
upon in vacuo removal of the chloroform/methanol/DMF, placed in a
2-mL fritted funnel, and washed with ∼30 mL of diethyl ether and ∼30
mL of ice-cold methanol without any further puriﬁcation. The resulting
Suzuki adduct was then dissolved in 1:1 AcOH/HBr and reﬂuxed for 1.5
h. The solution was allowed to cool to room temperature and poured
onto ice and water. Next, the crude compound was isolated via ﬁltration
and washed with 100 mL of water. The product was placed in a 60 °C
oven, dried for 1 h, and then re-crystallized from DMF.
Preparation and Characterization of Compounds. 6-Chloro-7-
methoxy-2-methyl-3-(o-tolyl)quinolin-4(1H)-one (12). Compound
12 was prepared using general procedure A in 31% yield as a white
powder, mp = 337−339 °C. 1H NMR (400 MHz, DMSO): δ 11.66 (s,
1H), 7.99 (s, 1H), 7.22 (dt, J = 22.4, 7.1, 3H), 7.08 (s, 1H), 7.03 (d, J =
6.9, 1H), 3.96 (s, 3H), 2.05 (s, 3H), 2.02 (s, 3H). 13C NMR (101 MHz,
DMSO): δ 173.16, 156.63, 146.50, 139.71, 137.35, 135.92, 130.81,
129.48, 127.04, 126.11, 125.46, 120.44, 118.58, 117.91, 99.44, 56.37,
19.30, 18.39. HRMS: calcd for C18H16ClNO2 (M+H)
+ 314.09423,
found 314.09470.
6-Chloro-7-methoxy-2-methyl-3-(p-tolyl)quinolin-4(1H)-one (13).
Compound 13 was prepared using general procedure A in 78% as a tan
solid, mp = 336−341 °C. 1HNMR (400MHz, DMSO): δ 11.59 (s, 1H),
7.99 (s, 1H), 7.18 (d, J = 7.7 Hz, 2H), 7.10 (d, J = 7.7 Hz, 2H), 7.03 (s,
1H), 3.94 (s, 3H), 2.33 (s, 3H), 2.18 (s, 3H). 13C NMR (101 MHz,
DMSO): δ 173.57, 156.58, 146.33, 139.54, 135.51, 132.79, 130.75,
128.34, 126.16, 120.64, 118.74, 117.86, 99.35, 56.32, 20.80, 18.83.
HRMS: calcd for C18H16ClNO2 (M+H)
+ 314.09423, found 314.09456.
6-Chloro-3-(2,4-dimethylphenyl)-7-methoxy-2-methylquinolin-
4(1H)-one (14). Compound 14 was a prepared using general procedure
A in 28%, mp = decomp at 346 °C. 1H NMR (400 MHz, DMSO): δ
11.63 (s, 1H), 7.98 (s, 1H), 7.06 (s, 2H), 6.99 (d, J = 7.6 Hz, 1H), 6.89
(d, J = 7.6 Hz, 1H), 3.95 (s, 3H), 2.29 (s, 3H), 2.04 (s, 3H), 1.97 (s, 3H).
13C NMR (101 MHz, DMSO): δ 173.98, 157.27, 147.26, 140.39,
137.77, 136.64, 133.58, 131.36, 130.91, 126.79, 121.02, 119.27, 118.54,
100.12, 57.04, 21.40, 19.95, 19.11. HRMS: calcd for C19H18ClNO2 (M
+H)+ 328.1099, found 328.1102.
6-Chloro-3-mesityl-7-methoxy-2-methylquinolin-4(1H)-one (15).
Compound 15 was prepared using general procedure G in 10% as a tan
solid, mp = 350−352 °C. 1HNMR (250MHz, DMSO): δ 11.68 (s, 1H),
7.99 (s, 1H), 7.07 (s, 1H), 6.89 (s, 2H), 3.95 (s, 3H), 2.25 (s, 3H), 1.93
(d, J = 13.5 Hz, 9H). 13C NMR (126 MHz, DMSO): δ 173.2, 156.6,
146.4, 139.8, 136.6, 135.6, 132.5, 127.8, 126.1, 118.8, 118.5, 117.8, 99.5,
56.4, 20.7, 19.6, 17.8. HRMS: calcd for C20H20ClNO2 (M+H)
+
342.12553, found 342.12447.
6-Chloro-3-(2-ethylphenyl)-7-methoxy-2-methylquinolin-4(1H)-
one (16).Compound 16 was prepared following general procedure A in
8% yield, mp = decomp at 322 °C. 1H NMR (400 MHz, DMSO): δ
11.68 (s, 1H), 7.99 (s, 1H), 7.27 (d, J = 12.6 Hz, 2H), 7.21 (d, J = 5.2 Hz,
1H), 7.08 (s, 1H), 7.00 (d, J = 7.3 Hz, 1H), 3.96 (s, 3H), 2.35 (q, J = 7.3
Hz, 2H), 2.05 (s, 3H), 0.99 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz,
DMSO): δ 173.49, 156.63, 146.61, 143.23, 139.77, 135.35, 131.03,
127.86, 127.33, 126.13, 125.57, 120.42, 118.58, 117.93, 99.49, 56.38,
25.82, 18.59, 14.87.HRMS: calcd for C19H18ClNO2 (M+H)
+ 328.1099,
found 328.1107.
6-Chloro-3-(4-isopropylphenyl)-7-methoxy-2-methylquinolin-
4(1H)-one (17).Compound 17 was prepared using general procedure A
in 66% as a white solid, mp = 359−360 °C. 1H NMR (400 MHz,
DMSO): δ 11.60 (s, 1H), 7.99 (s, 1H), 7.24 (d, J = 7.8Hz, 2H), 7.14 (d, J
= 7.8 Hz, 2H), 7.05 (s, 1H), 3.95 (s, 3H), 2.91 (m, 1H), 2.19 (s, 3H),
1.24 (d, J = 6.8 Hz, 6H). 13C NMR (101 MHz, DMSO): δ 173.61,
164.24, 156.60, 146.41, 139.54, 133.16, 130.80, 126.17, 125.64, 120.65,
118.73, 117.87, 99.35, 56.34, 33.17, 23.91, 18.89. HRMS: calcd for
C20H20ClNO2 (M+H)
+ 342.12553, found 342.12436.
3-(4-tert-Butylphenyl)-6-chloro-7-methoxy-2-methylquinolin-
4(1H)-one (18).Compound 18 was prepared using general procedure A
in 35% as a white solid, mp = 360−362 °C. 1H NMR (400 MHz,
DMSO): δ 11.60 (s, 1H), 7.99 (s, 1H), 7.40 (d, J = 8.1Hz, 2H), 7.15 (d, J
= 8.1 Hz, 2H), 7.06 (s, 1H), 3.96 (s, 3H), 2.20 (s, 3H), 1.32 (s, 9H). 13C
NMR (101 MHz, DMSO): δ 174.30, 157.31, 149.34, 147.07, 140.24,
133.48, 131.24, 126.86, 125.16, 121.26, 119.42, 118.57, 100.06, 57.05,
34.90, 31.88, 19.60. HRMS: calcd for C21H22ClNO2 (M+H)
+
356.14118, found 356.14311.
6-Chloro-7-methoxy-2-methyl-3-(pyridin-2-yl)quinolin-4(1H)-one
(19). Compound 19 was prepared using general procedure F in 29%
over two steps, mp = decomp at 305 °C. 1H NMR (400 MHz, DMSO):
δ 11.69 (s, 1H), 8.56 (s, 1H), 7.98 (s, 1H), 7.75 (td, J = 7.7, 1.7 Hz, 1H),
7.43 (d, J = 7.8 Hz, 1H), 7.24 (dd, J = 6.6, 5.1 Hz, 1H), 7.05 (s, 1H), 3.93
(s, 3H), 2.22 (s, 3H). 13C NMR (101 MHz, DMSO): δ 173.74, 157.23,
155.44, 149.10, 148.55, 139.97, 135.88, 127.29, 126.55, 122.03, 120.53,
119.50, 118.68, 100.05, 56.83, 19.03. HRMS: calcd for C16H13ClN2O2
(M+H)+ 301.0738, found 301.0747.
6-Chloro-7-methoxy-2-methyl-3-(pyridin-3-yl)quinolin-4(1H)-one
(20).Compound 20was prepared using general procedure D in 12% as a
purple solid, mp = 301−304 °C. 1H NMR (400 MHz, DMSO): δ 11.85
(s, 1H), 8.49 (s, 1H), 8.45 (s, 1H), 8.00 (s, 1H), 7.68 (d, J = 6.7, 1H),
7.43 (d, J = 4.5, 1H), 7.10 (s, 1H), 3.96 (s, 3H), 2.24 (s, 3H). 13C NMR
(101 MHz, DMSO): δ 173.40, 156.83, 151.34, 147.48, 147.24, 139.72,
138.44, 131.58, 126.10, 122.96, 118.62, 118.23, 117.24, 99.60, 56.42,
18.85. HRMS: calcd for C16H13ClN2O2 (M+H)
+ 301.07383, found
314.07266.
6-Chloro-7-methoxy-2-methyl-3-(pyridin-4-yl)quinolin-4(1H)-one
(21).Compound 21was prepared using general procedure B in 19% as a
tan solid, mp = 307−309 °C. 1H NMR (400 MHz, DMSO): δ 11.80 (s,
1H), 8.58 (d, J = 5.8, 2H), 8.00 (s, 1H), 7.31−7.28 (m, 2H), 7.07 (s,
1H), 3.96 (s, 3H), 2.25 (s, 3H). 13C NMR (101 MHz, DMSO): δ
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172.85, 156.90, 149.05, 146.95, 143.94, 139.60, 126.21, 126.11, 118.68,
118.34, 118.18, 99.55, 56.42, 18.78. HRMS: calcd for C16H13ClN2O2 (M
+H)+ 301.07383, found 301.07303.
6-Chloro-7-methoxy-2-methyl-3-(pyrimidin-5-yl)quinolin-4(1H)-
one (22). Compound 22 was prepared using general procedure A in
12%. 1H NMR (400 MHz, DMSO): δ 11.90 (s, 1H), 9.11 (s, 1H), 8.74
(s, 2H), 8.01 (s, 1H), 7.09 (s, 1H), 3.97 (s, 3H), 2.30 (s, 3H). 13C NMR
(101 MHz, DMSO): δ 173.88, 159.05, 157.73, 157.12, 148.56, 140.37,
130.39, 126.76, 119.27, 114.44, 108.95, 100.35, 57.15, 19.52. HRMS:
calcd for C15H12ClN3O2 (M+H)
+ 302.0691, found 302.0688.
6-Chloro-3-(6-(dimethylamino)pyridin-3-yl)-7-methoxy-2-meth-
ylquinolin-4(1H)-one (23). Compound 23 was prepared using general
procedure E in 16%, mp = decomp at 330 °C. 1H NMR (400 MHz,
DMSO): δ 11.61 (s, 1H), 7.98 (s, 1H), 7.94 (d, J = 1.9Hz, 1H), 7.39 (dd,
J = 8.7, 2.2 Hz, 1H), 7.03 (s, 1H), 6.64 (d, J = 8.7 Hz, 1H), 3.95 (s, 3H),
3.04 (s, 6H), 2.24 (s, 3H). 13C NMR (101 MHz, DMSO): δ 173.90,
157.69, 156.58, 148.91, 146.65, 139.75, 139.49, 126.17, 118.68, 118.52,
117.88, 117.84, 104.83, 99.35, 56.33, 37.72, 18.93. HRMS: calcd for
C18H18ClN3O2 (M+H)
+ 344.11603, found 344.12216.
6-Chloro-7-methoxy-2-methyl-3-(6-(4-methylpiperazin-1-yl)-
pyridin-3-yl)quinolin-4(1H)-one (24). Compound 24 was prepared
using general procedure B in 10%, mp = decomp at 277 °C. 1H NMR
(400 MHz, DMSO): δ 11.70 (s, 1H), 8.04 (s, 1H), 7.99 (d, J = 1.2 Hz,
1H), 7.52 (d, J = 8.6 Hz, 1H), 7.08 (s, 1H), 6.98 (d, J = 8.5 Hz, 1H), 3.97
(s, 3H), 2.80 (s, 3H), 2.26 (s, 3H). 13C NMR (101 MHz, DMSO): δ
174.20, 157.12, 156.91, 149.45, 147.35, 140.91, 139.97, 126.57, 122.05,
118.94, 118.47, 117.73, 107.18, 99.86, 56.85, 52.74, 42.87, 42.72, 19.35.
HRMS: calcd for C21H23ClN4O2 (M+H)
+ 399.1582, found 399.1583.
6-Chloro-3-(furan-2-yl)-7-methoxy-2-methylquinolin-4(1H)-one
(25).Compound 25was prepared using general procedure A in 72% as a
yellow solid, mp = 300−301 °C. 1H NMR (400 MHz, DMSO): δ 11.78
(s, 1H), 8.03 (s, 1H), 7.68 (s, 1H), 7.07 (s, 1H), 6.78 (d, J = 3.0 Hz, 1H),
6.55 (s, 1H), 3.96 (s, 3H), 2.45 (s, 3H). 13C NMR (101 MHz, DMSO):
δ 173.17, 157.42, 149.37, 148.82, 141.91, 139.68, 126.81, 119.17, 119.09,
111.42, 111.27, 111.06, 100.24, 57.06, 20.11. HRMS: calcd for
C15H12ClNO3 (M+H)
+ 290.05785, found 290.05890.
6-Chloro-3-(furan-3-yl)-7-methoxy-2-methylquinolin-4(1H)-one
(26).Compound 26was prepared using general procedure B in 45%, mp
= 318−324 °C. 1H NMR (400 MHz, DMSO): δ 11.59 (s, 1H), 7.96 (s,
1H), 7.79 (s, 1H), 7.64 (d, J = 0.8 Hz, 1H), 6.99 (s, 1H), 6.61 (d, J = 0.8
Hz, 1H), 3.91 (s, 3H), 2.36 (s, 3H). 13C NMR (101 MHz, DMSO): δ
173.41, 156.74, 147.03, 142.01, 141.82, 139.25, 126.28, 118.37, 118.33,
118.23, 112.80, 111.63, 99.42, 56.48, 19.44. HRMS: calcd for
C15H12ClNO3 (M+H)
+ 290.0579, found 290.0574.
6-Chloro-3-(3,5-dimethylisoxazol-4-yl)-7-methoxy-2-methylqui-
nolin-4(1H)-one (27). Compound 27 was prepared using general
procedure A in 16% as a red solid, mp = 274−275 °C. 1H NMR (400
MHz, DMSO): δ 11.82 (s, 1H), 7.99 (s, 1H), 7.08 (s, 1H), 3.96 (s, 3H),
2.17 (s, 6H), 1.98 (s, 3H). 13C NMR (101 MHz, DMSO): δ 174.14,
166.58, 160.84, 157.54, 149.51, 140.41, 126.74, 118.98, 118.87, 111.11,
108.96, 100.24, 57.12, 19.00, 11.94, 10.89. HRMS: calcd for
C16H15ClN2O3 (M+H)
+ 319.08440, found 319.08290.
3-(Benzo[c][1,2,5]oxadiazol-5-yl)-6-chloro-7-methoxy-2-methyl-
quinolin-4(1H)-one (28). Compound 28 was prepared using general
procedure B in 22%. 1H NMR (400 MHz, DMSO): δ 11.87 (s, 1H),
8.03−7.94 (m, 2H), 7.90 (s, 1H), 7.50 (d, J = 9.3 Hz, 1H), 7.08 (s, 1H),
3.97 (s, 3H), 2.34 (s, 3H). 13C NMR (101 MHz, DMSO): δ 173.1,
157.0, 149.2, 148.1, 147.7, 140.8, 139.6, 137.4, 134.1, 126.0, 118.6, 118.5,
116.1, 114.3, 99.6, 56.5, 18.9. HRMS: calcd for C17H12ClN3O3 (M+H)
+
342.0640, found 342.0651.
3-(Benzofuran-2-yl)-6-chloro-7-methoxy-2-methylquinolin-
4(1H)-one (29).Compound 29 was prepared using general procedure A
in 59%, mp = 322−323 °C. 1H NMR (400 MHz, DMSO): δ 11.94 (s,
1H), 8.06 (s, 1H), 7.67−7.62 (m, 1H), 7.54 (d, J = 7.8 Hz, 1H), 7.29−
7.21 (m, 3H), 7.09 (s, 1H), 3.97 (s, 3H), 2.56 (s, 3H). 13C NMR (101
MHz, DMSO): δ 172.67, 156.95, 153.40, 151.64, 149.42, 139.08,
128.58, 126.15, 123.60, 122.59, 120.60, 118.73, 118.50, 110.67, 109.95,
106.91, 99.74, 56.44, 19.66. HRMS: calcd for C19H14ClNO3 (M+H)
+
340.0735, found 340.0734.
3-(Benzo[b]thiophen-2-yl)-6-chloro-7-methoxy-2-methylquino-
lin-4(1H)-one (30). Compound 30 was prepared using general
procedure C in 53%, mp = 345−346 °C. 1H NMR (500 MHz,
DMSO): δ 11.91 (s, 1H), 8.04 (s, 1H), 7.93 (d, J = 7.7, 1H), 7.82 (d, J =
7.2, 1H), 7.38−7.30 (m, 3H), 7.09 (s, 1H), 3.98 (s, 3H), 2.47 (s, 3H).
13C NMR (126 MHz, DMSO): δ 173.60, 157.43, 149.08, 140.43,
139.77, 139.62, 138.12, 126.68, 124.70, 124.36, 124.29, 123.60, 122.33,
119.04, 118.83, 113.76, 100.10, 56.95, 20.08. HRMS: calcd for
C19H14ClNO2S (M+H)
+ 356.05065, found 356.05077.
6-Chloro-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-7-methoxy-2-
methylquinolin-4(1H)-one (31). Compound 31 was prepared using
general procedure A in 61%, mp = 330−332 °C. 1H NMR (400 MHz,
DMSO): δ 11.58 (s, 1H), 7.98 (s, 1H), 7.03 (s, 1H), 6.84 (d, J = 8.2 Hz,
1H), 6.74−6.59 (m, 2H), 4.25 (s, 4H), 3.94 (s, 3H), 2.20 (s, 3H). 13C
NMR (101 MHz, DMSO): δ 174.29, 157.26, 147.21, 143.39, 142.77,
140.18, 129.37, 126.84, 124.46, 120.90, 120.20, 119.38, 118.56, 116.97,
100.02, 64.74, 64.69, 57.01, 19.54. HRMS: calcd for C19H16ClNO4 (M
+H)+ 358.08406, found 358.08474.
6-Chloro-3-(dibenzo[b,d]furan-4-yl)-7-methoxy-2-methylquino-
lin-4(1H)-one (32). Compound 32 was prepared using general
procedure B in 24%, mp = decomp at 220 °C. 1H NMR (400 MHz,
DMSO): δ 11.86 (s, 1H), 8.14 (dd, J = 18.0, 6.8 Hz, 2H), 8.02 (s, 1H),
7.62 (d, J = 8.2 Hz, 1H), 7.50−7.37 (m, 4H), 7.13 (s, 1H), 3.99 (s, 3H),
2.17 (s, 3H). 13C NMR (101 MHz, DMSO): δ 173.27, 156.84, 155.22,
154.07, 147.61, 139.81, 130.28, 127.35, 126.15, 123.86, 123.45, 122.95,
122.81, 121.04, 120.42, 119.95, 118.60, 118.25, 115.37, 111.63, 99.60,
56.44, 18.62. HRMS: calcd for C23H16ClNO3 (M+H)
+ 390.0892, found
390.0892.
6-Chloro-7-methoxy-3-(4-methoxyphenyl)-2-methylquinolin-
4(1H)-one (33).Compound 33 was prepared using general procedure A
in 68% as an oﬀ-white solid, mp = 297−298 °C. 1H NMR (400 MHz,
DMSO): δ 11.59 (s, 1H), 7.99 (s, 1H), 7.14 (d, J = 7.8 Hz, 2H), 7.05 (s,
1H), 6.94 (d, J = 7.9 Hz, 2H), 3.95 (s, 3H), 3.78 (s, 3H), 2.20 (s, 3H).
13C NMR (101 MHz, DMSO): δ 173.73, 157.92, 156.61, 146.46,
139.55, 131.99, 127.82, 126.21, 120.39, 118.74, 117.88, 113.25, 99.38,
56.37, 55.01, 18.90. HRMS: calcd for C18H16ClNO3 (M+H)
+
330.08915, found 330.08983.
6-Chloro-3-(4-isopropoxyphenyl)-7-methoxy-2-methylquinolin-
4(1H)-one (34).Compound 34 was prepared using general procedure A
in 62% as a brown solid, mp = 342−343 °C. 1H NMR (600 MHz,
DMSO): δ 11.59 (s, 1H), 7.99 (s, 1H), 7.12 (d, J = 8.6 Hz, 2H), 7.05 (s,
1H), 6.90 (d, J = 8.6 Hz, 2H), 4.61 (m, 1H), 3.95 (s, 3H), 2.20 (s, 3H),
1.29 (d, J = 6.0 Hz, 6H). 13C NMR (126 MHz, DMSO): δ 173.70,
156.58, 156.10, 146.41, 139.53, 132.02, 127.51, 126.19, 120.41, 118.72,
117.83, 114.77, 99.35, 68.95, 56.35, 21.94, 18.92. HRMS: calcd for
C20H20ClNO3 (M+H)
+ 358.12045, found 358.11946.
4-(6-Chloro-7-methoxy-2-methyl-4-oxo-1,4-dihydroquinolin-3-
yl)benzaldehyde (35). Compound 35 was prepared using general
procedure B in 15%, mp = decomp at 341 °C. 1H NMR (400 MHz,
DMSO): δ 11.72 (s, 1H), 10.00 (s, 1H), 7.96 (s, 1H), 7.88 (d, J = 7.8 Hz,
2H), 7.47 (s, 2H), 7.03 (s, 1H), 3.92 (s, 3H), 2.20 (s, 3H). 13C NMR
(101 MHz, CDCl3): δ 197.97, 178.31, 162.03, 152.00, 147.81, 144.78,
139.73, 137.01, 134.08, 131.33, 124.86, 123.92, 123.44, 104.71, 61.60,
24.06. HRMS: calcd for C18H14ClNO3 (M+H)
+ 328.0735, found
328.0740.
3-(4-Acetylphenyl)-6-chloro-7-methoxy-2-methylquinolin-4(1H)-
one (36). Compound 36 was prepared using general procedure A in
13% as a yellow solid, mp = 266−269 °C. 1HNMR (250MHz, DMSO):
δ 11.65 (s, 1H), 7.94−7.80 (m, 3H), 7.30 (d, J = 8.0 Hz, 2H), 6.96 (s,
1H), 3.85 (s, 3H), 2.39 (s, 3H), 2.11 (s, 3H). 13C NMR (101 MHz,
DMSO): δ 198.28, 173.87, 157.48, 147.38, 141.81, 140.28, 135.75,
131.99, 128.32, 126.84, 120.46, 119.41, 118.86, 100.18, 57.09, 27.38,
19.54. HRMS: calcd for C19H16ClNO3 (M+H)
+ 342.08915, found
342.08955.
4-(6-Chloro-7-methoxy-2-methyl-4-oxo-1,4-dihydroquinolin-3-
yl)benzoic Acid (37). Compound 37 was prepared using general
procedure, mp = > 352 °C. 1H NMR (400 MHz, DMSO): δ 12.86 (s,
1H), 11.71 (s, 1H), 7.96 (dd, J = 13.4, 10.2 Hz, 3H), 7.37 (d, J = 8.1 Hz,
2H), 7.05 (s, 1H), 3.95 (s, 3H), 2.21 (s, 3H). 13C NMR (101 MHz,
DMSO): δ 173.22, 167.32, 156.79, 146.70, 140.75, 139.60, 131.22,
128.92, 128.73, 126.15, 119.85, 118.73, 118.19, 99.49, 56.39, 18.85.
HRMS: calcd for C18H14ClNO4 (M+H)
+ 344.0684, found 344.0686.
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Methyl 4-(6-Chloro-7-methoxy-2-methyl-4-oxo-1,4-dihydroqui-
nolin-3-yl)benzoate (38). Compound 38 was prepared using general
procedure A in 32%. 1H NMR (400 MHz, DMSO): δ 11.73 (s, 1H),
7.98 (dd, J = 9.5, 1.8 Hz, 2H), 7.89 (d, J = 10.4 Hz, 1H), 7.43−7.34 (m,
2H), 7.05 (s, 1H), 3.95 (s, 3H), 3.87 (s, 3H), 2.21 (s, 3H). 13C NMR
(101 MHz, DMSO): δ 173.16, 166.23, 156.81, 146.74, 141.23, 139.60,
131.41, 128.55, 127.75, 126.14, 119.68, 118.73, 118.22, 99.51, 95.86,
56.40, 52.07, 18.85. HRMS: calcd for C19H16ClNO4 (M+H)
+ 358.0841,
found 358.0847.
6-Chloro-3-(4-(dimethylamino)phenyl)-7-methoxy-2-methylqui-
nolin-4(1H)-one (39). Compound 39 was prepared using general
procedure E in 49% as a tan solid, mp = 324−325 °C. 1H NMR (400
MHz, DMSO): δ 11.52 (s, 1H), 7.99 (s, 1H), 7.03 (s, 2H), 6.72 (d, J =
8.0 Hz, 2H), 3.94 (s, 3H), 2.91 (s, 6H), 2.20 (s, 3H). 13C NMR (101
MHz, DMSO): δ 173.86, 156.46, 149.07, 146.14, 139.45, 131.36,
126.21, 123.29, 120.83, 118.72, 117.65, 111.81, 99.29, 56.30, 40.19,
18.92. HRMS: calcd for C19H19ClN2O2 (M+H)
+ 343.12078, found
343.12216.
4-(6-Chloro-7-methoxy-2-methyl-4-oxo-1,4-dihydroquinolin-3-
yl)-N,N-dimethylbenzenesulfonamide (40). Compound 40 was
prepared using general procedure A in 34% as a brown solid, mp =
335−337 °C. 1H NMR (400 MHz, DMSO): δ 11.78 (s, 1H), 8.01 (s,
1H), 7.75 (d, J = 8.2 Hz, 2H), 7.54 (d, J = 8.2 Hz, 2H), 7.08 (s, 1H), 3.97
(s, 3H), 2.66 (s, 6H), 2.24 (s, 3H). 13C NMR (101 MHz, DMSO): δ
173.06, 156.87, 146.98, 140.84, 139.60, 132.84, 131.88, 126.92, 126.09,
119.14, 118.69, 118.28, 99.54, 56.42, 37.60, 18.87. HRMS: calcd for
C19H19ClN2O4S (M+H)
+ 407.08268, found 407.08128.
6-Chloro-3-(4-hydroxyphenyl)-7-methoxy-2-methylquinolin-
4(1H)-one (41).Compound 41 was prepared using general procedure A
in 44% as a gray solid, mp = 270−274 °C. 1HNMR (400MHz, DMSO):
δ 11.54 (s, 1H), 9.32 (s, 1H), 7.98 (s, 1H), 7.04 (s, 1H), 7.01 (d, J = 8.1
Hz, 2H), 6.76 (d, J = 8.0 Hz, 2H), 3.95 (s, 3H), 2.19 (s, 3H). 13C NMR
(101 MHz, DMSO): δ 174.44, 157.22, 156.64, 146.98, 140.18, 132.55,
126.87, 126.74, 121.40, 119.40, 118.43, 115.28, 100.00, 57.02, 19.58.
HRMS: calcd for C17H14ClNO3 (M+H)
+ 316.07350, found 316.07254.
6-Chloro-3-(2-(hydroxymethyl)phenyl)-7-methoxy-2-methylqui-
nolin-4(1H)-one (42). Compound 42 was prepared using general
procedure A in 32% as a white solid, mp = 267−269 °C. 1H NMR (400
MHz, DMSO): δ 11.74 (s, 1H), 7.99 (s, 1H), 7.53 (d, J = 7.5 Hz, 1H),
7.34 (t, J = 7.4 Hz, 1H), 7.26 (t, J = 7.3 Hz, 1H), 7.09 (s, 1H), 7.03 (d, J =
7.3 Hz, 1H), 4.90 (s, 1H), 4.28 (d, J = 13.4 Hz, 1H), 4.17 (d, J = 13.5 Hz,
1H), 3.96 (s, 3H), 2.06 (s, 3H). 13C NMR (101 MHz, DMSO): δ
173.50, 156.70, 147.16, 141.69, 139.74, 134.08, 130.70, 127.12, 126.80,
126.49, 126.09, 119.60, 118.49, 118.11, 99.51, 61.05, 56.41, 18.73.
HRMS: calcd for C18H16ClNO3 (M+H)
+ 330.08915, found 330.08830.
6-Chloro-3-(3-(hydroxymethyl)phenyl)-7-methoxy-2-methylqui-
nolin-4(1H)-one (43). Compound 43 was prepared using general
procedure A in 23%, mp = 265−267 °C. 1H NMR (250 MHz, DMSO):
δ 11.64 (s, 1H), 7.99 (s, 1H), 7.34 (t, J = 7.4 Hz, 1H), 7.24 (d, J = 7.6 Hz,
1H), 7.16 (s, 1H), 7.08 (d, J = 6.9 Hz, 2H), 5.19 (s, 1H), 4.51 (d, J = 4.2
Hz, 2H), 3.96 (s, 3H), 2.19 (s, 3H). 13C NMR (101 MHz, DMSO): δ
174.19, 157.30, 147.08, 142.64, 140.29, 136.30, 129.90, 129.69, 128.18,
126.83, 125.41, 121.60, 119.46, 118.57, 100.11, 63.62, 57.03, 19.53.
HRMS: calcd for C18H16ClNO3 (M+H)
+ 330.08915, found 330.09014.
6-Chloro-3-(4-(hydroxymethyl)phenyl)-7-methoxy-2-methylqui-
nolin-4(1H)-one (44). Compound 44 was prepared using general
procedure A in 49% as a yellow solid, mp = 310−315 °C. 1H NMR (400
MHz, DMSO): δ 11.61 (s, 1H), 7.99 (s, 1H), 7.32 (d, J = 8.0 Hz, 2H),
7.17 (d, J = 8.0 Hz, 2H), 7.05 (s, 1H), 5.17 (s, 1H), 4.52 (d, J = 3.7 Hz,
2H), 3.95 (s, 3H), 2.19 (s, 3H). 13C NMR (101 MHz, DMSO): δ
173.56, 156.62, 146.37, 140.71, 139.58, 134.15, 130.60, 126.17, 125.94,
120.70, 118.77, 117.89, 99.39, 62.87, 56.34, 18.85. HRMS: calcd for
C18H16ClNO3 (M+H)
+ 330.08915, found 330.09001.
3-([1,1′-Biphenyl]-4-yl)-6-chloro-7-methoxy-2-methylquinolin-
4(1H)-one (45).Compound 45 was prepared using general procedure A
in 53% as a gray solid, mp = 352−353 °C. 1HNMR (400MHz, DMSO):
δ 11.63 (s, 1H), 7.99 (s, 1H), 7.65 (dd, J = 15.1, 7.6 Hz, 4H), 7.54−7.16
(m, 5H), 7.03 (s, 1H), 3.92 (s, 3H), 2.22 (s, 3H). 13C NMR (101 MHz,
DMSO): δ 174.21, 157.36, 147.21, 140.75, 140.26, 138.98, 135.73,
132.22, 129.61, 127.97, 127.23, 126.87, 126.70, 120.95, 119.44, 118.68,
100.10, 57.05, 19.61. HRMS: calcd for C23H18ClNO2 (M+H)
+
376.10988, found 376.10541.
6-Chloro-7-methoxy-2-methyl-3-(4-phenoxyphenyl)quinolin-
4(1H)-one (46).Compound 46 was prepared using general procedure A
in 65% as a white solid, mp = 303−305 °C. 1H NMR (400 MHz,
DMSO): δ 11.64 (s, 1H), 8.00 (s, 1H), 7.41 (t, J = 7.9 Hz, 2H), 7.24 (d, J
= 8.5 Hz, 2H), 7.15 (t, J = 7.4 Hz, 1H), 7.03 (dd, J = 22.4, 8.1 Hz, 5H),
3.95 (s, 3H), 2.23 (s, 3H). 13C NMR (101 MHz, DMSO): δ 173.53,
156.64, 155.31, 146.54, 139.55, 132.52, 130.80, 130.02, 126.15, 123.43,
120.00, 118.71, 117.94, 117.78, 99.38, 56.35, 18.90. HRMS: calcd for
C23H18ClNO3 (M+H)
+ 392.10480, found 392.10580.
3-(4-(Benzyloxy)phenyl)-6-chloro-7-methoxy-2-methylquinolin-
4(1H)-one (47).Compound 47 was prepared using general procedure A
in 62%. 1H NMR (400 MHz, DMSO): δ 11.60 (s, 1H), 7.99 (s, 1H),
7.48 (d, J = 6.9 Hz, 2H), 7.41 (t, J = 6.9 Hz, 2H), 7.35 (d, J = 6.7 Hz, 1H),
7.15 (d, J = 7.7 Hz, 2H), 7.05 (s, 1H), 7.02 (d, J = 7.9 Hz, 2H), 5.13 (s,
2H), 3.95 (s, 3H), 2.20 (s, 3H). 13C NMR (101 MHz, DMSO): δ
173.64, 157.03, 156.59, 146.38, 139.53, 137.23, 131.98, 128.41, 128.04,
127.76, 127.64, 126.18, 120.32, 118.72, 117.83, 114.06, 99.36, 69.15,
56.35, 18.89. HRMS: calcd for C24H20ClNO3 (M+H)
+ 406.12045,
found 406.12204.
6-Chloro-7-methoxy-2-methyl-3-(4-(phenoxymethyl)phenyl)-
quinolin-4(1H)-one (48). Compound 48 was prepared using general
procedure A in 57% as a beige solid, mp = 301−302 °C. 1H NMR (400
MHz, DMSO): δ 11.60 (s, 1H), 7.96 (s, 1H), 7.42 (d, J = 7.6 Hz, 2H),
7.35−7.20 (m, 4H), 7.06−6.87 (m, 4H), 5.08 (s, 2H), 3.92 (s, 3H), 2.17
(s, 3H). 13C NMR (101 MHz, DMSO): δ 174.17, 159.11, 157.35,
147.15, 140.25, 136.07, 135.95, 131.67, 130.16, 127.90, 126.85, 121.34,
121.09, 119.43, 118.65, 115.39, 100.09, 69.74, 57.04, 19.55. HRMS:
calcd for C24H20ClNO3 (M+H)
+ 406.12045, found 406.12223.
6-Chloro-3-(4-ﬂuorophenyl)-7-methoxy-2-methylquinolin-4(1H)-
one (49).Compound 49was prepared using general procedure B in 52%
as a gray solid, mp = 344−345 °C. 1H NMR (400 MHz, DMSO): δ
11.66 (s, 1H), 7.99 (s, 1H), 7.27 (dd, J = 8.5, 5.9, 2H), 7.20 (t, J = 8.9,
2H), 7.07 (s, 1H), 3.96 (s, 3H), 2.20 (s, 3H). 19F NMR (376 MHz,
DMSO): δ −116.51. 13C NMR (101 MHz, DMSO): δ 171.50, 160.26
(d, J = 242.4), 154.66, 152.60, 145.84, 135.60, 132.845 (d, J = 7.07),
125.55, 120.67, 118.38, 115.66, 113.93 (d, J = 21.21), 104.47, 55.83,
22.45. HRMS: calcd for C17H13ClFNO2 (M+H)
+ 318.06916, found
318.06988.
6-Chloro-3-(2,4-diﬂuorophenyl)-7-methoxy-2-methylquinolin-
4(1H)-one (50).Compound 50 was prepared using general procedure A
in 20% as a tan solid, mp = 318−323 °C. 1H NMR (400 MHz, DMSO):
δ 11.79 (s, 1H), 7.98 (s, 1H), 7.32−7.26 (m, 2H), 7.12−7.07 (m, 2H),
3.97 (s, 3H), 2.16 (s, 3H). 19F NMR (376 MHz, DMSO): δ −108.97,
−111.77. 13C NMR (101 MHz, DMSO): δ 173.73, 162.32 (dd, J =
246.44, 12.12), 160.81 (dd, J = 247.45, 13.13), 157.53, 148.29, 140.40,
134.95, 126.72, 120.37 (d, J = 17.17), 118.99 (d, J = 7.07), 114.51,
111.78 (d, J = 202.20), 104.52 (d, J = 26.26), 104.26 (d, J = 26.26),
100.24, 57.10, 19.12. HRMS: calcd for C17H12ClF2NO2 (M+H)
+
336.05974, found 336.06018.
6-Chloro-3-(2,6-diﬂuorophenyl)-7-methoxy-2-methylquinolin-
4(1H)-one (51).mp= decomp at 278 °C. 1HNMR (400MHz, DMSO):
δ 11.95 (s, 1H), 7.99 (s, 1H), 7.41−7.52 (m, 1H), 7.15 (t, J = 7.69 Hz,
2H), 7.10 (s, 1H), 3.97 (s, 3H), 2.17 (s, 3H). 19F NMR (376 MHz,
DMSO): δ −111.5. 13C NMR (101 MHz, DMSO): δ 172.67, 160.55
(dd, J = 245.2, 7.8 Hz), 156.98, 148.32, 139.83, 129.97 (t, J = 10.2 Hz),
126.20, 125.99, 118.32 (d, J = 39.6 Hz), 112.47, 111.40 (d, J = 25.6 Hz),
108.41, 99.70, 56.44, 18.25. HRMS: calcd for C17H12ClF2NO2 (M+H)
+
336.0597, found 336.0598.
6-Chloro-7-methoxy-2-methyl-3-(4-(triﬂuoromethyl)phenyl)-
quinolin-4(1H)-one (52). Compound 52 was prepared using general
procedure A in 31% as a yellow solid, mp = 322−323 °C. 1H NMR (400
MHz, DMSO): δ 11.79 (s, 1H), 8.00 (s, 1H), 7.74 (d, J = 8.1, 2H), 7.49
(d, J = 8.0, 2H), 7.09 (s, 1H), 3.97 (s, 3H), 2.22 (s, 3H). 19F NMR (376
MHz, DMSO): δ −61.24 13C NMR (126 MHz, DMSO): δ 173.20,
156.85, 146.87, 140.39, 139.64, 131.87, 127.11 (q, J = 31.6 Hz), 126.13,
124.56 (q, J = 3.6 Hz), 124.47 (q, J = 271.9 Hz), 119.37, 118.71, 118.26,
99.52, 56.43, 18.85. HRMS: calcd for C18H13ClF3NO2 (M+H)
+
368.06597, found 368.06445.
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3-(3,5-Bis(triﬂuoromethyl)phenyl)-6-chloro-7-methoxy-2-methyl-
quinolin-4(1H)-one (53). Compound 53 was prepared using general
procedure A in 7% as a yellow solid, mp = 305−307 °C. 1H NMR (400
MHz, DMSO): δ 11.88 (s, 1H), 8.12−7.81 (m, 4H), 7.10 (s, 1H), 3.98
(s, 3H), 2.28 (s, 3H). 19F NMR (376 MHz, DMSO): δ −61.54. 19F
NMR (376 MHz, DMSO): δ −61.16. 13C NMR (101 MHz, DMSO): δ
172.99, 156.99, 147.62, 139.63, 138.52, 131.83, 129.73 (q, J = 32.5 Hz),
126.08, 123.49 (q, J = 271.0 Hz), 120.24, 118.54 (d, J = 12.5 Hz), 117.67,
99.60, 56.43, 18.84. HRMS: calcd for C19H12ClF6NO2 (M+H)
+
356.14118, found 356.14311.
6-Chloro-3-(2-ﬂuoro-4-(triﬂuoromethyl)phenyl)-7-methoxy-2-
methylquinolin-4(1H)-one (54). Compound 54 was prepared using
general procedure F in 75% over two steps, mp = decomp at 342 °C. 1H
NMR (400 MHz, DMSO): δ 11.88 (s, 1H), 7.99 (d, J = 0.8 Hz, 1H),
7.70 (d, J = 9.5 Hz, 1H), 7.62 (d, J = 8.5 Hz, 1H), 7.55 (t, J = 7.5 Hz, 1H),
7.09 (s, 1H), 3.97 (s, 3H), 2.19 (s, 3H). 19F NMR (376MHz, DMSO): δ
−61.03, −110.61. 13C NMR (101 MHz, DMSO): δ 173.20, 160.35 (d, J
= 246.3 Hz), 157.41, 148.12, 140.19, 136.29−134.27 (m), 130.43−
129.90 (m), 129.06−128.16 (m), 126.44, 122.03−120.77 (m), 118.93,
118.74, 113.88, 113.55−112.85 (m), 100.08, 56.88, 18.87. HRMS: calcd
for C18H12ClF4NO2 (M+H)
+ 386.0565, found 386.0576.
6-Chloro-3-(3-ethoxy-4-ﬂuorophenyl)-7-methoxy-2-methylqui-
nolin-4(1H)-one (55). Compound 55 was prepared using general
procedure A in 77% as a tan solid, mp = 328−329 °C. 1H NMR (400
MHz, DMSO): δ 11.64 (s, 1H), 7.98 (s, 1H), 7.16−7.03 (m, 3H), 6.97
(d, J = 8.0 Hz, 1H), 4.13 (q, J = 6.6 Hz, 2H), 3.95 (s, 3H), 2.21 (s, 3H),
1.37 (t, J = 6.7 Hz, 3H). 19F NMR (376 MHz, DMSO): δ −136.21. 13C
NMR (101 MHz, DMSO): δ 174.12, 157.34, 151.76 (d, J = 243.41),
147.38, 145.62 (d, J = 11.11), 140.19, 129.15, 127.81, 126.82, 120.04,
119.28 (d, J = 15.15), 119.03, 118.66, 114.75, 100.06, 64.90, 57.03,
19.54, 15.33. HRMS: calcd for C19H17ClFNO3 (M+H)
+ 362.09538,
found 362.09390.
6-Chloro-3-(2,3-diﬂuoro-4-methoxyphenyl)-7-methoxy-2-methyl-
quinolin-4(1H)-one (56).mp = decomp at 328 °C. 1HNMR (400MHz,
DMSO): δ 11.79 (s, 1H), 7.98 (s, 1H), 6.97−7.11 (m, 3H), 3.97 (s, 3H),
3.91 (s, 3H), 2.19 (s, 3H). 19F NMR (376 MHz, DMSO): δ −137.30,
−161.36 13C NMR (101 MHz, DMSO): δ 173.07, 156.86, 148.60 (dd, J
= 243.7, 10.1 Hz), 147.82, 147.72−147.56 (m), 140.29 (dd, J = 244.3,
16.2 Hz), 139.70, 126.76 (t, J = 4.0 Hz), 126.06, 118.31 (d, J = 4.4 Hz),
117.00, 116.86, 113.68, 108.54, 99.56, 56.51, 56.42, 18.49. HRMS: calcd
for C18H14ClF2NO3 (M+H)
+ 366.0703, found 366.0707.
6-Chloro-7-methoxy-2-methyl-3-(2-(triﬂuoromethoxy)phenyl)-
quinolin-4(1H)-one (57). Compound 57 was prepared using general
procedure A in 25% as a gray solid, mp = 312−316 °C. 1H NMR (400
MHz, DMSO): δ 11.87−11.79 (s, 1H), 7.99 (s, 1H), 7.46 (dt, J = 18.2,
8.8 Hz, 3H), 7.34 (d, J = 7.3 Hz, 1H), 7.10 (s, 1H), 3.97 (s, 3H), 2.12 (s,
3H). 19F NMR (376 MHz, DMSO): δ −56.13. 13C NMR (101 MHz,
DMSO): δ 172.83, 156.83, 147.15, 139.74, 133.53, 129.49, 129.12,
128.13, 127.14, 126.05, 120.67, 120.02 (q, J = 256.0 Hz), 118.28, 118.24,
115.78, 99.65, 56.40, 18.28. HRMS: calcd for C18H13ClF3NO3 (M+H)
+
384.06088, found 384.06162.
6-Chloro-7-methoxy-2-methyl-3-(4-(triﬂuoromethoxy)phenyl)-
quinolin-4(1H)-one (58). Compound 58 was prepared using general
procedure B in 47% as a white solid, mp = 321−322 °C. 1H NMR (400
MHz, DMSO): δ 11.69 (s, 1H), 7.99 (s, 1H), 7.37 (s, 4H), 7.05 (s, 1H),
3.96 (s, 3H), 2.21 (s, 3H). 19F NMR (376 MHz, DMSO): δ−56.71. 13C
NMR (101 MHz, DMSO): δ 173.31, 156.75, 146.97, 146.71, 139.57,
135.15, 132.83, 126.10, 120.30, 119.29, 118.65, 118.12, 99.43, 56.37,
18.83. HRMS: calcd for C18H13ClF3NO3 (M+H)
+ 384.06088, found
384.06184.
6-Chloro-3-(4-ﬂuoro-2-methylphenyl)-7-methoxy-2-methylqui-
nolin-4(1H)-one (59). Compound 59 was prepared using general
procedure B in 34% yield, mp = decomp at 336 °C. 1HNMR (400MHz,
DMSO): δ 7.95 (s, 1H), 7.07 (d, J = 2.6 Hz, 1H), 7.04−7.00 (m, 3H),
3.92 (s, 3H), 2.00 (d, J = 12.1 Hz, 6H). 19F NMR (376MHz, DMSO): δ
−116.63. 13C NMR (101 MHz, DMSO): δ 173.19, 161.26 (d, J = 242.2
Hz), 156.67, 146.88, 140.26 (d, J = 8.0 Hz), 139.73, 132.56, 132.09,
126.09, 119.33, 118.53, 118.00, 115.97 (d, J = 20.9 Hz), 112.11 (d, J =
20.8 Hz), 99.47, 56.38, 19.34 (d, J = 1.3 Hz), 18.41. HRMS: calcd for
C18H15ClFNO2 (M+H)
+ 332.0848, found 332.0846.
6-Chloro-3-(4-chloro-2-methylphenyl)-7-methoxy-2-methylqui-
nolin-4(1H)-one (60). Compound 60 was prepared using general
procedure A in 17% as a tan solid, mp = 340−341 °C. 1H NMR (400
MHz, DMSO): δ 11.68 (s, 1H), 7.95 (s, 1H), 7.32 (s, 1H), 7.22 (d, J =
7.9 Hz, 1H), 7.03 (d, J = 10.3 Hz, 2H), 3.93 (s, 3H), 2.01 (d, J = 15.7 Hz,
6H). 13C NMR (101 MHz, DMSO): δ 173.71, 157.40, 147.46, 140.82,
140.42, 135.62, 133.30, 132.18, 129.84, 126.76, 126.09, 119.83, 119.19,
118.75, 100.18, 57.08, 19.80, 19.08. HRMS: calcd for C18H15Cl2NO2 (M
+H)+ 348.05526, found 348.05562.
6-Chloro-7-methoxy-2-methyl-3-(2-methyl-4-(triﬂuoromethyl)-
phenyl)quinolin-4(1H)-one (61). Compound 61 was prepared using
general procedure B in 10% yield, mp = 326−332 °C. 1H NMR (400
MHz, DMSO): δ 11.73 (s, 1H), 7.96 (d, J = 2.4 Hz, 1H), 7.61 (s, 1H),
7.51 (d, J = 8.3 Hz, 1H), 7.25 (d, J = 8.1 Hz, 1H), 7.05 (d, J = 2.1 Hz,
1H), 3.93 (d, J = 2.2 Hz, 3H), 2.08 (s, 3H), 2.03 (d, J = 2.2 Hz, 3H). 19F
NMR (376 MHz, DMSO): δ −60.88. 13C NMR (101 MHz, DMSO): δ
172.86, 156.79, 146.72, 140.62, 139.77, 139.18, 131.82, 127.74 (q, J =
31.2 Hz), 126.04, 125.99 (q, J = 3.4 Hz), 124.45 (q, J = 271.9 Hz),
122.20 (q, J = 3.3Hz), 119.14, 118.49, 118.20, 99.54, 56.42, 19.16, 18.38.
HRMS: calcd for C19H15ClF3NO2 (M+H)
+ 382.0816, found 382.0824.
6 - C h l o r o - 7 -me t h o x y - 2 -me t h y l - 3 - ( 2 -me t h y l - 4 - ( 4 -
(triﬂuoromethoxy)phenoxy)phenyl)-quinolin-4(1H)-one (62). Com-
pound 62was prepared using general procedure B in 20%, mp = decomp
at 311 °C. 1H NMR (400 MHz, DMSO): δ 7.98 (s, 1H), 7.40 (d, J = 9.0
Hz, 2H), 7.14 (d, J = 9.0 Hz, 2H), 7.06 (d, J = 10.5 Hz, 2H), 6.98 (s, 1H),
6.88 (s, 1H), 3.96 (s, 3H), 2.08 (s, 3H), 2.01 (s, 3H). 19F NMR (376
MHz, DMSO): δ −57.20. 13C NMR (126 MHz, DMSO): δ 173.25,
156.67, 155.92, 155.01, 146.91, 143.49, 139.90, 139.74, 132.50, 131.83,
126.12, 122.97, 120.12 (q, J = 255.0 Hz), 119.98, 119.62, 118.56, 117.98,
116.02, 99.47, 56.41, 19.45, 18.51. HRMS: calcd for C25H19ClF3NO4 (M
+H)+ 490.1028, found 490.1042.
6-Chloro-7-methoxy-2-methyl-3-(4-((4-(triﬂuoromethoxy)-
phenoxy)methyl)phenyl)-quinolin-4(1H)-one (63). Compound 63
was prepared using general procedure B in 3%. 1H NMR (400 MHz,
DMSO): δ 11.66 (s, 1H), 8.01 (s, 1H), 7.48 (d, J = 8.0Hz, 2H), 7.33 (d, J
= 9.1 Hz, 2H), 7.28 (d, J = 7.9 Hz, 2H), 7.16 (d, J = 9.1 Hz, 2H), 7.08 (s,
1H), 5.17 (s, 2H), 3.98 (s, 3H), 2.23 (s, 3H). 19F NMR (376 MHz,
DMSO): δ −57.30. 13C NMR (126 MHz, DMSO): δ 173.48, 157.33,
156.69, 146.54, 141.81, 139.63, 135.59, 134.81, 131.06, 127.36, 126.18,
122.56, 120.38, 120.19 (q, J = 255.1 Hz), 118.77, 117.98, 115.95, 99.46,
69.71, 56.39, 18.91. HRMS: calcd for C25H19ClF3NO4 (M+H)
+
490.1028, found 490.1043.
6-Chloro-3-(4-(4-ﬂuorobenzyloxy)phenyl)-7-methoxy-2-methyl-
quinolin-4(1H)-one (64). Compound 64 was prepared using general
procedure B in 25%, mp = decomp at 304 °C. 1H NMR (400 MHz,
DMSO): δ 11.59 (s, 1H), 7.99 (s, 1H), 7.53 (dd, J = 8.3, 5.7 Hz, 2H),
7.24 (t, J = 8.7 Hz, 2H), 7.15 (d, J = 8.3 Hz, 2H), 7.06−7.00 (m, 3H),
5.11 (s, 2H), 3.96 (s, 3H), 2.20 (s, 3H). 19F NMR (376MHz, DMSO): δ
−114.60. 13C NMR (126 MHz, DMSO): δ 173.61, 161.72 (d, J = 243.2
Hz), 156.93, 156.60, 146.43, 139.52, 133.42, 131.99, 129.88 (d, J = 8.2
Hz), 128.09, 126.17, 120.30, 118.69, 117.87, 115.22 (d, J = 21.4 Hz),
114.07, 99.36, 68.43, 56.35, 18.89. HRMS: calcd for C24H19ClFNO3 (M
+H)+ 424.1110, found 424.1123.
3-(4-(Benzyloxy)-3-ﬂuorophenyl)-6-chloro-7-methoxy-2-methyl-
quinolin-4(1H)-one (65). Compound 65 was prepared using general
procedure A in 41%, mp = 302−303 °C. 1H NMR (400 MHz, DMSO):
δ 11.65 (s, 1H), 7.98 (s, 1H), 7.42 (ddd, J = 33.2, 19.1, 7.1 Hz, 5H), 7.24
(t, J = 8.7 Hz, 1H), 7.13−6.94 (m, 3H), 5.21 (s, 1H), 3.96 (s, 3H), 2.22
(s, 3H). 19F NMR (376 MHz, DMSO): δ −136.41. 13C NMR (101
MHz, DMSO): δ 174.09, 157.37, 151.87 (d, J = 244.42), 147.40, 145.50,
140.20, 137.36, 129.57, 129.16, 128.69, 128.47, 127.79, 126.83, 119.98,
119.35, 119.24 (d, J = 17.17), 118.68, 115.29, 100.08, 70.88, 57.05,
19.56. HRMS: calcd for C24H19ClFNO3 (M+H)
+ 424.11103, found
424.10894.
6-Chloro-3-(6-(2-ﬂuoro-4-(triﬂuoromethyl)phenyl)pyridin-3-yl)-7-
methoxy-2-methylquinolin-4(1H)-one (66). 1H NMR (400 MHz,
DMSO): δ 11.83 (s, 1H), 8.64−8.67 (m, 1H), 8.24 (t, J = 8.00 Hz, 1H),
8.02 (s, 1H), 7.81−7.95 (m, 3H), 7.74 (d, J = 8.20 Hz, 1H), 7.08 (s, 1H),
3.97 (s, 3H), 2.31 (s, 3H). 19F NMR (376 MHz, DMSO): δ −61.21,
−114.51. 13C NMR (101 MHz, DMSO): δ 173.38, 159.56 (d, J = 251.0
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Hz), 156.91, 151.79, 148.72, 147.44, 139.63, 139.36, 132.04 (d, J = 3.2
Hz), 131.57, 131.32−130.19 (m), 126.12, 123.61 (d, J = 8.5 Hz), 123.29
(q, J = 273.9 Hz), 121.57 (dd, J = 7.1, 2.9 Hz), 118.56, 118.38, 116.60,
114.00 (d, J = 26.8 Hz), 99.57, 56.42, 18.93. HRMS: calcd for
C23H15ClF4N2O2 (M+H)
+ 463.0831, found 463.0850.
6-Chloro-7-methoxy-2-methyl-3-(6-(4-(triﬂuoromethoxy)phenyl)-
pyridin-3-yl)quinolin-4(1H)-one (67). 1H NMR (400 MHz, DMSO): δ
11.80 (br. s., 1H), 8.57 (s, 1H), 8.26 (d, J = 7.81 Hz, 2H), 7.99−8.08 (m,
2H), 7.81 (d, J = 8.20 Hz, 1H), 7.49 (d, J = 8.20 Hz, 2H), 7.09 (s, 1H),
3.97 (s, 3H), 2.30 (s, 3H). 19F NMR (376 MHz, DMSO): δ−56.70. 13C
NMR (101 MHz, DMSO): δ 173.4, 156.9, 152.4, 151.4, 148.8, 147.3,
139.6, 137.8, 130.7, 128.3, 126.1, 121.1, 119.5, 118.6, 118.3, 116.8, 99.5,
56.4, 18.9. HRMS: calcd for C23H16ClF3N2O3 (M+H)
+ 461.0874, found
461.0880.
Determination of Physicochemical Properties. Aqueous
Solubility, Permeability Pe, and Partition Coeﬃcient log D. Aqueous
solubility, permeability Pe and partition coeﬃcient have been
determined as previously reported.20,25,28
Microsomal Stability.Themicrosomal stability of 4(1H)-quinolones
was determined as previously reported.20 Brieﬂy, compounds were
incubated at a concentration of 1 μMwith human microsomes at 37 °C
and 0.4 mg/mL of microsomal protein. The metabolic reaction was
initiated with the addition of an NADPH-regenerating system (i.e.,
NADPH is the cofactor required for CYP450-mediated metabolism)
and quenched at various time points over the incubation period by the
addition of acetonitrile. Controls were included in the absence of
NADPH to assess the non-CYP-mediated degradation. The relative loss
of compound was monitored by LC-MS using a Waters/Micromass ZQ
mass spectrometer.
Test compound concentration versus time data were ﬁtted to an
exponential decay function to determine the ﬁrst-order rate constant for
substrate degradation and the in vitro intrinsic clearance (CLint, μL/
(min·mg protein)). CLint values of <7 μL/(min·mg) indicate little to no
observable degradation throughout the assay duration (typically 250
min), whereas N.D. entries indicate molecules that were not assayed.
Evaluation for Antimalarial Activity and Cytotoxicity. In Vitro
Antimalarial Activity and Cytotoxicity. In vitro antimalarial activity
and cytotoxicity were determined as previously reported.20,22,25,28
Screening for in Vivo Eﬃcacy. For the in vivo studies, female Balb/c
mice (average weight 18 g) were obtained from Harlan (Fredrick, MD).
An initial assessment of the in vivo antimalarial activity of selected
compounds was performed using a rapid screening assay. Brieﬂy, 38
compounds with potent activity against P. falciparum in vitro were
selected. Experimental mice (n = 2 per compound) were infected with 1
× 106 P. berghei-GFP ANKA parasites. On day 1 PE, mice were treated
with a single dose of the test compound or control drug atovaquone
(ATOV) at a concentration of 50 mg/kg. All compounds were
reconstituted in poly(etheylene glycol)400 (PEG400). Parasitemia were
determined from blood collected from the tail vein on days 3 and 6 PE.
Compounds with >50% inhibition of parasitemia on days 3 and 6 PE
were selected for more in-depth study using the Thompson test.
In Vivo Thomson Test. The in vivo eﬃcacies of the new compounds
were determined by a modiﬁed Thompson test. This test measures the
survivability of mice and parasite clearance following administration of
the drug on days 3−5 post-exposure. In brief, 1 × 106 P. berghei-infected
erythrocytes (ANKA-GFP) were inoculated into the intraperitoneal
cavity of female mice that weighed 18−20 g. By day 3 PE, parasitemia
ranged from 0.1 to 1.0%. There were ﬁve mice per dosage group, and
each drug, suspended in PEG400, was administered orally (p.o.) once
daily from days 3 to 5 PE. Blood smears were prepared on days 6, 9, 13,
21, and 30 PE. Compounds were considered active if suppression of
parasitemia was ≥80% on day 6 PE. Mice that were blood-ﬁlm negative
on day 30 PE were considered cured. Mice developing ≥40%
parasitemia or more were sacriﬁced. All animal studies for antimalarial
eﬃcacy were approved by the University of South Florida Institutional
Animal Care and Use Committee.
Plasma Exposure of Frontrunner Compounds in Swiss Mice. The
plasma exposure of four frontrunner compounds (7, 52, 66 and 67) was
studied in non-fasted male Swiss outbred mice (5−7 weeks) according
to procedures approved by the Monash Institute of Pharmaceutical
Sciences Animal Ethics Committee (protocol no. VCPA.2010.41). Mice
had access to food and water ad libitum throughout the pre- and post-
dose sampling period.
Each compound was administered orally via gavage (0.2 mL of a 1−
1.5 mg/mL suspension in PEG400), and blood samples were collected
via sub-mandibular bleed or cardiac puncture at three sample time
points (0.5, 7.5/8, and 24 h). Blood was collected directly into
polypropylene Eppendorf tubes containing heparin as anticoagulant and
stabilization cocktail [containing Complete (a protease inhibitor
cocktail), potassium ﬂuoride, and EDTA] to minimize potential for ex
vivo compound degradation. Blood samples were centrifuged, and
supernatant plasma was removed and stored frozen until analysis by LC-
MS.
In Vivo Pharmacokinetics in Rats. The pharmacokinetics of the
most promising frontrunner (compound 7) were studied in overnight-
fasted male Sprague−Dawley rats (6−8 weeks; weighing 291−299 g)
according to procedures approved by the Monash Institute of
Pharmaceutical Sciences Animal Ethics Committee (protocol no.
VCPA.2010.38). Rats had access to water ad libitum throughout the
pre- and post-dose sampling period, and access to food was re-instated 4
h post-dose. Compound 7 was administered intravenously as a 10 min
constant rate infusion (1 mL of a 0.044 mg/mL solution in 80:20 (v/v)
propylene glycol/ethanol; n = 2 rats) and orally by gavage (1 mL of a 3
mg/mL solution in PEG400, followed by 1 mL of water; n = 2 rats).
Samples of arterial blood were collected up to 48 h post-dose into
borosilicate vials (at 4 °C) containing heparin, Complete (a protease
inhibitor cocktail), potassium ﬂuoride, and EDTA to minimize potential
for ex vivo compound degradation. Blood samples were centrifuged, and
supernatant plasma was removed and stored frozen (−20 °C) until
plasma concentrations were determined by LC-MS. The analytical limit
of quantitation (LLQ) was 0.0020 μM. Pharmacokinetic parameters
were determined via standard non-compartmental methods using
WinNonLin software (version 5.2.1).
Plasma Protein Binding. Plasma protein binding was determined via
an ultracentrifugation method based on that described by Nakai et al.41
Brieﬂy, frozen plasma was thawed and spiked with a DMSO/
acetonitrile/water solution of test compound, with the ﬁnal DMSO
and acetonitrile concentrations being 0.2% (v/v) and 0.4% (v/v),
respectively. Plasma was incubated at 37 °C for 60 min to equilibrate,
and aliquots were transferred into polyallomer ultracentrifuge tubes and
subjected to ultracentrifugation (Beckman Rotor type 42.2 Ti; 223000g
and 37 °C) for 4.2 h, resulting in removal of >99% of the plasma proteins
(and bound compound) from the supernate. Following ultra-
centrifugation, aliquots of supernate (containing the unbound fraction)
were taken and stored frozen together with non-centrifuged samples at
−20 °C until analysis by LC-MS. Based on the concentrations observed
in non-centrifuged plasma maintained at 37 °C (Cplasma) and in the
protein-free supernate (Cplasma‑water), the percentage of compound
bound to plasma proteins (% bound) was calculated according to the
following equation:
= − ×−C C C% bound ( )/ 100%plasma plasma water plasma
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